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ABSTRACT 
A novel osteopathic treatment has been discovered during the clinical practice of the author 
which alleviates many of the symptoms of chronic fatigue syndrome (CFS) known in the 
UK as CFS/ME. The efficacy of this manual approach was tested using two separate 
clinical trials. The first examined the change in the symptoms following a year of treatment. 
The second repeated the first study and examined the possible mechanisms of the 
improvement. The studies were designed to develop a greater understanding of the disorder, 
for which there is much scientific uncertainty regarding the cause, diagnosis and treatment. 
Phase 1 of the research trials included self report questionnaires to examine overall 
symptom change. With post-exercise fatigue being a major symptom of CFS/ME, the 
treatment protocol was best evaluated by determining its effects on muscle function which 
was analysed utilising isometric testing of the knee extensor muscles measuring the impulse 
torque. 
The second trial, which included the same self report questionnaires assessing symptom 
relief as in the initial trial, was divided into two parallel phases. Phase 2 primarily took the 
form of brain analysis using magnetic resonance imaging (MRI) to confirm if brain 
abnormalities seen in previous research were found in sufferers of CFS/ME. No cerebral 
abnormality was detected in the patient group. Central lymph scans were also carried out 
showing a possible trend of enlargement in CFS/ME sufferers. In the other part, phase 3, 
isometric tests were repeated with more accurate equipment than in phase 1. Integrated 
EMG and median frequency of the power spectrum were measured using surface 
electromyography (sEMG). 
Overall this study has provided strong evidence that an important component of CFS/ME 
involves a disturbance of lymphatic drainage of the brain and muscles. The novel 
osteopathic treatment developed by the author has been statistically validated in both 
phases of the study, emphasising the need to focus future research on the biomechanical 
aspects of this disorder. 
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Chapter 1 
1 General Introduction 
1.1 CFS/ME: A definition 
Chronic fatigue syndrome (CFS) or Myalgic Encephalomyelitis (ME) as it has been known 
in the UK since the 1950s (Ramsay, 1978; Ramsay and O'Sullivan, 1956) is a clinically 
accepted condition now referred to in Britain as CFS/ME (Hutchinson et al., 2002). It is 
characterized by generalised abnormal muscle fatigue that occurs after relatively mild 
activity. Other common symptoms include sleep disturbances, headaches, cognitive 
dysfunction, depression, increased sensitivity to light and sound, back and neck pain, sore 
throat, and irritable bowel and bladder pain (Ramsay, 1978; Acheson, 1959; Macintyre, 
1992; Dowsett et al., 1990). 
The use of the name "chronic fatigue syndrome", compared with alternative terms, is not 
intended in any way to trivialize this illness. However without adequate scientific 
justification the use of the term M. E. (Myalgic Encephalomyelitis/ Myalgic 
Encephalomyelopathy) which is not widely used except in the UK and Canada, could lead 
to confusion and will substantially undermine the progress that has been made by the 
original research. The author supports changing the name when more is known about the 
underlying pathophysiological process or processes associated with this syndrome. The 
joint term CFS/ME has been agreed upon in the recent Chief Medical Officers report into 
the condition (Hutchinson et al., 2002) and thus it was felt by the author to be the most 
suitable name at this present time. 
CFS/ME, according to The CDC, is currently defined by the presence of the following: 
Clinically evaluated, unexplained persistent or relapsing chronic fatigue that is of new or 
definite onset (has not been lifelong); is not the result of ongoing exertion; is not 
substantially alleviated by rest; and results in substantial reduction in previous levels of 
occupational, educational, social, or personal activities. 
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In addition, the concurrent occurrence of four or more of the following symptoms, all of 
which must have persisted or recurred during 6 or more consecutive months of illness and 
must not have predated the fatigue. 
Self-reported impairment in short-term memory or concentration severe enough to cause 
substantial reduction in previous levels of occupational, educational, social, or personal 
activities; sore throat; tender cervical or axillary lymph nodes; muscle pain; multijoint pain 
without joint swelling or redness; headaches of a new type, pattern, or severity; un- 
refreshing sleep; and malaise lasting more than 24 hours following exertion (Fukuda et al., 
1994). 
Another frequently used set of diagnostic criteria used in this country is the UK (Oxford) 
criteria (Sharpe et al., 1991) which is similar to the CDC definition mentioned above but 
differs in the number of symptoms needed to confirm the diagnosis and most significantly 
allows for minor psychiatric comorbidity to exist. 
1.2 CFS/ME: A brief history 
In the past, many terms have been given to CFS type disorders which are probably different 
names for the same disorder. As early as 1871 union army doctor J. M. DaCosta described 
a fatigue disorder that affected about three hundred soldiers during the American Civil War. 
The soldiers had all been in active service for quite a while. 
The symptoms listed were as follows: 
Abdominal problems, including diarrhoea and frequent indigestion. 
Palpitations usually induced by exertion. 
Chest pain. 
Shortness of breath, again aggravated by exertion. 
Rapid pulse. 
Headaches and dizziness. 
Disturbed sleep. 
Excessive perspiration. 
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DaCosta also noted that when the soldiers' symptoms had eased, and after they had 
returned to duty, their performance on the battlefield was of low standard and that they 
were unable to keep up with their healthy comrades. DaCosta suggested that the cause of 
the problem was due to physical over-exertion and physical stress of the body, leading to an 
irritation of the heart. He proposed that the condition was sustained due to an imbalance in 
the nerve supply to the heart (DaCosta, 1871). The `innervation of the heart' DaCosta 
referred to is predominantly part of the sympathetic nervous system, with the 
parasympathetic vagus innervation also controlling the heart beat. DaCosta's syndrome, 
also known as "Irritable Heart", was recognised in the Crimean War. Sir Thomas Lewis 
wrote a paper in 1920 noting similar cases during the first World War which he labelled 
"Effort Syndrome" also known as Neurocirculatory Asthenia (Oppenheimer and Levine, 
1918). Lewis concluded that an infection was at the root of the problem (Lewis, 1920). 
Since Lewis, a number of physicians, neurologists, cardiologists and others have searched 
for the cause, constantly redefining this mysterious disorder. Eminent psychiatrists have 
pointed to a possible psychological source of the disease. From the label "Yuppie Flu" of 
the 1980's to the totally dismissive attitudes of some practitioners, many patients feel 
isolated and depressed as a result of ignorance. The inability of the health-care profession 
as a whole to legitimise this illness has been shown to aggravate psychiatric morbidity in 
sufferers (Lehman et al., 2002). Sufferers have been labelled as unmotivated and school or 
work-phobic although clinically one sees that most patients are well motivated, high 
achieving type `A' personalities. 
To add insult to injury research findings continue to lay the blame of CFS/ME on the 
patient's inability to cope with daily problems (Van Houdenhove et al., 1995), fear of 
physical activity (Silver et al., 2002), altered perception of the sufferer (Metzger and 
Denney, 2002) or worse, as a result of parental attitude such as maternal overprotection in 
childhood (Fisher and Chalder, 2003). It remains a condition that attracts controversy since 
many of the symptoms are non-specific, common to many other illnesses including 
psychiatric disorders. However atypical depression, which is a common feature of the 
disease, has been viewed as a sickness behaviour seen in many chronic illnesses rather than 
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an affective disorder (Van Hoof et al., 2003). An Australian study on 23 matched CFS/ME 
patients demonstrated an insignificant effect on cognitive ability due to depression and 
showed similar anxiety scores in the healthy group and the sufferers (Short et al., 2002). 
Nevertheless it still continues to be an enigma that confounds medical research to the extent 
that it has recently been conceptualised as "The Black Hole" of medicine (Eidelman, 2003). 
Apart from the strain of suffering from a severely debilitating illness, much emotional 
stress emerges from the refusal of others to accept the validity of the illness leading to 
many strained relationships at home, work and school and with members of the social 
services and medical profession (Shafran, 1991). 
1.3 The cost of CFS/ME 
The prevalence of CFS/ME in the UK has been estimated as 0.5% when comorbid 
psychological disorders were excluded (Wessely et al., 1997) The government's working 
group in January 2002 estimated that a general practice with 10,000 patients is likely to 
have between thirty to forty CFS/ME sufferers (Hutchinson et al., 2002). Prognosis of this 
complex disorder is recognised as highly variable. At 12 to 18 months, rates of 
improvement range from 11 to 64 % and worsening of symptoms range from 15- 20 %. 
However these rates are based on subjective self reported changes (Mulrow et al., 2001). 
The economic impact on individuals in the form of informal care and lost employment is 
devastating (McCrone et al., 2003). Statistical analysis recently carried out by the Survey 
and Statistical Research Centre at the Sheffield Hallam University revealed that CFS/ME 
annually costs the UK government around £3.5 billion in benefits payment, caring and loss 
of taxation (AfME, 2003). Thus on a global scale the impact of CFS/ME on society in both 
human and economic terms is of great magnitude. 
1.4 Research into CFS/ME 
Although many relatively small research projects have been carried out, financed mainly 
from private charitable trusts, pharmaceutical firms which are the main funders of medical 
research have tended to shy away from financing any major studies investigating CFS/ME. 
As demonstrated from present socio-economic research there is clearly no evidence to 
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justify this lack of interest compared with the research funding for other global diseases 
such as Aids (Pinching, 2003). 
Some breakthroughs have been made which may soon mean clinical tests are available to 
objectively assess the severity of CFS/ME; such as the head-up tilt test using 
haemodynamic instability score (Naschitz et al., 2003). Yet there are still no universally 
accepted investigative tests for this condition that have been validated in scientific studies. 
Thus from the diagnostic viewpoint there has been little movement in classifying the 
disease in over a decade (Holmes et al., 1988). The problem of clinical diagnosis is 
compounded by the fact that the cardiopulmonary functional capacity of patients varies 
greatly (Vanness etal., 2003). 
The symptoms of CFS/ME typically become apparent following a common viral infection 
(Dowsett, 1990), or a less common infection such as the Q fever outbreak in the Midlands, 
UK in 1989 caused by Coxiella burnetii, although many other causative factors have been 
suggested. Vaccinations against cholera, tetanus, typhoid and influenza have been 
associated with the onset of CFS/ME (Lloyd et al., 1988). Organophosphate pesticides have 
been suggested as an aetiological factor (Gershon and Shaw, 1961; Tahmaz et al., 2003) as 
have other environmental toxins (Rogers, 1990; Dustan et al., 1995). Patients with CFS/ME 
have been shown to have greater chemical sensitivity than healthy controls. They also have 
similar clinical presentations and are demographically analogous to those suffering from 
multiple chemical sensitivities (MCS) (Buchwald and Garrity, 1994; Fiedler et al., 1996; 
Nawab et al., 2000). It has also been observed that the psychological disturbances in 
CFS/ME occur secondary to, or share a common pathophysiology with immunological 
dysfunction (Hickie et al., 1992) However, in many cases there appears to be no apparent 
cause triggering the condition (Harvey, 1989). Diagnosis of CFS/ME can be made only 
after all other medical and psychiatric causes of chronic fatiguing illness have been 
excluded (Fukuda et al., 1994). There is mounting pathological evidence from more recent 
studies for elevated ribonuclease L enzymic activity (Tiev et al., 2003; Snell et al., 2002) 
and decreased levels of the immune regulating endogenous opioid, beta-endorphin in 
peripheral blood mononuclear cells (Panerai et al., 2002). New research has found 
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significant pathological disturbances in CFS/ME subjects such as reduction of membrane 
NA+-K+ ATPase activity, reduced serum magnesium, increased levels of tryptophan 
catabolites such as nicotine, altered levels of hypothalamic digoxin and other disturbed 
neuro-chemical and immune pathways (Georgiades et al., 2003). Microbial flora have 
shown to be demonstrably altered in CFS/ME and there is much pathological evidence to 
indicate that these patients are subjected to increased oxidative stress, have increased type 2 
helper cell cytokines, altered levels of essential fatty acid and malabsorption of certain 
nutrients (Logan et al., 2003). 
Simpson (1989) and Spurgin (1995) have studied red blood cell structure in various 
diseases and showed that the most common aberrant shape of a red blood cell in CFS/ME 
patients is a flattened disc with up to 80% of cells having this abnormal shape. This 
alteration may lead to loss of fluidity and flexibility of the RBC membrane resulting in 
reduced access of these cells to the deep capillary beds reducing oxygen supply to tissues 
exacerbating any fatigue. Decreased concentrations of essential fatty acids (EFA) in red cell 
membranes of CFS patients were thought to be causing the malformation of the 
erythrocytes. Recent research analyzing the essential fatty acid content in the blood found 
that the levels of the EFA arachidonic acid (ARA) and docosahexanoic acid (DHA) were 
decreased in patients suffering from CFS. However, the levels of the palmitic acid and oleic 
acid in the same lipid analysis were found to be increased which questions the aetiological 
relevance of the above finding (Liu et al., 2003). 
CFS/ME is not only restricted to man. Blood in animals presenting with symptoms of 
CFS/ME has been shown to contain micrococci-like organisms with positive staphylococci 
blood cultures. 80% of CFS/ME patients were shown to have micrococci in their blood 
especially if they were in constant contact with animals (Tarello, 2001). 
Considerable evidence now indicates that the central nervous system is profoundly 
involved in the pathogenesis of CFS/ME (Georgiades et al., 2003). What is also 
increasingly evident is that many research studies are now focussing on the high levels of 
toxicity found in CFS/ME patients such as organic solvents causing autonomic dysfunction 
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or heavy metals such as mercury that have neurotoxic properties (Hokama et al., 2003; 
Smith and Sullivan, 2003; Hotopf et al., 2000; Shaheen, 2000 ). 
Thus a significant number of distinct possibilities have emerged as being important in the 
development of CFS/ME. The areas of particular importance and relevance to the present 
work are reviewed in more detail in the following sections. 
1.5 Causes and treatment of CFS/ME 
Numerous suggestions have been made concerning the cause for the disorder. A rational 
classification is difficult because of the extensive overlaps between the different areas. 
Furthermore several theories have been developed largely from the apparent success of 
some therapies and therefore the possible causes and treatments are considered together in 
the following sections. There are, moreover, great difficulties in accurately defining the 
significance of psychological terms such as stress in a physiological context. Not 
surprisingly there has been much debate concerning the immunological, psychological and 
hormonal aspects. Nevertheless there is now available considerable data regarding these 
areas as well as the toxicological associations. The relevant information is reviewed in the 
following sections. 
1.5.1 Immunological 
The body provides two forms of specific adaptive immunity: Humoral and Cellular (Cell- 
mediated). Both are co-ordinated by the cells of the immune system and their mediators. 
1.5.1.1 Humoral immunity 
Humoral immunity is the major defence mechanism against bacterial infections and utilises 
circulating antibodies that are produced by specialised cells, B-cells, supported by other 
cells called T-helper/inducer cells. After recognising foreign material B-cells multiply 
rapidly and produce antibodies comprised of large immunoglobulins. These protein 
molecules are produced in large numbers and are usually specific to the infective or foreign 
agent. The antibodies form complexes with the foreign material and these complexes are 
then destroyed by other cells, such as macrophages. A particularly important 
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immunoglobulin is secretory IgA (sIgA) which is secreted at mucous membranes, e. g., gut, 
lungs, etc, where it is a major barrier to pathogenic organisms (Bai et al., 2004) 
1.5.1.2 Cellular (cell-mediated) immunity 
Cellular immunity involves a variety of T-cells that are responsible for protection against 
viruses, cancers, and some disease-causing bacteria such as tuberculosis. T-helper (Th) 
cells assist B-cells in mounting a humoral response and cytotoxic T lymphocytes (Tc) can 
actively destroy abnormal cells in disease and malignancies. A further group of cells are 
natural killer (NK), cells, which also play an important role in counteracting viral infections 
and cancer. 
The complex interactions between all the B and T-cells require cytokines which are large 
protein signalling molecules. There are many types of cytokines which are subdivided into 
smaller groups (e. g. interleukins and interferons). During an infection both T and B-cells 
multiply rapidly with cell numbers returning to normal levels after the antigen has been 
defeated. However some memory cells remain so that a second infection is more rapidly 
combated. Some recent research findings have demonstrated a cytokine involvement in the 
pathophysiological mechanisms found in CFS/ME. The underlying immune activation 
results in a Th2-type response with significantly increased levels of T-cells producing 
interferon-gamma or interleukin-4 (type 2) (Skowera et al., 2004). 
1.5.1.3 The inflammatory response 
This is a complex response to local injury or trauma and although it is usually acute there 
are a number of chronic inflammatory diseases that are well known such as rheumatoid 
arthritis and sinusitis. The inflammatory response also involves cytokines plus other classes 
of inflammatory modulators such as the prostaglandins. 
The recent controversy about the role of the MMR (measles, mumps and rubella) vaccine 
being associated with the development of autism involved the identification of grossly 
inflamed lymphoid tissue in the lower part of the small intestine (Wakefield et al., 2002). 
Inflammation of this part of the gut is common among CFS/ME patients and many have 
been diagnosed with irritable bowel syndrome, inflammatory bowel disease, and Crohn's 
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disease. Allergic reactions to food containing gluten are common. The best known of these 
is coeliac disease in which the structure of the small bowel is destroyed, with a flattening of 
the deeply folded villi of the gut wall, and a loss of the capacity to properly absorb many 
key food components. Generally CFS/ME patients do not test positive for coeliac disease 
but many become sensitive to many chemicals and foodstuffs, especially gluten (Logan and 
Wong, 2001). 
When digestion is impaired then the larger peptide fragments are not broken down. Among 
these are opioid peptides derived from two principal sources, casein in milk (the 
casomorphins) and gliadin in gluten (the gliadomorphins) which occurs in wheat and 
related cereal crops. Opioids are peptides that have been found to possess morphine-like 
activity and are known to be naturally occurring in important transmitter molecules, 
particularly, in the gut, brain and immune system. 
When the gut wall has increased permeability, these opioid peptides, which would normally 
be excluded, are absorbed and act both locally in the gut and in other organs, particularly 
the brain. The same factors that render the gut permeable also appear to increase the 
permeability of the blood-brain barrier and allow access of these compounds to the brain 
(Gershon, 1999; Hooper, 2003). 
Depending on the concentration of opioids in the gut, as well as permeability of the gut and 
blood-brain barrier, then the overall level of these compounds in the bloodstream and the 
brain may vary and give rise to variable expressions of symptoms and dysfunction. Opioids 
also play a significant role in the immune response through receptors found on cells of the 
immune system. Generally they suppress the immune response and increase susceptibility 
to infection (Hooper, 2003) 
The gut and the brain also communicate via messenger molecules generated by the immune 
response. There are receptors on brain cells for interleukins e. g. IL-1 (Dantzer, 2004). 
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Many symptoms associated with CFS/ME such as enlarged lymph glands, fever, gut 
symptoms, recurrent infections and non-exudative pharyngitis appear to indicate an 
immunological disorder. Indeed the onset of the disease often follows a viral infection. As 
reviewed below, many treatment approaches have been of an antiviral nature (Lerner et al., 
2002; Agut and Aubin, 1994; Blondel-Hill and Shafran, 1993). Some infections do cause 
long term fatigue. Patients exposed to Q fever (Coxiella burnetii infection) may develop 
chronic fatigue. Research determined that subjects involved in the West Midlands Q fever 
outbreak of 1989 had increased fatigue, compared to non-exposed controls 10 years after 
exposure (Wildman et al., 2002). More serious pathology may be also linked to the 
pathogenesis of CFS/ME. A subset of disease-free breast cancer patients complained of a 
level of symptoms almost identical to CFS/ME sufferers, such as fatigue, sleep and loss of 
concentration (Servaes et al., 2002). In an earlier study the fact that CFS/ME anecdotally 
had been linked with incidences of lymphoid hyperplasia and malignancy was examined. In 
Nevada (U. S. A. ), patterns of Non-Hodgkin's Lymphoma were seen in a group of CFS/ME 
patients between 1984 and 1988. The researchers concluded however that there was no 
significant correlation between the incidence of malignancy and CFS/ME (Levine et al., 
1992). However a previous link was made between Non-Hodgkin's lymphomas and 
CFS/ME after an epidemiological investigation into a cluster of CFS/ME sufferers in North 
Carolina (Eby et al., 1988). 
1.5.1.4 Rnase L 
A recent study has further confirmed the existence high levels of low molecular weight 2- 
5A binding polypeptide of 2-5A dependent ribonuclease L (Rnase L), generated by an 
increased proteolytic activity (Demettre et al., 2002). Snell and co-workers discovered that 
increase in Rnase L enzyme activity may be linked to the low exercise tolerance and 
functional impairment found in CFS/ME. They suggest that both exercise testing and the 
Rnase L biomarker may be potential aids in the diagnosis of CFS (Snell et al., 2002). 
This disturbance in the 2-5A synthetase/RnaseL pathway and findings of abnormalities in 
T-cell subsets, IgG subset deficiencies and reduced natural killer cell activity plus increased 
delayed type hypersensitivity responses all support the hypothesis that CFS/ME is a disease 
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affecting the immune system (Shepherd, 1998). However in another study at the University 
of Glasgow, Rnase L pathway activation in the group of patients with acute gastroenteritis 
differed significantly from that of a healthy group and a group with CFS/ME, in whom 
there was no evidence of upregulation. This study strongly suggests that an assay of Rnase 
L antiviral pathway activation is unlikely to form a rational basis for a diagnostic test for 
CFS/ME (Gow et al., 2001). 
Chronic, low level immune activation leads to an overproduction of inflammatory 
mediators including cytokines which may lead to many of the symptoms of CFS/ME. 
Cytokines can bind to receptor sites within neurones mediating their effects. Studies by 
Suhadolnik and co-workers (1997 and 1999) have demonstrated upregulation of the 2-5A 
synthetase/RnaseL antiviral pathways in CFS/ME, signifying ongoing stimulation of T-type 
immune cells by interferons, viruses or other factors. Upregulation of these pathways can 
also be induced by chemical exposure (Vojdani, 1998). 
Lloyd et al., (1991) showed that disturbances in cellular immunity are factors in 
pathogenesis and response to treatment. 5mg of low-dose hydrocortisone treatment for 
CFS/ME has been shown to reduce the fatigue and also to reduce the level of disability 
(Cleare et al., 1995), although there was a significant decline in improvement when the 
treatment ended. The symptoms and signs of CFS/ME are very similar to Addison's 
disease (primary adrenal insufficiency). However corticosteroid replacement where there 
are no physical signs of adrenal compromise is clearly unwarrantable as it would further 
exacerbate symptoms (Baschetti, 1998). In fact the only physical sign clinically identified 
by the author of adrenal dysfunction in CFS/ME is one usually attributed to high levels of 
cortisol, namely striae gravida (stretch marks) seen in Cushing's syndrome. 
1.5.1.5 Cytokines 
Cytokines have an important role in regulation of the immune system (Maier et al., 1998) 
which exerts numerous effects on autonomic function via the hypothalamus. Exposure to 
toxins, as well as infections, stimulates cytokine release (Reichlin 1993). There is also 
increasing evidence that exposure to emotionally stressful events induces cytokine release 
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and these mediate the neuroendocrine, neurochemical and behavioural effects of emotional 
stress. Cytokines stimulate the release of a number of neurotransmitters including 
noradrenalin acetylcholine, and serotonin. The cytokine interleukin -1 can stimulate 
hypothalamic release of CRH. Activation of CRH in turn stimulates noradrenalin release by 
increasing the availability of the enzyme tyrosine hydroxylase (Black, 1994). 
There is also evidence of another way by which immune cells can communicate with the 
central nervous system. Lymphocytes have been shown to be capable of synthesising 
anterior pituitary hormones such as growth hormone and ACTH (Glaser and Kiecolt- 
Glaser, 1998) and small amounts of neurotransmitters, neurohormones and neuropeptides 
(Black, 1994). It has been proposed that viral or other infectious agents can directly and 
indirectly affect the regions of the brain that connect with the limbic system. Goldstein 
(1993) hypothesises that the limbic system response to cytokines may be abnormal in 
CFS/ME. Specifically, he speculates whether CFS/ME might be associated with altered 
levels of IL-1 antagonists which could potentially alter neuro-immune interactions and that 
infection results in immune activation leading to disturbed regulation of the CNS, 
particularly in the temperolimbic area. 
The limbic system performs many key functions: regulation of memory and learning, 
integration of affect and psychosocial events, modulation of drive, integration of behaviour 
and higher control of hypothalamic and autonomic function. According to Goldstein (1993) 
`limbic encephalopathy' could potentially explain many symptoms that are associated with 
this illness. These include pain; chemical sensitivity; immunological, neuroendocrine, 
neuropsychological and autonomic dysfunction; allergies and sleep impairment. Limbic 
system involvement is also consistent with the fluctuating nature of symptoms, particularly 
the exacerbation of symptoms in response to a range of stressors. Alterations in the activity 
of NMDA receptors in this region could explain a very common symptom of CFS/ME, 
namely alcohol intolerance. In one study CFS/ME patients exposed to toxic factors, such as 
ciguatera poisoning, organochlorine pesticides or those found in Gulf War veterans, 
showed more severe dysfunction of the immune system compared with CFS/ME patients 
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not exposed to toxins, whereas all the patients in that trial had disturbances in hypothalamic 
function (Racciatti et al., 2001). 
A number of studies have shown that hypothalamic, pituitary and limbic system lesions can 
alter many aspects of immune function. Depending on location, both immunosuppressive 
and immune-enhancing effects of such lesions have been reported, including reductions in 
immune cell numbers, proliferative responses to mitogens, natural killer cell activity and 
antibody responses (Ader et al., 1995). 
Data from a number of studies has shown that immunosuppression can be conditioned 
according to the principles of Pavlov. It has been repeatedly demonstrated that the pairing 
of an immunosuppresive drug with a sensory stimulus can eventually condition the subject 
to respond to the sensory stimulus alone with immunosuppression (Black, 1994). This 
demonstrates a strong interaction between the brain and the immune system. 
As discussed further in section 1.5.8 the free radical nitric oxide has been shown to have 
neurotoxic properties. Reichlin (1993) proposes that in the CNS activated monocyte and 
glia can release nitric oxide, which exerts toxic effects via its ability to hyperstimulate 
glutamate receptors. 
Detoxification systems in the liver play a key role in generalised stress response via their 
role in dealing with the metabolic products of stress (Sternberg et al., 1992). The gut has an 
intricate immune system network, abundant autonomic innervation and produces a number 
of neurotransmitters. Lymphocytes in the gut secrete small amounts of hormones that are 
thought to play a local role in regulating inflammation in the gut (Reichlin 1993). It is 
possible that the release of hormones in the gut is influenced by stress. Indeed 
psychoneuroimmunomodulation is likely to contribute to the balance of gut function 
(Anisman et al., 1996). It is conceivable, that with recognition of the importance of 
neuroimmune interactions, these impairments may be a result of disrupted communications 
in the neuroimmune network. 
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The immune system has been shown to exert numerous effects on the hypothalamus and 
thus the autonomic nervous system. Immune activation is associated with increased firing 
rate of hypothalamic neurones. Activated immune cells release cytokines that are important 
mediators of the stress response (Ader et al., 1995). How cytokines reach and activate the 
central nervous system is still not fully understood (Watkins et al., 1995). It is known that 
activated immune cells can cross the blood-brain barrier and release cytokines and other 
immune mediators into the central nervous system (Reichlin, 1993). Central and peripheral 
administration of cytokines impacts on a range of behaviours including feeding, sleeping, 
drinking, levels of activity and mood, presumably by their action on receptor sites in the 
limbic system. Infections have an effect on the limbic system which plays a major role in 
regulation of memory and learning, and is directly involved in hypothalamic and autonomic 
function. Dysfunction of the limbic system may lead to many of the symptoms associated 
with this illness and thus CFS/ME patients are very sensitive to both physical and 
psychological stress. Also functional changes in limbic areas have been demonstrated in 
CFS/ME using SPELT scans (Goldstein, 1993). The limbic system controls emotions and 
dream states and it is noteworthy that patients with CFS/ME often complain of mood 
swings and weird or extremely vivid dreams, nightmares or, in extreme cases, 
hallucinations. 
In the acute stage of infection cytokines are responsible for fatigue, inactivity, anorexia 
and associated neuroendocrine and metabolic changes (Reichlin, 1993; Anisman et al 
1996). Exposure to infection, toxins and injury has been shown to stimulate cytokine 
release (Reichlin, 1993). It is significant that interferons, when used medicinally, have 
been associated with neurological and psychiatric side effects (Morag et al., 1998). There is 
also evidence that exposure to stressful events induces cytokine release. These cytokines 
mediate the neuroendocrine, neurochemical and behavioural effects of stress. The cytokine 
interleukin IL-1 inhibits neuronal secretion of acetylcholine (Reichlin, 1993), whereas some 
cytokines stimulate the release of acetylcholine and other neurotransmitters including 
noradrenalin, and serotonin. IL-ira inhibits cytokine effects and thus inhibits these 
neurotransmitters (Reichlin, 1993). Cytokine IL-1 has been shown to stimulate 
hypothalamic release of corticotropin releasing hormone (CRH) which stimulates 
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noradrenalin release. There is also evidence that lymphocytes can synthesise 
neurotransmitters (Black, 1994). 
1.5.1.6 Immunological therapies 
An alternative term for CFS/ME in the USA is Chronic Fatigue Immune Deficiency 
Syndrome (CFIDS) recognising that dysfunction of the immune system is a major feature 
of this disease. Many immune modulatory treatments are expensive, not freely available 
and produce unpleasant side effects (Shepherd, 1998). The results of randomised controlled 
trials of immunoglobulin therapy have been contradictory (Hickie et al., 1992; Uchida, 
1992; Lloyd et al., 1990; Matsuda J, 1992; Vollmer-Conna et al., 1997). 
1.5.2 Viruses and anti-viral therapy 
Some viruses, known as enteroviruses such as the Coxsackie B group, are known to be 
particularly important in triggering CFS/ME (Richardson, 2001). Hence treatment 
approaches over the years have focussed on antiviral medications (Blondel-Hill and 
Shafran, 1993). Drugs such as acyclovir have been unsuccessfully tested on CFS/ME 
patients with abnormal Epstein-Barr virus (EBV) serology following glandular fever in a 
randomised controlled trial (Straus et al., 1988). Patients treated with cytokine interferon a 
showed no significant improvement but some of them developed major side effects such as 
palpitations, worsened fatigue, flu-like symptoms, diarrhoea, hair loss and mild boils (See 
and Tilles, 1996). The Effect on cytokine levels of the oriental medicine Bojungikki-tang 
(BIT), which has been widely used in the Far East to treat CFS/ME, was investigated and 
showed a slightly lower inhibitory effect of LPS-induced Interferon (IFN)-gamma 
production. These results suggest that BIT may be useful in treating CFS/ME (Shin, 2003). 
A subset of CFS/ME patients, all having significant IgG type human cytomegalovirus 
titres, showed significant improvement following treatment with the antiviral agent 
ganciclovir (Agut and Aubin, 1994). Lerner et al., (2002) later showed that another anti- 
viral drug valacyclovir was successful in improving cardiac function in CFS/ME patients 
who were initially infected by the Epstein-Barr virus. 
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It has been shown in some CFS/ME patients that there is an up-regulation of 2-5A 
synthetase/RnaseL pathway which is involved in the normal defence against viruses 
(Suhadolnik et al., 1997). Poly (1)-poly (C12U), better known as ampligen (a synthetic, 
mismatched double-stranded RNA), has potent anti-viral and regulatory properties, and 
came to prominence in the 1980's when it was billed as a potential cure for AIDS. In trials 
baseline RnaseL levels were significantly reduced in the treatment group but not in the 
placebo group (Cotton, 1991). In view of the mode of action of ampligen, there is a 
potential risk that it could interfere with genetic material in the cell. For this reason it has 
not received approval for treatment of this condition in the USA, Europe or in the UK. 
1.5.3 Allergies and sensitivities 
Studies of the part played by allergies in CFS/ME have shown that they cause chemical and 
food sensitivities (Straus, 1994; Bell et al., 1998), with many cases of hypoergy or anergy 
reported (Lloyd et al., 1988). Excessive N-methyl-D-aspartate (NMDA) receptor activity 
has been implicated in multiple-chemical sensitivity brought on by previous exposure to 
hydrophobic organic solvents or pesticides (Pall and Satterlee, 2001). Some CFS/ME 
patients, with high levels of sensitivity bordering on allergy, have been treated by Miller 
neutralisation. The latter involves provocation of the skin or sublingual mucosa followed by 
the administration of a neutralisation `vaccine' of individual allergens. It acts by 
stimulating the body to produce higher levels of detoxification enzymes, thus helping the 
body cope with the allergen (Miller, 1987). Enzyme-potentiated desensitisation (EPD) is 
another anti-allergy treatment that clinically has benefited many CFS/ME patients by 
actively adding enzymes to enhance the desensitising effect and is applied to a scratch in 
the skin or can be given by intradermal injection (Fell and Brostoff 1990). 
1.5.4 Hormonal imbalances 
Since the hypothalamus is the principal coordinator of hormonal secretion, hypothalamic 
dysfunction in CFS/ME, proposed in this thesis, will likely affect the entire endocrine 
system and thus one might find excesses or deficiencies in many hormonal levels in 
patients with this disease. Both raised (Scott and Dinan, 1999) and reduced (Kuratsune et 
al., 1998) levels of a precursor of the major sex hormones serum dehydroepiandrosterone 
16 
(DHEA-S), secreted from the adrenal glands, have been found in CFS/ME. As with many 
hormones, both high and low levels of melatonin, produced by the pineal gland, have been 
reported in a sample of patients with CFS/ME (Knook et al., 2000; Sterzl et al., 1998). 
Melatonin levels are found to be high when day-time drowsiness and excess sleep are 
reported. However when insomnia is a major symptom, supplements of melatonin are 
usually beneficial (Shepherd, 1998). 
Reduction of insulin-like growth factor (IGF-1), the main mediator of growth hormone 
effects, is also found in CFS/ME. Hypoglycaemia, often found in CFS/ME, stimulates the 
hypothalamus to reduce the growth hormone level (Allain et al., 1997). 
1.5.4.1 Corticotropin releasing hormone (CRH) 
Corticosteroids have immunosuppresssive, antiallergenic and anti-inflammatory effects. 
During the stress response increased levels of circulating cortisol ensure that several aspects 
of immune function are restrained (Ader et al., 1991). The restraining effect of 
corticosteroid on immune function is achieved via a negative feedback loop. They inhibit 
cytokine synthesis at a genetic level (Maier et al., 1994). This is associated with the 
inhibition of general functions such as growth, reproduction and thyroid function in 
response to stress (Black, 1994). 
Data from a number of studies suggests that both primary and secondary lymphoid tissues 
are innervated by the sympathetic nervous system. This is evidence of a direct neural link 
between the SNS and the immune system and suggests that activation of the sympathetic 
nervous system can directly influence immune cell function (Black, 1994). Activation of 
the SNS leads to increased catecholamine release, which is associated with increased 
leukocytosis, increased lymphopenia and reduces natural killer cell activity. There is also 
substantial evidence for neural connections between autonomic nuclei in the noradrenalin- 
producing locus coeruleus of the brain stem and the paraventricular nucleus of the 
hypothalamus. Indeed it has been shown that neurones in the locus coeruleus have receptors 
for CRH. The noradrenalin produced by noradrenergic neurones in the locus coeruleus and 
CRH participate in a positive feedback loop, with each system reinforcing the function of 
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the other (Sternberg et al., 1992) Glucocorticoids, ACTH, and CRH itself exert negative 
feedback controls on the production of CRH and noradrenalin. 
Corticotropin Releasing Hormone (CRH) and noradrenalin are thus thought to have a 
central role in precipitating the generalised stress response. Some studies indicate that 
neurotransmitters including acetylcholine, serotonin, and noradrenalin can mediate much of 
the neurogenic stimulation of CRH production (Black, 1994). Serotoninergic 
neurotransmission is activated in response to stress. It has also been shown that 
glucocorticoids can influence serotonin levels by altering receptor density or regulating 
synthesising enzymes (Herbert, 1997). The immune system has been shown via chemical 
mediators to have distant effects on the central nervous system, particularly the HPA axis, 
the limbic system and autonomic nuclei (Sternberg et al., 1992). The salivary cortisol 
response to awakening is used as a non-invasive test of the capacity of the HPA axis to 
respond to stress. Measuring salivary cortisol in 56 patients with CFS/ME comparing them 
with 35 healthy controls the HPA axis response to stress in CFS/ME was shown to be 
significantly impaired (Roberts et al., 2004). Even depression is sometimes associated with 
hypercortisolaemia and reduced serotoninergic function (Herbert, 1997). 
It has been proposed that CRH may be the key co-ordinator of the stress response in 
humans (Dunne and Berridge, 1990). These workers have shown that arousal pathways are 
activated in response to stressful external stimuli leading to activation of neurones in the 
paraventricular nucleus of the hypothalamus. Stimulation of CRH neurones leads to 
increased CRH release. It has been shown that psychological stress can upregulate the 
expression of CRH, thereby activating the HPA axis. 
There is growing evidence to suggest that the brain responds to stress through alterations in 
the expression of immediate-early genes in the hypothalamus, the brain stem, the amygdala, 
monoaminergic and autonomic nuclei (Herbert, 1997). In circumstances of repeated stress, 
patterns of gene expression can change. Herbert (1997) proposes that these immediate-early 
genes play a role in the regulation of the expression of later genes, which determine peptide 
synthesis and receptor expression. This may explain how stress can alter the levels of 
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neurotransmitters and can up or down-regulate receptors for hormones and 
neurotransmitters. Acute stress has been shown to be associated with increased levels of 
CRH produced by the hypothalamus and consequent increases in levels of ACTH and 
cortisol. Cortisol has important immunomodulatory effects, but it is only one of many 
immunomodulators. The production of all of the pituitary hormones is influenced by stress. 
Some are immunoinhibitory such as glucocorticoids and ACTH whilst others are 
immunostimulatory including growth hormone, prolactin, and CRH (Reichlin, 1993). The 
release of growth hormone and prolactin is initially activated during the stress response but 
this is later inhibited by alterations in the levels of neurotransmitters such as dopamine in 
the case of prolactin (Black, 1994). Data from a number of studies shows that exposure to 
recurrent or chronic stress can result in a lowering of growth hormone and prolactin levels. 
As immune cells contain receptors for these hormones, alterations in their levels are likely 
to have consequences for immune activity. Levels of dopamine and opioids, particularly 13- 
endorphins, increase during the generalised stress response. Immune cells have been shown 
to hold receptors for various neurotransmitters, neuropeptides and neurohormones. 
Noradrenalin can act at receptor sites on lymphocytes and macrophages inhibiting 
mitogenesis and complement activation, increasing the expression of cell surface antigens 
and antibody responses. The neuropeptide substance P can bind to receptors on 
lymphocytes enhancing lymphocyte migration to sites of inflammation, and lymphocyte 
production of IgA (Ader et al., 1995). 
1.5.4.2 Hormone therapy 
Since growth hormone deficiency leads to symptoms similar to those of CFS/ME, growth 
hormone has been used in the treatment of CFS/ME patients (Bennett et al., 1998), showing 
a significant reduction of symptoms after six months in the experimental group compared 
with the control group of patients treated with a placebo. However the improvement was 
short lived after therapy was discontinued. 
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1.5.5 Depression and anti-depressant treatments 
It has been stated that two out of three patients in primary care with CFS/ME have co- 
morbid psychiatric disorders (Wesseley, 1997), with major depression being partially 
common. 
Antidepressant drugs have been used for symptomatic relief in many non-psychiatric 
illnesses such as Parkinson's disease, multiple sclerosis, hypothyroidism and even in cases 
of brain tumours (Lynch et al., 1991). Likewise they can sometimes reduce the symptoms 
of CFS/ME (Lynch et al., 1991, Wilson et al., 1994). However symptomatic improvement 
occurs at much lower doses and more rapidly than in depression (Wilson et al., 1994, 
Natelson et al., 1996). 
In addition to the use of antidepressants to lessen the symptoms of anxiety and depression 
in CFS/ME they have been shown to alleviate sleep disturbances (Klonoff, 1992) and 
decrease pain perception. Occasionally symptoms of depression in CFS/ME may be severe 
enough to require antidepressant therapy (Lynch et al., 1991) which was shown to have a 
low placebo effect (Natelson et at., 1996). However the patients in these cases may have 
two distinct co-morbid conditions. 
Insomnia and hypersomnia have been validated via polysomnography techniques as 
symptoms of CFS/ME and not due to a co-morbid psychiatric condition (Stores et al., 
1998). Low doses of tricyclic antidepressants such as amitryptiline are frequently 
prescribed to aid a return to a normal sleeping pattern. Many patients with CFS/ME who 
find it difficult to `switch off' when trying to fall asleep are regularly advised to take 10 to 
25 mg of amitryptiline one hour before retiring to bed. This is significantly less than the 
normal dose of this mild tricyclic antidepressant, which when prescribed for 
anxiety/depression would normally be 75 mg twice a day. Many patients with CFS/ME 
cannot endure the effects of antidepressants, thus dropout rates from studies into 
antidepressant therapy in CFS/ME exceed those of patients with depression (Natelson 
1996; Vercoulen et al., 1996). 
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1.5.6 The role of toxins in the pathogenesis of CFS/ME 
The term toxin was originally coined in the late nineteenth century and is defined as an 
antigenic poison or venom of plant or animal origin, especially one produced or derived 
from micro-organisms and causing disease when present at low concentrations in the body 
(The New Oxford Dictionary of English, 2001). To allow semantic simplicity "toxin" is 
used in this work in the broader sense of any substance harmful to the body. For instance 
mercury, which is a heavy metal toxin, is neither from plant or animal source but it still is a 
major "toxin" to the body. 
This section will review evidence that CFS/ME is one of many syndromes which can be 
caused by the breakdown in the detoxifying mechanisms in the body especially within the 
central nervous system. Further references will present evidence supporting the hypothesis 
that impairment of drainage of toxins via the CSF-lymphatic pathway from the neuraxis 
(Cserr and Knopf, 1992) is a major factor in the pathogenesis of this disorder. 
1.5.6.1 Pollutants 
Environmental pollutants have long been seen as predominant aetiological factors in 
neurodegenerative disease, although there are also very probably genetically determined 
susceptibilities ( Johnson, Hodge and Duvoisin, 1990) Studies have revealed major 
variations in individual ability to detoxify noxious agents and shown that neurological 
disease may derive from an exceptional vulnerability to certain neurotoxins from both 
external sources in the environment and from toxic free radicals and/or excitatory amino 
acids normally found within the central nervous system (Caine et al., 1992. ) 
Over 60,000 chemicals were identified in the 1990's as known or potential toxic substances 
by the United States environmental protection agency (Veronesi, 1992). The U. S. 
Government Office of Technology estimated that up to 25% of all chemicals may be 
neurotoxic (Tilson and Mitchell, 1992). Each year approximately 1000 new chemicals are 
produced and no matter what safety procedures are taken they all are inadvertently or 
deliberately introduced into the environment via air or water or in our food (Sabljic et al., 
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1991). There are 8 basic sources of toxic exposure and most of the following have been 
implicated as potential aetiological factors of CFS/ME: 
1. Air Pollutants (indoor and outdoor) such as benzene and chloroform. These may 
originate from domestic fires: e. g. CFCs, PCBs or automobile-related activities: e. g. carbon 
monoxide and toluene and obviously in tobacco smoke: e. g. nicotine 
2. Food Contaminants and Additives: e. g. caffeine and saccharin. 
3. Water Pollutants: e. g. chlordane and toluene. Most water supplies contain toxic amounts 
of heavy metals e. g. mercury and aluminium (Gardner and Comber, 2003; Kazantis, 2002) 
4. Soil Contaminants: e. g. lindane some of which may arise from domestic garden and lawn 
activities: e. g. aldrin and dieldrin, including pesticides such as DDT and other 
organophosphates. 
5. Hobbies and Crafts: e. g. formaldehyde; trichloroethane. 
6. Household Activities: e. g. ammonia; fluoride. 
7. Accidental Spills: e. g. truck accidents or pipeline ruptures. 
8. Workplace contaminants such as solvents or radioactive substances. 
Toxic chemical exposure can cause many serious conditions including cardiovascular, 
kidney or endocrine diseases, depression and even psychosis (Rea, 1993). Many different 
neurotoxins have been implicated in the pathogenesis of CFS/ME including 
organophosphates and mercury (Gimenez et al., 1999). As early as 1961 chronic fatigue 
was seen as a major symptom following chronic exposure to organophosphates (Gershon 
and Shaw, 1961), so it is of no surprise that levels of serum organochlorides have been 
found to be higher in CFS/ME patients compared with normal subjects (Dunstan et al., 
1995). Aerosol propellants found in hair spray, deodorants and spray paints contain high 
levels of methylene chloride which when inhaled affects the brain and liver causing 
symptoms such as fatigue, lethargy, headaches and chest pain. Analysis of the breath in 
residents in a New Jersey suburb revealed traces of many toxic compounds including 
chloroform, benzene, carbon tetrachloride, trichlorethane and many other harmful 
pollutants (Wallace et al., 1986). 
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1.5.6.2 Effects of neurotoxins 
The most common organ affected by toxins is the brain leading to fatigue, exhaustion, 
cognitive impairment, loss of memory, insomnia and sleep apnea and other disturbing 
symptoms (Rogers, 1990). As mentioned above, toxic chemical exposure can cause many 
serious conditions including cardiovascular, kidney or endocrine diseases, depression and 
even psychosis (Rea, 1993). 
There are several specialised regions of the brain's ventricular system, termed 
circumventricular organs, which interact closely with the CSF. These zones, for example 
the area postrema in the fourth ventricle, are chemical sensitive regions that may react with 
toxins sending messages to other parts of the brain. One important circumventricular organ 
is the cup-shaped lamina terminalis situated at the rostral end of the third ventricle 
projecting around the ventricle into the hypothalamus. In inflammatory or infective 
disorders cytokines such as IL-1 have been shown to pass through to the hypothalamus via 
the lamina terminalis raising the body's temperature. Also, one of the most permeable 
regions of the blood brain barrier is at the hypothalamus facilitating its ability to the 
monitor hormone level in blood. This increased permeability also makes the hypothalamus 
one of the most prone regions in the brain to suffer a toxic insult. 
In the central nervous system there are several populations of electrically inexcitable cells 
that are known collectively as glia. Since glia are highly interactive with neurones they are 
potentially critical as targets and mediators of neurotoxicity, (Lopachin and Aschner, 1993). 
The class of glial cells termed astrocytes are capable of phagocytic activity (Iacono, et al., 
1991; Lindo, et al., 1993; Noske, et al., 1982) as are microglia (Perry and Gordon, 1988). 
This capacity is involved in the remodelling of synapses during development but also may 
be used for engulfing foreign material and is essential in the brain's defence against 
neurotoxins. Glia are also known to produce and respond to cytokines and related 
molecules (Morganti-Kossman, et al., 1992; McMillan, et al., 1994). Certain cytokines, 
such as IL-1 and INF-y, stimulate astrocytes to proliferate and release further cytokines 
(Benveniste, 1993; Suzumura, et al., 1993; Yong, 1992). Others may have down-regulatory 
effects: for example, Lindholm and colleagues (1992) have demonstrated that transforming 
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growth factor-B1 can inhibit astrocyte proliferation as well as simultaneously increasing 
secretion of nerve growth factor (Sawada, et al., 1993). 
Clinically CFS/ME resembles the symptoms of chronic ciguatera fish poisoning (CCFP). 
These similarities suggested the exploration of lipids in sera of CFS/ME, CCFP, and other 
diseases with the membrane immunobead assay (MIA), which is typically used for 
screening ciguateric ocean fish. In a recent study using the MIA to examine lipids in sera 
of CFS/ME, 95.6% of the patient group had greater or equal to 1: 40 titre with a significant 
increase (P<0.001) in chronic phase lipids (CPLs) relative to a healthy normal group 
(Hokama et al., 2003). 
Autonomic dysfunction has long been associated with many toxic substances especially 
following exposure to organic solvents, with some exhibiting symptoms of peripheral 
neuropathy (Matikainen. and Juntunen, 1985). 
Under normal conditions, the blood-brain barrier protects the CNS from rapid fluctuations 
in levels of ions, neurotransmitters, bacterial toxins, growth factors and other substances. 
The permeability of the blood-brain barrier to the acetylcholinestease inhibitor 
pyridostigmine has been shown to be enhanced by stress (Hanin, 1996). 
Each organ or tissue may act as a discrete target for some toxic substances which may lead 
to dysfunction of the whole organism. Specific molecules within a particular cell type act as 
primary targets. Neurotoxicology is extremely complicated due to the diverse nature of its 
cellular and biochemical composition (Cookson, 1995). For example, biochemical 
specialisations of differentiated neurons lead to varied susceptibility to neurotoxicants. 
Some neurons are less susceptible to toxic damage (e. g., serotonergic neurons) leading to 
regions of the brain that are not as sensitive to toxins (Langston et al., 1983). Dopaminergic 
neurons, conversely, are particularly sensitive especially to the toxicant MPTP (1-Methyl- 
4-phenyl-1,2,3,6-tetrahydropyridinium). This leads to a loss of neuronal function in the 
substantia nigra, where these neurons are concentrated, leading to Parkinsonism 
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(O'Callaghan, 1991). Inhibition of mitochondrial oxidation, resulting in ATP depletion, has 
been found after toxic exposure to MPTP in Parkinson's disease (Langston et al., 1983). 
An increase of choline has been found in the occipital cortex of CFS/ME sufferers (Puri, et 
al., 2002). Excess breakdown in acetylcholine could lead to high levels of choline in the 
brain. Organophosphates irreversibly inhibit the action of acetyl-cholinesterases at 
muscarinic and nicotinic synapses leading to a surplus of acetylcholine (Ellenhorn, 1997). 
Cholinergic dysfunction has been suggested as a primary aetiology in CFS/ME. A 
hyperactive peripheral cholinergic vascular response, vascular endothelial cell dysfunction, 
chronic inflammation and apoptosis have been noted in organophosphate exposed patients 
and patients who served in the first Gulf War (Spence et al., 2000). 
1.5.6.3 Mercury poisoning 
The doses of neurotoxins required to produce behavioural and or sensory dysfunctions are 
low and may also be cumulative, such as with methylmercury exposure in adult humans 
(Weiss, 1988). The nervous system may also be particularly vulnerable during 
development. Toxicants such as ethanol may exert greatest effect in utero whilst others, 
such as lead, produce IQ defects in children (Needleman et al., 1990). It has also been 
suggested that heavy metal toxins pass through to the infant via ingested mother's milk and 
that higher concentrations of toxicity transfer to the older child particularly the firstborn if 
breast-fed (Drasch et al., 1998; Drasch and Roider, 1995; Drasch et al., 1994). 
Mercury has been implicated as a major heavy metal neurotoxin to affect the body leading 
to neurological dysfunction and oxidative stress (Sarafian and Verity, 1991). A primary 
source of mercury poisoning is the amalgam in dental fillings (Mutter et al., 2004). Heavy 
metals also transfer from expectant mothers to their children, with first born being more 
affected by this "dumping ground" of mercury (Drasch and Roider, 1995). 
Mercury is also present in the preservative thiomersal, a major component of vaccinations. 
Long before the questions raised by MMR, various vaccinations have been implicated as 
25 
aetiological factors of CFS/ME. Aluminium has been also shown, like mercury, to exert 
neuro-toxic effects (Garrel et al., 1994). 
1.5.6.4 Diet and toxicity 
Exposure to chemicals will affect people in different ways depending on the status of 
several factors. Diet plays a pivotal role in the body's ability to withstand toxicity. Toxins 
can be produced from non-toxic foods that we eat, building up in the central nervous 
system, liver or kidneys. Sugar may not be broken down correctly when energy is required 
leading to brain and muscle fatigue and many other symptoms. 
Trace elements often used as supplements for prompting good health may become toxic if 
ingested in too high a dose. Selenium may be taken up from the soil by certain plants such 
as species of the Astralagus genus in sufficient quantities to render them toxic. Chronic 
selenium poisoning in animals, known as Alkali Disease, leads to livestock presenting with 
lameness, depressed appetite, lack of vitality, hair loss and emaciation (Witte et al., 1993). 
Healthy food may not be properly digested or absorbed. A leaky gut due to the insult of the 
intestinal wall may be present leading to semi-digested food entering the blood stream 
causing immune responses propagating further toxicity. This has been the focus of recent 
interest (Schwarz et al., 1999; White, 2003). 
Damage of the lining of the alimentary canal may be caused by a variety of irritants, most 
common being alcohol, aspirin, gluten and Candida albicans (Burke and Gracey 1980). 
Deficiencies in some vitamins, proteins, essential fatty acids and minerals are also known 
to lead to poor intestinal cell growth causing increased permeability of the gut wall 
(Schumann, 2001). 
1.5.6.5 Vaccinations and Gulf War syndrome 
Vaccines are clearly associated with Gulf War Syndrome/illness which shares many similar 
symptoms with CFS/ME (Hotopf et al., 2000; Shaheen, 2000). Central as well as peripheral 
nervous system dysfunction occurred in veterans of the first Gulf War (GWVs) who were 
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exposed to both chemical and severe psychological war stresses (Hooper, 1999; Nicolson, 
1998). However environmental factors could be responsible for some of the complaints of 
GWVs (Haley and Kurt, 1997). Exposure to pesticides (particularly organophosphates), oil 
and smoke from the oil well fires, depleted uranium, chemical weapons, as well as 
vaccines, could all have contributed to the many cases of acute and chronic respiratory 
illnesses reported in GWVs. In fact as many as 70% of those receiving two or more 
vaccines given simultaneously during deployment showed symptoms of acute or chronic 
respiratory illnesses. The war to free Kuwait from the invading forces of Iraq has been 
described as the most toxic war in Western Military History, with at least 14% of US 
GWVs fulfilling the CDC criteria of chronic fatigue syndrome (Hooper, 2000). 
A further important conclusion from research on GWVs is that post-traumatic stress 
disorder is not a major factor and any soldiers diagnosed with this psychological disorder 
were mostly ill before deployment at the time when vaccinations were at their highest level. 
In fact occurrences of post-traumatic stress disorder lessened during deployment. This 
throws doubt on any suggestion that GWVs are simply suffering from a psychiatric War 
Syndrome (Unwin et al., 1999; Ismail et al., 1999; Jones and Wessley, 1999; Hyams et al., 
1996) 
Other studies offer further evidence of vaccination linked toxicity found in GWVs. 
Mycoplasma infections were three times more likely to occur in non deployed vaccinated 
GWVs than in veterans not vaccinated (Steele, 2000). It was hypothesised by the 
researchers that gene-modified Mycoplasma could have come from an experimental HIV 
vaccine or from a biological weapon leading to extensive contamination of Coalition 
Forces. Mycoplasmas have the potential to act as super-antigens thereby triggering a range 
of autoimmune diseases. The transmission to other family members has been demonstrated 
to involve Mycoplasma. Autism and Autism-related Disorders have been found in children 
born to GWVs. Also many family members of GWVs have been diagnosed as suffering 
from CFS/ME with over 50% giving a positive result when tested for any species of 
Mycoplasma, with Mycoplasma fermentans being the most commonly found (Nicolson et 
al., 2000). 
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1.5.6.6 Radiation 
In the present era we are exposed to invisible agents as well as the more discernible. 
Radiation exposure can cause release of a range of toxic compounds in the damaged tissue. 
A survey on 11,000 Norwegians and Swedes found that many were suffering headaches 
and fatigue from using mobile phones. Risk of brain tumours in the temporal lobe has been 
shown to be increased by the use of the analogue cellular mobile phones on the same side 
as the tumour (Hardell et al., 2002). Scientists working for the Radiation and Nuclear 
Safety Authority in Finland have found that exposing humans to one hour of mobile phone 
radiation affected the integrity of the blood-brain barrier leading to larger toxic molecules 
passing into the CSF, with the potential of causing damage to brain tissue (Leszczynski, 
2001). 
1.5.6.7 Predisposition to toxicity 
Previous exposure of toxins will increase the sensitivity to further toxic insult. Genetically 
some people have a greater ability to detoxify and, unfortunately, some are much more 
likely to have worse symptoms from toxic causes due to hereditary predisposition. 
Likewise prior state of health, with emphasis on the immune system, will be a major 
significant factor to consider when assessing ability to withstand exposure to poisonous 
chemicals. Age is obviously important, with children much more susceptible to toxic 
overload than an adult, hence the smaller dosages of prescribed medicine allowed to 
children (Jett et al., 1997). 
Several toxic chemicals of low-molecular weight have the potential to induce autoimmune 
diseases such as Systemic Lupus Erythematosus (SLE) (Kammuller, et al., 1989, Rogers, 
1990; Tilson and Mitchell, 1992; Offit et al., 2004). This adds support to the theory of Itoh 
et al. (1999) which proposes that the immune system changes in CFS/ME are likely to 
render individuals prone to autoimmune attack. Genetic susceptibilities for immune 
expression have been discovered in diseases such as autoimmune hepatitis (Czaj a and 
Donaldson, 2000) which may also be important determinants of susceptibility for a disease 
such as CFS/ME. 
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1.5.7 Diet and dietary therapies 
1.5.7.1 Supplements 
Many CFS/ME patients suffer from food intolerances. Dietary interventions involving low 
carbohydrate, gluten and yeast have been proposed. However, nutritionists at Harvard 
Medical School found that there is no clinical scientific research evidence to substantiate 
claims about the appropriateness and efficacy of various dietary approaches (Moriss and 
Stare, 1993). Vitamin and mineral supplements are widely recommended in the treatment 
of CFS/ME but there is no evidence that megadoses of vitamins and minerals will relieve 
any of the CFS/ME symptoms for which they are promoted. However the antioxidant 
action of vitamin C does improve the body's immune response. With patients taking no 
more than 500mg per day there have been no reported toxic side effects (see also section 
1.58). Similarly the vitamin B group is known to aid the health of the nervous system. 
Functional deficiencies of the B vitamins pyridoxine, riboflavin and thiamine has been 
shown to occur in CFS/ME (Heap et al., 1999) and thus patients are often advised to take 
one full and complete Vitamin B complex pill per day as long as no complications are 
reported. 
Magnesium deficiency is associated with disorders of neuromuscular and psychiatric 
functioning. It also results in an inability to cope with viral infections (Werbach, 1998). In a 
randomised controlled trial of magnesium treatment in CFS/ME, Cox and colleagues 
(1991) found that the 20 patients they studied had significantly lower red blood cell 
magnesium levels compared with healthy controls. Werbach (1998) recommended taking a 
combination of magnesium and malic acid to aid production of ATP. The benefits of 
magnesium for CFS/ME were refuted in another paper (Russell et al., 1995). Rude et al. 
(2004) found that in magnesium deficient rats, there were increases in the concentrations of 
proinflammatory cytokines and substance P. Also chronic stress and the associated 
enhanced catecholamine release can result in magnesium deficiency. 
Deficiency of sodium can produce similar symptoms to CFS/ME and is associated with 
neurally mediated hypotension, which occurs frequently in CFS/ME (Werbach, 1998). 
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However the increase in salt intake that is occasionally advised may pose extreme danger 
for the many CFS/ME patients who suffer from concurrent hypertension. 
Essential fatty acids are used in oxidative phosphorylation in the mitochondria of muscle 
and in neuronal metabolic processes. Disordered metabolism of fatty acids may play a role 
in CFS/ME, with patients receiving Efamol Marine showing significant improvement 
(Behan et al., 1990). 
1.5.7.2 Elimination and avoidance diets 
Infection with the yeast Candida albicans can cause a chronic candidiasis hypersensitivity 
syndrome (CCHS) (Crook, 1984). Renfro and co-workers (1989) noted that the 'yeast 
connection' is frequently a condition that is self-diagnosed on the basis of having typical 
symptoms and a history of frequent yeast infections and multiple courses of antibiotics. 
Diets are available to eliminate the yeast Candida albicans by avoidance of foods on which 
Candida thrives. Low sugar diets are recommended as a means of combating Candida 
overgrowth, as yeast requires sugar for metabolism. There is no scientific evidence that 
such regimes actually control Candida overgrowth and these diets are nutritionally 
unbalanced which if followed for longer than 2-3 months could result in long-term 
nutritional deficiencies that may impair recovery. 
1.5.7.3 NADH 
Upregulation of the enzyme RNAseL and 2'-5' A synthetase has been observed which 
could lead to reduced levels of cellular ATP resulting in physical and cognitive fatigue. 
Depletion of ATP has been improved by supplementation with NADH (the reduced form of 
nicotinamide adenine dinucleotide) enhancing energy production at the cellular level 
(Forsyth et al., 1999). 
1.5.7.4 L-Carnitine 
Histological and biochemical muscle abnormalities have been reported in some patients 
with CFS (Behan and Behan, 1988) and specifically mitochondrial abnormalities have been 
noted in a number of studies (Kuratsune et al., 1994). L-carnitine is a product of two of the 
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essential amino acids that the body cannot produce on its own: lysine and methionine. L- 
carnitine is often referred to as a vitamin-like molecule because it is synthesized in the liver 
and kidneys from the amino acid lysine and other nutrients. At a basic cellular level, L- 
carnitine plays a critical role in the metabolism of fat, contributing to the oxidation of fatty 
acids and transporting long-chain fatty acids to the place in the cells (mitochondria) where 
they are processed to help provide energy, among other things. It is possible that L- 
carnitine deficiency could contribute to skeletal muscle symptoms. 
L-camitine levels are very difficult to measure and thus most studies focus on the derivative 
acylcarnitine. Periods of recovery from generalised fatigue were found to be associated 
with increases in serum acylcarnitine levels in the patients studied in a trial of L-carnitine 
therapy with CFS/ME (Plioplys and Plioplys, 1995). 
1.5.8 Oxidative stress 
Oxidative stress has been acknowledged as a common feature in many disease processes 
including CFS/ME. Oxidative stress may induce many of the symptoms of CFS/ME. 
Excessive production of the free radical nitric oxide could induce vascular, neurological, 
immunological, and muscular effects. Nitric oxide can be released in cells of the central 
nervous system which exerts neurotoxic effects by over-stimulating glutamate receptors 
(Reichlin, 1993). A free radical is a highly unstable and reactive molecule due to the loss of 
an electron from the shared covalent outer ring. It will damage the healthy tissue by trying 
to obtain another electron from an adjacent molecule. Oxygen reacts with free radicals to 
form peroxidised radicals which further insult healthy molecules. Oxidative stress increases 
free radical production leading to further cell damage and worsening toxicity. External 
factors such as environmental pollutants and radiation also can lead to major free radical 
production. Overall nitric oxide synthesis is increased in CFS/ME and may be induced by 
inflammatory cytokines (Pall, 2000). The neurotoxic affect is further aggravated by 
amplified sensitivity due to increased nitric oxide stimulation of the neurotransmitter 
glutamate (Pall and Saterlee, 2001). 
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The free radical nitric oxide has a positive function in aiding leukocytes to kill invading 
pathogens and also aids vascular tone. The most common free radical naturally produced 
in the body is superoxide derived from oxidative phosphorylation of glucose in the 
mitochondria. Tissue inflammation (via the Haber-Weiss reaction) leads to free ion 
converting superoxide into highly toxic hydroxyl free radical. 
Antioxidants convert free radicals back to healthy molecules again. Antioxidants such as 
vitamin C have been shown to be major combatants to fight disease ever since the 1950's 
when Harman discovered the role of free radicals (Harman, 1956). The rationale for 
vitamin C infusion in CFS/ME rests on the use of megadose vitamin C infusion treatments 
traditionally in autoimmune disease, allergy and a range of other conditions (Kodama et al., 
1996). 
Multiple chemical sensitivity, together with raised nitric oxide, plus an increase in blood- 
brain barrier permeability and gut wall permeability will lead to a group of patients with an 
inability to prevent toxic overload within the neuraxis. Furthermore they lead to an inability 
to cope with the toxins. 
The results of recent research confirm that the immune system is activated in CFS/ME and 
may offer a future pathological differential diagnostic test between CFS/ME and 
depression. In a controlled study examining peripheral blood mononuclear cells, 
concentrations of beta-endorphin, an endogenous opioid involved in regulation of the 
immune system function, were found to be significantly lower in patients with chronic 
fatigue syndrome than in normal subjects and depressed patients (p <0.001 and p <0.01, 
respectively). Also they were significantly higher in depressed patients than in controls (p 
<0.01) (Panerai et al., 2002). 
1.5.9 Other treatment protocols 
Numerous treatment strategies have been suggested for CFS/ME over the last few decades 
with most involving some pharmacological intervention. Yet it is interesting that the 
majority of successful trials have been non-drug based, namely graded exercise therapy 
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(Fulcher and White, 1997 and 2000), pacing (Hutchinson et al., 2002), cognitive 
behavioural therapy (CBT) (Deale et al., 1996) and osteopathic treatment (Perrin et al., 
1998). Graded exercise has been shown to improve the patient's performance when 
substituting activities that exacerbated stress levels with more relaxed, mood enhancing 
activities (Friedberg, 2002). A recent trial demonstrated good outcomes after 1 year for 
patients with CFS/ME who received an educational intervention designed to encourage 
graded activity. Benefits of the intervention were maintained at 2 years. Delayed treatment 
is associated with reduced efficacy and requires more intensive therapy (Powell et al., 
2004). As with graded exercise, pacing and CBT techniques probably help improve the 
symptoms in that they reduce the physical or psychological stress on the body's 
sympathetic nervous system 
1.5.9.1 Graded activity 
Many in the psychological "camp" believe that patients with CFS/ME perceive greater 
fatigue during exercise as a result of the interaction of psychological distress, physical de- 
conditioning and/ or sleep disturbance. Most psychiatrists believe that the patient's fear of 
worsening their symptoms may lead to reducing their activity and that the resultant physical 
deconditioning can spiral into chronic disability which further leads to adverse 
psychological effects. The rationale of graded activity is to circumvent total inactivity and 
counter this fear-avoidance and de-conditioning by the introduction of a gentle increase in 
activity to pre-morbid levels. The patients are expected to follow the prescribed exercises 
irrespective of any worsening in the symptoms and to combat this "perceived" fatigue and 
recovery from exertion which differs from patient to patient (Paul et al., 1999). 
The idea of graded exercise seems unsuitable, if not abhorrent, to some patients who are 
struggling just to achieve basic activity at work or home. There is a ceiling, above which 
activity is counterproductive in many cases (Shepherd, 1998). Friedberg and Jason (2001) 
advise exercise on an individual patient-by patient basis whilst many clinicians do not 
recommend it (Shepherd, 1998). However, significant improvement in functional capacity 
was noted in a year long study involving a graded exercise regime. Unfortunately, nearly 
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half of the patients studied were taking antidepressants throughout the trial which questions 
the validity of this study (Fulcher and White, 1997). 
1.5.9.2 Cognitive behavioural therapy 
The effectiveness of Cognitive Behavioural Therapy (CBT) in the treatment of CFS/ME 
has been comprehensively reviewed. It has been shown to be more effective when delivered 
by properly trained clinicians in specialised clinics (Reid et al., 2000). Distorted thought 
patterns may lead to anxiety and depression. CBT is based on the supposition that 
psychological factors are maintaining CFS/ME in all patients (Blenkiron et al., 1999). 
Such factors may include faulty beliefs, ineffective coping behaviour or negative mood 
states (Sharpe, 1996). It is the author's belief that the depression and anxiety are secondary 
to CFS/ME. This creates a sense of frustration in the patient who also feels a terrible burden 
on family and friends. This may be exacerbated by reactions of people including health care 
providers who refuse to acknowledge the existence of CFS/ME. CBT may help the patient 
with these secondary feelings of guilt and worthlessness. 
In a randomised study fulfilling the Oxford criteria, patients receiving CBT were 
functionally improved, but many reported continuing fatigue (Sharpe et al., 1996). 
However, in a separate study, patients in the CBT group demonstrated significant 
improvements in physical functioning and substantial reductions in fatigue (Deale et al., 
2000). Some patients in the latter study had a current psychiatric diagnosis and others were 
receiving additional antidepressant therapy. In most of the British studies into the efficacy 
of CBT and graded exercise, the inclusion criteria require that patients fulfil the Oxford 
criteria for CFS/ME. It has been suggested that the Oxford criteria and the original CDC 
criteria may select patients with two distinct clinical entities and in many trials using the 
Oxford, also known as the UK criteria, the patients studied may in fact have had a high 
frequency of psychiatric co-morbidity (Baschetti, 1998). 
It is most probable that CFS/ME patients who have difficulty in coping with their illness 
will benefit from CBT. Like other chronic illnesses, positive coping strategies and lifestyle 
management approaches may be of significant benefit to the depression and anxiety levels 
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although there is little evidence that CBT has a significant effect on other symptoms of the 
illness. It is interesting that when the research patients were diagnosed using the Australian 
criteria, which excludes psychiatric diagnosis, few differences were noted between the CBT 
treatment group and the controls (Lloyd et al., 1993). 
Avoiding exercise due to a belief that it will exacerbate symptoms has been held 
responsible for maintaining symptoms in CFS/ME patients (Silver et al., 2002). However, 
this thesis will show that there is a significant improvement when patients are advised to 
avoid too much activity and only carry out 50% of their perceived capabilities. 
Psychiatrists in one study acknowledged that the lack of illness legitimization ranked high 
as a source of dissatisfaction for CFS/ME patients, and they suggested it may aggravate the 
psychiatric condition. In the same study they agreed that the symptoms improved if 
CFS/ME patients stayed within what they felt to be their physical limits. The psychiatrists 
felt that the improvement was not due to a reduction in physical strain. They believed the 
progress was due to the patient's "psychosis" being improved by sense of control over their 
symptoms (Lehman et al., 2002). This is despite a recent study into sets of twins one with 
chronic fatigue compared to their unaffected co-twin, which showed that levels of fatigue 
affect physical functioning (Herell et al., 2002). 
1.5.9.3 Hypnosis 
Hypnosis has been tested in a pilot study involving 3 patients with CFS. Patients reported 
that hypnosis helped in muscle pain management both at rest and after exertion with a 
slight improvement in quality of life, but there was no increase in cognitive ability 
(Gregg, 1997). 
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1.5.9.4 Osteopathy 
Another recent treatment pioneered by the author has involved a bio-mechanical 
procedure. This was originally based on the observation of a high incidence of thoracic 
spinal dysfunction in the CFS/ME patients presenting at the author's practice between 
1989 and 1991, all sharing similar structural dysfunctions. Six such cases are described 
below. 
Case 1 
Sex: Female 
Age: 41 
Occupation: Housewife, ex-typist 
Status: Married, Multiparous 
Diagnosed by GP 
CFS/ME Symptoms began after moving house in the previous year. 
Prior aches in low back for a few years. 
On examination her dorsal spine presented with a rotational torsion with flatness in the 
upper part of her dorsal spine, and accentuated kyphosis at the cervico-dorsal junction (Fig. 
1A and B). 
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Figure 1 Case 1 demonstrating rotation and flatness of mid thoracic spine 
Photo A. shows the rotational torsion occurring in a CFS patient's dorsal spine. Photo B. 
shows flatness in the upper part of her dorsal spine, and accentuated kyphosis at the 
cervico-dorsal junction. The postural problems in the patient are compared with the normal 
curvature of a healthy subject seen in photos C and D. 
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Case 2. 
Sex: Female 
Age: 21 
Occupation: Student of occupational therapy. 
Status: Single, Nulliparous 
Aches in shoulder and upper back. 
Diagnosed by consultant physician in one year prior to initial consultation. 
This student was not too severely affected by the CFS/ME and was still able to attend 
college. There were no severe curves in this patient's spine which may explain partially 
why her symptoms were not intense. On examination a minor scoliosis was detected in the 
patient's thoracic spine with a characteristic flatness in the mid-thoracic of her spine rather 
than the normal convex curve we would expect as shown in Fig. 2A. 
r B. 
Figure 2 Case 2 further illustrating flatness and rotation of mid dorsals 
Photo A. demonstrates minor scoliosis in the patient's thoracic spine. The two arrows 
pointing towards the spinal column show a lordotic region of her spine rather than the 
normal convex curve we would expect to find at this region. The postural disturbances seen 
are compared to a normal posture in a healthy subject seen in photo B. 
38 
ý: 
Case 3 
Sex: Female 
Age: 70 
Occupation: Housewife, Multiparous 
Status: Married 
Diagnosed by GP 
Suffered for many years with severe pain throughout her body, particularly her back, head 
and neck. She also suffered with dryness in her eyes and mouth due to a problem with tear 
and saliva production. This may be due to the disturbance of the sympathetic control of the 
tear and salivary glands. This patient suffers with degeneration of her spine partly due to 
her age. There is a kypho-scoliosis in the mid and upper parts of the dorsal spine, where the 
vertebrae are fused and there is no joint movement whatsoever (see Fig. 3A). 
A. B. 
Figure 3 Case 3 Spondylitis seen in severe long term sufferer of CFS/ME 
Photo A. shows the fusion that has taken place in the patient's thoracic spine due to marked 
spondylotic changes that have taken place concurrently with over two decades of severe 
symptoms of CFS/ME. The postural disturbances contrast greatly from a normal s-shaped 
curvature in a healthy spine seen in photo B. 
39 
Case 4. 
Sex: Female 
Age: 24 
Occupation: Occupational therapist 
Status: Single, Nulliparous 
Road Traffic Accident in May 1992, CFS/ME Symptoms began in July 1992. 
Diagnosed by her GP. 
On examination there was the familiar flattening of the mid thoracic spine. A slight 
scoliosis of the whole thoracic spine was also noted with a concavity on the left (see Fig. 
4A). 
Figure 4 Case 4 showing a flattened mid thoracic spine 
Photo A. on the left shows the familiar flattening of the mid thoracic spine seen in many 
CFS/ME patients. This differs from a normal spinal posture in the healthy subject on the 
right. 
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Case 5. 
Sex: Male 
Age: 36 
Occupation: Shop Manager 
Status: Married with young family. 
Diagnosed by GP. 
Throughout his treatment he managed to stay at work and run his business. As the 
photograph Fig. 5A indicates, there are no severe curves in this patient's spine, which may 
explain partially why his symptoms were not intense. The arrows yet again demonstrate a 
recognisable flatness in the thoracic spine. 
Figure 5 Photograph showing a male patient with a loss of mid thoracic kyphosis 
In photo A. on the left arrows indicate a flatness in the mid thoracic spine compared with 
photo B. of a straight and healthy spine 
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Case 6 
Sex: Female 
Age: 30 
Occupation: Credit Controller, clerical work. 
Status: Single, Nulliparous 
Onset of back pain 1986. 
CFS/ME symptoms began seven years later, nine years previous to initial consultation. 
Diagnosed By Consultant 
On examination the patient presented with a noticeable side bending of the thoracic spine to 
the right with apparent rotation to the left (Fig. 6A). As with other CFS/ME patients seen 
by the author, the intense chronic symptoms of this lady seemed to mirror the severity of 
the postural and mechanical dysfunction. 
A. 
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Figure 6 Case 6 illustrating scoliotic thoracic spine 
Photo A. shows a CFS/ME patient with noticeable side bending of the thoracic spine to the 
right with apparent rotation to the left. The scoliosis contrasts with the straight healthy 
spine in photo B. 
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The above cases are just six of the hundreds of CFS/ME patients examined and treated by 
the author over the last fifteen years. A sample of thirty nine of these patients, from the 
author's first three years treating this disorder, are reviewed by the author in section 2.1 to 
summarise common biomechanical findings. The emphasis on biomechanical dysfunction 
in CFS/ME is central to this thesis and is reviewed thoroughly in the following chapters. 
Many patients suffering from a range of disorders may develop one or more of the 
symptoms reviewed in the previous sections, yet not develop CFS/ME. In addition, many 
of the above treatment methods have focussed on single therapeutic approaches, although it 
would seem logical that no mode, in isolation, would be completely beneficial in an illness 
that has multiple symptoms involving many body systems (Gantz and Holmes, 1989). 
From the review of the literature summarised in this chapter, a major problem exists with 
the treatment strategies and arguments over the exact aetiology of this most complex 
disorder. There has been the tendency to search for one cause, one stressor or one virus, 
which may provide a common link. Each time different research teams around the globe 
conclude that they have found the definitive blood test or the common pathophysiological 
mechanism, they ignore the fact that many perfectly healthy people who do not display 
symptoms of CFS/ME may be suffering from the same suspect virus, or are atopic and 
sensitive to all types of allergens. Likewise people suffer many stressors which may lead to 
suffering from depression and anxiety without any other symptoms of CFS/ME. Alternative 
questions scientists, psychiatrists, immunologists and endocrinologists could be asking are: 
a. Why do CFS/ME patients not just have straightforward diagnosable diseases rather than 
a complex array of signs and symptoms? 
b. Is there a common factor that could be affecting all sufferers? 
Some authors have chosen to subdivide patients into different groups and claim that there 
are many diverse types of CFS/ME. There are other scientists who have reached a 
compromise in classifying CFS/ME. They have recognised that the disease can be viewed 
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as a complex of psychological, neurological and immunological dysfunction. Glaser and 
Kiecolt-Glaser (1998) proposed that CFS/ME is a psycho-neuroimmunological disorder 
with a number of stressors affecting communication between the nervous system, the 
endocrine system and the immune system. 
1.6 Aims of the study 
This thesis examines certain physiological and anatomical parameters which to date do not 
appear to have been identified as having a potentially important role in the development of 
CFS/ME. The primary aims of the study are to investigate the theory that this disease may 
be associated with a biomechanical disorder affecting principally the lymphatic drainage of 
the neuraxis via the cerebrospinal fluid (CSF), and to also demonstrate the benefit of a 
chosen method of osteopathic treatment in reducing the main symptoms associated with 
CFS/ME. 
1.6.1 Research objectives 
The objectives of this research are: 
1 To determine the strength of correlation between the mechanical dysfunction of the 
spine, and the incidence of the symptoms arising from CFS/ME. 
2 To test if a chosen method of osteopathic treatment reduces symptoms associated with 
CFS/ME compared with those of a matched control group, who receives no such 
treatment. 
3 To reveal the sustainability of any improvement by a year follow up study and to 
investigate the likely repeatability of the initial study thus strengthening the argument of 
a relationship between the set osteopathic procedure and the improvement in symptoms 
associated with CFS/ME. 
4 To determine if there is any pathology in the brain that may be causing the symptoms of 
CFS/ME. 
44 
5 To determine if there is any intrinsic muscle disorder that may be causing the symptom 
of fatigue in CFS/ME. 
1.6.2 Null hypotheses 
The null hypotheses for the objectives listed above are: 
1. There is no relationship between the mechanical dysfunction of the spine, and the 
incidence of the symptoms arising from CFS/ME. 
2. There is no difference in the symptoms associated with CFS/ME following a chosen 
method of osteopathic treatment compared with those of a matched control group, who 
received no such treatment. 
3. Any improvement of symptoms associated with CFS/ME following a chosen method of 
osteopathic treatment compared with those of a matched control group, who received 
no such treatment will not be sustainable or repeatable. 
4. There is no relationship between pathological findings in the structure of the brain and 
the symptoms in CFS/ME. 
5. There is no relationship between the symptom of muscular fatigue in CFS/ME and any 
intrinsic disorder of the muscle. 
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Chapter 2 
2 Assessment of the chosen osteopathic method for 
treatment of CFS/ME: Phase 1: Symptoms, muscle 
fatigue and spinal mobility 
2.1 Introduction 
The chosen osteopathic method in treating CFS/ME was initially proposed by the author in 
a clinical review (Perrin, 1994). Initially, the basis for this particular approach was that 
CFS/ME had a likely origin in dysfunction of the sympathetic nervous system in the 
thoracic region of the spine. 
The concept of CFS/ME being a bio-mechanical disorder requires a substantial paradigm 
shift in current thinking within the orthodox medical world. Unfortunately before the 
author's initial research there had been no prior data correlated to demonstrate a connection 
between the spinal mechanics and the incidence of CFS/ME. With only anecdotal evidence 
and clinical findings to go on, a review took place at the author's practice of cases seen 
between 1989 and 1992, where the patients had either presented with CFS/ME type 
symptoms or had been already diagnosed as suffering from the disorder. Below are two 
tables summarising the relevant details of thirty nine such patients from this period. None 
of these patients were included in either clinical trials of phase 1 and 2. 
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Female 
Patients 
Age Occupation Area of 
Dysfunction 
in Thoracic 
Spine 
Acute 
onset of 
Back 
Symptoms 
Chronic 
Irritation of 
Thoracic 
Spine 
Time 
between 
Onset of 
Back 
Problems 
and CFS 
Symptoms 
35 Nurse All 4 years 3 years 3 years 
74 Housewife All N/A 28 years 28 years 
17 Student Upper and 
Lower 
14 months 14 months 3 months 
49 Clerk All 30 years 30 years 4 years 
21 Student Upper N/A 6years 5.5 years 
20 T-sales Upper N/A 10 years 9.5 years 
31 VDU's Lower N/A 13 years 4 years 
51 Housewife Upper + Mid N/A 13 years 9 years 
40 Bookkeeper Upper N/A 4.2 years 4 years 
40 Teacher All N/A 14 years 7 years 
60 Clerk All 15 years 15 years 7 years 
29 Social Worker Upper N/A 4.5 years 4 years 
45 Teacher All 21 years 21 years 20 years 
32 Shopkeeper All N/A 7 years 2 years 
48 Housewife Upper N/A 7 years 3 years 
48 Teacher Upper N/A 10 years 4 years 
52 Ex-Teacher Upper N/A 10 years 5 years 
28 Secretary Upper N/A 10 years 6 years 
22 Housewife Upper + Mid 15 years 15 years 11 years 
35 Housewife Mid N/A 10 years 9.5 years 
Table 1 Thoracic dysfunction in CFS/ME patients - female 
A table of 20 female patients seen in the clinic of the author between 1989 and 1992 all 
suffering with thoracic spinal problems together with symptoms associated with CFS/ME. 
(NB. None of these patients were included in the clinical trials of phase 1 and 2). 
N/A = Not applicable as the onset was not acute. 
3 `d column: all = T1 to T12; upper = Ti to T3; mid = T4 to T7; lower = T8 to T12 
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Male Patients 
Age Occupation Area of Acute onset Chronic Time 
between 
Dysfunction Of Back Irritation Onset of 
Back 
in Thoracic Symptoms Of 
Thoracic 
Problems 
and 
Spine Spine CFS 
Symptoms 
46 Teacher All 6 years 6 years 0 
46 Optician All N/A 10 years 8 years 
38 Dentist Upper 9 years 9 years 8.8 years 
25 Student Upper N/A 2 years 1.5 years 
30 Designer Upper + Mid 8 years 8 years 4 years 
36 Shopkeeper Upper + Mid 9 years 9 years 5 years 
16 Student Upper N/A 4 years 3 years 
35 Shopkeeper Upper N/A 5 years 4 years 
27 Footballer Upper N/A 5 years 1 year 
31 Ex-Cyclist All N/A 8 years 1 year 
42 Teacher All 20 years 20 years 17 years 
35 Student All N/A 12.3 years 4 months 
20 Student Lower N/A 3 years 1.5 years 
45 Joiner Upper 5 years 5 years 3 years 
31 Manager Upper + Mid N/A 16 years 11 years 
26 Bank Clerk Upper + Mid N/A 12 years 1 month 
29 Scientist Upper 7 years 7 years 1 year 
60 Film Director Upper N/A 20 years 19.5 years ý40 
Tea-c-he-r-- T Upper N/A 1.5 years 1 year 
Table 2 Thoracic dysfunction in CFS/ME patients - male 
A table of 19 male patients seen in the clinic of the author between 1989 and 1992 all 
suffering with thoracic spinal problems together with symptoms associated with CFS/ME. 
(NB. None of these patients were included in the clinical trials of phase 1 and 2). 
N/A = Not applicable as the onset was not acute. 
3 `d column: all = Ti to T12; upper = Ti to T3; mid = T4 to T7; lower = T8 to T12 
The files were selected from patients over the three year period. The first column 
demonstrates that CFS can strike people from a wide spread of ages. Column 2 shows the 
variety of different occupations of the patients. The majority were engaged in vocations 
which place extra strain on the thoracic spine, with the person constantly exerting repetitive 
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strain on the upper part of the body. All of the patients had a particular dysfunction in the 
thoracic region, whether it was inflammation, lordosis, kyphosis or just a restricted area. 
Column 3 of the table shows if all or part of the thoracic spine was affected. 
The data in tables 1 and 2 indicates which patients suffered from a previous acute injury 
that might have precipitated any back problem. If the onset of the spinal problem followed 
an acute injury, then the time the injury occurred is recorded in column 4, i. e. the number of 
years previous to the onset of CFS/ME symptoms that the accident happened. If the onset 
of the back pain was gradual and insidious, due to constant repetitive trauma, or the 
aetiology was postural, then N/A has been placed in this column. Column 5 lists the total 
time that the patient has been suffering with the spinal symptoms, including stiffness, pain 
or spondylitis. 
The final column shows the length of the interval between the onset of back problems and 
the commencement of CFS/ME symptoms. This value allowed the relationship between the 
interval and the nature of the aetiology to be examined. 
A review of the data compiled above leads to the following conclusions: 
The most prevalent occupations in the CFS/ME patients studied, were Teachers (7 
patients), Secretarial/clerical (6 patients), and Students (6 patients). These occupations, in 
particular are likely to place a major postural strain on the upper spine due to the position 
adopted at work including spending many hours each day bent over a desk, sat at a 
computer all day, slumped in an uncomfortable chair in a lecture hall or slouching in an 
unhealthy easy chair whilst revising. Of the total 39 patients reviewed, 27 (i. e., 69%) were 
involved in jobs that put extra demand on the thoracic spine, more than any other region of 
the back. 
The average time-lag between the onset of back pain and the onset of CFS/ME seems to 
differ slightly, depending on the original cause. If at first there was an acute injury, the 
average time-lag is 6.5 years. If however the aetiology is postural, or due to a chronic 
repetitive strain, then the average time-lag is 5.8 years. 
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2.1.1 Aims of phase 1 
The above patient data pointed to a possible biomechanical cause of CFS/ME. Thus it was 
concluded that a mode of treatment to improve the biomechanical situation in the thoracic 
spine may help alleviate the symptoms. The primary aim of this part of the work was to 
assess the hypothesis that osteopathic treatment reduces the detrimental effect of the 
symptoms associated with CFS/ME on the patient. 
The objectives of phase 1 of the research were: 
1. To determine the strength of correlation between the mechanical dysfunction of the 
dorsal spine specifically hypomobility, with or without inflammation, lordosis or 
kyphosis, and the incidence of the symptoms arising from CFS/ME. 
2. To demonstrate and evaluate the effectiveness of the osteopathic method developed 
by the author, in the treatment of CFS/ME, utilising self report questionnaires, 
clinical examination and objective muscle-fatigue tests. 
2.2 Patients and methods 
The study was a repeated measures and a matched between-group design. The initial year- 
long study carried out in the department of Orthopaedic Mechanics at Salford University 
was aimed at evaluating the effect of osteopathic treatment in reducing the main symptoms 
associated with CFS/ME. In that initial project, which began in July 1994, a study was 
carried out on the symptoms of forty volunteers who had suffered from CFS/ME but 
received no other new therapy over the 12 month period of the study, except for the chosen 
osteopathic treatment. Symptoms were assessed using self report questionnaires and 
compared to those of forty control group members who were allowed any therapy except 
the chosen osteopathic treatment during the same 12 month period. Muscle fatigue plus 
spinal mobility were examined in the patient group. 
The patient and control group were all aged between 18 and 55. Both groups were matched 
for marital status with a value of 1 allocated to a single person and 2 if the subject had a 
partner. There were 33 patient group members who completed the year with five being 
disqualified for not fulfilling the inclusion criteria, one had to leave the country, 
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unexpectedly and one dropped out (see Table 3). 16 control group members failed to 
comply with the instructions over the year and so only 24 controls completed the study 
satisfactorily (see Table 4). Both the patient and control groups who completed the study 
contained slightly more single subjects than married scoring an identical mean of 1.42 with 
equal standard deviations of 0.5. The two groups who completed the year's project were 
also matched for gender with 17 women and 7 men in the control group compared with 22 
women and 11 men in the patient group. All participants in the study volunteered for twelve 
months, and met the Centres for Disease Control and Prevention (CDC) revised working 
case definition for chronic fatigue syndrome (Fukuda et al., 1994). The CDC criteria, 
originally formulated by Holmes et al. (1988), are the internationally accepted standard 
criteria required for any valid research project involving subjects diagnosed as suffering 
from CFS/ME. These criteria have been used in other major research projects on CFS/ME 
patients in this country (Costa et al., 1994). 
The London Criteria was also used in this study to determine the CFS/ME diagnosis of 
patients. This was formulated by scientific advisors for the ME association and Action for 
ME, based on criteria (Ramsay, 1978; Dowsett et al., 1990) proposed in the Report of the 
National Task Force on CFS (Tyrrell et al., 1994). They are more stringent than the CDC 
criteria and pay particular attention to two factors when diagnosing CFS/ME for research 
purposes. Many of the symptoms and signs evident in people suffering from CFS/ME could 
be due to a large number of other important conditions. Furthermore, CFS/ME may be 
active in parallel with other diseases having similar symptoms and signs. 
The study was approved by the Research Ethics Committees of both Salford and Bury 
Health Authorities (see appendix Al). 
2.2.1 Inclusion criteria 
Initially, a total of eighty patients volunteered to take part in the project. They had either 
been diagnosed as suffering from CFS/ME by a consultant or their GP. They had also been 
excluded from having any other major untreated pathology. Forty sufferers had asked to be 
group members and forty had volunteered to be members of the patient group. They all had 
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initially responded to a notice in the national CFS/ME journal ' INTERACTION', or had 
heard about the project through word of mouth. All the subjects selected for the project had 
to satisfy the following criteria: 
1. Subjects were aged betweenl8 and 55 inclusively. 
2. Subjects in both the osteopathically treated and control groups had to conform to the 
Centre for Disease Control diagnostic criteria for Chronic Fatigue Syndrome and the 
London Criteria for ME. 
3. Members of the patient group were able to afford £400 of treatment over the year period 
at a rate of £20 per treatment for twenty sessions. If further treatment was required during 
the year, it was given free of charge. 
4. The patients receiving osteopathic treatment were able to travel to and from the treatment 
clinics in Salford, Prestwich or Manchester. 
5. Subjects understood the importance of continuing the treatment until the end of the year, 
although they knew they were free to leave the project at any time. 
6. Subjects had to be honest at all times with the author and any members of his research 
team regarding the amount of exertion placed on the pad when testing for muscular fatigue. 
7 The patient was willing to be part of a longer follow-up study. 
2.2.2 Exclusion criteria 
1. Patients receiving other treatment for their CFS/ME symptoms were excluded from 
being part of the patient group, unless they had received the other treatment as ongoing 
therapy for at least six months prior to the start of their participation in the project. 
2. Patient group members receiving any other manual treatment for their CFS/ME 
symptoms other than from the author were excluded from the study. Subjects were also 
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eliminated from the project if they had received any prior physical therapy for their present 
symptoms. 
3. Any group members receiving any form of manual treatment for their CFS/ME 
symptoms were also excluded from the trials. 
Subjects were also excluded from the study if they exhibited any of the following: 
4. Premorbid symptoms of depression. 
5. If there was a doubt as to the psychiatric state of the patient, or the subject was 
experiencing a primary depressive illness. 
6. Any psychiatric history in the family 
7. Tested positive for any other untreated pathophysiological cause of the symptoms. 
8. If they had suffered from any other neurological disorder. 
9. If there was reasonable doubt as to the compliance of any member of the treated patient 
group with any of the author's instructions specifically regarding exercises and lifestyle 
changes. 
10. If there was any misgiving concerning the veracity of any individual subject's isometric 
tests due to pushing with far less effort than reasonably expected. 
11. If a subject's questionnaires produced conflicting answers on a regular basis 
demonstrating a lack of concern, or worse, a deviation from the truth. 
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Code No. Gender age Status 
RP01 F 32 S 
R P02 F 35 S 
RP03 F 23 S 
R P04 F 22 S 
RP05 F 31 S 
RP06 F 49 S 
R P07 M 29 S 
RP11 M 39 M 
RP12 F 38 S 
RP13 F 44 M 
RP14 M 41 S 
R P15 F 34 S 
RP16 F 53 M 
RP17 F 42 M 
RP19 F 51 M 
R P20 F 40 M 
R P21 F 28 S 
RP23 M 26 S 
R P24 F 28 S 
R P25 F 40 M 
R P26 M 44 M 
RP27 F 18 S 
R P28 M 47 M 
R P29 M 27 S 
R P30 F 52 M 
R P31 F 47 M 
R P32 M 46 M 
R P33 F 43 M 
R P34 M 27 S 
R P35 F 42 S 
R P36 M 32 M 
R P38 M 30 S 
R P40 F 34 S 
Female=22 Mean=37 Single=19 
male =11 married=14 
Table 3 Demographic data of patient group members - phase 1. 
This table lists all the CFS/ME patient group members who completed the year-long course 
of osteopathic treatment during phase 1 of the study. Note in final column, divorcees were 
classified as single. 
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Code No. Gender Age Status 
C01 F 41 S 
C05 M 38 S 
C08 M 39 S 
C10 M 33 S 
C14 F 40 S 
C17 M 36 S 
C19 F 22 S 
C21 F 21 S 
C22 F 36 S 
C23 F 41 M 
C25 F 42 S 
C26 F 45 M 
C27 F 49 M 
C28 M 46 M 
C30 F 54 M 
C31 M 47 S 
C33 F 47 M 
C34 F 49 S 
C35 F 40 M 
C36 F 46 M 
C37 M 45 M 
C39 F 45 M 
C40 F 39 S 
C41 F 34 M 
17 female mean =41 13 single 
7male 11 married 
Table 4 Demographic data of control group members - phase 1. 
This table lists all the control group members who remained on the study for the entire year 
of phase 1. The control group consisted of CFS/ME sufferers not having osteopathic 
treatment. Note in final column, divorcees were classified as single. 
2.2.3 Symptom assessment 
The members of the treated group received code numbers RPO1 to RP40 to protect their 
anonymity. They also received secret code numbers which were given to them by an 
independent observer to be used by the subjects when completing their questionnaires. The 
identity of the secret code was kept hidden from the researcher until later on in the project. 
This number allowed the patient the freedom to answer the questionnaires truthfully 
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without the researcher influencing the reply given. This system was adopted to reduce bias 
and thus increase the validity of the questionnaires. The control group members were coded 
Cl to C41. 
Improvement in the condition of each CFS/ME subject, as well as each subject group, was 
assessed utilising objective and subjective measures of each of the main symptoms of 
CFS/ME. The measurements were carried out using laboratory tests and self report 
questionnaires. Background research material was evaluated to validate the use of the 
questionnaires in this study (Beck et al., 1979; Beck, et al., 1988; Hunt et al., 1981; 
Broadbent et al., 1982; Tomeny and Morgan, 1900; Behan and Bakheit, 1991; Smith, et al., 
1993; Ray et al., 1993; Schmaling et al., 1994; Swanink et al., 1995). Finally, objective 
investigative procedures, and recognised diagnostic tests for CFS/ME were examined 
(Fukuda et al., 1994; Costa et al., 1995). 
2.2.3.1 Questionnaires 
The following eight self-report questionnaires were filled out by all members of the patient 
and control groups every three months for the year. A follow up set of questionnaires were 
completed by the patient group at one year after the conclusion of the study to see if any 
improvement that occurred after 12 months of treatment was maintained. It did not prove 
possible to determine a one year follow up score for subjects of the control group as some 
of them had opted for manual treatment and several patients did not wish to carry on 
cooperating with this research. Although it would have been preferable to compare the 
follow up results with the control group, the main reason for a follow up was to see if any 
improvement in the patient group was sustained and this could still be evaluated without 
reference to the control group's progress. Thus only the patient group was assessed in the 
follow up study. 
The first two questionnaires were developed by the author specifically for this study and 
tested in a pilot study. Questionnaires 3 to 8 were chosen for the project as they had already 
been sufficiently validated by inclusion in previous research studies, most involving 
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CFS/ME. After examining other similar inventories and reviewing the literature on these 
questionnaires, they were deemed suitable, precise, and easy to use (See Appendix A6). 
Questionnaire No. 1 
HEALTH: General Health questionnaire, which was developed especially for the study and 
was based on twenty six of the most common symptoms, complained of by CFS/ME 
patients. This health score increased with the severity of the symptoms. Although many of 
these symptoms were included in the other questionnaires, it was felt that an extra general 
health questionnaire would strengthen their validity 
Questionnaire No. 2 
BACK PAIN: This was developed by the researcher to examine any correlation between 
the amount of back pain and the severity of the other symptoms associated with CFS/ME. 
Questionnaire No. 3 
THE REVISED BECK DEPRESSION INVENTORY (Beck et al., 1979): This was chosen 
as the most suitable questionnaire for assessment of depression. It was short and required 
only 5- 10 minutes to complete. It was quick and easy to score and had a cut off point. 
Over the last 26 years, the BDI has become one of the most widely accepted instruments 
for detecting and assessing the intensity of depression in non-psychiatric patients (Beck et 
al., 1985). 
Questionnaire No. 4 
THE BECK ANXIETY INVENTORY (Beck et al., 1988): The author's previous clinical 
findings revealed a high level of anxiety in patients diagnosed as suffering from CFS/ME. 
Given that anxiety and depression frequently co-exist (Clark, 1989; Watson and Kendall, 
1989), the results from instruments designed to measure the severity of anxiety or 
depression had been found to be highly correlated with one another (Beck, et al., 1988; 
Gotlib and Cane, 1989). The BAI was formulated to measure symptoms of anxiety which 
are minimally shared with those of depression, and thus it was a suitable anxiety 
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questionnaire to use with the BDI. It was formulated to use with adult populations. 
Furthermore, it is simple and quick to fill in and score. 
Questionnaire No. 5 
THE MORGAN-GLEDHILL SLEEP QUESTIONNAIRE (Tomeny and Morgan, 1990): 
Sleep disturbance is one of the most common symptoms of CFS/ME (Krupp, 1993). A 
recent study showed that many patients with CFS/ME had trouble staying asleep (Schaefer, 
1995). EEG and actimetering (Home et al., 1994) measuring techniques were first 
considered for the project but were found to be too costly and difficult to use. The Morgan- 
Gledhill sleep questionnaire was one of only a few established sleep questionnaires which 
provide a score suitable for statistical analysis. The exact scoring system chosen is seen on 
the questionnaire in Appendix A6. 
Questionnaire No. 6 
BROADBENT'S COGNITIVE FUNCTION QUESTIONNAIRE (Broadbent et al., 1982): 
Pronounced and frequent deficits have been found in patients with CFS/ME when 
attempting to carry out performance tests (Daugherty et al., 1991). Originally the use of 
practical cognitive function tests was considered. However, these tests can only be 
satisfactorily assessed when they are carried out on the control group as well as the patient 
group. Since no direct contact was made with the control group by the author, it was 
decided to use a cognitive function questionnaire. The Broadbent's CFQ was previously 
validated through its use in other CFS/ME research projects (Smith et al., 1993). 
Again this questionnaire was easy to complete and score. 
Questionnaire No. 7 
THE NOTTINGHAM HEALTH QUESTIONNAIRE (Hunt et al., 1981): It was felt that 
the Nottingham Health Questionnaire is a quick, simple indicator for the general symptoms 
of CFS/ME and widely accepted. Dr. Charles Shepherd, the then medical advisor of "The 
ME Association", advised the author to include this questionnaire in the project to gain 
acceptance of the research findings by his national group. 
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Questionnaire No. 8 
THE PROFILE OF FATIGUE RELATED STATES (Ray et al., 1992): The PFRS is a 
multidimensional measure incorporating nearly all the symptoms associated with CFS/ME. 
It was developed at Brunel University especially to measure the symptoms of this illness 
and evaluate the effects of treatments (Ray et at., 1993). It is longer than the other 
questionnaires, but it is still quite easy to complete and not too difficult to score. It has four 
scales: emotional stress, cognitive difficulty, fatigue and somatic symptoms. 
These eight questionnaires were not being used to diagnose any disorder, but to compare 
the function and symptoms of subjects before and after treatment. They also provided a 
means of comparing the overall health of the patient and control groups. Health 
psychologist Dr. Pat Hartley PhD (Reader in Psychology, University of Salford) was 
directly involved in the entire running of all the psychological tests. She was licensed to 
perform all the questionnaires included in this study. 
The mean scores of the patients for each of these questionnaires were expressed as a 
percentage, where 100% represented the most severe symptom. Scores took place over 12 
months comparing means of each questionnaire of the two groups. Questionnaire 1 (health) 
had a minimum value of 26 where each separate complaint scored from a range of 1-4 from 
symptom-free to maximum severity with a highest total score of 104. The back pain 
questionnaire scored a minimum of 12, as each region of the back scored `1' if pain free 
with a maximum score of 48. Likewise, questionnaire No. 8 had a minimum value of 54 
based upon the score of 1 for each symptom free section with a maximum total score of 
378. All the other inventories scored zero for each symptom free item with a maximum 
total score of 63 for both questionnaires 3 (depression) and 4 (anxiety). Questionnaire 5 
(sleep) scored a maximum total score of 14, questionnaire 6 (cognitive ability) scored a 
maximum of 100 and the Nottingham health questionnaire (No. 7) scored a maximum 38. 
The complete scoring system for questionnaires 1 to 8 is detailed in Appendix A6 and is 
summarised in Table 5 below. 
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No problem Max problem 
Questionnaire No. 1 HEALTH 26 104 
Questionnaire No. 2 BACK PAIN 12 48 
Questionnaire No. 3 DEPRESSION 0 63 
Questionnaire No. 4 ANXIETY 0 63 
Questionnaire No. 5 SLEEP 0 14 
Questionnaire No. 6 COGNITION 0 100 
Questionnaire No. 7 NOTTINGHAM 0 38 
Questionnaire No. 8 PFRS 54 378 
Table 5 Self report questionnaire scores 
Each questionnaire had a different scoring system. Most had 0= no problem for different 
symptoms. However, questionnaires 1,2 and 8 all had a minimum score of 1 for the 
individual questions thus their minimum total score was 26,12 and 54 respectively. The 
questionnaires and their scoring systems can be seen in Appendix A6. 
2.2.3.2 Measurement of exercise induced muscle fatigue. 
Since fatigue is the most common clinical symptom of CFS/ME, it was considered essential 
to assess whether there was a reduction of fatigue following osteopathic intervention. 
Measurement of the strength of the right knee extensors were chosen because clinical 
practice with CFS/ME subjects had shown that fatigue was particularly evident in these 
muscles. The fatigue test involved isometric measurement of the static torque exerted about 
the knee by the extensor muscles of that joint using a specially designed calibrated chair as 
shown in Fig. 7 below. 
Fatigue may be defined as a progressive impairment of maximal force generating capacity 
that develops during muscular activity. A muscle is said to fatigue when the point at which 
a contraction can no longer be maintained, the failure point, has been reached. Onset of 
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fatigue has been found to occur after only a few seconds of maximal-effort muscle 
contractions (Lewis and Haller, 1991). 
During each measurement the patient was seated with the leg hanging vertically. A lever 
attached to a torque transducer mounted at the level of the knee joint axis was aligned along 
the lateral side of the leg with a padded extension that projected across the front of the shin. 
During each test the lever was clamped in a fixed position. The patient was asked to exert 
as much force as possible against the padded extension and the resulting trace of torque at 
the knee was plotted against time on a pen recorder. After 30 secs. the patient was 
instructed to stop pushing. 
The main problem encountered in measuring fatigue of the knee extensors was that of 
achieving maximal force without causing major damage to the patients' muscles. This 
difficulty was overcome by carrying out a pre-test in which the patient was initially asked 
to exert a maximal force for just a few seconds followed by a series of pushes at a third of 
maximum on the leg pad a number of times and then resting for three minutes before the 
final test. These preliminary ten contractions served a dual purpose. Firstly they allowed 
patients to accustom themselves to the machine before applying maximal torque for at least 
30 secs., and secondly they provided a safe exercise to induce some preset fatigue of the 
muscle. 
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Figure 7 The Salford biomechanics chair 
T= torque transducer P= pressure pad R= chart recorder C= clock 
The top diagram shows the four parameters that were measured before each session in order 
to ensure that the subject remained in a very similar position as at the start of the study. 
Below, the photo shows the position of the patient on the chair at Salford University's 
human performance laboratory. 
Everyone has an in-built sensation of discomfort which safeguards them against exerting 
excessive levels of muscle force which can damage the muscle fibres. This is partly 
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psychological and partly due to the physical sensation of pain. The psychological element 
of this is variable and will cause the subject to exert different levels of maximal force on 
separate occasions. However, on any one instance if the subject attempted to maintain the 
exertion of muscle force over an extended period of time, fatigue eventually set in and 
caused the force to drop. Therefore the rate of decline in muscle force due to fatigue was 
more significant than the peak force. 
It was found that the optimum sequence for the pre-test exercise was ten pushes, each 
lasting twenty secs. with an interval of ten secs. between each push. A typical plot with 
time of torque exerted about the knee during this sequence is shown in Fig. 8. 
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Figure 8 Example of chart recorder printout of the pre-test fatigue induction 
To fatigue the right quadriceps muscle safely, ten intermittent pushes each of 20 secs. were 
carried out with an interval of 10 secs. The reduction in the maximum torque and the 
increase in the graduation of the slope in the latter pushes indicate fatigue in the muscle 
tested. The patient then rested for three minutes before the final push. 
As one can see from the chart above, throughout the first four pushes after the initial peak, 
the torque was held relatively constant until the subject stopped pushing. During pushes 5, 
6 and 7, after the initial peak, fatigue caused a gradual drop in torque over the 20 secs. time 
period when the patient was attempting to keep the torque at maximum. Sometimes, after a 
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10 second rest, the subject was able to momentarily achieve an initially high peak torque as 
in push no. 8 similar to the original level at push no. 1. However, this was short lived and 
subsequently torque levels rapidly fell to a magnitude below push no 7. By the tenth cycle 
of pushes the effect of fatigue had become fully established. A similar picture of fatigue 
with exercise pushes was evident in all of the patients, as well as the normal group selected 
from university staff for the pilot study. Therefore, ten repeated push cycles was chosen as 
the modus operandi to induce fatigue in all the isometric tests completed in both phases of 
this study. After completing these ten cycles the subject was allowed three minutes rest for 
the muscles to recover. Then, the patient was asked to push as hard as possible again, only 
this time they were requested to maintain the maximal push until they could no longer 
continue. During early tests a difficulty arose in evaluating exactly what was meant by 'as 
long as possible'. It was not the author's intention to cause muscle damage and this would 
have added far too many subjective factors into the experiment increasing the margin of 
error. In the preliminary pilot test it was noted that CFS/ME patients could sustain a thirty 
second final push before relaxing. Subsequently the first thirty seconds were chosen to 
evaluate the muscle fatigability. The patient was then told to stop pushing after this time to 
prevent any injury. A typical recording for this final push is shown in Fig. 9, where the 
torque about the knee axis is plotted vertically against time on the horizontal axis. 
Newton's second law states "The change in linear momentum of a body under the action of 
an unbalanced force will be proportional to the product of the force and the time for which 
it acts" This change is known linearly as impulse. In Fig. 9, where the torque about the knee 
axis in Newton metres is plotted vertically against time on the horizontal axis, this product 
of torque x time is represented by the area under the graph. This area, coloured yellow on 
the graph, is an angular measurement of the change in impulse torque over the first thirty 
secs. of the final push test. The torque, also known as the turning moment, is defined as: 
M=Fxd. 
Where M=Turning Moment 
F= the magnitude of force (how hard the patient pushes) 
d= the perpendicular distance of the line of action of the force away from the centre 
of rotation of the knee joint. 
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The area under the pen recorder graph of torque against time, the impulse torque, was 
measured by counting the minute boxes of the recorder readout. It relates to the maximum 
torque produced and how long it may be sustained. It is inversely proportional to the fatigue 
of the muscle and thus is a good indicator of the fatiguability of the knee extensors. Hence, 
the larger the area under the graph, measured in Newton metre seconds (Nms), the less the 
fatigue of the muscle. 
The impulse torque has been mistakenly referred to as work done by the muscle. From a 
true mechanics viewpoint, this is not valid, although it can be related to the physiological 
work done in the cells of the muscle to produce energy for the contraction. With isometric 
exercise no actual movement in the joint takes place. Therefore no biomechanical work has 
been done, work done being the product of force x distance (Richards, 1999). 
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Figure 9 The measurement of impulse torque 
The graph of time (x-axis)/seconds V Torque (y-axis) / Newton metres of the final push 
which took place exactly three minutes after the end of the ten pushes shown in Fig. 8. The 
impulse torque is the area under the graph. This area for the first 30 seconds was measured 
by count of boxes on pen recorder paper. A reduction in fatigue was indicated if this area 
increased compared with earlier results. 
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After each test the subjects' final push were rated on the Borg Scale of Perceived Exertion 
(Borg and Linderholm, 1970). This perceptual effort rating was formulated as a behavioural 
and psychological measurement of physical performance and work capacity. The real value 
of exertion is proportional to the heart rate of the patient i. e. if the pulse after exertion was 
100 then the real value of exertion scored 10 on the Borg scale (see Appendix A7). 
Each subject was asked to score the perceived amount of strain they felt during the last 
exercise by using the Borg scale where 6= minimum effort required and 20 = maximum 
effort required. As long as the difference between the real and perceived exertion during the 
initial tests did not increase in the final test, then any torque improvement would imply that 
the patient was not simply putting in more effort at the end compared to the beginning of 
the project. 
2.2.3.3 Thoracic spinal mobility 
One of the objects of phase 1 was to determine the correlation between the mechanical 
dysfunction of the spine, and the incidence of symptoms linked with CFS/ME. Some 
physiological evidence supports the possibility that thoracic spinal dysfunction may be 
intrinsically linked to several disorders. It has been demonstrated by three physiologists that 
postural changes in the spine produced alterations in the rate of perspiration (Korr et al., 
1962). This team developed their hypothesis relating to sympathetic nerve involvement in 
disease processes. The initial conclusions that they reached were as follows: 
The manifestations of altered sympathetic activity represent an actual defect in the normal 
existing patterns of sympathetic activity. 
These alterations are due to effects of impulses originating from either the viscera or 
somatic sources. 
Other components, such as adaptive or pathological changes, and altered excitability within 
the central nervous system, may eventually become involved. This may directly affect local 
tissues outside the expected route of the nerve impulses. 
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Further studies revealed that areas of altered sympathetic activity also appeared in 
apparently normal subjects. Korr (1978) suggested that this was due to sub-clinical 
bombardment of nerve impulses into the spinal cord. These impulses cause no symptoms 
themselves but, added to other stimuli affecting the same spinal segment they could 
combine to cause major problems. Long lasting hyperactivity of innervating sympathetic 
pathways seems to be a prevailing theme in many clinical conditions, involving various 
organs and tissues (Korr, 1978). 
Korr also suggested that spinal dysfunction would lead to disturbances in the muscular 
fatigability, sensory excitability, immunological mechanisms and endocrine functions due 
to impairment in normal sympathetic efferent flow (Korr, 1979). Based on this hypothesis, 
it was felt that a method to determine spinal mobility was needed in the present study. If the 
amount of movement in the thoracic spine was shown to be proportional to the symptom 
picture, then it could support the hypothesis concerning a possible spinal link in a 
mechanical aetiology of CFS/ME. 
There are many methods of measuring mobility of the spine, and several were assessed 
ranging from the use of a flexicurve (Burton, 1985), to the more technological MAC 
Reflex, which utilises infra-red scanning together with computerised digitisation. The latter 
was found to be too time consuming, and difficult to use as it had to be re-calibrated after 
each patient. The chosen method involved the use of the Salford Biomechanics Work- 
station. This device digitised the movement of the thoracic spine from video film of the 
patient bending forwards from an upright position to full flexion. The patient was 
positioned with the camera placed laterally focused on three probes that were fixed by 
adhesive tape to specific points on the subjects back overlying the spine when the subject 
was at rest in an upright position. The points of the spine in question were Ti (referred to as 
point C; T7 (point T) and Ll (point Q. At maximum flexion, the angle CTL was recorded 
via the digitiser. This method was painless and the speediest, plus the standard error factor 
of the workstation was minimal at 0.03% in the horizontal view and 0.9% in the vertical 
view (Harrison and Littler, 1991). The position of C, T and L were recorded and remained 
unchanged in each individual case. A measurement chart was developed in order to position 
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the probes exactly over the same segment as the previous recording of the spinal 
movement, thus keeping the distances O-C; C-T and T-L constant for each subject, where 
0 is the occipital protuberance (See Appendix A8 for chart showing calibration of probe 
positions). 
Since the probes were placed on the skin of the patient and not on the actual bone of the 
spinal column, the tone of the skin overlying the spine had to be taken into consideration. 
This was assessed each time by placing two strips of adhesive tape next to each other at the 
position the probe was to be fixed. The patient was then asked to fully flex, and the distance 
between the two strips during full flexion was measured and recorded. This method 
revealed how much skin stretch there was under each probe during active flexion. If the 
distances measured between the two strips of tape were markedly different during each 
recording, then it would have affected the reliability of the results as any difference in the 
angles between the probes would be partially due to changed skin elasticity. Thus, only 
recordings with overall skin stretch that remain similar over the year could be considered 
accurate as a valid measurement of the angle of flexion. 
2.2.4 Osteopathic treatment 
2.2.4.1 Background 
The treatment for CFS/ME as seen in the initial chapter includes dietary regimes, with 
evidence to suggest that an essential fatty acid intake must be normalized in the 
management of CFS (Gray and Martinovic, 1994). Psychotherapy, physiotherapy, 
exercise programmes, and antidepressants have all been advocated (Artsimovich et al., 
1994). The different treatment programmes each focus on one facet of this complex 
disorder whether it is chemical, hormonal, environmental or psychological, offering 
palliative treatment and not a cure. 
2.2.4.2 Aim of treatment 
The main objective of the chosen osteopathic treatment of CFS/ME is to reduce the 
irritation of the sympathetic nervous system, thus allowing a return to a healthier 
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homeostatic state within the patient. It is hypothesized by the author that this would be 
achieved by increasing drainage of toxins from the cerebrospinal fluid via the lymphatics 
(See Section 5.1). Also the treatment would reduce sympathetic tone by improving 
structure and overall quality of movement of the lower cervical, dorsal and upper lumbar 
regions of the spine together with relaxation of surrounding musculature. 
The two sympathetic trunks are integrally related to the overall structure of this area. Thus 
by reducing mechanical irritation, disturbed sympathetic afferent impulses may minimize 
further helping to stabilize blood and lymph flow. 
The therapy lies at the very heart of traditional osteopathic philosophy and practice (Still, 
1902). The core theory of this thesis proposes that this system breakdown is central to the 
disease process of CFS/ME. It is also hypothesised that by rebalancing the neurological 
equilibrium, one reduces the metabolic disturbance, thus improving the overall symptom 
picture (Perrin, 1993). 
2.2.4.3 History and philosophy of osteopathy- an overview 
Osteopathy is the knowledge of the structure, relations and functions of each part and tissue 
of the human body applied to the adjustment and correction of whatever may be interfering 
with their harmonious operation (Webster, 1928). 
Dr. Andrew Taylor Still in Kirksville, Missouri founded osteopathy in the latter part of the 
nineteenth century as an alternative to the poor quality of medicine practiced at the time. 
Still called his new system of medicine "osteopathy" from the Greek words for bone Osteon 
and disease Pathos. His basic tenet for viewing the body as a machine was religiously 
based and one of despair, due to the futility of most medication at the time. He formulated 
his original hypothesis from biblical text. "Let us make man in our image" Genesis Chl, 
Verse 26. Taylor Still who was the son of a minister took this verse literally. He postulated 
that if The Creator is perfect then man must have been made perfect. As he stated "The 
principles of osteopathy gives us an understanding of the perfect plans and specifications 
followed in man's construction" (Still, 1902). Osteopathy teaches that structure governs 
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function. Thus illness, Still maintained, develops when the perfect structure is out of 
balance. 
It became extremely popular in the American Mid-West and there are now twenty 
established osteopathic medical schools in the USA, with an enrolment of nearly 10,000 
students (AOA, 2002). The first osteopathic college in the UK was The British School of 
Osteopathy established in 1921 (Hall and Wernham, 2003). Today there are over 3,000 
osteopaths in this country registered with the General Osteopathic Council formed by act of 
parliament in 1998 (OIS, 2000). The profession is now generally accepted alongside other 
mainstream medical disciplines. 
According to the General Osteopathic Council, osteopathy is an established recognised 
system of diagnosis and treatment, which lays its main emphasis on the structural and 
functional integrity of the body. It is distinctive by the fact that it recognises that much of 
the pain and disability, which we suffer, stems from abnormalities in the function of the 
body structure as well as damage caused to it by disease (OIS, 2000). 
One of the major philosophical concepts of osteopathy is that the structure of the body 
governs the function of the organs within. Osteopaths also work on the principle that a 
patient's history of illnesses and physical traumas are written into the body's structure 
(Webster, 1928). It is the osteopath's developed palpatory sense that enables the practitioner 
to manually diagnose whilst treating the patient. The osteopath's job is to restore a healthy 
structure of the body and thus its function. The osteopath gently applies manual techniques 
of massage and manipulation to encourage movement of the bodily fluids, eliminate 
dysfunction in the motion of the tissues, relax muscular tension and release compressed 
bones and joints. The areas being treated also require proper positioning to assist the body's 
ability to regain normal tissue function. 
There is a palpable rhythmic motion along the spinal cord and around the brain together 
with that of normal breathing, which is transmitted to the rest of the body. The accepted 
hypothesis among most of the osteopathic profession for what is termed the involuntary 
mechanism or the "cranio-sacral rhythm" is movement through the tension and continuity 
70 
of membranes, dura and fascia. The fascia is continuous with the membranes that surround 
the brain and spinal cord (meninges), thus allowing the different motions (and tension) of 
the body to be transmitted everywhere. One of Still's students, William Sutherland, noticed 
that when the bones of a disarticulated skull were viewed in a certain way, they resembled 
gills of a fish. Therefore, he hypothesised, in 1898, that their shape was designed to allow 
for movement. He postulated that there was an inherent primary respiratory movement 
within the cranium bones and of the sacrum between the ilea. This movement corresponds 
with the motility of the neural tube and the fluctuating rhythm of the cerebrospinal fluid. 
The average pulsation of this primary respiratory mechanism, as it is also commonly 
known, is between 7 and12 beats per min in health (Sutherland, 1990). 
Sutherland also proposed that the primary respiratory mechanism produces a rhythmic 
alternation of flexion and extension of structures in the midline. This movement occurs 
simultaneously with rhythmic external and internal rotation of all paired lateral structures in 
the cranium (Sutherland, 1990). 
2.2.4.4 The lymphatic drainage 
The main lymphatic vessels are known to be under sympathetic control (Browse, 1968). 
The smooth muscle wall of the thoracic duct, when stimulated, produces a wave of 
contraction aiding lymph drainage into the subclavian vein. This produces a negative 
pressure along the lymphatics and aids further lymph drainage. The associated peristaltic 
wave within the normal human thoracic duct was found to be 4 beats per minute with a 
maximum pressure of around 10-mmHg building up to 50 mmHg if obstructed (Kinmonth 
and Sharpey-Schafer, 1959). 
Sutherland emphasised the importance of the choroid plexus in the chemical exchange 
between cerebrospinal fluid and the blood, but also stressed the part played by the 
lymphatics in the drainage of toxins from the neuraxis. Sutherland (1990) said "When you 
tap the waters of the brain by compressing the fourth ventricle see what happens in the 
lymphatic system. Visualise the lymph node that is holding some poison that has gathered 
there, changing the constituency before the lymph is moved along into the venous system" 
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"We strike at the source of life and death when we go into the lymphatics" (Still, 1899). 
Andrew Taylor Still discussed the importance of examining disturbed fluid motion in the 
head, in the pathogenesis of many symptoms such as headaches, enlarged tonsils, dizziness 
and loss of memory, all associated with CFS/ME. He emphasised that alongside good blood 
supply it was equally important to have perfect drainage (Still, 1902). 
Sutherland (1990) postulated that each facial sinus has one or more other bones which help 
drain the mucus, produced in the goblet cells of the sinus epithelial lining, by a gentle 
pumping action. This facilitates the wafting action of ciliated epithelium, which forces the 
mucus into the nasopharynx. When mechanical or other forces damage this mechanism the 
sinus is less able to drain its mucus. As a result the mucus pools, thickens and makes the 
subject prone to infection. The nasal mucosa becomes continually inflamed with an 
abundance of purulent mucus and associated enlargement of adenoids and tonsils. 
Lymphatic vessels in the submucosa of the nasal sinuses are the initial recipients of the 
drainage of CSF through the cribriform plate (Knopf and Cserr, 1995). As osteopathy's 
founder stated over a century ago "Harmony only dwells where obstructions do not exist" 
(Still, 1899). 
It is the above pathway that the author believes to be compromised mechanically as part of 
the common pathogenesis in CFS/ME. Mechanical dysfunction such as this can be detected 
by palpation and can be released by gentle pressure techniques applied to the cranium and 
the spine. As early as the1890's, Still noted "The lymphatics are closely and universally 
connected with the spinal cord and all other nerves, and all drink from the waters of the 
brain" (Still, 1902). From the earliest days of osteopathy the importance of good lymphatic 
drainage in the thoracic duct has been seen as paramount to sustain health. Still himself 
wrote: "At this point I will draw your attention to what I consider is the cause of a whole 
list of hitherto unexplained diseases, which are only effects of the blood and other fluids 
being prohibited from doing normal service by constrictions at the various openings of the 
diaphragm. Thus prohibition of the free action of the thoracic duct would produce 
congestion" (Still, 1902). 
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At present there is no means of measuring the patient's cerebrospinal fluid's drainage into 
the lymphatic ducts although it is safe to assume that it is directly influenced by the thoracic 
duct pump. Palpation of the CFS/ME patients revealed a notable reduction in the 
involuntary mechanism compared with the healthy group. 
2.2.4.5 The scientific validity of osteopathy and other manual 
therapies 
The author, being a fully trained osteopath of almost twenty years experience, may be more 
familiar with osteopathic manual techniques as compared with chiropractic and 
physiotherapy personnel. However there is no reason why trained manual therapists from 
any discipline cannot treat CFS/ME using similar methods. In fact osteopathy and 
chiropractic share common roots. Palmer established chiropractic in the late 19th century in 
the United States after meeting with Still, the founder of osteopathy. The therapies remain 
relatively comparable with the term "manipulative therapy" referring to both osteopathy and 
chiropractic. However these two established professions do not hold a monopoly in 
manipulation. Many physiotherapists and massage therapists also use manipulative 
techniques similar to those of chiropractors and osteopaths. Although chiropractic is known 
more for its specific and sometimes quite forceful manipulative procedures of the spine, 
there has emerged a relatively recent branch of chiropractic, the McTimoney School, which 
has developed some of its own gentle manipulative techniques that do not place as great an 
emphasis on high velocity thrusts as do osteopathy and mainstream chiropractic. 
Some osteopaths also practise a technique known as cranial osteopathy or craniosacral 
therapy. Practitioners place their hands on the cranium and sacrum and gently handle the 
bones of the skull, feeling for subtle rhythmic pulsations of the cerebrospinal fluid, and 
attempting to correct disturbances in the neuromuscular system. There are some therapists, 
usually known as craniosacral therapists, who use similar techniques but who do not have 
an osteopathic background. 
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Both osteopathy and chiropractic were originally regarded as complete systems of 
medicine. Early chiropractors believed that most diseases could be treated by treatment of 
misalignments of the spine. Present-day practitioners concentrate primarily on 
musculoskeletal disorders. Low back pain is the most common presenting complaint. 
Guidelines from the Royal College of General Practitioners recommend physical therapy 
(any of the manipulative techniques) within six weeks of the start of persisting 
uncomplicated back pain. 
There is considerable evidence from randomised controlled trials on the effectiveness of 
spinal manipulation in the region of the back and neck pain. Although this evidence is 
largely positive, it has been criticised for failing to exclude non-specific effects of treatment. 
In the best known UK trial 741 patients with low back pain were randomised to 
chiropractic or hospital outpatient-care (Meade et al., 1995). In both groups the treating 
practitioners were free to treat patients as they saw fit. The authors concluded, 
"Chiropractic almost certainly confers worthwhile, long term benefit. " However Koes et al. 
(1996) disagree with some measured outcomes in that study such as pain and disability, 
since the self-score system used by patients was unblinded. 
In one earlier trial that did involve blinded assessment of outcome, patients with back or 
neck pain were randomised to routine general practitioner care, placebo (deactivated heat 
treatment), physiotherapy, or manipulation (Koes et al., 1991). Physiotherapy and 
manipulation were superior to placebo and general practitioner care after six weeks, and 
manipulation was superior to physiotherapy at a one-year follow up (Koes et al., 1992). 
In addition to effects on back and neck pain, randomised trials have also indicated that 
manipulative treatment is beneficial for headache, including migraine (Tuchin et al., 2000). 
However, the numbers of studies are small, so further work to confirm this result is needed. 
There is little or no reliable evidence of beneficial effects for many of the other 
musculoskeletal conditions that are commonly treated. Apart from dysmenorrhoea, for 
which a small number of trials have shown a positive effect, current evidence suggests that 
74 
manipulative therapy does not benefit patients with problems related to smooth muscles or 
viscera, such as asthma and hypertension. There has been little research on cranial 
osteopathy or McTimoney chiropractic. 
Adverse effects of osteopathy and chiropractic if applied by a trained practitioner are few, 
but stroke and spinal cord injury has occurred after cervical manipulation. Estimates of such 
severe adverse events vary widely, ranging from 1 in 20 000 patients undergoing cervical 
manipulation to 1 per million procedures. Osteopathic and chiropractic professions have 
shown greater appreciation of the risks of cervical manipulation, and it is possible that 
improved practice is leading to a reduction in the rate of severe complications (Koes et al., 
1992,1996; Balon et al., 1998; Meade et al., 1995,1990) 
There has been a promising pilot study providing evidence that spinal manipulation is more 
effective than acupuncture or non-steroidal anti-inflammation drugs (NSAIDs) for chronic 
spinal pain syndromes (Giles and Muller, 1999). Furthermore a panel of 20 leading experts 
on low back pain was in favour of osteopathy and chiropractic for acute uncomplicated low 
back pain (Ernst and Pittler, 2000). Spinal manipulation has also been shown to help in 
non-mechanical problems e. g. migraine (Tuchin et al., 2000). 
2.2.4.6 Stages of treatment 
The specific osteopathic techniques used in the treatment protocol developed by the author 
are based on standard procedures used by trained osteopathic practitioners (Stoddard, 1982; 
Hartman, 1983). 
The manual treatment of each CFS/ME subject consisted of the following stages: 
1. Effleurage to aid drainage in thoracic and cervical lymphatic vessels. 
2. Gentle articulation of thoracic and upper lumbar spine, plus the ribs. This was achieved 
by both long and short lever techniques. 
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3. Soft tissue massage of the paravertebral muscles, the trapezii, levator scapulae, 
rhomboids and muscles of respiration. 
4. High and low velocity manipulation of the thoracic and upper lumbar spinal segments 
using supine and side-lying combined leverage and thrust techniques. 
5. Functional techniques to the suboccipital region and the sacrum. 
6. Stimulation of the cranio-sacral rhythm by functional-cranial techniques. 
Exercises were also prescribed to improve the quality of thoracic spine mobility, and to 
improve the coordination of the patient. 
The treatment schedule listed below was the protocol followed throughout the year. It 
altered slightly depending on the physical state of the patient and on the symptom picture at 
that particular stage in their therapy. 
2.2.4.6.1 Effleurage to aid drainage in thoracic and cervical lymphatic vessels 
Congested lymph and oedematous changes that often occurred was relieved by effleurage, 
which is a method of massage involving stroking motions along the surface of the body. 
The gentle strokes were carried out rhythmically towards the subclavian region, overlying 
the subclavian veins which drain all the lymph fluid into the blood circulation. Effleurage 
stimulated the lymphatic drainage through direct routes into the thoracic duct and hence 
into the venous return (see Fig. 10). Care was taken to avoid stimulating drainage into the 
axillary lymph nodes which were prone to swelling and congestion in CFS/ME sufferers. It 
is hypothesised that the more direct route forced a high pressure within the smaller 
parasternal vessels which created enough force within the thoracic duct to alleviate the 
back-pressure and return to a healthy drainage of toxins into the venous return. 
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The red arrows show the direction of the massage technique which was always towards 
either clavicle on both sides. This is the region overlying the drainage of lymphatic fluid 
from the right lymphatic duct and the thoracic duct into the right and left subclavian veins 
respectively. 
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Figure 10 Effleurage down neck and up chest to clavicle 
With female patients effleurage to the breast tissue was carried out with a chaperone 
present after explaining the exact nature of the treatment and using further consent forms 
supplied by the General Osteopathic Council as well as the initial trial consent forms (See 
appendix A4). The gentle stroking was applied upwards covering the entire breast tissue 
towards the clavicle 
The effleurage technique was also used on the lymphatic vessels of the neck, head and 
back, stroking downwards along the back and sides of the neck and head and upwards 
along each side of the thoracic spine. Each stroking motion finished at the level of the 
subclavian vein creating the pressure mentioned above. 
2.2.4.6.2 Gentle articulation of thoracic and upper lumbar spine plus the ribs 
The main objective of the articulatory, soft tissue techniques and high velocity 
manipulation (stages 2,3 and 4) was to improve the structure and overall quality of 
movement of the dorsal and upper lumbar spine. 
The two sympathetic trunks are integrally related to the overall structure of the area. Thus 
by reducing the mechanical irritation at this region as well as relaxing disturbed afferent 
impulses, the dysfunction of the sympathetic nervous system can be corrected. 
In cases of hypermobility which was rarely found in the patient's thoracic spine, mobility 
of the adjoining areas of the spine was improved by articulation and manipulation. This 
took the strain off the hypermobile segments. What was predominantly found in patients 
with CFS/ME was a restricted dorsal spine. Frequently the entire thoracic region was stiff, 
but occasionally only a few segments were affected. 
Treatment to increase mobility of the spine can take many forms (Stoddard, 1982; Hartman, 
1983). The general articulatory manoeuvres employed were short lever mobilisation using 
gentle pressure on the pars articularis and spinal processes, plus long lever rhythmic 
stretching of the dorsal and lumbar spinal segments using the upper and lower extremities 
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for the appropriate leverage. All the articulatory techniques were slowly and gently applied 
with minimal force to avoid irritating spinal inflammation and to reduce any reactive spasm 
from the surrounding musculature. 
This method was also carried out with the patient lying supine, but mostly the patient lay on 
the side to allow a gentle stretch of periscapular and paravertebral muscles together with 
gentle massage upwards along the spine to improve lymphatic flow. This was often 
combined with gentle stretch of the ribs performed by holding the patient's arm with one 
hand, fixing the ribs with the other hand, and gently moving the held arm upwards 
stretching the thorax above the fixed rib. Combined stretch and massage, using the patient's 
arm as a long-lever produced excellent results, with movement of the ribs also increased by 
articulatory stretch techniques (see Fig. 11). 
To remedy the problems caused by hypermobile joints, as was the case of restricted joints, 
the first task was to reduce any possible inflammation present at the damaged segments. 
This could have been achieved in various ways. Most practitioners would prescribe anti- 
inflammatory drugs. However, contrast bathing was deemed preferable as it has no toxic 
side effects. 
The hot compress usually consists of a warm water bottle. "Warm" and not hot, as too hot 
a compress may have scalded the patient's skin. The "cold" was close to freezing point; 
however some CFS/ME patients can not tolerate extreme temperatures and so in those 
cases the frozen pack was wrapped with a cover. Frozen peas, which easily mould around 
the back, were used although special cold compress packs which remain soft even when 
frozen were found to be more suitable. Clinical experience of the author has shown that the 
sequence of contrast bathing that seemed to give the best results in reducing the 
inflammation in CFS/ME was as follows: 
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COLD -3 minutes } 
WARM -1 minute ) 
COLD -1 minute) TOTAL 10 AMLNUTES 
WARM -1 minute ) 
COLD -1 minute) 
WARM -3 minutes) 
This process has no adverse side effects, and so was safe to be used as many times as 
required. Applications of at least three times a day to the upper thoracic region was the 
recommended dose if there was inflammation in the neck and shoulders (or there were 
cerebral symptoms) and the lower thoracic area when the abdominal or lower extremities 
were affected. The main advantage of contrast bathing over anti-inflammatory drugs is that 
it worked quickly and directly on the affected area. Even when there was no palpable or 
visible inflammation, shown by heat and redness, contrast bathing to improve circulation in 
the thoracic region, was still advised. 
2.2.4.6.3 Soft tissue massage of the paravertebral muscles, trapezii, levator 
scapulae, rhomboids and muscles of respiration. 
Generally the massage technique for the relaxation of the aforementioned muscle groups 
took the form of gentle longitudinal and cross-fibre stretching (Hartman, 1983. ) Non- 
perfumed sweet almond oil was used as it is the most common used base oil in massage and 
seems to be fairly hypoallergenic. 
With the patient lying on the side, paravertebral muscles, primarily the dorsal erector 
spinae, were manually stretched using direct longitudinal pressure up to a level parallel 
with the first thoracic vertebra. Combined with long lever stretching via movement of the 
patient's arm and shoulder joint, this method has the added advantage of increasing rib 
movement and stimulating deep lymphatic drainage from the spine (see Fig. 11). 
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Figure 11 Combined articulation, soft tissue stretch and paraspinal effleurage 
The method illustrated is a combination of three soft tissue techniques: Long lever stretch 
of the intercostals, using the patients arm as a lever; direct longitudinal stretch of the dorsal 
erector spinae and with the finger tips, effleurage to the paravertebral lymphatics. The red 
arrow illustrates the direction of the massage; the yellow arrows show the direction of 
movement of the patient's arm. 
The patient was not usually in a prone position. However if it was necessary for the patient 
to lie down prone their face was placed into a breathing hole to avoid unnecessary strain on 
the neck. The patient was positioned on to the side as soon as possible to carry out the soft 
tissue work in this healthier position, whilst keeping the head level and knees apart with the 
aid of pillows Soft tissue stretching commenced with both cross fibre and longitudinal 
stretch applied rhythmically to the cervical, dorsal and lumbar erector spinae (see Fig. 12). 
Treatment was also given to relax the trapezii (see Fig. 12) and periscapular muscles e. g. 
rhomboids, as well as any other hypertonic back and shoulder muscles. Besides stretching, 
occasionally inhibition or functional techniques were used to reduce the tone of the 
tightened musculature (see Fig. 16) 
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Figure 12 Cross fibre stretching of lower neck and shoulders 
This technique involves a slow rhythmic kneading action applied to across the fibres of the 
lower cervical erector spinae, trapezii and levator scapulae. 
After increasing movement of the restricted spine and relaxing the surrounding 
musculature, an attempt to improve the respiratory mechanics was undertaken. This is 
important in CFS/ME patients, since the amount of oxygen in the body affects the chemical 
content of the body, and also has a direct affect on general functioning of the body's 
tissues. Reduced oxygen will produce greater fatigue in the patient and will aggravate the 
symptoms. By improving the mechanics of respiration in the rib-cage, one increases the 
lung capacity during inspiration thus raising the oxygen intake of the patient. 
Although increasing spinal mobility and relaxing paravertebral muscles will also enhance 
movement of the ribs, there are specific muscles-of-respiration that should be treated to 
improve the respiratory mechanics. 
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These include the intercostal muscles, serratus anterior and posterior, pectorals, abdominals 
and most importantly the diaphragm. Gentle inhibition to the edge of the diaphragm dome 
will usually reduce the tone of the muscle and aid breathing. This technique is known as 
"diaphragmatic release". 
After increasing mobility of the thorax by articulation and stretching, as well as relaxing the 
musculature, the patient was usually feeling more comfortable and lay in a supine position 
with knees slightly bent in readiness for the next stage of therapy. 
2.2.4.6.4 High velocity-low amplitude manipulation 
If any of the joints were severely immobile, it proved necessary to increase movement by 
high velocity low amplitude thrust techniques (see Figs. 13,14 and 15). In Osteopathy, this 
technique is called High Velocity-Low Amplitude HVLA or simply the high velocity thrust 
(HVT). In Chiropractic this manoeuvre is called an "adjustment" and is commonly known 
as a "manipulation" by the general public. This manoeuvre is the best known technique in 
the osteopath's armoury and involves a short, sharp motion usually applied to the spine. 
This procedure is designed to release structures with a restricted range of movement. There 
are various methods of delivering a high velocity thrust. Chiropractors are more likely to 
push on vertebrae with their hands, whereas osteopaths tend to use the limbs to make 
levered thrusts. That said, osteopathic and chiropractic techniques are converging, and 
much of their therapeutic repertoire is shared. This technique may produce a 'cracking' 
sound. 
The HVTs can be achieved with the patient lying prone, but it was preferable and safer to 
turn the patient onto their back and manipulate them in the supine position. Vertebral joints 
in some patients appeared slightly fused, and so strong manipulation was avoided thus 
averting damage to the bone. 
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Figure 13 Combined leverage and thrust of mid thoracic vertebrae 
The author's left hand is positioned in a loose fist to gap the facet joints. When the tension 
has built up by positioning the patient's upper spine in a flexed and rotated position, a fast 
but gentle pressure is applied through the direction of force as illustrated by the arrow. 
ä 
1:, 10 
1w --- 
, XIK MMR" 
i 
Figure 14 Combined leverage and thrust on the upper lumbar spine 
0 direction of rotation; __f direction of force 
The upper lumbar vertebrae were gently manipulated, gapping any restricted facet joint. 
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Figure 15 Gentle combined leverage and thrust on the lower cervical spine 
This manipulative procedure involves side bending the patient's neck to the left whilst 
rotating the cervical spine towards his right. Gentle pressure is placed towards the direction 
of the arrow gapping the lower cervical facet joints. 
The sequence, strength, and duration of all above techniques was based on each individual 
case but care was taken not to over-manipulate especially in the lower cervical region, as 
this may have worsened the symptoms by over-stimulating somatico-sympathetic reflex 
arcs (Korr, 1978). 
2.2.4.6.5 Functional techniques to the sub-occipital region and the sacrum. 
It is important when one treats posturo-mechanical strain of the spine to balance the sub- 
occipital and lumbosacral segments. Any abnormal kyphosis, lordosis or scoliosis will alter 
muscular tone along the spinal column and thus place extra load on the uppermost section 
and base of the spine. Similarly positional alterations of the spinal poles will affect the 
overall mechanics of the entire spine. Osteopaths and chiropractors may also use an 
affective "fine-tuning" procedure in these regions known as " functional techniques, " If 
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during subtle movement of the spine a restriction is detected, however slight, the back is 
held at the point of restriction until a release of muscle tension occurs. Techniques like 
these are based on an understanding of subtle neuromuscular behaviour, which conforms to 
mainstream osteopathic theory. In practice, they also rely on finely developed palpatory 
skills. As mentioned previously, the main principle behind any osteopathic treatment is that 
structure governs function. The principle of the functional technique is that by placing a 
joint or a group of muscles in a certain position that is functionally suited for that particular 
bodily part, the result is a relaxation of tissues and an overall improvement in muscular and 
fascial tone in the region. 
The sub-occipital muscles and the pelvic and lower lumbar muscles can be relaxed 
efficiently and painlessly by gentle positioning of the occiput and sacrum respectively. 
With the patient lying supine the operator's hands were placed at each side cradling the 
occiput, which was then slightly lifted off the pillow. The cervical spine was then gently 
extended and slowly rotated and side-bent right. Traction or compression was then applied 
and by asking the patient to breathe deeply, one was able to utilise exhalation as a 
relaxation tool. There was a fixed position whereby palpating the muscular tone just 
beneath the occiput, using the finger tips, one was able to feel the point of maximum 
relaxation for the sub-occipital muscles. This position was held for a few seconds resulting 
in a reduction of tone in this muscular group. 
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Figure 16 Functional technique to the suboccipital region 
With the patient lying supine the operator's hands were placed at each side cradling the 
occiput, which was then slightly lifted off the pillow and held in a fixed position to produce 
comfort and relaxation of the tissues in the upper cervical region. 
The same technique was applied to the pelvic and lower lumbar region by cradling one 
hand under the patient's sacrum and palpating the muscular tone in the lumbar sacral 
region. 
2.2.4.6.6 Treatment to the cranio-sacral rhythm 
Stage six commenced near the end of each consultation (see Fig. 17). This was found to be 
very effective at restoring energy and improving the cognitive ability of the patient and was 
thus extremely useful in the overall treatment. 
The fluctuation of the slow wave previously described by Sutherland is known as the 
cranial rhythmic impulse CRI. The CRI has a flexion (inspiration) phase and an extension 
(expiration) phase faintly changing the shape of the ventricles (Lay, 1997). Similar to the 
affects of the thoracic duct pump influencing the entire lymphatic system (Kinmonth, 
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1982), the CRI is transmitted via fascia and can be palpated throughout the body (Upledger 
and Vredevoogd, 1983). 
The fourth ventricle lies above the pons and below the cerebellum and between the lateral 
peduncles. The dorsal surface of the cerebellar hemispheres lies adjacent to the 
supraocciput. The main cranial technique used by the author was a procedure known as a 
CV4 (i. e. the compression of the fourth ventricle). This compression is achieved by gentle 
force applied with both hands pressing medially at the lateral angles of the occiput. This 
causes the occiput to slightly tilt inward increasing tension on the tentorium drawing it 
firmly on to the cerebellum which as a consequence, moves down on the roof of the pons 
and medulla. This downward compression coincides with an upward force on the pons and 
medulla from the brachium pontis (Meyer, 1980). 
By using the CV4 technique, the volume within the fourth ventricle is reduced, forcing the 
cerebrospinal fluid out through the aqueduct of Sylvius. The foramina of Lushka and 
Magendie allow drainage into the ventricle and subarachnoid spaces with reabsorption into 
the venous return via arachnoid villi (See Fig. 32) (Magoun, 1966). 
It is hypothesised that CSF drainage through the cribriform plate and down the spine will 
also be enhanced by the above procedure. Thus it plays an important role in the overall 
treatment. Care was taken not to over-stimulate the cranial rhythm with too long or forceful 
a treatment. After resuming a seated position the patient was advised to remain sitting for a 
moment and not to stand abruptly. This was aimed at reducing dizziness due to the neural 
mediated hypotension commonly found in CFS/ME (Werbach, 1998). 
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Figure 17 Cranial treatment 
The operators hand is placed in two different positions cradling the head laterally and 
antero-posteriorly. The cranial procedure involves very gentle pressure and movements 
that are very minimal. 
2.2.5 Other advice to patients 
Osteopathic treatment is not synonymous with manipulation. Many treatments of numerous 
conditions were found to be insufficient if they relied on manual therapy alone (Stoddard, 
1982). As in standard osteopathic practice, advice was also given to the patient group to 
help improve their general health. 
2.2.5.1 Dorsal rotation exercise 
Manual treatment of the patient improved function of the thorax and the spine especially 
when enhanced by routine mobility exercises. An effective exercise prescribed to improve 
and maintain the quality of movement of the dorsal spine was as follows (see Figs 18,19 
and 20) : 
The patient is seated. 
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The patient's hands are placed around the side of the neck. 
The patient should then slowly rotate the trunk, together with the head and neck. This 
gentle rotation is not designed to stretch muscles and joints, but to gradually and subtly 
increase movement of the upper thoracic vertebrae. The arc of rotation should only be 
about forty five degrees in total from right to left This should be repeated five times each 
way, without stopping in the middle. The movement must be rhythmic, with the patient 
feeling relaxed during the entire process. 
Figure 18 Upper thoracic rotation exercise 
The patient slowly rotates his upper back 5 times each way, through an arc of 45 degrees 
whist sitting. When holding the side of his neck, this rotation gently stretches the upper 
thoracic spine. 
Patients should then cross their arms and hug their shoulders with their hands. The 
movement to the right and left is then repeated five times each way as above, making sure 
that the head, neck and shoulders all move in unison. This part of the exercise encourages 
movement in the middle section of the thoracic spine. 
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_I Figure 19 Mid-thoracic rotation exercise The patient slowly rotates his back 5 times each way, through an arc of 45 degrees whilst 
sitting. When holding the shoulders, this rotation exercise gently stretches the mid thoracic 
spine. 
With the patient remaining seated, the exercise should be repeated, again five times each 
way, with the arms folded at the waist. Rotating the trunk in this position improves 
mobility of the lower dorsal and upper lumbar segments of the spine. 
Figure 20 Lower thoracic rotation exercise 
The patient slowly rotates his back 5 times each way, through an arc of 45 degrees whilst 
sitting. When folding the arms, this rotation exercise gently stretches the lower thoracic 
spine. 
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Patients were instructed to carry out the entire sequence three times a day. Since it is only a 
very gentle exercise, even the most severe cases of CFS/ME should not restrict the patient 
from doing the above exercise. However the patient was advised to cease exercises if pain 
developed at any time during or following the routine. The complete routine in all three 
positions took about one minute, if done at the correct speed. 
Following the above exercise, the patient was advised to stand up, and gently shrug his/her 
shoulders, rolling them slowly forward five times and then slowly repeating with 
backwards rolls five times. This exercise was also carried out at least three times a day (see 
Fig. 21) 
Figure 21 Shoulder shrug exercise 
Whilst standing the patient gently shrugs his shoulders, rolling them slowly forward five 
times and then slowly repeating with backwards rolls five times 
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2.2.5.2 Cross crawl 
By co-ordinating activity between the right and left sides of the patient, one can stimulate 
both halves of the brain to work together in harmony with the whole body. This is the 
principal of the following exercise, known as the cross-crawl. The cross-crawl exercise is 
basically marching on the spot. The marching action should be slow and deliberate, with 
the patient's right arm moving in unison with the left leg. This action is then repeated 
moving the left arm forward together with the right leg. CFS/ME patients usually find this 
simple task difficult to perform at the beginning of therapy, since their bodies are so un- 
synchronised. It is very important not to move the arm and leg of the same side together, as 
this will only succeed in throwing the body and mind further out of balance. After 
practising for a while the patients were able to carry out the cross-crawl exercise without 
too much difficulty. The marching routine was to be done up to five minutes during an 
entire day, a minute or so at a time. Any exercises that over-exerted the patient were 
definitely to be avoided. 
2.2.5.3 Self massage routine 
The patient was advised to aid the lymphatic drainage of the head and spine through a self 
massage routine developed by the author. 
2.2.5.3.1 Nasal release 
This massage schedule begins with the patient seated applying gentle pressure to open the 
fronto-nasal suture and aid drainage in the sinus mucous membrane. The minimal force is 
accomplished by mildly pressing the pads of both second digits up against the inner canthus 
or conversely pulling slightly down just above the bridge of the nose. The patients choose 
the technique with which they feel most comfortable and which enable them to breathe 
easiest through the nose. During the first ten days of self treatment, the pressure referred to 
by the author as 'nasal release' was held for a7 minute period. Clinically this has been 
shown to bring about a lasting release of the region by enhancing breathing and lymphatic 
drainage. After the first ten days, patients continued with `nasal release' but only for a one 
minute period to maintain the improvement (see Fig. 22). 
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Figure 22 Nasal release 
The seated patient gently presses the pads of both second digits up against the inner canthus 
or conversely pulls slightly down just above the bridge of the nose. 
2.2.5.3.2 Facial massage 
The patients, whilst remaining seated, were then advised to gently stroke the finger-tips of 
one spread hand down their faces to the chin (see Fig. 23). They were instructed to carry 
out gentle facial effleurage for only twenty seconds with a rate of one stroke roughly every 
four seconds. 
Figure 23 Facial self massage 
The patient gently strokes the finger-tips of one spread hand down his face to the chin for 
twenty seconds. 
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2.2.5.3.3 Head massage 
The above gentle stroking method was then repeated for twenty seconds at a time on both 
sides and the back of the head down to the neck (see Fig. 24). 
Figure 24 Self massage to head 
The patient gently strokes the fingers of both spread hands down the sides of his head to the 
neck for twenty seconds. 
2.2.5.3.4 Anterior neck massage 
The patient was then instructed to lie down and using sweet almond oil or baby oil to 
continue with bilateral effleurage of the neck down to the clavicles for twenty seconds 
each side (see Fig. 25) 
Figure 25 Cervical self massage 
The red arrows show the direction of the self-massage technique which was always towards 
either clavicle on both sides for 20 secs. each side. The pressure applied by the patient 
should be much less than during a treatment session concentrating only on the superficial 
lymphatics in the self massage. 
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2.2.5.3.5 Breast massage 
The patient massaged the lateral, central and medial sections of the breast in turn for twenty 
seconds, with a slow rhythmic stroking manoeuvre up towards the clavicles, thus directing 
the lymph away from the axillary lymph nodes to avoid risk of glandular swelling (see Fig. 
26). 
Figure 26 Self massage of the breast 
The red arrows show the direction of the self-massage technique. The patient massages the 
lateral, central and medial sections of each breast in turn for twenty seconds, with a slow 
rhythmic stroking manoeuvre up towards the clavicles. The pressure applied by the patient 
should be much less than during a treatment session concentrating only on the superficial 
lymphatics in the self massage. 
2.2.5.3.6 Back massage 
Having adopted a prone position, the patient received back massage from a family member 
or friend. The massage routine comprised of one minute of gentle upward effleurage to the 
sides of the spine, finishing in the shoulder region level with the clavicles. If no help was 
available, patients used back brushes to accomplish the back massage. 
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2.2.5.3.7 Posterior neck massage 
The self massage routine was completed with downward effleurage of the back of the neck 
for twenty seconds bilaterally, just in case the upward back massage was too vigorous and 
upward pressure was applied too high above the clavicles. 
2.2.5.4 Advice on lifestyle 
The patients were given the following general guidelines to aid return to good health. 
They were advised to avoid any stress whether physical, mental or emotional where 
possible. No activities that exert strain on the body were allowed. If the patient's 
occupation involved too much physical activity, they were advised to stop work 
temporarily or reduce their workload. This especially applied to jobs that put extra 
mechanical strain on the thoracic spine. 
Physical tasks that exerted too much strain on the patient were, if possible, to be done by a 
helpful colleague. Members of the patient's family were advised to share the workload at 
home, to make life as bearable as possible, until treatment had restored the sufferer to better 
health. 
If the patient usually spent time in front of a computer, or VDU, or if they were desk-bound 
at work, then they were advised to stand up every half-hour for a minute or two, and walk 
around the office. 
The patient was instructed to avoid slumping into a soft chair. When relaxing, patients 
were advised to lie on their side on a couch or a bed with the head well supported and a 
pillow between their knees. Lying on the side puts minimal strain onto the spine. 
Patients were advised to strictly rotate their diet with as much diversity as possible. This 
reduced placing strain on any particular region of the gastro-intestinal system. Processed 
foods were to be avoided and brown flour and brown sugar was to replace the white 
variety. Stimulants such as caffeine are not healthy, particularly in CFS/ME. 
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Decaffeinated coffee and decaffeinated tea or herbal tea was to be drunk instead. Patients 
were told to eat regular, healthy meals and to drink plenty of healthy fluids such as fruit 
juice, or even plain mineral water. The intake of tobacco, alcohol and too much medication 
may exert a strain on the internal viscera, and thus the sympathetics. This will undoubtedly 
worsen the symptoms of CFS/ME. Therefore smoking, drinking alcohol and the taking of 
medication was to be kept to the minimum, and avoided if possible. 
As well as the vitamin intake inherent in a healthy diet, a supplement of Vitamins C and B 
complex was prescribed. The former increases the patient's resistance to infection, while 
the latter improves general functioning of the nervous system. A high dose Vitamin C pill 
of 1000mg was recommended to be taken three times a week and a strong, or whole B 
complex tablet, to be taken once a day. Vitamins B and C are both water soluble so that 
any excess can be excreted from the body. However, there is a risk of developing kidney 
stones if the Vitamin C intake is too high, thus it is safer not to take the 1000mg pill every 
day (Baxmann et al., 2003). 
At the beginning of treatment, the patient was treated once a week. As the symptom picture 
improved, there was a gradual increase in the time between the consultations. 
2.3 Statistical methods 
2.3.1 Symptom picture 
Firstly, for each questionnaire, separate two-sample t-tests were performed on the 
difference of mean scores from start to months 3,6,9 and 12. The most important statistic 
after each 3 months is the p-value. Those tests with p<0.05 indicate significant differences 
between symptom reduction of the control group and the patient group at the 5% level of 
significance (see Appendix A9). 
Secondly the estimated differences in mean reductions between the two groups were 
calculated, with corresponding 95% confidence intervals. These provide an alternative way 
of presenting the information instead of hypothesis tests. An interval that excludes zero 
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corresponds with a significant test. Each interval is a range of values inside which the 
difference in the mean score of symptom reduction (controls minus patients) lies with 95% 
confidence (significant if the interval excludes zero). The confidence interval also provides 
information about the size of the difference (note that the estimated difference lies in the 
middle of the interval). 
Finally, for each questionnaire, a one-sample t-test was performed for patients only, to 
analyse any difference from month 12 until a year follow up. Ho = increase in mean score 
indicating a worsening of symptoms over the follow-up period. 
2.3.2 Muscle fatigue. 
The mean results of the knee extensor fatigability tests were statistically analysed using a 
paired t-test comparing torque X time before and after the year long study (See appendix 
A9). 
2.3.3 Spinal mobility 
The preliminary results of the spinal mobility tests of patients RP01 to RP07 on five test 
occasions at three monthly intervals were examined to see if there was any statistical 
significance. If there was, all the results would be examined and statistically analysed. 
However if these preliminary results showed no significance then, since the analysis was 
extremely labour intensive, it was deemed by the researchers an unnecessary excess of 
valuable research time and effort to continue in this line of investigation. 
2.4 Results 
2.4.1 Self report questionnaires 
The tables and bar charts below represent the mean score obtained from all the patients for 
each of the questionnaires at intervals during the 12 month test period, and subsequently at 
a one year follow up. The score values are expressed as the mean from the group of 
subjects as a percentage of the maximum severity of the symptom. 
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2.4.1.1 Mean value results 
In the table below (Table 4), the columns represent the mean value of each questionnaire 
result where 100% = the most severe case possible and 0% = symptom free. 
Beneath the means are the p-values calculated using two-sample t-tests on the reductions in 
the scores from the start to 3,6,9, and 12 months respectively, comparing the mean 
reduction of symptoms for both groups. Those tests with p<0.05 indicate significant 
differences between the mean reductions of the control group and the patient group at the 
5% level of significance. Thus if p>0.05 then it would signify that there was no statistical 
difference between the mean improvement of the patient group (1) and the control group 
(2). A p-value of <0.05 in all the questionnaires would show a significant improvement in 
the overall health of the patient group compared to that of the control. 
Note that the final row of Table 4 only pertains to the patient group, and shows the mean 
scores in the follow up a year after the end of the trial. The p-values in this row were 
calculated using a one-sample t-test. The scores at the end of the follow-up year were 
compared with the scores at 12 months. If there is no significant deterioration in the health 
of the patient group the p-values will all exceed 0.05. 
The results are further illustrated graphically in the two bar charts Figs. 27 and 28. A 
reduction of symptoms is represented by a diminution of the height of the corresponding 
bar. 
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health back-pain Bdi Bai sleep cfq Nott Pfrs 
Start 
Group 1 40.58 38.64 32.87 29.26 34.96 57.40 38.9 48.90 
Group 2 33.92 26.97 25.44 24.80 42.68 61.40 31.1 44.95 
3 months 
1. 33.28 31.59 20.99 21.31 32.23 53.9 31.56 38.32 
2. 31.49 27.11 24.49 25.28 40.75 58.60 34.98 42.78 
p-value 0.180 0.151 0.023 0.023 0.706 0.853 0.122 0.032 
6 months 
1. 27.9 26.41 17.33 20.61 30.65 50.00 24.72 31.56 
2. 34.05 28.36 21.31 28.46 40.18 61.5 37.35 44.80 
p-value 0.002 0.005 0.033 0.001 0.535 0.004 0.001 0.000 
9 months 
1. 26.88 24.19 15.26 17.01 28.83 47.70 23.14 29.05 
2. 33.66 28.36 20.99 25.76 46.08 60.20 37.08 44.10 
p-value 0.000 0.000 0.003 0.000 0.005 0.002 0.000 0.000 
12 months 
1. 23.94 23.07 15.26 19.40 24.97 45.00 21.04 27.34 
2. 36.22 29.19 22.66 27.51 41.54 61.70 39.45 47.43 
p-value 0.000 0.000 0.000 0.000 0.006 0.000 0.000 0.000 
Follow up 
(Group 1 27.01 23.35 13.67 8.92 24.74 44.2 20.78 31.9 
only) 
p-value 0.678 0.529 0.298 0.069 0.850 0.837 0.545 0.194 
Table 6 Phase 1: Means for symptom severity showing statistical significance 
The columns represent the mean value of each questionnaire result where 100% = the most 
severe case possible and 0% = symptom free. The p-values were calculated using two- 
sample t-tests on the reductions in the scores from the start to 3,6,9, and 12 months 
respectively, comparing the mean percentage change in both groups. The p-values in the 
final row were calculated using a one-sample t-test, comparing the final scores with those at 
the end of the follow-up year. 
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The bar chart shows the changes in the questionnaire scores in the treated group over the 
course of the first clinical trial and the year follow-up. The questionnaires were as follows: 
Column 1. Health =A general health questionnaire examining most common symptoms of 
CFS/ME; Column 2. examined back pain; Column 3. bdi = The revised Beck depression 
inventory; Column 4. bai = The Beck anxiety inventory; Column 5= The Morgan-Gledhill 
sleep questionnaire; Column cfq = Broadbent's cognitive function questionnaire; Column 
7. = The Nottingham Health Questionnaire which concentrates on symptoms of fatigue; 
Column 8. pfrs= The Profile of Fatigue Related States. As all the questionnaires have 
different scales and scoring systems, the results were converted to a percentage of the 
maximum score possible. 
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Figure 27 Bar chart of patient group's mean scores (phase 1) 
100 
90 
80 
70 
O 
C at 60 - - - 
L L 50 
1 
'co y a 
C 0 
1 40 
30 
20 
10 
0 
back- 
health bdi bai sleep cfq nott pfrs 
Index pain 
  start 33.92 26.97 25.44 24.8 42.68 61.4 37.1 44.95 
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Figure 28 Bar chart of control group's mean scores (Phase 1) 
The bar chart shows the changes in the questionnaire scores in the untreated control group 
over the course of the first clinical trial. As in Fig. 27 the results were converted to a 
percentage of the maximum score possible for each questionnaire. 
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2.4.2 Muscle fatigue 
The individual results of the isometric tests are listed in Table 7. Torque X time, the 
impulse torque, measured in Newton metre seconds (Nms) for each member of the patient 
group before and after the year's treatment was recorded. The difference and percentage 
change in impulse torque was calculated and is inversely proportional to the post exercise 
fatigue, thus the greater the percentage change the less the fatigue. This test was only 
carried out on the patient group as the control group members of phase 1 were completely 
anonymous to the author having been independently selected by Action for M. E. Also the 
control group members were CFS/ME sufferers living throughout the UK. The task of 
bringing them to Salford for the tests to be carried out would have proved logistically too 
difficult and possibly stressful and potentially harmful to the subjects. 
There are only five negative values with only one, RP13, recording a statistically 
significant lower value of impulse torque after the year. All the other patients showed an 
increase in the impulse torque with some over 100% improved on their first score. 
The mean results of the knee extensor fatiguability tests for all subjects in the patient group 
were statistically analysed using a paired t-test, comparing the impulse torque before and 
after the year long study. 
The mean value at the beginning was 1791Nms and at the completion had risen 
significantly to 2266 Nms. The results of the paired t-test on the above data are shown in 
Table 8, where the null hypothesis was that the mean impulse torque /Nms of right knee 
during first 30 seconds of final push was the same for tests 1 and 2. 
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Test 1 Test 2 Difference Percentage 
Patient (year start) 
(year 
end) Between Change 
code no. /Nms Nms Test 1& 2/ ms % 
RP01 606 2211 1605 264.85 
RP02 1077 1767 690 64.07 
RP03 512 1255 743 145.12 
RP04 716 1783 1067 149.02 
RP05 732 1182 450 61.48 
RP06 1264 1559 295 23.34 
RP07 1982 2641 659 33.25 
RP11 583 711 128 21.96 
RP12 1691 2971 1280 75.69 
RP13 1917 1366 -551 -28.74 
RP14 5033 5014 -19 -0.38 
RP15 2484 2945 461 18.55 
RP16 2653 2990 337 12.7 
RP17 1807 2604 797 44.11 
RP19 245 704 459 187.35 
RP20 518 826 308 59.46 
RP21 659 1331 672 101.97 
RP23 4776 4670 -106 -2.22 
RP24 475 1179 704 148.21 
R P25 1440 1777 337 23.4 
RP26 5140 4658 -482 -9.38 
RP27 277 1343 1066 384.84 
RP28 1793 2118 325 18.13 
RP29 1109 1320 211 19.03 
RP30 1594 1866 272 17.06 
RP31 700 863 163 23.29 
RP32 1695 3221 1526 90.03 
RP33 3002 2927 -75 -2.5 
RP34 3698 3742 44 1.19 
RP35 1727 2658 931 53.91 
RP36 2757 3476 719 26.08 
RP38 1364 1998 634 46.48 
RP40 3093 3103 10 0.32 
MEAN 1791.48 2266.03 474.55 26.49 
Table 7 Phase 1: Impulse torque /Nms of right knee during first 30 seconds of final 
push 
Column 3= impulse torque at the start of the research. Column 4= impulse torque at the 
end of the year. Column 6= column 4-3. The final column shows the percentage change 
in the impulse torque. A minus sign indicates a reduction in the impulse torque. 
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Number of Mean Standard 
subjects Impulse Torque/ Deviation 
Nms 
Test 1 33 1791 1,353 
Test 2 33 2266 1,170 
Mean % Mean Difference 
Difference 26.49 
= 475 
Table 8 Mean difference of impulse torque in patient group (phase 1) 
The table shows the mean difference in impulse torque, pre and post treatment over a year, 
calculated from the results in Table 7. 
Estimated difference in means µ2- µl is 474.5 with 95% confidence interval (296.4,652.7). 
V1 = µ2 has a two-sided test statistic of 5.43 on 32 degrees of freedom, resulting in a p- 
value of 0.000 to three decimal places. Hence, the null hypothesis HO was rejected at the 
5% (even at the 0.1%) level demonstrating that the means are significantly different. 
2.4.3 Spinal mobility 
The preliminary results of spinal mobility tests of patients RPO1 to RP07 on five occasions 
at three monthly intervals are listed below in Table 9 measuring the angle CTL at probe 
position T in the mid thoracic spine (see Appendix A8). The percentage changes both 
periodically, every three months (table 10), and relative to the start of treatment (table 11), 
have been recorded. The mobility tests were meant to be carried out every 3 months 
although due to damaged equipment many missed out on the examination at 9 months, thus 
the % change in patients RP04-07 could not be calculated from 6-9 months and 9-12 
months. 
The mean values in both charts clearly demonstrate that the thoracic mobility of these 
patients varied very little from the beginning to the conclusion of Phase 1. It was also noted 
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that there was no correlation with the amount of mobility and improvement of CFS/ME 
symptoms, the significance of which is discussed at length in section 2.5.3. 
As was the case with the tests on muscle fatiguability, the spinal mobility investigation was 
only carried out on the patient group to avoid compromising the anonymity and health of 
the control group members of phase 1. 
Start 
0 3 months 6 months 9 months 
End 
12 months 
RP 01 150.19 150.30 152.51 154.42 144.06 
R P02 139.27 151.10 144.76 146.65 146.07 
R P03 138.04 144.04 140.05 138.86 140.13 
RP04 149.60 145.41 151.42 150.97 
R P05 138.87 134.99 133.14 ''**** 133.57 
RP06 139.43 136.62 138.94 ***** 137.17 
RP07 137.74 137.67 135.00 ***** 135.45 
Table 9 Chart showing angular values of mobility in thoracic spine of patients RPO1-7 
The table shows the angular values of probes CTL for flexion of the mid thoracic spine in 7 
of the patients treated with the chosen osteopathic method in phase 1 of the study. The 
angles were calculated using the Salford biomechanics workstation which digitised the 
video footage of the patients bending in full flexion (see Appendix A8). 
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% 
change 
ßö 
change 
9ü 
change change 
0-3 
months 
3-6 
months 
6-9 
months 
9-12 
months 
RP01 0.07 1.47 1.25 -6.71 
RP02 8.49 -4.2 1.31 -0.4 
RP03 4.35 -2.77 -0.85 0.91 
RP04 -2.8 4.13 ***** ***** 
R P05 -2.79 -1.37 
RP06 -2.02 1.7 
RP07 -0.05 -1.94 
Mean 0.75 -0.42 0.57 -2.06 
Table 10 Chart showing periodic % change in angular values of mobility 
in thoracic spine of patients RP01-7 
The table examines the percentage change in CTL angular value of full flexion in the mid- 
thoracic spine, point T, in the first 7 patients at each 3 monthly stage compared with the 
previous stage. The mobility tests were meant to be carried out every 3 months although 
due to damaged equipment many missed out on the examination at 9 months, thus the % 
change in patients RP04-07 could not be calculated from 6-9 months and 9-12 months. 
% 
change 
% 
change 
% 
change 
% 
change 
0-3 
months 
0-6 
months 
0-9 
months 
0-12 
months 
R POI 0.07 1.54 2.82 -4.08 
RP02 8.49 3.94 5.3 4.88 
RP03 4.35 1.46 0.59 1.51 
R P04 -2.8 1.22 ****'' 0.92 
R P05 -2.79 -4.13 ***** -3.82 
RP06 -2.02 -0.35 -1.62 
RP07 -0.05 -1.99 ***** -1.66 
Mean 0.75 0.24 2.9 -0.55 
Table 11 Chart showing % change from start in angular values of mobility 
in thoracic spine of patients RPO1-7 
The table examines the percentage change in CTL angular value of full flexion in the mid- 
thoracic spine, point T, in the first 7 patients at each 3 monthly stage compared with the 
value at the start of the study. As mentioned above damaged equipment caused many of the 
subjects to miss out on the examination at 9 months, thus the % change in patients RP04-07 
could not be calculated from 0-9 months. 
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The digital analysis of the video footage was extremely labour intensive and time 
consuming, thus as there was no correlation in the first group of patients, without even 
showing a trend of increased angular movement, the digital analysis of spinal movements 
was discontinued. 
2.5 Discussion 
2.5.1 Questionnaire results 
Some results require a more detailed analysis and explanation. It was postulated that pain in 
the neck and back of the CFS/ME subjects is likely related to a mechanical dysfunction. 
Osteopathic practitioners would expect this pain to be relieved by manual treatment of this 
region. The questionnaire relating to back pain (Questionnaire 2) produced the anticipated 
result, considering the control group were not able to receive manual treatment for the 
duration of their involvement in the project and supported the original postulation as shown 
in Table 4, column 2. Note that when the standard treatment ceased for most subjects in the 
patient group during the year follow-up, the back pain scores worsened. Four members of 
the patient group chose to continue treatment with the author as private fee-paying patients 
during the follow up year 
The Beck Depression Inventory (Questionnaire 3) produced an interesting result as shown 
in Table 4, column 3. These scores clearly demonstrate that the depression level of the 
control was steadily decreasing during the first 9 months. This may be due to the 
antidepressants taken by some of the control subjects. This particular result differs from 
most of the other symptoms of the control group, all of which deteriorated with time. This 
corroborates the claim that CFS/ME is not a depressive disorder otherwise we would have 
expected to show some improvement in the other symptoms as the depression levels 
dropped. 
The results of the final questionnaire No. 8 (The Profile of Fatigue Related States) see 
Table 4, column 8, are particularly important as this was the only established and tested 
questionnaire developed specifically for the symptoms associated with CFS/ME (Ray, 
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1992). The overall improvement in the PFRS scores of the patient group from a mean score 
of symptom severity of 48.9% down to 27.34% compared with the control group's score 
increasing in symptom severity of 44.95% up to 47.43%, adequately demonstrates the 
validity of the treatment programme. 
In the follow up study (see Appendix A9, p297) the p-value in all questionnaire results 
exceeded 0.05, demonstrating that the treatment effects were long-lasting with most of the 
patients discontinuing treatment following the initial year's study with insignificant change 
in symptom picture. 
2.5.2 Muscle fatigue 
The tests involving measurement of impulse torque by the quadriceps muscle also clearly 
demonstrated that the treatment had caused a change for the better. A previous study on 
patients with CFS/ME (Wong et al., 1992) has demonstrated that the reduced capacity for 
dynamic exercise is also associated with reaching exhaustion much more rapidly than 
normal subjects, at which point these patients have relatively reduced intracellular 
concentrations of ATP. The study concluded that there was a defect in oxidative 
metabolism with a resultant acceleration of glycolysis in the working skeletal muscles of a 
CFS/ME sufferer. Impaired blood flow is a possible explanation for a reduced oxygen 
supply to the muscle resulting in the above finding. However, at the end of this stage it was 
felt more research had to be conducted to understand the nature of the fatigue and to 
investigate the reason for the improvement following the chosen osteopathic treatment. 
2.5.3 Spinal mobility 
As mentioned earlier Korr (1979) proposed that spinal dysfunction would lead to 
disturbances in the muscular fatigability, sensory excitability, immunological mechanisms 
and endocrine functions due to an impairment in normal sympathetic efferent flow If 
Korr's (1979) findings were correct then Spinal mobility in the present study would be 
expected to improve as the severity of the symptoms lessened. 
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The present results of the spinal mobility test (Tables. 9,10 and 11) suggest that there is 
little correlation between thoracic spinal movement and the symptoms of the patients. The 
effects of the treatment could be analogous to lubricating a rusty door hinge. The result will 
be a door that opens and closes smoothly and quietly but the range of movement is limited 
to the arc between the doorpost and the adjoining wall. In other words, by relaxation of 
surrounding soft tissue with less spinal and paraspinal discomfort, the treatment improves 
the quality of movement of the spine but not quantity. 
Clinical findings argue strongly for a biomechanical and/or drainage component (See 
section 5.2). The precise nature of the processes that produce the significant improvement 
given by osteopathic treatment was an important question that remained unanswered 
following Phase 1 of this study. In relation to this a common clinical feature observed in the 
patients was a reduction in the quality of movement of the upper spine with evidence of 
long term mechanical dysfunction. The latter often appeared to be associated with the 
patient's past history (e. g. work, accident or physical exertion related upper spine 
involvement). In turn there was a strong indication that the osteopathic manipulation and 
relaxation of soft tissue improved circulation of blood, cerebrospinal fluid and lymph in the 
cranial and upper spinal regions of the patients. The following two cardinal features of the 
CFS/ME patients were palpated using standard osteopathic manual proprioceptive and 
palpatory techniques: 
1. A significant reduction of mobility in the cranio-sacral rhythm / involuntary mechanism. 
2. Congestion of the cervical and thoracic lymph vessels especially in the breasts and in 
most cases significantly more in the left side than the right. 
In relation to the latter it is thought that there is drainage of approximately 75% of lymph in 
the breast tissue to the axillary nodes. Lymph vessels from deep tissues of the thoracic wall 
drain mainly to the parasternal, intercostal and diaphragmatic nodes. A plexus in the 
interlobular connective tissue and walls of the milk ducts communicate with the plexus 
around the nipple, and also with a plexus of minute vessels on adjacent deep fascia. This 
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pathway offers an alternative route when the usual pathway is blocked. Congested lymph 
vessels are apparently found in all cases of CFS/ME and this can be explained when 
viewing the factors aiding propulsion of lymph from tissue spaces to lymph nodes and the 
venous blood stream. These are as follows: 
1. Filtration pressure 
2. Contraction of neighbouring muscles 
3. Pulsation of neighbouring arteries 
4. Respiratory movements 
5. Sympathetic nerve control of smooth muscle walls causing pulsatile contractions in 
thoracic duct aided by valves along its structure which maintain unidirectional flow 
(Kinmonth, 1982). 
This last factor has been largely overlooked for decades and has received little attention 
from the medical world. However it has a potential of major significance when analysing 
the possible pathological process leading to CFS/ME. The afferent sympathetic outflow, in 
particular, may be modified by the treatments. 
To further understand how the sympathetic nervous system may be involved in the 
pathogenesis of CFS/ME and how the improvement of sympathetic function may be 
responsible for some of the decline in the symptoms discussed in this section, one has to 
examine the control mechanisms involved. In this respect aspects of the Autonomic 
Nervous System (ANS) and its centre the hypothalamus are discussed. 
2.5.3.1 The hypothalamus 
The hypothalamus is approximately four cubic centimetres in size and represents 0.3% of 
the human brain (Williams, 1995). It has a central role in the control of the ANS and 
hormonal activity. Thus a dysfunctional hypothalamus can have major effects on these two 
important homeostatic systems which are considered separately below. 
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This MR image shows just how small the hypothalamus is in relation to the entire brain. 
The scan also reveals the central location of the hypothalamus close to the important pons, 
frontal lobe, just below the limbic system and in the heart of the ventricular system. 
2.5.3.1.1 Autonomic activity 
Whilst the overall control centre of the autonomic nerves lies in the brain, the sympathetic 
nervous system largely resides within the spinal cord. Along with the rest of the autonomic 
system, the parasympathetic and the endocrine system, they are responsible for controlling 
visceral, circulatory and metabolic activity. However, the performance of the sympathetic 
system can be greatly affected by mechanical and postural strain in the mid section of the 
spine, from the first thoracic vertebra to the second lumbar segment. 
Osteopathic philosophy views the neuromuscular-skeletal system as the primary machinery 
of life, with the internal organs being secondary and supportive (Korr, 1978). It is important 
to understand why osteopaths view the muscles and bones as the main apparatus of the 
body. When a person moves, talks and breathes, the musculo-skeletal system is the 
structure which is directly involved. When one compliments a friend on how they look, one 
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Figure 29 Sagittal view of brain showing position of the hypothalamus 
doesn't say "Oh what a beautiful spleen you have! " and likewise, if one is praising the 
performance of an employee, a manager is unlikely to declare, "His liver and kidney 
certainly work well. " 
When one observes a fellow human, it is the make-up of the person that is apparent, 
including their build, shape and how they utilise their structural assets. In everyday 
existence, it is the muscles, tendons, ligaments, joints, skin and bones, together with the 
nerves supplying these structures (the Somatic Nerves), that form the `Primary Machinery 
of Life' (Korr, 1978). 
Rapid adjustments in accordance with levels of exertion and posture are orchestrated 
largely by the sympathetic nerves. The parasympathetic system makes long term 
adjustments, maintaining and replenishing stores of nutrients and fuel which have been 
utilised under the direction of the sympathetic system. In other words, both sections of the 
autonomic nervous system work in conjunction with each other. From this viewpoint, 
illness can result from inconsistency between demands of the neuromuscular-skeletal 
system (the Primary Machinery) and the ability of bodily systems to maintain adequate 
provision for normal function. Thus a patient requires rest when ill, reducing demand until 
this disparity is corrected. Traditional medicine places more emphasis on demands from the 
internal organs. However, by virtue of their mass and their rapidly changing metabolic rate, 
muscles are definitely the main consumers of the body. 
The parasympathetic ganglia are mainly situated in the target organ. Their postganglionic 
fibres innervate all the internal organs including the eye. The uppermost fibres in the head 
supply the lacrimal glands of the eye which produce tears. A major parasympathetic nerve 
from the brain is the vagus, which supplies the organs of the neck, thorax, pelvis and 
genitalia. 
The sympathetic postganglionic fibres supply all the organs innervated by the 
parasympathetic nerves, although the distribution to different parts of the organ may vary. 
The blood supply to the body is almost entirely under the control of the sympathetic 
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nervous system, except the vasculature of the pelvic organs and genitalia which are under 
parasympathetic regulation. A disturbance of sympathetic control over the peripheral 
circulation including the muscles may be part of the cause of the muscular symptoms in 
CFS/ME. This phenomenon was explored in phase 2 of the research. 
It should be noted that the reduced fatigability of the quadriceps was not achieved by any 
direct treatment on the lower extremity, or by any exercise regime to improve muscle 
strength in the legs. The author's treatment programme was based solely on the hypothesis 
that by using manual techniques to reduce disturbed afferent sympathetic impulses, the 
overall sympathetic nervous system eventually begins to function normally, thus improving 
visceral function and the circulation in body tissues, including skeletal muscle. 
Sympathetic influence over arterial pressure and peripheral blood resistance affects the 
cardiac output, as well as many other metabolic processes. The parasympathetic vagus 
nerve modifies the rhythm of the heart, but the sympathetic nerves regulate the entire 
cardiovascular system, in accordance with what is going on in the body as a whole. 
The sympathetic nervous system differs from the parasympathetic in the following four 
ways: 
1. The parasympathetic nerve supply is almost entirely visceral, exerting most of its control 
over the internal organs. The sympathetic nerves, however, regulate functioning of the skin, 
bones, ligaments, tendons and parts of the somatic nervous system, plus the skeletal muscle 
as well as the organs. 
2. The parasympathetic nerves are more specific, with individual nerves supplying a 
specific target organ. The sympathetic effects are more widespread due to a fanning out of 
the nerves to all tissues. 
3. The parasympathetic nerves control blood supply only to the genitalia. The sympathetic 
nerves control the circulation throughout the rest of the body. 
4. The parasympathetic system is not directly affected by the requirements of the body, but 
the sympathetic nerves are influenced and controlled by the demand of other bodily 
systems (See Fig. 30). 
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Figure 30 The efferent (motor) component of the autonomic nervous system 
Waugh H. Mahon M. 2001, 
Reprinted with permission of Dept of BioSciences, University of Manchester 
Since the sympathetic ganglia are centrally located, post-ganglionic sympathetic efferents 
can spread out exerting their influence systemically, unlike the parasympathetic ganglia 
located at the target organ. 
Anatomically the somatic motor nerves, which stimulate skeletal muscle contraction, 
contain fibres that lie alongside the preganglionic fibres of the sympathetic nerves as they 
leave the spinal cord. The postganglionic sympathetic fibres also connect with the motor 
nerves as they travel down to the muscles. Sympathetic nerves, due to their close proximity 
to motor nerves, are also equally sensitive to stimuli from sensory inputs, higher centres or 
interspinal nerves. Also, since spinal nerve roots contain both somatic and sympathetic 
fibres, both are vulnerable to mechanical trauma. 
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The connection between peripheral somatic nociceptive afferent fibres and sympathetic 
nerves has been observed in pathological mechanisms (Janig, 1988). 
Sympathetic influence has been noted via: 
1. Noradrenalin directly on peripheral afferent via alpha 1 adrenergic receptors. 
2. Noradrenalin exciting alpha 2 adrenergic receptors mediating the release of 
prostaglandins exciting the primary afferent fibre. 
3. Sympathetic and sensory fibres coupled electrically via synapses or the lesser known 
ephapses either in the terminal region or between fibres within Remak bundles (aggregation 
of C fibres) resulting in `cross talk' (Gasser, 1955). 
4. Noradrenalin release may have local effects on blood flow, environment in skin 
enhancing activity. 
While many autonomic nerves are purely sensory, certain primary afferent nerve fibres also 
have an efferent (and trophic) function. Sensory neurotoxins stimulate transmitters released 
at peripheral endings to produce vasodilation and smooth muscle contractility. Furthermore, 
they may have effects on the regional leukocytes and fibroblasts leading to what is known 
as "neurogenic inflammation", with eventual stimulation of somatic afferent fibres causing 
pain (Mense, 2004). This may explain many of the more severe musculo-skeletal and 
sensory symptoms affecting the patient with CFS/ME. 
The general medical view, pre-1990's, was that the sympathetic nervous system was largely 
efferent, producing an array of disturbed physiological symptoms (Cunningham, 1973; 
Burn, 1971; Korr et al., 1964,1960,1947). It is now accepted that the sympathetic nervous 
system has a large afferent component that sends disturbed messages to the central nervous 
system in cases of bodily distress and disease (see Fig. 31). The afferent nerves run 
alongside somatic sensory nerves throughout the body (Bonica, 1990). It is also now 
realised that autonomic diseases can occur in association with a broad range of 
neurological, cardiovascular, endocrine, and general medical disorders (Guyton and Hall, 
1996; Bannister and Mathias, 1993). 
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Figure 31 The afferent (sensory) component of the autonomic "er"ous system 
A schematic diagram simplifying a complex interaction within the nervous and hormonal 
systems of the sensory component of the ANS. A barrage of messages are continuously 
sent to the hypothalamus from all manner of stimuli. 
The errant sensory component of a disturbed sympathetic nervous system appears to be the 
main neurological feature seen in CFS/ME. This dysfunction may produce an increase or a 
reduction of sympathetic activity in the sufferer, often with hypo- and hyper- 
sympatheticonia affecting different target organs concurrently in the same patient, e. g. a 
patient may complain of increased perspiration, dryness of mouth and coldness of 
extremities simultaneously. This explains the multi-variant characteristics of this disorder. 
The role of the sympathetic nervous system (SNS) in the pathogenesis of CFS/ME can be 
demonstrated when examining other individual symptoms of the disorder. Most patients 
with CFS/ME have undergone some form of prior stress, whether it is physical, emotional, 
chemical or viral. That has obviously placed extra strain on the SNS (Noll et al., 1996; 
Jansen et al., 1995). Pain, in the joints, muscles or even viscera, is a frequent complaint of 
the patients. The sympathetic nerves are integrally related to the neurological pathways 
involved in the "pain system" (Bonica, 1990; Janig, 1988). 
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Pain reception is transmitted to the brain via spinothalamic and spinoreticular pathways 
(Bonica, 1990; Campbell, 1985). Projections of these spinal tracts directly connect to the 
hypothalamus (Giesler et al., 1981; 1979) which demonstrates how nociception pathways 
can influence normal bodily function. 
As previously mentioned, the immune system's role in this disease has been widely 
investigated. A common finding is T-cell hyperproliferation. Research in Hungary has 
produced neurochemical, electrophysiological and immunocytochemical evidence for a 
noradrenergic link between the sympathetic nervous system and the production of T-cells in 
the thymus gland (Vizi et al., 1995). 
Hypotension and hypertension are common findings in CFS/ME patients and salt 
imbalance is frequently blamed. The SNS has been shown to influence salt appetite 
(Bourjeili et al., 1995). A dysfunction of the SNS could account for this finding. Another 
common complaint is an irritable bladder. This is possibly due to SNS effects on bladder 
pressure and afferent nerve activity from the bladder (Khadra et al., 1995). Irritable Bowel 
Syndrome (IBS) is characterised by chronic bouts of alternating constipation and diarrhoea 
plus associated abdominal pain. The role of the SNS in gastric and bowel function is well 
documented (lovino et al., 1995). IBS is often reported in CFS/ME cases and may be due to 
changes in gastric and bowel control due to SNS dysfunction. 
Experiments in the former Soviet Union demonstrated behavioural changes in rabbits after 
impairment of the functioning of the sympathetic nervous system (Sollertinskaia, 1957; 
Koramian, 1958). Following a sympathectomy, certain reflexes controlled by the central 
nervous system were shown to be diminished. This early work demonstrated a connection 
between sympathetic nerves and the higher centres of the central nervous system. In other 
words, impaired sympathetic activity could lead to changes in brain function. This could 
explain why psychological symptoms develop with the advancing CFS/ME. 
An early symptom complained of in CFS/ME is hyperacusis (acute sensitivity to sound). A 
recent study showed that cervical SNS stimulation had a protective effect on the 
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susceptibility to acoustic trauma (Wada et al., 1995). Thus a dysfunctional SNS may 
provide the explanation for this symptom. Likewise photophobia in CFS/ME may be due to 
pupil dilation caused by increased sympathetic activity. 
Recent research supports the dual nature of the sympathetic dysfunction in this disorder. An 
increase of choline has been reported in the occipital cortex of CFS/hIE sufferers (Puri et 
al., 2002). Excess cholinergic neurotransmission due to sympathetic overload would result 
in toxic amounts of choline. Conversely in some CFS/ME patients there is clearly a 
reduction of cholinergic neurotransmission. Galanthamine hydrobromide interacts with the 
enzyme acetylcholinesterase, thereby increasing levels of acetylcholine in the brain 
(Chaudhuri et al., 2000). In a placebo-controlled trial of galanthamine hydrobromide on 49 
patients with CFSIME, 43% of the 39 who completed the treatment reported a 50% 
beneficial change in fatigue, myalgia and sleep (Snorrasson et al., 1991). 
2.5.3.1.2 Hormonal activity 
Hormonal activation via the hypothalamic pituitary-adrenal axis in response to stressors 
was initially coined the General Adaptation Syndrome by Hans Selye (1946; 1936). The 
nucleus paragigantocellularis (PGi), a part of the ventromedial medullary reticular 
formation, sends signals into the midbrain area known as the locus coeruleus (LC). This is a 
major source of adrenergic axons and believed to be the brain's centre for vigilance and 
arousal increasing awareness of potentially harmful stressors. The PGi-LC system is thus 
very sensitive to pain. With prolonged somatic dysfunction often leading to repetitive 
nociceptive input, a consequential overstimulation of the PGi-LC may contribute to the 
chronic adaptive response that ensues (Aston-Jones et al., 1990). Corticotropin-releasing 
hormone (CRH) is a neuropeptide released from the paraventricular nucleus (PVN) of the 
hypothalamus following stimulation of the locus coeruleus via adrenergic neuronal 
pathways. The PVN is a key area in regulating both the autonomic and endocrine systems. 
Thus activation of the LC-PVN pathway by stressors leads to an increase in activity of the 
sympathetic nervous system and enhanced output of the Hypothalamic-Pituitary-Adrenal 
(HPA) axis. 
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Recently published research (Papanicolaou et a1., 2004) to emerge from the US maintains 
that over 800,000 North Americans suffer from CFS/ME. The scientists of this study 
suggest that the responsibility for this disease lies in the neuroendocrine system. 
Stressors affect neuroendocrine events via neurotransmitters and other neuro- 
immunomodulators (Auveneshine, 1997). Mounting evidence demonstrates that the 
interconnections between the CNS and the immune system via the HPA axis are 
bidirectional (Black, 1994). 
The connection between somatic and sympathetic components is clearly observed in the 
disorder called reflex sympathetic dystrophy RSD. This is also known as 'algodystrophy' 
which is a sympathetically maintained form of sensitisation presenting with a unilateral 
dystrophic limb plus increased vascularisation, flushing and warmth, compared with the 
healthy side. The condition may arise through minor injury causing sensitisation of a 
nociceptor and the onset may be within hours of the initial insult and may take weeks to 
spontaneously resolve. Alternatively it may become a chronic condition being maintained 
by increased sympathetic activity reducing local blood flow, lessening the removal of 
sensitising factors and by stimulating the release of sensitising chemicals. Spinal cord 
changes may also occur which may further increase sensitivity (Bossi et a!., 1989; Schott, 
1989). 
The onset of CFSIME is frequently linked to pre-morbid psychological stressors, 
categorising CFS/ME as a stress-related illness. The mere association between exposure to 
emotional stress and alterations in immune, endocrinological and central nervous function 
does not prove cause and effect. Unfortunately there has been too much emphasis on the 
role of psychosocial stressors, with the concept of a physical aetiology largely being 
ignored. CFS/ME occasionally presents as a genetic disease with multiple sufferers found 
in different generations of one family. Thus CFS/ME, although being a neuroimmune 
disorder with many differing aetiologies, may actually target genetically predisposed 
individuals" (Goldstein, 1993). Environmental and genetic factors will alter the rate of 
chemical metabolism (McKeown-Eyssen et al., 2004) and may predispose the development 
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of multiple chemical sensitivity. The prognosis of diseases such as CFS/ME will depend on 
the many factors affecting the body's capability to eliminate toxins 
Later chapters in this thesis aim to demonstrate that the immune malfunction featured in 
CFS/ME may arise from a relationship between hypothalamic dysfunction and a 
breakdown in the integrity of the lymphatic system. 
In conclusion the results of the first stage of the study have shown that osteopathic 
treatment reduces the severity of symptoms in the patient group compared to the control 
group. The following section of the work (chapters 3.4 and 5) attempts to assess the 
possible physiological basis for these improvements. 
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Chapter 3 
3 Assessment of the osteopathic method for the 
treatment of CFS/ME: Phase 2; Cerebrospinal 
fluid, lymphatics and CNS drainage 
3.1 Introduction 
The results of the first phase of the study clearly demonstrated a significant improvement in 
the symptoms of the CFS/ME patient following osteopathic treatment. The question arises 
as to the reasons for the apparent success of such treatment. Because of the plausible 
associations in the ANS and its control of lymphatic circulation attention was turned to the 
possible involvement of the spinal drainage systems, and in turn the CNS lymphatic 
drainage systems in general. The rationale was that the osteopathic manipulations were 
modifying these, thus enhancing the clearing of toxins or viral components from these 
systems. In the following sections brief overviews are given of the cerebrospinal fluid 
(CSF) and the lymphatic/CSF drainage systems of the CNS. 
3.1.1 The cerebrospinal fluid 
Since impaired drainage of CSF into the lymphatics lies at the root of the author's 
neurotoxic hypothesis of CFSI ME then it is crucial to understand the physiology of what 
Still (1902) termed 'The waters of the brain'. . 
There are two main aspects of CSF to consider when assessing any physiological change 
that may take place in a disease process. 
1. The chemical composition of the CSF. 
2. The circulation of CSF in the spine and ventricular system. 
3.1.1.1 The composition of CSF 
The CSF is a clear, colourless fluid containing inorganic salts similar to the blood plasma 
with a chloride level of approximately 720-750 mg/100ml. The glucose level is half that of 
blood around 50-85 mg/100ml and there is only a small amount of protein 15-45 
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mg/100ml. The only cells normally present in the CSF are 0-3 lymphocytes per cubic 
millimetre of fluid. The standard lateral recumbent CSF pressure is roughly 60 to 150 mm 
H2O and is subject to increase following any strain or compression to the head and neck. 
The average total volume of CSF in the ventricles and subarachnoid space of an adult is in 
the region of 130ml. 
The production of CSF takes place in the choroid plexus of the ventricular system and 
relies on the brain's ability to draw the necessary ions and solutes from the blood plasma. 
An efficient blood flow of at least four millilitres per minute per gram of tissue is required 
to maintain the necessary CSF output. Cerebral arterial supply has indeed been shown to be 
reduced in CFSIME (Costa et al., 1994). Hydroxyl and hydrogen ions together with 
positively charged sodium ions, negatively charged chloride and bicarbonate ions transfer 
over the blood brain barrier, altering the osmotic pressure leading to a diffusion of water 
into the ventricles. About 99% of CSF is water and the ion transfer is important to maintain 
a healthy environment for the brain to function normally. 
3.1.1.2 The circulation of CSF 
CSF is produced in the lateral ventricles passing into the third ventricle through the 
interventricular foramina and then via the cerebral aqueduct to the fourth ventricle. The 
movement is aided by arterial pulsations of the choroid plexus and ciliated cells lining the 
ventricles. From the fourth ventricle the CSF drains out via the lateral foramen of Luschka 
and median foramen of Magendie to the subarachnoid space. Slowly moving through 
cerebellomedullary and pontine cisterns, most of the CSF travels upward through the 
tentorium cerebelli to the inferior surface of the cerebrum flowing laterally and superiorly 
over each cerebral hemisphere. The rest moves inferiorly in the subarachnoid space down 
the spinal cord aided by cerebral and spinal arterial pulsations and vertebral movement 
(Fig. 32). 
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Figure 32 Diagram showing cerebrospinal fluid flow 
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(Drawn by the author based on original drawing by Netter in Felten and Joszefowicz, 2003) 
The fluid's journey is shown from its production at the choroid plexus around the brain and 
spinal cord with most of the CSF draining into the venous sinuses. Further drainage also 
takes place via the extra-cerebral and extra-spinal lymphatics (see section 3.1.2). 
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3.1.1.3 CSF volume assessment by measurement of brain atrophy 
Distinctive patterns of brain atrophy occur in many disease processes (Thacker et al., 2002) 
and as is seen in Fig. 33 below, a difference in lateral ventricle size between CFS/ME 
patients and healthy controls has been described previously (Lange et al., 2001), although 
the difference found in the group as a whole was not quite significant. 
In accordance with the Monro-Kellie hypothesis (Mokri, 2001) any change in the sum of 
grey matter, white matter and intracranial blood volume should result in a corresponding 
change in the volume of CSF. Since the proportion of CSF volume to other structures is 
small the CSF volume is sensitive to small changes in brain volume. As such the 
measurement of CSF is used to detect changes in the brain tissue volume, while increases in 
ventricular volume are generally regarded as a measure of deep white matter loss (Lange, 
1999). 
The examples overleaf are taken from the Lange and colleagues study (Lange et al., 2001) 
showing the obvious visible size increase in two contiguous slices in a CFS/ME sufferer 
(right) compared with a healthy control (left). 
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Figure 33 Ventricular enlargement in CFS/ME (Lange et al., 2001) 
Ventricular size increase has been seen in some CFS/ME patients compare with normal 
scans. The size of lateral ventricles in two contiguous slices in a cfs/me sufferer (right) are 
much larger than the healthy control (left). 
3.1.1.4 The functions of CSF 
There are five main functions of the CSF (Snell, 1995). 
1. Protection of the CNS: The CSF provides a cushioning of the brain and spinal cord from 
external physical trauma. 
2. Buoyancy: The CSF allows the brain to "float" giving support to its delicate structure. 
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3. Nourishment: The CSF provides nutrients needed to maintain the integrity of the CNS 
4. Reservoir: The CSF aids intracranial volume equilibrium in accordance with the Monro- 
Kellie doctrine increasing or decreasing following changes in blood or brain volume (Greitz 
et al., 1992). 
5. Hormonal Medium: There is evidence of pineal gland secretions circulating through the 
CSF affecting the functioning of the hypothalamic-pituitary-adrenal axis. Sympathetic 
nerves release norepinephrine into the pineal gland stimulating the release of serotonin and 
melatonin. These hormones mostly inhibit the production of other hormones and also 
inhibit releasing factors produced by the hypothalamus Mappers, 1976). 
There is a sixth function of CSF that is most important to the pathogenesis of CFS/ME and 
has already been discussed at length. That is the role of aiding in the drainage of excess 
neuro-metabolites and toxin removal (Cserr, and Knopff, 1992). 
3.1.2 Extracellular fluid in the CNS; CSF and lymphatic 
drainage 
The perivascular space is formed between the blood vessels that supply the brain and the 
pia mater, as far as the arterioles and the venules but not the capillaries. CSF travels into the 
subarachnoid spaces flowing down to the arachnoid villi and is consequently absorbed into 
the cerebral veins (see Fig. 34). 
As well as conveying fluid and traces of proteins, the perivascular space provides a 
thoroughfare for other particles, e. g., during infection in the brain, dead white blood cells 
and other infectious debris are transported away through the perivascular spaces (Guyton 
and Hall, 1996). 
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Figure 34 Section of the meninges illustrating perivascular spaces 
(Illustration from Gray's Anatomy 38`h Edition p. 1213, Zhang et al., 1990) 
The diagram shows the perivascular space between the blood vessels that supply the brain 
and the pia mater. 
The major reason for a secondary drainage system in the body is molecular size. The 
capillaries cannot absorb the larger molecular structures from the interstitial tissue via 
filtration through the blood vessel membrane. The lymph vessels take in any size of debris 
due to the mechanism outlined below. 
Although it has been established that the CNS does not have a true lymphatic system, there 
is considerable evidence for a robust fluid drainage system, which in many ways is 
129 
-- ý_' 
ýý-ýý 
analogous to the lymphatics. Relatively little is known for man, but quite comprehensive 
studies have been made on several experimental animals including rodents, rabbits and cats 
(Kids et al., 1993). 
CSF drains directly from the subarachnoid space into nasal lymphatics in the rat (see Fig. 
36). The Russian scientist Speransky first described the existence of a direct link between 
CSF and the nasal lymphatics and onwards to the cervical lymph vessels (Speransky, 
1943). Thus a major drainage pathway involving the olfactory region has been 
demonstrated in mammals with many channels draining through the cribriform plate into 
the nasal submucosa and from there into the cervical lymph nodes. In addition a small but 
significant drainage takes place via dural lymphatics, which run parallel with the spinal 
cord. Tracer material injected into the CSF in the brain of rabbits accumulates in the cuffs 
around the spinal roots, which form a link between the subarachnoid spaces and the 
lymphatics. In rabbits it has also been shown that there is a flow of fluid from the brain to 
the deep lymph nodes of the neck, and a flow of fluid from the nasal mucosa to the brain 
(Czerniaswska, 1970). 
This bi-directional movement is relatively poorly understood but it will ultimately be 
dependent on the relative pressures in the subarachnoid spaces at different parts of the 
neuraxis and in the CNS parenchyma (McComb et al., 1982). In the rabbit approximately 
30% and in the cat 10-15% of the total normal CSF drainage occurs via these routes 
(Bradbury and Cole, 1980). It has also been shown that almost a half of the total volume of 
CSF in sheep drains into the extracranial lymphatics especially in the cervical region. Also 
the CSF drainage into the cervical lymphatic system rises with increased ICP (Silver et al., 
1999). 
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Figure 35 Superior view of ethmoid showing the perforations in the cribriform plate 
mmmmy = arterial supply P= venous return = CSF drainage to lymph 
mmmo. = Nerves (both afferent and efferent). 
The perforations seen above allow the passage of blood vessels, nerve fibres and the 
passage of CSF from the brain to the nasal sinuses situated directly below the ethmoid 
bone. 
Of great interest is the demonstration that by tilting the angle of the experimental animal's 
head (angle of 20 degrees to horizontal), the drainage from brain to cervical lymph can be 
markedly increased; thus gravity affects the lymph flow (Simmonds, 1952). This drainage 
may further act as a valve to relieve ICP which would explain why pressure did not build 
up until the "break point" was reached in the study on hydrocephalic rats (Jones and 
Lopman. 1998). 
Cerebrospinal fluid transport occurs down the spinal subarachnoid spaces as well as in the 
brain. CSF is drained out via microscopic spinal arachnoid granulations similar to the 
granulations in those found in the choroid plexus of the brain's superior sagittal sinus. The 
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spinal component of CSF clearance accounts for about 25% of total CSF transport 
(BozanovicSocic et al., 2001). 
Cranially most of the extra drainage is via the olfactory pathway through the cribriform 
plate (see Fig. 35), but there is also evidence of some drainage along other cranial nerves, 
namely the optic, trigeminal and acoustic nerves (Kida et al., 1993). 
Arachnoid 
V illi 
Dural 
Lymphatics 
Olfactory 
Pathway 
_ 
Figure 36 The lymphatic drainage of the rat's brain (Kida et al., 1993) 
Note that as well as through the arachnoid granulations directly to venous return; there is a 
potential substantial drainage of toxins from the cerebrospinal fluid through the dural 
lymphatics, and along the I, II, V and VIII cranial nerves to the cervical lymphatics. 
Although the drainage pathways of CSF to facial and spinal lymphatics have been 
demonstrated principally in animal studies, more recent research examined this connection 
in the human (Cserr and Knopf, 1992; Czemiaswska, 1970; McComb et al., 1982). In man 
recent evidence has shown that CSF can leave the CNS via several routes (Fig. 37) As in 
the animal studies, these include pathways from the cranial and spinal sübarachnoid space 
across the arachnoid villi to the dural sinuses and along the cranial, mostly via olfactory 
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pathways through the cribriform perforations, and spinal nerves to the lymphatics (Knopf 
and Cserr, 1995). 
Sinus arachnoid villi 
II 
Spinal 
Mrves 
Lymphatics 
Lymphatics 
Lymph node Lymph node 
Figure 37 Schematic demonstrating the lymphatic drainage of the human brain 
(Knopf and Cserr, 1995) 
I= Olfactory II= Optic V= Trigeminal VIII= Acoustic 
As well as drainage into the sinus arachnoid villi there is further passage of CSF down the 
spine into the paravertebral lymphatics and alongside the cranial nerves shown in the 
diagram. The CSF then flows into the facial, cervical and eventually into the thoracic 
lymphatics. 
The system of CSF drainage in man is believed to be very similar to other mammals except 
the CSF-lymphatic component is proportionally much smaller in humans. The above 
drainage of CSF would indicate increased CSF volume may not necessarily cause an 
immediate increase in ICP with all the associated symptoms. There may very well be a 
"break point" in humans as with animals. 
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Cerebral hypotension may be just as symptomatic as an increase in ICP with orthostatic 
headaches common but not always present when there is over-drainage of CSF (Mokri et 
al., 2000). Postural headaches most often occur after a lumbar puncture where the 
procedure reduces ICP. 
Palpation of the cranial flow in all members of the patient group indicated that there was a 
reduction in the normal rhythm of CSF. This palpably reduced flow may possibly be the 
result of reduced CSF flow into the lymphatics leading to a build up of toxic debris which 
would affect the normal functioning of the brain cells. 
3.2 Aims of phase 2 
The overall aims of the second stage are to examine the involvement of alterations in CSF 
flow and drainage into cervical and thoracic lymphatics in the aetiology of CFS/ME and 
further study the effects of osteopathic treatment. The close association of the treatment 
with a potential underlying anatomical and physiological pathway is strong argument for 
such a study. It is intended to analyse any recordable physical changes taking place within 
the CSF pathway and or lymphatic drainage of the neuraxis. The results of this analysis will 
be compared with similar measurements on two control groups, one group consisting of 
CFS/ME patients not receiving osteopathy, and the second control group made up of 
healthy norms. The possible involvement of CSF drainage into the CNS lymphatics has not 
yet been evaluated in the CFS/ME patients. 
3.3 Patients and methods 
As in the first phase the study design for this section was repeated measures, although this 
part was a comparative study of three groups as opposed to two in phase 1. Also all the 
participants in this stage, including the controls, were subjected to the same tests and 
analyses carried out under the supervision of the author. 
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3.3.1 Participant recruitment 
Volunteers were recruited using adverts placed in local and national press with the first nine 
patients who fulfilled the CDC criteria (Fukuda et al., 1994) selected to be on the treatment 
group; these were only accepted after independent corroboration from their GP. It was also 
important to ensure that the diagnosis of CFS/ME was confirmed by independent medical 
opinion. Therefore the subjects in this study had all been validated as having no other 
possible patho-physiological cause of the symptoms and were all certified by their GP as 
having no other coexisting pathology and fulfilling the CDC criteria (Fukuda et al 1994). 
The inclusion and exclusion criteria were the same as those used in phase 1 (see sections 
2.2.1. and 2.2.2), except that in phase 2 the patients did not pay for their treatment. The 
control groups consisted of age, gender, height and weight matched CFS/ME sufferers not 
receiving manual treatment and healthy subjects. The demographic data of each individual 
subject is listed in Table 12 and summarised in Table 13. All subjects followed the same 
recruitment procedures as the treatment group. Subjects were only included if they were 
aged between 18 and 55 and not pregnant and were not included if they had received any 
physical therapy for their present symptoms during the previous six months. 
The CFS/ME patients were divided into 2 groups, the first group (CFS1,5 men and 4 
women: age range 20-53 years; mean age 35.3 years ± 12.6 [SD]) received only an 
osteopathic treatment for 1 year (see Table 12A), while patients in the other group, (CFS2; 
5 men and 4 women: age range 22-55 years; mean age 36.1 years ± 12.3) were allowed to 
pursue treatment regimes of their own choice, excluding osteopathic treatment (see Table 
12B). None of the CFS patients were considered to be from the extreme end of the 
symptomatic spectrum (i. e. bedridden, with intense sensitivity to any external stimuli). The 
control group (NORM, 5 men and 4 women: age range 22-53 years; mean age 36.1 years ± 
12.4) were normal volunteers in good general health and with no history of significant 
neurological abnormality (see Table 12 Q. 
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Code Gender Age/Yrs. Wt. / kg Ht. /m 
RVO1 F 29 69.9 1.8 
RV03 M 28 82.6 1.88 
RV04 M 43 85.7 1.83 
RV05 M 53 95.3 1.88 
RV06 F 19 81.6 1.8 
RV07 F 42 58.1 1.52 
RV08 M 22 79.4 1.83 
RV09 M 52 101.6 1.8 
RV10 F 27 44.5 1.58 
Standard 
Deviation 
12.75 17.80 0.13 
Mean M: F= 5: 4 35 77.6 1.77 
A. CFS/ME Patients receiving manual treatment (CFS1) 
Code Gender Age/Yrs. Wt. / kg Ht. /m 
CPo1 M 43 78.5 1.78 
CP02 F 43 66.2 1.63 
CP03 F 29 73 1.63 
CP04 M 52 95.3 1.78 
CP05 M 26 69.9 1.83 
CP06 F 24 63.5 1.73 
CP07 M 54 81.6 1.75 
C P08 M 29 92.1 1.98 
CP09 F 20 66.7 1.68 
Standard 
Deviation 
12.62 11.48 0.11 
MEAN M: F=5: 4 35.6 76.3 1.75 
B. CFS/ME Patients not receiving any manual treatment (CFS2) 
Code Gender Age/Yrs. Wt. / kg Ht. /m 
NCO1 M 52 79.4 1.78 
NC02 M 53 85.7 1.79 
NC03 F 30 61.2 1.6 
NC04 F 41 95.3 1.73 
NC05 M 26 83.5 1.87 
NC06 M 44 78 1.78 
NC07 F 19 52.6 1.62 
NC08 M 24 88.9 1.85 
NC09 F 29 73 1.58 
Standard 
Deviation 
12.49 13.51 0.11 
MEAN M: F=5: 4 35 77.5 1.73 
C. Healthy subjects (NORM) 
Table 12 Demographic data of subjects (phase 2) 
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As shown in Table 12 all three subject groups were all gender, age, weight and height 
matched. The subjects were all instructed to try and maintain their weight at the start of the 
project for the year-long trial. A summary of the data listed in Table 12 A, B and C is 
shown in the chart below (Table 13). 
Gender Age (years) Weight (kg) Height (m) mean 
M: F mean (range) Mean (s. d. ) (s. d. ) 
Treated patients 5: 4 35 (19-53) 77.6 (17.8) 1.77 (0.19) 
(CFS1) 
Non-treated patients 5: 4 36 (20-54) 76.3 (11.48) 1.75 (0.11) 
(CFS2) 
Healthy norms 5: 4 35(19-53) 77.5 (13.51) 1.73 (0.11) 
(NORM) 
Table 13 Summary of demographic data (phase 2) 
As shown the three subject groups were all gender, age, weight and height matched. The 
numbers in brackets in column 2 are the range of age in the different groups. The numbers 
in brackets in the 3" and 4th columns give the standard deviations for mean weight and 
height, which were similar in all three groups. 
To ensure that the no volunteer was suffering from a unipolar depression or primary anxiety 
state all the subjects who volunteered were included only after being independently 
approved of by a consultant psychiatrist as suffering with CFS/ME, and not in any 
depressive or anxiety state. The psychiatrist conducted an hour long consultation with each 
subject, using both the Hospital Anxiety and Depression Scale (HADS) (Moorey, 1991; 
Zigmond and Snaith, 1983) and the much more precise Schedules for Clinical Assessment 
in Neuropsychiatry (SCAN) which via a set of instruments provides a comprehensive, 
accurate and technically specific means of describing and classifying psychiatric 
phenomena (Mavreas, 1990; Tomov and Nikolov, 1990; Ustan, 1990; Wing, 1990). 
The HADS system is an inventory of 14 questions half examining the depression, the other 
half anxiety. The subjects were asked to score 0 to 3 depending on the severity of how they 
felt in the previous week, with a total score of over 10 signifying a state of anxiety and/or 
depression (See Appendix A3). 
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The SCAN system is a set of instruments and manuals aimed at assessing, measuring and 
classifying the psychopathology and behaviour associated with the major psychiatric 
disorders of adult life. The SCAN text has 3 components: the tenth edition of the Present 
State Examination (PSE10), the Item Group Checklist (IGC) and the Clinical History 
Schedule (CHS). 
PSE10 itself has two parts. Part I covers somatoform, dissociative, anxiety, depressive and 
bipolar disorders, and problems associated with eating, alcohol and other substance abuse. 
There is also a screen for Part II conditions. Part II covers psychotic and cognitive disorders 
and observed abnormalities of speech, affect and behavior. 
The SCAN system contains two other essential elements: the Glossary of differential 
definitions and CATEGO, a set of computer programs for processing SCAN data and 
providing output (see Appendix A3 for more details of SCAN) 
The use of the above exclusion criteria reduced, as much as possible, any chance of a 
psychiatric disorder being responsible for the symptom picture in the patients, and 
confirmed that the diagnosis of the cohort of eighteen CFS/ME sufferers was as robust as 
possible. 
3.3.2 Treatment 
The manual treatment of each CFS/ME research volunteer, RV01-9 followed the same 
technique protocol of the first phase (see section 2.2.4.6) (Stoddard, 1982; Hartman, 1983). 
3.3.3 Symptom assessment 
Change in the condition of each patient was assessed using the same eight self-report 
questionnaires as in phase one (Appendix A6). These were filled out by all 27 members of 
the patient and control groups and a further set of questionnaires were completed by the 
subjects after twelve months. 
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3.3.4 MRI analysis of the brain and associated lymphatics 
MRI was performed by means of a 1.5 Tesla whole body scanner (ACS-NT PT 6000, 
Phillips Medical Systems, Best. Netherlands), using a birdcage head coil receiver, in the 
imaging science department of the University of Manchester (See Fig. 38). MRI was 
performed at the start of the study and was repeated after 90 minutes rest to ensure 
reproducibility. All imaging was repeated after 1 year to assess longitudinal changes. 
Figure 38 The Philips MRI scanner at the University of Manchester 
The patient remained supine with wedge under knees throughout all the scan sequences and 
sound defenders or foam was placed over their ears. 
The work involved the development of some novel image and numerical analysis 
procedures in addition to those already used for imaging of intracranial and spinal CSF- 
circulation (Detre et al., 1995). A series of MRI scans were made at the start and again at 
the end of the twelve months programme. 
3.3.4.1 Why choose MRI? 
MRI studies have already demonstrated that small discrete, patchy brain stem subcortical 
lesions can often be seen in CFS (Keenan, 1999; Lange et al., 1999). However SPECT and 
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SPET studies have shown cerebral blood flow reductions in CFS, in particular in the 
hindbrain (Ichise et al., 1992; Costa et al., 1994). 
Positron emission tomography (PET) has an advantage compared with other imaging 
techniques in that technological advances in this method permit direct visualisation and 
quantitative measurements of neurotransmitters in the brain (Brooks et al., 1990), yet it is 
extremely expensive and too invasive. PET and SPECT (single photon emission computed 
tomography) scans can be used to determine the amount of cerebral circulation in the 
patient (Ibanez et al., 1995). Until recently the only accurate measurements of blood flow 
within the capillary beds of the brain were indeed performed using radioactively- labelled 
water molecules and PET. 
SPECT (single photon emission computerised tomography) has been also used to measure 
cerebral blood flow combined with 99mTc HMPAO, a tracer which is highly lipophilic and 
passes into the brain in quantities proportional to the regional blood flow. However this 
method exposes the patient to radiation and produces low spatial resolution images with no 
other anatomical data, thus one must also combine SPECT with other cross sectional 
imaging techniques such as MRI or CT. Xenon enhanced CT provides a high resolution 
anatomical and accurate flow image, but uses high levels of radiation and presents other 
clinical difficulties due to anaesthetic properties of xenon. 
Magnetic Resonance Imaging (MRI) scans can also determine the amount of cerebral blood 
flow and offer non- invasive in vivo measurement of structure-function relationships of the 
brain (Toft et al., 1995). They are more available and less costly than the PET or SPET 
techniques. They can be used repeatedly without any known harmful side-effects, whereas 
the PET and SPET techniques produce too great a level of radiation to be repeated 
frequently. MRI scans have also been successfully utilised in previous studies to analyse 
cerebrospinal fluid (CSF) volume changes (Vogels, 1995). The MR scan of CFS/ME 
patients before and after treatment would reveal any volume change in CSF. Previous 
studies aimed at qualitative and quantitative assessments of lateral ventricular volumes 
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have revealed evidence of subtle structural changes of some patients with CFS/ME (Lange 
et al., 1999). 
3.3.4.2 The scanning procedure 
The scanning procedure of the patient group was as follows: 
1. Scan. 
2. Rest for 90 minutes. 
3. Repeat scan. 
4. Rest for one hour followed by half an hour of osteopathic treatment. 
5. Repeat scan. 
This procedure was carried out at the beginning and end of the year-long treatment 
programme. 
Both control groups received a scan followed by a rest period for 90 minutes then a further 
scan. This procedure was also carried out at the start and end of the project. The repetition 
of the scans and comparison with controls was to show if there was any change in the CSF 
and/or lymph volume and flow due to manual intervention and not a just a normal 
occurrence. 
3.3.4.3 Sequences 
Morphological imaging consisted of inversion recovery and T1 weighted gradient echo 
images to measure CSF volume changes and allow segmentation of cerebral tissues and 
measurements of cerebral structures. 
The examinations were conducted by Professor Alan Jackson, the consultant 
neuroradiologist heading the project's Manchester University MR Scan team. To reduce 
bias, the images were viewed blind in that Prof. Jackson was unaware which group the 
subjects belonged to. 
The severity and distribution of deep white matter hyper-intensities (DWMH) was assessed 
by Prof. Jackson using the objective scoring scale described by Scheltens and co-workers 
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(1993). Scoring was performed from matched FLAIR and inversion recovery images. All 
examinations performed prior to follow up, consisting of 2 examinations per subject, were 
scored in random order with the scorer blind to the diagnosis. Follow up scans were scored 
by the same observer who remained blind to the diagnosis. Following this, direct 
comparison was performed between initial and follow-up scans to identify changes in 
individual DWMH to which the scoring system might be insensitive. 
Vessel localisation in flow velocity images was performed by manual selection of a small 
rectangular region of interest (ROI) in the centre of each vessel. The mean grey level (and 
hence flow velocity) was measured for each time point in the cardiac cycle. The resultant 
time curve of mean velocity for the ROI was then correlated with the corresponding time 
curve for every pixel in the image set. This resulted in a correlation image, where each 
pixel represented the correlation coefficient r of the waveform for that pixel location, with 
the waveform of the selected ROI. This image was then thresholded at an empirically 
determined value of 0.9 to determine the boundaries of each vessel. Flow through the 
vessels was calculated from heart rate, mean velocity and cross sectional area. Cerebral 
blood flow was calculated as the sum of the carotid and basilar flows. Between group 
comparisons were made of the total cerebral blood flow per minute, the proportion of the 
cycle through which CSF flow through the aqueduct was in the caudal direction (during 
systole), the total CSF flow in the caudal direction, the total CSF flow in the craniocaudal 
direction, the net CSF flow per cycle, the maximum craniocaudal CSF flow rate and the 
arterial to aqueduct delay defined as the time between the centre of the systolic peaks of the 
arterial and aqueductal flow velocity curves 
3.3.4.3.1 Multistack survey of head 
Initially an axial T1 sequence was used (see Fig. 39). The FH (foot-head axis) was offset at 
0. A check was made to ensure that the field of view FOV covered the area of the region of 
interest ROI. AP and RL offsets were changed to achieve this without changing the angle. 
The patient was repositioned to the centre of the head coil and a peripheral pulse unit (PPU) 
was applied to the finger of the patient, which was needed when examining cerebral blood 
flow in the carotid basilar phase contrast (see section 3.3.4.3.5). 
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Figure 39 Multistack survey Ti sequence 
Three views of the entire brain using Ti weighting. In a Ti contrast image fat, having a 
high signal appears bright, whereas water gives a low signal appearing dark on the Ti 
contrast images. 
3.3.4.3.2 Coronal turbo inversion recovery sequence 
This sequence was to examine the structure of the white matter contrasting greatly with the 
dark ventricular system (see Fig. 40). This was the choice sequence to analyse the degree 
and distribution of cerebral atrophy by examining both the volume of all the CSF within the 
skull vault of the prosencephalon and the volume of CSF within the lateral ventricles. 
The sequence for measurement of cerebral atrophy consisted of serial coronal fast spin- 
echo inversion-recovery images where the TR = 6,850 msec, TE = 18 msec, TI = 300 msec, 
echo train length = 9, field of view = 150 mm2, matrix = 256 x 256, slice thickness =3 mm 
and the interstice gap =1 mm. 
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A: Sagittal C: Axial B: Coronal 
A. Frontal B. Parietal C. Temporal D: Occipital 
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Figure 40 Corona] turbo inversion recovery perpendicular to the corpus collosum 
A short turbo factor decreases effective TE, increases T1 weighting, has a longer scan time 
plus has more slices per TR. It is effective in reducing the image blurring. An inversion 
recovery sequence (IR) is used to produce a heavily Ti weighted image where there is a 
high contrast between fat and water. The lateral ventricles (image C) thus appear black. 
3.3.4.3.3 Coronal FLAIR (fluid attenuated inverse recovery). 
The presence of diffuse white matter or grey matter lesions was imaged using an optimised 
fluid attenuated inversion recovery FLAIR sequence (see Fig. 41). The following coronal 
images of different regions of the brain were used to determine the number and severity of 
any deep white matter hyperintensities. These are inversion recovery sequences acquired 
with a long Ti time to suppress signal from CSF. The grey matter on these images is 
brighter than the white matter. The coronal FLAIR sequence obtained for assessment of 
WMHs had a TR = 11000 msec, TE = 140 msec, TI = 2600 msec, with the image geometry 
identical to the previous sequence. The 4 different regions of the brain were examined 
separately for white matter hyperintesities and scored in the Scan Table 1 (section 3.4.2.2). 
A. Frontal B. Parietal C. Temporal D: Occipital 
Figure 41 Coronal FLAIR sequence perpendicular to the corpus collosum 
The usually high CSF signal in the T2 weighted images above are suppressed using a 
process known as FLAIR to allow pathological changes in adjacent tissue to be more 
visible. (The arrows point to the ROI in the different coronal images). 
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DWMH are seen in major cerebral neuropathology as shown in the FLAIR image below of 
a 20 year old woman with multiple sclerosis (Fig. 42). 
Figure 42 Multiple DWMH shown in axial FLAIR images in a 20-year-old woman 
with MS (Okuda et al. 1999) 
MS plaques are seen on the image above as patches of varying hyperintensity indicated by 
white arrows. Note that the grey matter on a FLAIR image is brighter than the white matter. 
3.3.4.3.4 Phased contrast angiography 
A sequence known as phased contrast angiography was used to produce quantitative flow 
measurements in the carotid and basilar arteries to provide an estimate of the overall 
cerebral blood flow. Flow velocity images were produced using flow sensitivity in each of 
the cardinal directions and cardiac gating to produce 15 time points in the cardiac cycle. 
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Below is a sagittal image of the cerebral circulation of one of the healthy subjects showing 
important anatomical points (Fig. 43). Relevant to this current study is the position of the 
basilar and internal carotid arteries which were used to measure the cerebral blood flow 
utilising quantitative phase contrast angiography. 
1. Cavernous sinus 2. Internal cerebral vein 3. Basilar artery 4. Internal carotid artery 
5. straight sinus 6. Superior sagittal sinus. 
3.3.4.3.5 Carotid basilar phase contrast (CAB PC) 
Quantitative phase contrast angiography was used to measure total cerebral blood flow in a 
single slice at a position perpendicular to the internal carotid and basilar arteries with a TR 
= 5.66-5.86 msec, TE = 3.45-3.60 msec, flip angle = 15°, velocity encoding profile = 
90cm. s"', field of view = 150mm2, matrix = 642 and slice thickness =6 mm. Below are 
axial images perpendicular to the carotid and basilar arteries on the phase contrast survey. 
A phase contrast image is created by producing a gradient in the magnetic field scanning 
the body followed by a second field gradient in the opposite direction cancelling them 
except if there is movement and will thus produce a signal which is proportional to the flow 
rate (see Fig. 44). 
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Figure 43 Sagittal image of the cerebral circulation 
Figure 44 The formation of a CAB PC Image. 
The magnitude image (A) shows the anatomical detail of the ROI, in this case the brain 
stem, where the right and left internal carotid arteries join the Circle of Willis (the two 
superior and lateral hyperintensities). The basilar artery is the central lower hyperintensity. 
The phase image (B) shows the presence of flow in these arteries. In the quantitive image 
(C) the flow is actually measured. 
The signal intensity in the quantitative image is linearly proportional to the exact flow rate. 
The PPU, a light sensor attached to the patient's finger, detected the pulsation of blood 
through the capillaries. The pulsation was used to trigger the excitation pulses so that each 
slice acquired was at the same phase of the cardiac cycle. This technique known as 
peripheral gating is a method of reducing phase mismapping from the periodic motion of 
the cardiac cycle. 
3.3.4.3.6 Cerebral aqueduct PC 
To examine and quantify CSF flow, a phase contrast sequence was initiated perpendicular 
to the cerebral aqueduct (Fig. 45) Again the cardiac frequency was changed in motion. The 
CSF flow through the cerebral aqueduct was scanned using a TR = 26.5msec, TE = 7.8 
msec, flip angle =15°, velocity encoding profile =5 cm. s 1, field of view = 160mm, matrix 
= 48 x 64, slice thickness =6 mm. 
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A: Magnitude Image B: Phase image C: Quantitative Image 
C. Quantitative image 
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Figure 45 Cerebral aqueduct PC image. 
The magnitude image (A) shows the anatomical detail of the ROI, in this case a section 
between the 3`d and 4`h ventricles, just anterior to the cerebellum and postero-superior to the 
pons (see Fig. 32). The phase image (B) shows the presence of flow in the aqueduct which 
is the brightest circular structure at the centre of the image (the other hyperintensities are 
blood vessels). In the quantitive image (C) the flow of cerebrospinal fluid is actually 
measured. 
3.3.4.3.7 Foramen Magnum PC 
The flow of CSF was also examined at the foramen magnum. An axial sequence 
perpendicular to the spinal canal at the level of C2 was carried out with the cardiac 
frequency yet again altered in motion using peripheral gating. 
A: Magnitude image B: Phase image C: Quantitative image 
Figure 46 Foramen magnum PC image 
The magnitude image (A) shows the anatomical detail of the ROI, in this case a section 
perpendicular to the spinal canal at the level of C2. The phase image (B) shows the 
presence of flow in the spinal canal which is the large bright structure at the centre of the 
image. In the quantitive image (C) the flow of cerebrospinal fluid is actually measured. 
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A. Magnitude image B. Phase image 
This is one the most comprehensive MRI studies of CFS/ME ever to be undertaken. 
Cerebral blood flow, CSF flow and volume changes, possible cerebral pathology plus 
cervical and thoracic duct lymphatic drainage were all examined by MR scanning. 
3.3.4.4 Image analysis 
Image analysis took place in the Neuro Image Analysis Centre (NIAC) in the University of 
Manchester Division of Imaging Science and Biomedical Engineering. Analysis was 
performed using the software tool (TINA) which has been developed locally to support 
neuroimaging analysis of tasks of this type. Morphological image analysis consisted of 
segmentation of grey matter, white matter, CSF and high signal lesions which are identified 
in the images. These were be assigned probabilistic values using a Bayesian probability 
cluster analysis technique. These probabilistic complex data maps were used to extract 
lobar and regional tissue volumes for direct comparison between control and experimental 
groups. High resolution imaging of cervical and upper lymph nodes was performed at the 
same examination. 
3.3.4.4.1 Cerebral atrophy 
The degree and distribution of cerebral atrophy were analysed using the method described 
by Thacker et al., (2002). CSF is segmented from the spin-echo inversion-recovery images 
and the resultant CSF image is registered into a standard orientation. A coordinate system, 
bounded by the extremes of the CSF space, was then applied and the proportion of CSF in 
each of 12 equally sized arbitrary divisions of the coordinate system was calculated. The 12 
segments were defined by the mid-sagittal plane, a plane midway between the superior and 
inferior boundaries of the coordinate space and two planes placed equidistantly between the 
anterior and posterior boundaries of the coordinate space (see Fig. 47). This produced a 
measure of CSF volume and distribution normalised for head size and scaling errors. 
CSF voxels representing the lateral ventricles were manually selected from the binary 
images for volumetric measurement of the lateral ventricles. The segmented ventricle 
images were manually checked by 3D volume rendering to ensure that voxels extraneous to 
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the ventricles were not included. If any such voxels were present they were manually 
removed. The measured ventricle volume was again normalised to the dimensions of the 
coordinate system enclosing the CSF space to correct for variations in head size. 
A= Anterior 
P= Posterior 
S= Superior 
I= Inferior 
R= Right 
L= Left 
Figure 47 Fast spin echo inversion-recovery images showing position of bounding box 
in coronal, transverse and sagittal planes (Thacker et al., 2002) 
The brain was divided into 12 equal boxes. The blue line in the transverse (top right) and 
sagittal (bottom) represent the original baseline of the image before being adjusted to fit 
into the collective bounding box. No rotation was required in the coronal plane (top left). 
In addition data was spatially normalised and registered into a standard Taliarach co- 
ordinate system to allow statistical comparison of grey matter and white matter density 
functions. This technique allowed automated non-biased identification of areas of focal 
atrophy with low spatial frequency which may be occurring within the data sets. 
3.3.4.4.2 Deep white matter hyperintensities 
White matter lesions were identified on heavily T2 weighted optimised FLAIR images and 
scoring was done blind and subjectively. Scoring was performed by an experienced 
neuroradiologist using a scoring system extensively tested and published by staff of the 
Neuroimaging Centre in Manchester (Scheltens et al., 1993). 
Diffusion tensor images were used to calculate mean diffusional tensors, apparent 
diffusional coefficients and regional fractional anisotropy measurements and to produce 
parametric images of each of these parameters. Images were then examined for statistical 
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outlyers based on normal values extracted from the data distribution in order to identify the 
possibility of white matter lesions. 
3.3.4.5 Imaging of the lymphatics 
3.3.4.5.1 The thoracic duct 
Visualisation of the thoracic duct by MR scanning is normally achieved using a contrast 
agent which would have raised health and safety issues. However a first scanning method 
was reported when Hayashi and Mityazaki used a short echo spacing 3D half-fourier, fast 
spin-echo sequence without a contrast agent and produced coronal and sagittal MIP 
(maximum intensity projection) images of the duct (Hayashi and Mityazaki, 1999). This 
method was not possible utilising the scanner at Manchester. At its abdominal origin the 
thoracic duct is only 0.5 to 2mm in diameter, however it was possible to visualise axial 
images of the lower part of the thoracic duct at the L2 level utilising the earlier protocol 
discussed in 3.3.4.5.2 but only when there is a large enough diameter of the duct lumen. 
Although general opinion is that the cisterna chyli is usual found at the L1-L2 level (see 
Fig. 48), it has been shown that the cistern is more of an anomaly than the norm and that 
there are many variations of the origin of the duct (Anson, 1963). In a recent study the 
cisterna, when present was found to be more in the L3-L4 segment (Lee and Cassar- 
Pullicino, 2000). The first area to be scanned was thus the lower end of the thoracic duct 
anterior to the L2 /L3 segment. 
The subject lay supine on the table on synergy spine coil, centred at L2. A wedge was 
placed under their knees for added comfort and an initial survey took place using a T1 
weighted series including the ROI from the base of L3 to the top of L2 (see Fig. 49). 
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Figure 48 The Thoracic Duct 
The thoracic ducts abdominal origin is usually at L1-L2 but may be lower. The enlarged 
cisterna chyli is not always present. The duct begins on the right side of the abdomen and 
passes across to the left side at the nipple line and ends at the left subclavian vein 
Patient Preparation: 
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3.3.4.5.2 Multistack MST survey. 
This sequence was a T1 weighted series of scans in three different planes. 
Figure 49 Multistack survey of the thorax and lumbar regions 
As was the protocol for the brain sequences, three views of the thoracic and lumbar regions 
using Ti weighting were first scanned. Note these sequences were not used for any 
diagnostic procedure but were analysed only to ensure that the FOV covered the area of the 
region of interest. 
To visualise the thoracic duct an axial T2 weighted sequence with spectral re-saturation 
with inversion recovery (SPIR) was used. This fat suppression technique was used to scan 
the area from the base of L3 to the top of L2. 
A primary hypothesis of this research maintains that the thoracic duct will be congested due 
to dysfunctional sympathetic tone controlling the thoracic duct pump. Inevitably this 
congestion will lead to an enlarged duct lumen which would be more visible on an axial 
MR image than a scan of a thoracic duct of normal sized diameter. Thus it is hypothesised 
that axial imaging of this region would reveal more visible thoracic ducts in the CFS/ME 
subjects compared with the healthy controls. This is not to say in healthy subjects the 
thoracic duct is not apparent. What is suggested is that a higher proportion of visible ducts 
should appear on images of the CFS/ME sufferers. The Null hypothesis would be achieved 
if there appeared an equal proportion of visible thoracic ducts in both the CFS/ME groups 
and the healthy control group. The thoracic duct was scanned at its lower origin at the 
L2/L3 segment. The sequence was T2 weighted to illustrate lymph-engorgement in thoracic 
duct viewed in an axial image with the thoracic duct lying posterior and slightly left of the 
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A. coronal B. sagittal C. axial 
aorta anterior of the vertebral column (see Fig. 58). Below is a simple T1 weighted axial 
image of the region of interest showing the anatomical detail before the SPIR technique 
was employed. 
Figure 50 Ti weighted scan of L2 segment of the thoracic duct 
This is a magnified image of the axial scans taken in the survey (Fig 49 C) Even though 
this image was not intended to show detailed anatomy it is still possible to see the thoracic 
duct lying posteriorly and just right of the aorta. 
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3.3.4.5.3 The Cervical Lymph 
The revised CDC criteria for CFS/ME (Fekuda et al., 1998) include slightly enlarged 
cervical and axillary lymph nodes as a physical diagnostic sign. Clinical findings by the 
author have also revealed palpable superficial swollen thoracic and cervical lymphatics in 
all CFS/ME patients. Enlarged lymph vessels are usually most noted in the breast tissue 
with accompanied tenderness and occasional mastitis. The left breast is the more commonly 
affected. 
As has already been stated the thoracic duct which in the upper thorax is left sided is 
controlled by sympathetic nerves. If the duct is not pumping sufficiently due to sympathetic 
dysfunction or an erroneous reflux mechanism pumped the chyle back into the tissues the 
first signs of blockage would probably arise in the neck and chest. This would explain the 
aforementioned swollen tissue. 
Lymphatics contain unidirectional valves which may be damaged if the normal flow 
became retrograde or congested. This would create engorged lymph vessels similar to 
varicose veins. It was originally planned to scan an enlarged lymph vessel in the breast 
which would have been easier to identify and not being next to major blood vessels the 
artefact would be less of a problem. This was not deemed practical as the scan sequence for 
breast lymphatics requires the patient to lie prone on an uncomfortable coil. This would 
have aggravated breast pain felt by most of the CFS/ME patients in the study. Examining 
the cervical lymph nodes was deemed less intrusive and the scanning was more 
comfortable for the subjects, although during this 3 minute sequence subjects had to avoid 
swallowing. 
The cervical scans were often marred by artefact from the carotid artery lying close by the 
coil. An enlarged lymph node adjacent to the anterior margin of the sterno-cleidomastoid 
was most commonly chosen (see Fig. 53). The choice of node to be examined was 
determined on two factors a: it was the most palpable, and b: it lay as far as possible away 
from the major arteries. 
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The treatment involved manual lymphatic drainage of the cervical region and so the size of 
lymph nodes may be reduced with a year of therapy. However if there has been a reflux of 
lymph for a long period prior to the treatment the valves may be permanently damaged 
which would mean that the disease could only be helped by improving the drainage of 
toxins but the lymphatic vessels would always be prone to engorgement. 
Patient Preparation: 
1. A cervical lymph node was identified by palpation and marked with pen. 
2. The patient was repositioned to scan the cervical region and the surface coil was 
positioned over the marked lymph node. 
3. A multistack survey was employed using a synergy coil, also known as a spine coil and 
then repeated using a C4 coil (See Figs. 51 and 52). 
A: Sagittal B: Coronal C: Axial 
Figure 51 Multistack image of cervical region 
The cross lines guided the radiographer to the exact ROI which was determined before the 
scan by the author after palpating the cervical region for a suitably enlarged lymph node. 
The cervical scans were prepared using a surface coil positioned in the anterior part of the 
neck adjacent to the border of the sternocleidomastoid. Note the disturbance in the images 
due to artefact (see Fig. 51C). 
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Figure 52 Artefact in cervical lymph scans 
There was a good probability that artefact would affect the clarity of the cervical images as 
is seen in the axial scan C. This is due to the signal disturbance from breathing and affects 
from the strong pulsations in the cervical arteries. The patient was instructed not to swallow 
during these sequences to reduce a further source of artefact. 
Figure 53 Sternomastoid and cervical lymph node 
Sagittal section showing magnified subcutaneous structures in anterolateral region of 
cervical soft tissue. Note the similarity between blood vessel and lymph node making 
identification extremely difficult. 
C: Axial A: Sagittal B: Coronal 
As with the other radiological examinations, all the scans of the thoracic and cervical 
lymphatics were conducted by Professor Alan Jackson, the consultant neuroradiologist 
heading the project's Manchester University MR Scan team. To reduce bias the images 
were viewed blind in that Prof. Jackson was unaware which group the subjects belonged to. 
3.3.5 Statistical analysis 
3.3.5.1 Statistical analysis of symptomatology 
Statistical analysis of the outcome of the patient group compared with the controls was 
carried out. Kruskal-Wallis nonparametric one-way analysis of variance was used to test for 
significant differences in questionnaire responses, as percentages of maximum scores 
possible, between the three treatment groups. This especially in view of the small number 
in the groups, nonparametric tests were used rather than parametric one-way and two-way 
analyses of variance, because the assumptions of normality might be deemed inappropriate 
for percentage changes. A p-value of less than 0.05 when examining the difference of 
questionnaire results over the year of research would indicate significant reduction in 
symptoms. 
3.3.5.2 Statistical analysis of brain scans 
Comparisons between the 3 groups were performed using Freidman's ANOVA for 
nonparametric matched sets. 
3.3.5.3 Statistical analysis of lymph scans 
Due to the small number of subjects analysed, the most appropriate statistical test on the 
thoracic duct scans was the 2- sided Fisher's Exact test. A p-value of <0.05 would mean 
that there was a statistically relevant difference in the diameter size of thoracic duct 
between groups. Not enough data was collected to make any meaningful analysis on the 
cervical lymph scans (see 3.4.4). 
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3.4 Results 
3.4.1 Results of symptom analysis 
The scores of the self report questionnaires were calculated and the differences between the 
mean percentage scores at the beginning and end of phase 2 were tabulated (see Table 14). 
The changes in symptom score in the treated group was compared with the control groups 
and subjected to statistical analysis. 
Questionnaire Treated Group 
% improved 
Non-Treated Group 
% improved 
Normal Control 
Group 
% improved 
Health 16.63 -1.99 0.14 
Back Pain 29.39 2.47 0.92 
Depression 8.86 -1.24 0.17 
Anxiety 8.64 2.83 -0.8 
Sleep 9.74 -1.39 0.98 
Cognition 19 -9.45 -6.11 
Nott. Health 15.42 2.92 1.37 
PFRS 23.74 -5.82 -0.93 
Table 14 Mean percentage change in symptom questionnaires (Phase 2 results) 
The values listed above are the differences between the mean percentage scores at the 
beginning and end of phase 2, where 0% = symptom free and 100% was maximum severity 
possible. The improvement in the treated group compared with the control groups is seen in 
the higher scores in the 2°d column. Note that a -ve value =a worsening in the symptoms 
over the year. 
Due to the smaller numbers involved in phase 2 compared with phase 1, different statistical 
tests were conducted. This time the Kruskal-Wallis nonparametric one-way analysis of 
variance was used to test for significant differences in questionnaire responses, as 
percentages of maximum scores possible, between the three treatment groups (See 
Appendix A10). 
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Table 14 lists the scores obtained for the symptom questionnaires, expressed in overall 
mean percentage change relative to the maximum score possible. A p-value less than 0.05 
indicates significance at the 5% level. For all eight questionnaires the estimated median 
increase was greatest in the treatment (RV) group. 
Significant reductions in most symptoms, notably fatigue (PFRS), pain and cognitive 
function were reported to result from treatment of the CFS/ME group. However the 
symptoms of depression, anxiety and symptoms such as insomnia were not significantly 
reduced following treatment. 
The p-values of the statistical tests are listed below: 
Health versus Group p= 0.009 (adjusted for ties) 
Back Pain versus Group p=0.002 (adjusted for ties) 
Depression versus Group p= 0.057 (adjusted for ties) 
Anxiety versus Group 
Sleep versus Group 
p=0.507 (adjusted for ties) 
p. 0.069 (adjusted for ties) 
Cognition versus Group p=0.019 (adjusted for ties) 
Nott Health versus Group p=0.263 (adjusted for ties) 
PFRS versus Group p= 0.007 (adjusted for ties) 
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3.4.2 Results of brain scan analysis 
3.4.2.1 Ventricular volume 
The present study examined both the volume of all the CSF within the skull vault of the 
prosencephalon and the volume of CSF within the lateral ventricles. Early on in this second 
phase of the study ventricular volume was observed visually to be increased in some of the 
CFS/ME group compared with the matched control (see Fig. 54). However statistical 
analysis would show if there was a significant increase in the patient group as a whole 
compared with the healthy controls. 
Figure 54 Observable ventricular volume increase in a CFS/ME patient 
The two axial scans above were taken from equivalent slices of a CFS/ME patient and an 
age, gender and weight matched control; the wider lateral ventricles on the right image 
indicate a greater ventricular volume in CFS/ME. 
In the present study measurements of proportionate CSF volume made from scans obtained 
90 minutes apart were very similar. The 2nd measurement converted to a proportion of the 
first a mean value of 0.9976± 0.0505 was calculated for all 27 subjects, showing good 
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reproducibility for the technique in the short term. Comparison of the proportionate CSF 
volume between the 3 subject groups at the beginning of the study showed no significant 
difference between either of the CFS/ME patient groups or the control group (Freidman's 
ANOVA, P=0.339). See appendix All for full data. 
As described in 3.3.4.4.1 cerebral atrophy was analysed using a coordinate system, 
bounded by the extremes of the CSF space. This consisted of 12 equally sized arbitrary 
divisions of a larger `bounding box' which produced a measure of CSF volume and 
distribution normalised for head size and scaling errors. To assess and compare longitudinal 
changes in CSF volume, the proportion of CSF in the total bounding box after 1 year was 
converted to a proportion of that at study commencement. All three groups showed a slight 
mean increase in CSF proportional volume with the treatment Group = 1.040 ± 0.061; 
CFS/ME non treatment group =1.025 ± 0.133 and NORM = 1.067 ± 0.078. There was no 
significant difference in change between the control and patient (including successful 
treatment) groups (P = 0.73). 
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Figure 55 Cerebrospinal fluid proportional volume 
The scattergram of CSF proportional volume compared with the overall volume in the 
bounding box, expressed as a percentage, after one year against volume at study 
commencement. 
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Figure 55. shows CSF proportional volume after 1 year against volume at study 
commencement. It suggests no significant difference between any of the groups and no 
significant inter-group differences in the change over the course of 1 year. It is interesting 
however, that the 2 outliers were both non-treated CFS/ME patients with one showing a 
large reduction in proportional volume and the other a substantial increase for no apparent 
reason. 
Comparison of ventricular volume at commencement of the study showed no significant 
differences between the 3 groups (p = 0.339) and no significant inter-group differences in 
the change over the course of 1 year (p = 0.733). 
3.4.2.2 Deep white matter hyperintensities 
The table format portrayed in Scan Table 1 was employed to enumerate the amount of 
noticeable deep white matter hyperintensities found in the different sections of the brain. 
There are four levels of lesions which may produce differing sizes and brightness of the 
hyperintensities depending on the cause of pathological changes occurring in the white 
matter. 
The score of A, B, C or D were given if pathological lesions were seen with D being most 
serious pathological change. No letter score was recorded if the hyperintesity was not of 
any significant size or brightness. A numerical score was given for the number of minor 
sub-clinical hyperintensities seen. These lesions are too small to be caused by any 
pathology and occur naturally in brain tissue due to the ageing or other physiological 
processes. The presence of any periventricular hyperintensity was also noted. This finding 
may indicate pathology of the ventricular surface. 
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SCAN TABLE 1. 
DEEP WHITE MATTER HYPERINTENSITIES 
Code no: 
Scan no: 
Time: 
Left Right 
Frontal 
Parietal 
Occipital 
Temporal 
TOTAL BRAIN 
Periventricular hyperintensity (PVH) Q 
Figure 56 Chart used to tabulate occurrence of DWMH and PVH 
This chart was used by the consultant radiologist when examining the FLAIR scans of the 
brain to determine if and how many deep white matter hyperintensities were present (see 
Fig. 41). The presence of periventricular hyperintensities was also investigated as they are 
also a sign of pathology within the brain. 
The results from this part of the radiological investigation are tabulated below (see Tables 
15-17). 
Code 
number 
T2 left 
frontal 
T2 left 
parietal 
T2 left 
occipital 
T2 left 
temporal 
T2 right 
frontal 
T2 right 
Parietal 
T2 right 
Occipital 
T2 right 
temporal 
PVH 
RvOl 0 0 0 0 0 0 0 0 0 
Rv03 3 0 0 0 0 0 0 0 0 
Rv04 0 0 0 0 0 0 0 0 0 
Rv05 0 3 0 3 0 0 0 0 0 
Rv06 0 0 0 1 0 0 0 0 0 
Rv06 0 0 0 1 0 0 0 0 0 
Rv07 3 0 0 0 0 0 0 0 0 
RvO8 0 0 0 0 0 0 0 0 0 
Rv09 0 1 0 3 0 0 0 0 0 
Rv10 0 0 0 0 0 0 0 0 0 
Table 15 DWMH reported in the treated patient group (left and right) 
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Code 
number 
T2 left 
frontal 
T2 left 
Parietal 
T2 left 
occipital 
T2 left 
Temporal 
T2 right 
frontal 
T2 right 
parietal 
T2 right 
Occipital 
T2 right 
temporal 
PVH 
Cp01 0 0 0 0 0 0 1 0 0 
Cp02 0 0 0 0 0 0 0 0 0 
Cp03 0 0 0 0 0 0 0 0 0 
Cp04 3 2 3 1 2 3 3 1 2 
C p05 0 0 0 0 0 0 0 0 0 
Cp06 0 0 0 0 0 0 0 0 0 
Cp07 3 1 3 1 2 1 0 0 1 
Cp08 1 0 0 0 0 0 0 0 0 
Cp09 0 0 0 0 0 0 0 0 0 
Table 16 DWMH reported in the untreated patient group (left and right) 
Code 
number 
T2 left 
frontal 
T2 left 
Parietal 
T2 left 
occipital 
T2 left 
Temporal 
T2 right 
frontal 
T2 right 
Parietal 
T2 right 
occipital 
T2 right 
temporal 
PVH 
Nc01 0 2 0 2 3 3 1 2 0 
Nc02 1 0 0 0 1 0 0 0 0 
Nc05 0 0 0 0 0 0 0 0 0 
Nc06 0 0 0 0 0 0 0 0 0 
Nc07 0 0 0 0 0 0 0 0 0 
Nc09 1 3 1 0 3 1 0 0 0 
Nco3 0 0 0 0 0 0 0 0 0 
Nco4 0 0 0 0 0 0 0 0 0 
Nco8 0 0 0 0 0 1 0 0 1 
Table 17 DWMH reported in the healthy control group (left and right) 
All three groups showed low levels of WMH with no evidence of WMH in the basal 
ganglia or infratentorial structures in any patient. Mean scores were, for periventricular 
hyperintensity treated patients, 0.11 ± 0.33; untreated patients, 0.33 ± 0.71 and Norm, 0.11 
± 0.33 and for DWMH in the prosencephalon, treated patients, 1.55 ± 2.80; untreated 
patients, 1.67 ± 2.78 and NORM, 1.11 ± 1.45. There was no change in any of the summary 
(prosencephalic DWMH, basal ganglia hyperintensities and infratentorial hyperintensities) 
or individual component variables which make up the score between the baseline and 1 
year follow-up scans. Since the Scheltens' scale presents summaries of the frequency of 
lesions it is possible that individual lesions may appear, resolve or change over time 
without a corresponding change in the resultant score. Direct comparison of baseline and 1 
year follow up scans demonstrated new lesions in one subject (NORM, 3 lesions) and 
apparent resolution in two subjects (Norm, 1 lesion <3mm, untreated 1 lesion <3mm) (see 
appendix All) 
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An example of the small discreet DMWH seen in this study is seen on the enlarged scan 
below (Fig. 57) showing two small white patches in the left temporal lobe (white arrows). 
The 53 yr old male CFS/ME sufferer (subject RV05) with two left temporal DWMH which 
may be age related in this case (Schmidt et al., 1996). The patient RVO5, whose full 
medical history is recorded at the beginning of appendix A5, was the oldest of the treated 
group with very few hyperintensities being found in the other CFS/ME sufferers in the 
study. 
The small punctate white matter hyperintensities seen in the image below (Fig. 57) greatly 
differ with scans seen when the hyperintensities are of definite pathological aetiology. The 
latter is seen in Fig. 42 showing an axial FLAIR image of a much younger patient with 
multiple sclerosis showing numerous large hyperintensities throughout the brain. 
Figure 57 Small discreet temporal lobe hyperintensities seen in coronal FLAIR image 
of subject RVO5 
Coronal FLAIR image of a 53 yr old male CFS/ME sufferer (subject RV05) with two left 
temporal DWMH which are most probably age related in this case (Schmidt et al., 1996). 
The patient RVO5 was the oldest of the treated group with very few hyperintensities being 
found in the other CFS/ME sufferers in the study. 
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3.4.2.3 Blood and CSF flow 
Analysis of cerebral blood flow data through the internal carotid and basilar arteries 
showed no significant differences when comparing change of mean flow over the year 
giving a p-value of 0.2273 which is much higher than the 0.05 needed to be of statistical 
significance. CSF flow data showed no significant differences in any of the inter-group 
comparisons with net flow difference of csf through the cerebral aqueduct giving a p-value 
of 0.71653 and a difference between the maximum flow p=0.89484 (see Appendix All). 
NB. The cerebral aqueduct is the region most sensitive to any change to CSF flow. If 
significant changes were found in the aqueduct sequences, further investigation into the 
flow through the foramen magnum would have taken place. In view of the insignificant 
changes in aqueduct flow it was decided that analysis of the larger flow in the foramen 
magnum was unnecessary. 
3.4.3 Results of thoracic duct analysis 
If there was less congestion in the thoracic duct after the year of treatment it would be of 
smaller diameter and a duller image compared with the original view. Below (Fig 58) are 
axial SPIR T2 weighted images showing the lower end of the thoracic duct of the research 
patient RV04 at the start of the project and a corresponding image matched for anatomical 
position at the end of the project demonstrating a possible effect of treatment. 
The thoracic duct (TD) image brightness is much less intense in second scan indicating a 
possible sizeable reduction in the diameter. The lumen diameter of the thoracic duct of all 
subjects' scans was initially compared by the radiologist. The brightness of the image is an 
indicator of the amount of lymph fluid within the duct and thus a decrease in the signal 
intensity is demonstrative of a narrowing of the duct which is the expected finding when 
lymph engorgement has been reduced. Thus the hypothesis of central lymphatic 
engorgement as a major patho-physiological factor in CFSIME would be supported if there 
was a reduction in the post-study signal intensity i. e. the post-treatment scan is smaller 
and/or duller than the pre-treatment scan. 
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BEFORE TREATMENT COMMENCED AFTER YEAR OF TREATMENT 
Figure 58 Examining post-treatment diameter change of thoracic duct 
Axial scans of the thoracic duct of patient RV04 with a T2 weighting to show up fluid. 
TD= thoracic duct. In the first scan on the left the intense signal from the centre of the 
thoracic duct is due to the enlarged lumen filled with lymph fluid. The reduction in 
intensity and diameter size after treatment indicates a possible narrowing of the lumen with 
a reduction in any engorgement. 
However when the difference was less noticeable this technique became increasingly 
complicated for the radiologist to identify the thoracic duct rather than the many veins in 
this region. Using a MIP image of the region solved this difficulty where a three 
dimensional model is created by the computer from the images in this sequence (Fig. 59). 
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The MIP image concentrated on just the central area of the axial scan as shown in Fig. 48. 
A T2 weighted sequence with spectral re-saturation with inversion recovery (SPIR), a fat 
suppression technique, was used. The radiologist was able to rotate the image around the 
axis of the aorta and follow the path of the thoracic duct from L2 level up into the thorax, 
seen as the bright vessel, anatomically on right side, left on image. 
The presence and diameter of a visible lower section of the thoracic duct at the L2/3 
segment was recorded in Scan Table 2 which also noted whether the lateral aortic lymph 
nodes at this region were of significant size and number (see Fig. 60). 
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1 igurc i9 \111' image shun ing the thoracic duct 
SCAN TABLE 2. 
NAME: DATE: 
Code no: 
Scan no: Thoracic Duct Lateral aortic 
Time: Lymph nodes. 
Visual 
Diameter/ mm x 
Figure 60 Table used to record state of deep thoracic lymphatics 
This chart was used by the consultant radiologist when examining the MIP scans of the 
upper lumbar region to determine if the thoracic duct was visible and how large the 
diameter. 
In the first row a score of 1 was given if the thoracic duct was visible and 0 if the duct was 
too narrow to be seen. In the second row the diameter of the lumen of the thoracic duct was 
scored where 0=< 2mm; 1= 2-4mm and 2= 4-6mm. The presence of a large mass of 
lateral aortic lymph nodes was also noted as this could also be evidence of lymphatic 
engorgement. The results from this part of the radiological investigation are recorded in 
Table 18. 
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Code Number T Duct Visible Size 
RVO1 1 1 
RV03 1 1 
RV04 1 2 
RV05 1 2 
RV05 Change to narrower duct following last treatment 1 1 
RV06 1 1 
RV07 0 0 
RVO8 1 1 
RV09 1 1 
RV10 0 0 
CP01 0 0 
CP02 0 0 
CP03 1 2 
CP04 1 2 
CPO5 0 0 
CP06 1 1 
CP07 0 0 
CPO8 0 0 
CP09 0 0 
NC01 0 0 
NC02 0 0 
NC03 0 0 
NC04 0 0 
NC05 1 1 
NC06 1 2 
NC07 Seen in first scan at start of study 1 1 
NC07 0 Not seen in final scan at end of year 0 
NC08 0 0 
NC09 0 0 
Table 18 Comparative study of dimensions of thoracic duct 
The table lists the scores taken from the data recoded on the Scan Table 2 following visual 
examination and scoring by the consultant radiologist. In the first column a score of 1 
means that the thoracic duct was visible; 0= duct too narrow to be seen. The second 
column shows the diameter of the lumen of the thoracic duct where 0=< 2mm; 1= 2-4mm 
and 2= 4-6mm. 
A summary and the significance of the results listed in Table 18 are tabulated below (tables 
19,20 and 21). Note that all 18 subjects suffering CFS/ME treated RV and control group 
CP members, were included in one group for this analysis as the amount of visible scans in 
these 18 subjects was a constant for the whole year. 
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1s scan 
Number in Group 
Group Visible on scan =1 Not seen on scan =0 
CFS/ME 18 10 8 
Norm 9 3 6 
Table 19 Summary of thoracic duct visibility at start of phase 2 
Note that all 18 subjects who suffered from CFS/ME, treated RV and control group CP 
members, were regarded as one group only for the analysis recorded in this table and Table 
20. This was due to the fact that the number of visible scans in all 18 subjects (CFS1 and 
CFS2) did not change after the year. 
The data is graphically represented in the chart below (Fig. 61) comparing thoracic ducts 
seen in the first set of scans in the two groups expressed as a percentage of the total number 
in the group. 
Percentage of thoracic duct visibility 
100.00 
90.00- 
80.00- 44.44 
70.00 66.67 
60.00- 
% 50.00- 
40.00-   visible 
30.00 
20.00- 
10.00- 
0.00 
CFS/ME NORM 
group 
Figure 61 Comparison of thoracic duct visibility at start of phase 2, expressed as a 
percentage 
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The null hypothesis tested in this part was that there would be no statistically relevant 
difference between the visibility of the thoracic duct in the patient group and that of the 
healthy group. The p-value at the start of the second phase = 0.419 indicating no 
statistically relevant difference in diameter between groups. 
A repeat set of scans was performed at the end of the year in phase 2 of this study with 
slight differences in the results compared with the findings in the initial scans. 
2nd scan 
Number in Group 
Group Visible on scan =1 Not seen on scan =0 
CFS/ME 18 10 8 
Norm 9 2 7 
Table 20 Summary of thoracic duct visibility at end of phase 2 
Note that groups CFS1 and CFS2 were included in one group (CFS/ME) for this analysis, 
since the amount of visible scans in all 18 subjects did not change after the year long study. 
The data is graphically represented in the chart overleaf comparing thoracic ducts seen in 
the second set of scans at the end of the year. Again the values on the chart are expressed as 
a percentage of the total number in the group (see Fig. 62). 
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Percentage of thoracic duct visibility 
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Figure 62 Comparison of thoracic duct visibility at end of phase 2, expressed as a 
percentage 
The results were again statistically evaluated by a 2- sided Fisher's Exact test. The p-value 
at the end of the second phase = 0.2172, still insignificant. 
The diameters of the thoracic duct lumen of the CFS/ME subjects and the healthy controls 
are compared in Tables 21 and 22, where < 2mm; 2-4mm and 4-6mm. 
174 
_. ._,.. 
is scan 
Number in Group 
Group <2mm 2-4mm 4-6mm 
CFS/ME 18 8 6 4 
Norm 9 6 2 1 
Table 21 Comparison of thoracic duct diameter at start of phase 2 
2' scan 
Number in Group 
Group <2mm 2-4mm 4-6mm 
CFS/ME 18 8 7 3 
Norm 9 7 1 1 
Table 22 Comparison of thoracic duct diameter at end of phase 2 
Tables 21 and 22 differ due to: 
1. RV05 in the patient group appearing narrower in the post-treatment scan at the end 
of the year. 
2. The thoracic duct of NC07 from the healthy control group at the end of the year was 
not visible. 
The pie charts below offer a clearer picture to the differences in the thoracic duct diameter 
between the groups with the Figs. 63 and 64 showing values at the start of phase 2 and the 
second set of pie charts Figs. 65 and 66 showing the sizes at the end of phase 2. 
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CFS/ME 
22% 
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  2-4mm 
  4-6mm 
33% 
Figure 63 Pie chart of thoracic duct diameter size in CFS/ME patients at start of 
phase 2 
Norm 
11% 
22% o <2mm 
  2-4mm 
 4-6mm 
67% 
Figure 64 Pie chart of thoracic duct diameter size in healthy control group at start of 
phase 2 
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The pie charts below (Figs. 65 and 66) show the difference in diameter of the thoracic ducts 
at the end of the study. 
CFS/ME 
17% 
45% o <2mm 
  2-4mm 
 4-6mm 
38% 
Figure 65 Pie chart of thoracic duct diameter size in CFS/ME patients at end of phase 
2 
Norm 
11% 
11 °-o 
a <2m m 
  2-4mm 
  4-6mm 
78% 
Figure 66 Pie chart of thoracic duct diameter sizes in healthy group at end of phase 2 
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3.4.4 Results of cervical lymph gland analysis 
SCAN TABLE 3. 
NAME: DATE: 
Code no: 
Scan no: CERVICAL 
Time: Lymph node 
Visual 
Diameter/ mm x 
Figure 67 Table used to record state of superficial cervical lymphatics 
Scan Table 3 was used to record the maximum recordable length and width of the scanned 
cervical lymph node. Most of the cervical images contained far too much flow artefact 
from neighbouring blood vessels to read clearly (see Fig. 51). Also, there was great 
difficulty in determining the difference between the lymph node and blood vessel, so not 
enough data was collected to make any significant analysis. 
3.5 Discussion 
3.5.1 Symptoms 
As mentioned in section 3.4.1. Significant reductions in fatigue, pain and cognitive function 
were reported to result from treatment of the CFS/ME group. However, although the 
symptoms of depression, anxiety and insomnia were reduced in the treated group, they 
were not statistically significant (see Appendix A10). 
In the larger treated group of phase 1 all the eight questionnaires showed highly significant 
improvement after a year p<0.005 (see Table 4) and so one can argue that if the numbers 
were larger in this phase of the study then significant results would have also been 
achieved in all the questionnaires. 
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It is interesting that the disorders examined in the four questionnaires that did not show 
significant improvement are mainly psychological symptoms related to depression and 
anxiety (see Appendix A6). If one was to claim that a placebo affect was the main reason 
for improvement in the symptoms then surely the symptoms of depression and anxiety in 
CFS/ME would improve as least as much as cognitive ability, pain and fatigue. The fact 
that there is a major difference in the improvement in the questionnaires gives credibility 
to the claim by the author that the osteopathic treatment is having some form of 
physiological affect and it is more than just placebo. 
In addition to data collected by the physiological tests and questionnaires, patients were 
subjected to rigorous physical examinations by the author during treatment sessions which 
occurred up to once a week during the trial. It was noted that there was a palpable reduction 
in tone of the cervical and thoracic paravertebral muscles. The quality of movement in the 
thoracic spine improved and the cervical and thoracic lymphatics were less tender and less 
engorged following the year of treatment. Also the cranio-sacral rhythm had increased in 
amplitude and frequency in members of the treatment group. 
The present part of the study examined four intracranial CNS abnormalities that have 
previously been indicated to be of relevance in CFS/ME and a number of additional 
parameters concerned with intracranial blood and CSF flow. Inter group differences in 
these abnormalities between two patient and one control group were examined at 
commencement of the study. The change in these abnormalities after 1 year duration was 
also subjected to the same inter-group comparisons. 
3.5.2 Ventricular volume and brain atrophy 
No significant differences were found in total CSF or ventricular volume between the 
groups at commencement of the study, and after the year-long study. All three groups 
showed a very small increase in CSF volume over 1 year, consistent with a small degree of 
age related atrophy. Due to the small sample size and non-parametric test employed, the 
statistical analysis may not be very sensitive to small changes in group CSF volume. 
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However the scatter plot of CSF proportion before and after 1 year gives no indication of 
differences between the 3 groups (Fig. 56). It is notable that 2 of the non-treated CFS/NIE 
patients showed a marked change in CSF volume after 1 year, one significantly increasing 
and one significantly decreasing. Re-checking of the results and raw images confirms that 
these changes were genuine, however with only 2 time points one cannot be certain 
whether these changes were long term over the course of a year, or whether relate to shorter 
term fluctuations. 
3.5.3 White matter abnormalities 
As recorded in section 3.4.2.2, the groups showed low levels of WMH with no evidence of 
WMH in the basal ganglia or infratentorial structures in any patient with CFS/ME. Neither 
was there any significant change after a year even in the treated group. 
The author's hypothesis maintains that the aetiology of CFS/ME is one of functional 
disturbance of the toxic drainage of the brain which is remedied by manual techniques to 
improve drainage but have no actual influence in the structure of the brain. Thus it has 
always been the view of the author that pathological brain lesions should not be found to 
occur any more in the CFS/ME patient than in the healthy person. This view contradicts 
previous research findings. 
In a recent study using MRI, the images of 39 CFS/ME patients, 18 with psychiatric 
comorbidity and 21 without a psychiatric diagnosis since illness onset, were compared with 
19 healthy controls (Lange et al., 1999). The CFS/ME group with no psychiatric diagnosis 
showed a significantly larger number of brain abnormalities on T2 weighted images than 
the other two groups. The cerebral changes in the affected group consisted mostly of small, 
punctate, subcortical white matter hyperintensities, found predominantly in the frontal 
lobes. No significant difference was found when both CFS/ME groups were combined and 
compared to the HC group. The researchers, Lange et al., (1999) suggested that any frontal 
lobe pathology could explain the more severe cognitive impairment previously reported in 
this subset of CFS/ME patients. The presence of WMH is a brain abnormality that has been 
seen in earlier research on patients with CFS/ME. As early as 1992 Buchwald and his 
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colleagues first reported subcortical hyperintensities in a group of CFS/ME patients 
(Buchwald et al., 1992). These were observed again in 1995 by Cope and co-workers who 
noticed that the abnormalities were found more in a depressed control group than the 
CFS/ME group (Cope et al., 1995). To complicate matters further, a year later Natelson and 
co-workers (Natelson et al., 1993) following a similar study, reported that the abnormalities 
appeared more in the depressed group of CFS/ME patients. 
Although an increase in WMH in CFS/ME patients was observed by Natelson (1993) and 
Buchwald (1992), in both studies some of the CFS/ME patients showed symptoms 
uncharacteristic of CFS/ME and suggestive of other disease factors. Lange et al., (1999) 
found a significant increase in WMH in CFS/ME but only after splitting the CFS/ME group 
into those with and without DSM III-R Axis-I psychiatric disorder occurring since their 
CFS/ME diagnosis, the increase being found in the group with no Axis-I psychiatric 
disorder. On the other hand some studies have failed to find any significant difference in 
the presence of WMH in CFS/ME patients and controls (Cope and David, 1996; Schwartz 
et al., 1994). 
In the present study all subjects in patient and control groups were subjected to a thorough 
screening to ensure the absence of any psychiatric disorder including detailed consultation 
with a psychiatrist. Scoring of DWMH with a widely used semi quantitative scale 
demonstrated only small numbers of white matter abnormalities with no difference between 
experimental groups and no evidence of change over time. 
The clinical relevance of these white matter hyperintensities remains unclear but we now 
know that they may occur in clinically normal individuals due to increasing age or when 
the person is diabetic, suffering from hypertension or cardiac disease (Schmidt et al., 1996). 
It is the belief of the author that the conclusions of the previous studies which assumed the 
abnormalities to be due to the CFS/ME did not take into account a multitude of other 
factors which could have led to the formation of these hyperintensities. 
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It would be prudent to conclude that success of osteopathic treatment advocated by the 
author for the treatment of CFS/ME is not due to the eradication of damaged brain cells. 
There is no evidence to imply such an implausible effect of manual therapy. What is 
suggested is that by stimulating fluid drainage of the brain the probable outcome is a 
reduced level of toxicity which aids normal cerebral function. This viewpoint is supported 
by the results of this study which demonstrate that pathological brain lesions do not occur 
any more in the CFS/ME patients compared with the healthy normal control group. 
3.5.4 Blood and CSF flow 
During the cardiac cycle, the transient increase in blood volume in the skull is balanced by 
an outflow of CSF through the cerebral aqueduct. The mechanical coupling between 
arterial and CSF flow pulsations has a dampening effect dependant on the compliance of 
the blood vessels and surrounding tissues. Cerebrovascular disease may lead to alterations 
in this vascular compliance with corresponding alterations in the pattern of CSF pulsatility 
in the aqueduct. This can be considered a sensitive but non-specific indicator of small 
vessel disease in the brain. 
In this study the temporal dynamics of blood flow into the brain and the corresponding CSF 
flow pulsations through the cerebral aqueduct demonstrated no significant differences for 
any of the flow associated parameters tested. Thus no evidence was detected of small vessel 
disease in the brain associated with CFS/ME. 
3.5.5 Thoracic duct visibility 
Tables 19 and 20 and their associated charts (Figs. 61 and 62) show an increase in the 
visibility of the thoracic duct when comparing the CFS/ME scans with the healthy group at 
the start and end of the year. However, statistically this improvement has not been shown to 
be significant. This may very well be due to the small number of subjects which makes 
statistical significance difficult. Nevertheless, there is a definite trend showing an enlarged 
lumen diameter of the thoracic duct of in CFS/ME patients supporting the hypothesis that 
in CFS/ME retrograde flow may lead to lymphatic congestion in the thoracic duct. This 
trend is further supported when examining the diameter size of thoracic ducts which are 
182 
seen to be generally wider than those seen in the healthy group (tables 21 and 22), also 
shown in the pie charts (Figs. 63 and 66). 
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Chapter 4 
4 Assessment of the osteopathic method for the 
treatment of CFS/ME: Phase 3; further analysis of 
muscle fatigue 
4.1 Introduction 
In phase 1 of this study (see chapter 2) the initial assessment of muscle fatigue showed that 
the treatment did improve this major symptom. The aetiological process and 
pathophysiological mechanisms that lead to generalised abnormal muscle fatigue after 
relatively mild activity were undetermined by the first phase. Consequently in phase 3, 
which ran concurrently with phase 2, the possible myophysiological processes that could 
account for the fatigue in CFS/ME were investigated. 
Paul et al. (1999) investigated the delayed recovery from fatiguing exercise in CFS/ME 
patients. Recovery was assessed following three sessions of ten maximum voluntary 
isometric contractions over a 24 hour period. In this study, Paul and co-workers found that 
the healthy control group showed no significant difference in all three test sessions whereas 
the patient group showed a significant increase in recovery time as they progressed through 
the 24 hour period. 
Functional electrical stimulation (FES) of the quadriceps might have provided a more 
accurate way of measuring fatigue as it could produce a set level of stimulation in the 
muscle (Bajd et al., 1990). However, it was felt that FES would have been too painful for 
these patients to withstand, and for ethical reasons we preferred to use active contraction 
controlled by the patient. 
Abnormal single fibre electromyography has been seen in about 75% of 40 patients with 
CFS/ME indicating abnormality in the motor unit (Jamal and Hansen, 1985). The muscle 
fibre was considered the likely site of involvement although there was no abnormality of 
fibre density noted. Jamal and Hansen (1985) suggested that a defect in the muscle 
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membrane following a persistent viral infection via myogenic enzymic activity was a 
possible cause of the fatigue. Earlier findings in muscle biopsies taken from 20 CFS/ME 
patients suggested widespread minor necrotic and microscopic structural changes (Behan et 
al., 1985). On the basis of these findings, it was concluded that EMG studies were essential 
in the present study to exclude any other neurogenic or myopathic aetiologies of fatigue 
This stage of the study, as in phase 1, mainly focused on the maximum torque produced 
and whether this could be sustained over a set period of time. This was determined by 
calculating the area under the torque versus time graph (impulse torque). Impulse torque 
was inversely proportional to the fatigue of the muscle and so was a suitable method for 
determining the fatigability of the knee extensors. The maximum force applied by the 
muscle was also examined. It was important to avoid any muscle damage or unnecessary 
pain for the subject. Subsequently, as in phase 1, after thirty seconds of the final push, the 
patient was told to stop. However, in the actual test some subjects accidentally stopped 
fractionally before the thirty second mark and so the impulse torque was calculated over the 
initial twenty seconds. 
As in the earlier phase of the study, the subjects' final push was rated according to the Borg 
Scale of Perceived Exertion (see Appendix A7) (Borg and Linderholm, 1970). Furthermore 
the difference between real and perceived exertion during the initial tests were compared 
with the final test to guard against the possibility that subjects may exert more effort at the 
end compared to the beginning of the trial. 
4.2 Aims of phase 3 
This part of the study aimed to further evaluate the efficacy of the novel manual treatment 
protocol for CFS sufferers. Changes in exercise induced fatigue pre and post treatment were 
assessed. The objectives were to quantify and identify the source of muscular fatigue from 
the peak torque, impulse torque and sEMG signal measured during the isometric 
contraction of quadriceps thereby determining if there is any pathology in the muscles that 
may be causing the symptom of fatigue in CFS/ME, and to determine whether any of the 
major CFS/ME symptoms were improved following the manual treatment protocol. 
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4.3 Methods 
4.3.1 Isometric dynamometry 
Knee extensor tests were carried out using a Kin-Corn AP isokinetic dynamometer (see 
Figs. 68 and 69). This equipment has been validated in many prior research studies (Poulin, 
1992; Bennett and Stauber 1986 and Weltman et al., 1986). The system's reliability and 
validity was found to be 0.94 to 0.99 for both static and dynamic exercises (Farrell and 
Richards, 1986). 
On these grounds a plethora of publications exist on the use of such devices to investigate 
quadriceps function. Isometric torque produced by the quadriceps has been shown to be a 
useful measure of recovery in muscle function pre and post treatment. Peak torque during 
voluntary quadriceps muscle strength tests have been measured following knee injury 
(Holder-Powell et al., 1999); and during recovery of muscle strength after high tibial 
osteotomy (Kawazoe and Takahashi, 2003). Agre et al., (1997) investigated the efficacy of 
a 12-week home quadriceps muscle strengthening exercise program by investigating 
isometric torque and endurance. To assess endurance these authors used a measure of 
tension time index (TTI) defined as being the product of isometric endurance time and 40% 
of maximal torque. 
Subjects were seated comfortably in the dynamometer chair with the tibia at 90 degrees to 
the thigh, and an angle of 90 between the alignment of the spine and the femur. The pelvis 
was stabilised with a seatbelt and the right thigh with a wide Velcro strap. The centre of 
rotation of the knee was aligned with the axis of rotation of the dynamometer lever (see 
Figs. 68 and 69). 
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Figure 68 The Kin-Com dynamometer at Salford University's human kinetics 
laboratory 
C= Chair in which patient is strapped loosely in to stop unnecessary movement. 
D= Display unit (showing Force V time graph and giving visual instruction to operator). 
T= Torque Transducer connected to the pressure pad (via lever arm) and the computer. 
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Figure 69 Electromyography and isometric dynamometry of the subject's right 
quadriceps 
I. = Electrodes of surface EMG strapped to subject's right thigh. 
D= Dynamometer (transducer, converting torque into electrical signal) 
The lever attached to a torque transducer at the level of the knee joint axis was aligned 
along the lateral side of the leg with a padded lever arm extending in front of the shin, just 
above the ankle. Torque data was collected at a sample rate of 100 Hz. During each 
measurement the patient was seated with the leg hanging vertically with the lever. The seat, 
placed in the same fixed position for all tests on that particular subject who was asked to 
exert as much force as possible against the lever arm (see Fig. 70). The resulting trace of 
torque at the knee was plotted against time by the system's computer. After a set period of 
time the subject was instructed to stop pushing. 
Calibration of the pressure pad position along the longitudinal axis of the lever arm took 
place before each test to maintain constant distance from the torque transducer (see Fig 70). 
Note that when the subject was seated the lever arm was placed in the vertical position 
parallel with the lower leg. 
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Figure 70 Setting up the position of pressure pad on the long axis of lever arm 
The pressure pad was manually adjusted to attach to the same point on the subjects lower 
leg both at the start of the study and 12 months later. 
Before each test the angular position of the base of the transducer was also rotated to a 
preset positioned (Fig. 71). The base was also moved in both A/P and lateral planes to keep 
the position of the dynamometer a constant in both tests (Fig. 72). 
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Figure 71 Fixing the angular position of the base of the transducer 
The base of the Kin-Corn's transducer was adjusted using the machine's automatic control 
panel and positioned at the same angle at the start of the study and 12 months later. 
Figure 72 Fixing the a/p and lateral position of the base of the transducer 
The base of the Kin-Corn's transducer was adjusted using the machine's automatic control 
panel and moved to the same position at the start of the study and 12 months later. 
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4.3.2 Surface electromyography 
"Electromyography provides easy access to physiological processes that cause the muscle 
to generate force" (De Luca, 1997). Surface electromyography (sEMG) was used to 
monitor the action of the muscles tested. In every muscle there are a number of motor 
units, each controlled by a motor nerve which depolarises the muscle initiating a muscle 
action potential (m. a. p. ). This electric signal is generated in the muscle fibre when the 
muscle contracts. Calcium ions are rapidly diffused to the contractile filaments of actin and 
myosin resulting in a depolarisation and a subsequent repolarisation wave along the fibre. 
EMG measures the sum of all the m. a. p. s transmitted along the muscle fibres at that point 
in time. The frequency of an EMG signal is the rate at which the signal oscillates up and 
down, produced from twitching of muscle fibres (Winter, 1979). 
Surface electromyography utilises electrodes stuck to the skin surface. This is not as 
accurate as using a needle inserted into the skin due to problems of skin resistance and 
cross talk from other muscles. However the surface method was chosen purely due to 
ethical considerations (i. e. it was painless and non-invasive). The quantitative relationship 
between the EMG signal and force can only be assessed with isometric contractions (De 
Luca, 1997). 
The sEMG signals were recorded for rectus femoris using silver/silver chloride surface 
electrodes in a bipolar configuration at a sample rate of 1000 Hz, with an inter-electrode 
distance of 2 cm over the belly of rectus femoris. The skin was cleaned with electrode skin 
preparation. The midline of the belly of a muscle has been shown to have the greatest EMG 
signal amplitude (De Luca, 1997). Thus the electrodes were attached parallel to the muscle 
fibres on the longitudinal midline of the muscle 10 cm above the superior border of the 
patella. Surface EMG data was collected with an MT8 radio telemetry EMG system (MIE 
Medical Research Ltd. ). The signals from the electrodes were processed through 
differential amplifiers (gain of 4,000, Common Mode Rejection Ratio= 110 dB, and 
bandwidth of 4-1000 Hz). 
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In any EMG signal there is a range of frequencies of the muscle fibre twitches. These 
frequencies can be calculated from a graph of time plotted against the magnitude, also 
referred to as the amplitude, measured in microvolts (Fig. 73). However this is not 
directionally proportional to the force in the muscle. 
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Figure 73 The raw EMG signal (Richards, 1999) 
A recording of a raw EMG signal plotted in a graph of time v amplitude. The interference 
from mains electricity is reduced by amplifying the signal close to the electrodes and by 
filtering. The size of the signal indicates the amount of number of motor units active. 
The graph above was rectified to convert all negative values into positive to give the 
recording shown in figure 74. The graph is again of time in seconds plotted against the 
amplitude, measured in microvolts. 
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Figure 74 The rectified EMG signal (Richards, 1999) 
A recording of a rectified EMG signal plotted in a graph of time v amplitude. The size of 
the signal indicates the amount of number of motor units active and was rectified to convert 
all negative values into positive. 
The rectified signal (Fig. 74) was then smoothed using a low pass filter fitting a curve over 
the signal becoming similar to the graph of muscle force produced during isometric 
contractions by the Kin-Com. The area under this rectified enveloped graph (Fig. 75) gives 
the value of the integrated EMG (iEMG). 
Figure 75 Enveloped EMG signal (Richards, 1999) 
A rectified enveloped graph of time v amplitude, formed by using a low pass filter over the 
rectified EMG signal. The area under the graph is known as the integrated EMG. 
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Fatigue is shown in an EMG signal by a frequency shift in the frequency v amplitude 
graph. Previous investigators have quantified muscle fatigue by studying the median 
frequency shift in the sEMG power spectrum. This has been shown to be a useful objective 
indicator of muscular fatigue during isometric muscle testing (Allison and Fujiwara, 2002; 
De Luca, 1997). The reliability of sEMG and isometric torque has been extensively 
reported for isometric knee extensor testing (Allison and Fujiwara, 2002; Rainoldi et al., 
2001; Kollmitzer et al., 1999). The iEMG has been proposed as a better means of 
assessment of isometric muscle function than raw EMG. Zakaria et al., (1996) achieved 
excellent reliability with non-normalised iEMG of the vasti muscles. Furthermore Onishi et 
a!., (2000) investigated iEMG of vastus lateralis, and concluded that iEMG may be used to 
predict muscle force in kinesiological research. 
An example of frequency shift is seen below in an isometric test on a healthy subject 
holding a 10kg weight for one minute (Richards, 1999). In the first graph (Fig. 76) the 
amplitude (y-axis) measured in Microvolts initially tapers slowly as the frequency increases 
(x-axis) measured in Hertz showing little fatigue at start of this isometric test. 
Figure 76 Frequency response EMG at start of test holding 10kg (Richards, 1999) 
In the graph the amplitude (y-axis) measured in Microvolts initially tapers slowly as the 
frequency increases (x-axis) measured in Hertz showing little fatigue at start of this 
isometric test. 
194 
In the second graph of amplitude v frequency (Fig. 77), after holding the weight for 1 
minute a frequency shift is shown, with the frequency spectrum moving to the lower 
frequencies on the left with an increase in the amplitude (y-axis/ µV) tapering quickly as 
the frequency (x-axis/Hz) increases. This frequency shift is an indication of fatigue. 
Figure 77 Frequency response EMG while holding 10kg after 1 min (Richards, 1999) 
In the graph of amplitude v frequency, after holding the weight for 1 minute fatigue has 
been shown indicated by a frequency shift to the left with an increase in the amplitude (y- 
axis/ µV) tapering quickly as the frequency (x-axis/Hz) increases. 
The size of the signal is related to the number of activated motor units. However, this is not 
directly proportional to the force exerted by the muscle. In any EMG signal there exists a 
range of frequencies. From a plot of frequency Vs force magnitude, these can be analysed 
by utilising a mathematical algorithm known as Fast Fourier Transformation FIT. The 
parameter mostly used in measuring the dominant frequency when measuring muscle 
fatigue is the median (central) frequency (Richards, 1999). As a muscle fatigues, the 
median frequency declines due to an accumulation of lactic acid leading to a decrease in 
sodium, potassium and calcium exchange, which in turn reduces the firing rate of the motor 
units (Allen, 2004; Renaud, 2002). 
Frequency was plotted against the amplitude of the signal, which in this context is referred 
to as the 'power' of the signal. The power spectrum is a plot of the portion of a signal's 
power falling within given frequencies. The median frequency is then calculated as the 
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frequency when the power is at 50% of maximum. The difference between the frequency 
value at 50% of power before and after exercise/activity is the frequency shift and is an 
accurate indicator of muscle fatigue as demonstrated in the example shown in figure 78. 
Figure 78 Calculating the frequency shift (Richards, 1999) 
In the graph of power spectral density v frequency, after holding a weight for 1 minute 
fatigue is shown by the frequency shift indicated by 50% of the maximum signal being 
reached at a lower frequency after 1 min (40Hz) compared to the frequency at the 
beginning (80Hz). Thus in this example the frequency shift = 80 - 40 = 40Hz. 
4.4 Results 
4.4.1 Torque and impulse torque 
In the present study, which was a single-blind study, measurement of peak and impulse 
torque in the treated patient group increased significantly over the 12 month period, as 
shown in Table 23. The peak torque increased by 27% (p=0.038), and the impulse torque 
increased by 29% (p=0.027; column 1 and 2). This indicates an improvement in the ability 
of quadriceps to produce torque and sustain it during the maximal push following 
treatment. No significant changes were seen in either the untreated patient group or the 
normal control group (Columns 3,4 and 5 and 6). 
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TREATED TREATED UNTREATED UNTREATED NORMAL NORMAL 
(0 (12 (0 MONTHS) (12 MONTHS) CONTROL CONTROL 
MONTHS) MONTHS) (0 (12 
MONTHS) MONTHS) 
Peak 47.42 60.28 52.22 54.33 54.75 51 
Torque (38.2) (27.58) (24.91) (29.55) (16.59) (17.70) 
Mean 
(sd) 
/Nm 
Mean 12.89 2.11 -3.75 
diff 
t- test p=0.038 p=0.523 p=0.975 
Impulse 782 1015.14 834.22 875 892.3 871.56 
Torque/ (713.8) (534.14) (396.95) (486.11) (324.43) (298.70) 
Nms 
Mean 233.1 40.78 20.82 
diff 
t- test p=0.0270 P=0.4800 p=0.5680 
Table 23 Peak torque and impulse torque 
The table lists the values of peak torque/Newton metre and impulse torque/Newton metre 
second, during the final push in all three groups. The values were compared at the start of 
the treatment with those at the end of the year study. Only the treatment group showed a 
statistically significant increase in peak and impulse torque, both with a p-value < 0.05. 
The treated group showed the only significant rise in peak torque in the final thrust 
following the previous ten fatigue inducing pushes with a p-value of 0.038 (see Table 23). 
The difference in the groups is further illustrated by the bar chart below (Fig. 79) which 
shows the mean values of peak torque in each subject group, both at the start and end of the 
year trial. The y-axis values are measured in Newton metres. 
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Figure 79 Bar chart showing change in mean peak torque 
The bars in the above chart show the mean values of peak torque in each subject group, 
both at the start and end of the year trial. The peak torque measured was calculated from the 
distance of the pressure pad from the centre of the transducer multiplied by the maximum 
force produced in the final push when the subject was instructed to push as hard as 
possible. The y-axis values are measured in Newton metres. 
The comparison of the mean values of impulse torque in each subject group as shown in 
Table 23 demonstrates a significant increase in the treated group p=0.0270. This difference 
is further illustrated by bar chart below (Fig. 80), both at the start and end of the year trial. 
The impulse torque is a calculation of the area under the graph torque v time (Fig. 9) the y- 
axis values are measured in Newton- metres-secs. 
The significant increase in the peak torque and impulse torque illustrates an improved 
ability to produce a force in muscles following treatment. 
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Figure 80 Chart showing change in impulse torque 
The bars show the mean values of impulse torque in each subject group, both at the start 
and end of the year trial. The impulse torque measured was calculated from the distance of 
the pressure pad from the centre of the transducer multiplied by the mean force produced in 
the final push over the first 20 secs. when the subject was instructed to push as hard as 
possible. The impulse torque is thus a calculation of the area under the graph torque v time 
(Fig. 9) the y-axis values are measured in Newton- metres-secs. 
4.4.2 Electromyography (EMG) 
Table 24 presents the results for iEMG and frequency data at the start and end of the 
routine of 10 pushes for 20 secs., each with 10 secs. rest between. 
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TREATED TREATED UNTREATED UNTREATED NORMAL NORMAL 
(0 (12 (0 MONTHS) (12 CONTROL CONTROL 
MONTHS) MONTHS) MONTHS) (0 (12 
MONTHS) MONTHS) 
1 10 1` 10 1 10 1 10 i loll, 1 10 
Rep Rep Rep Rep Rep Rep Rep Rep Rep Rep Rep Rep 
iEMG 530 551 551 591 539 529 304 314 587 597 468 440 
Mean (sd) (95) (82) (219) (191) (272) (278) (190) (172) (135) (178) (269) (240) 
/ µV. s 
Change in 21 40 -10 10 10 -27 
iEMG / 
µV. s 
t- test p= 0.9624 p=0.7483 p=0.4959 
Median 57 56 47 44 44 42 46 40 47 49 43 41 
Frequency (13) (12) (7) (7) (7) (8) (8) (10) (5) (5) (4) (5) 
Mean 
(sd)/Hz 
Frequency -1 -3 -2 -7 2 -2 
Shift/Hz 
t-test p=0.3058 p=0.4184 p=0.5792 
Table 24 Table showing changes in iEMG and median frequency 
Both the values of iEMG and median frequency were calculated based on the surface EMG 
recordings during the initial ten repeat pushes. The difference between the first and last 
push would indicate if the fatigue, induced by these ten pushes and seen in the peak and 
impulse torque readings, was due to a lowered recruitment of motor units or had a different 
aetiology. The table also gives the statistical value following a t-test on the mean change of 
iEMG and median frequency, where a p-value of <0.05 statistically demonstrates a 
significant change in motor unit recruitment. 
4.4.2.1 The integrated EMG 
As previously mentioned in section 4.3.2, integrated EMG (iEMG) refers to the area under 
the full rectified enveloped EMG trace (see Fig. 75). The results of the iEMG, measured in 
micro-Volt seconds, are shown in Table 24. These demonstrate no significant difference 
(p>0.05) in the treated patient group (column 1 and 2) untreated patient group (column 3 
and 4) or the normal control group (column 5 and 6) over the year (see Table 24). This 
would indicate that a similar number of motor units were being recruited by all subjects 
during exercise at the beginning and end of the year. The results are graphically 
demonstrated in the bar chart below (Fig. 81). 
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Figure 81 Mean iEMG / µV. s of right rectus femoris before and after year of trial 
The bars show the mean values of integrated EMG in each subject group, both at the start 
and end of the year trial. The iEMG measured was calculated from the area under the 
microvoltage X time graph produced in the rectified EMG signal during the fatigue 
inducing, ten pre-test pushes. Where: la = ls` pre-test push at start of year, lb = 10`h pre-test 
push at start of year, 2a =1 S` pre-test push at end of year, 2b = 10th pre-test push at end of 
year. The y-axis values are measured in microvolt-secs. 
4.4.2.2 Median frequency 
The median frequency (table 24 and Fig. 82), measured in units of Hz, from the ls` and 10`h 
repetitive push was significantly no different in the treated patient group (column 1 and 2), 
untreated patient group (column 3 and 4) and the normal control group (column 5 and 6) 
over the year (table 24). This indicates that all subjects were fatiguing by the same amount 
during the exercise at the beginning and end of the year. 
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Figure 82 Median frequency/ Hz of right rectus femoris before and after year of trial 
The bar chart show the mean values of the median frequency in each subject group, both at 
the start and end of the year trial. The frequency measured the number of activated motor 
units which decline in muscle fatigue. The median frequency of the amplitude versus 
frequency graph was calculated for the first and tenth pre-test pushes. Where: 1a = 1s` pre- 
test push at start of year, lb = 10`h pre-test push at start of year, 2a = 1S` pre-test push at end 
of year, 2b =1 0`h pre-test push at end of year. The y-axis values are measured in Hertz. 
4.4.3 Symptoms 
Table 25 lists the scores obtained for the symptom questionnaires, expressed in overall 
mean percentage change relative to the maximum score possible. In the right hand column 
is shown the significance factor of each questionnaire result. The result is significant if 
p<0.05. This table summarises the detailed questionnaire results reported in the previous 
chapter. 
As stated in chapter three, significant reductions in most symptoms, notably fatigue 
(PFRS), pain and cognitive function were reported to result from treatment of the CFS/ME 
group. However the symptoms of depression, anxiety and symptoms such as insomnia were 
not significantly reduced following treatment. 
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Questionnaire Treated Group Non-Treated Group Normal Control 
% improved % improved Group 
% improved 
Health 16.63 -1.99 0.14 P= 
0.009 
Back Pain 29.39 2.47 0.92 p= 
0.002 
Depression 8.86 -1.24 0.17 p= 
0.057 
Anxiety 8.64 2.83 -0.8 p= 
0.507 
Sleep 9.74 -1.39 0.98 p= 
0.069 
Cognition 19 -9.45 -6.11 p= 
0.019 
Nott. Health 15.42 2.92 1.37 p= 
0.263 
PFRS. 23.74 -5.82 -0.93 p= 
0.007 
Table 25 Summary of symptom questionnaires (Phase 2 results) 
The values listed above are the differences between the mean percentage scores at the 
beginning and end of phase 2, where 0% = symptom free and 100% was maximum severity 
possible. The improvement in the treated group compared with the control groups is seen in 
the higher scores in the 2nd column. Note that a -ve value =a worsening in the symptoms 
over the year. Kruskal-Wallis nonparametric one-way analysis of variance was used to test 
for significant differences in questionnaire responses, as percentages of maximum scores 
possible, between the three groups. The final column shows the p-value which determines 
the statistical significance of the improvement in the symptoms of the treated group 
compared with the controls (See Appendix A10). 
4.5 Discussion 
There was no significant difference in the iEMG and median frequency shift between any 
of the three groups at the beginning and end of the pre-fatigue-exercises of 10 pushes at 
33% of maximum, each for 20 seconds. Furthermore, there was no change in these values 
between the beginning and end of the maximal push. Therefore, it was concluded that the 
level of fatigue was the same in the two visits. However, the isometric results showed that 
only the treated patients improved in the peak and impulse torque for the final maximal 
push. It could be argued that the controlled exercise protocol of 10 repetitions at 33% of 
maximal did not induce a fatigued state. Yet, the final maximal contraction did produce a 
greater impulse torque at the end of the year, indicating significant improvements in the 
performance of the quadriceps in the treated patients, with no change in those who had no 
treatment. 
203 
Note that the isometric results were based on the calculations of only 7 of the treated group. 
Two subjects (RV01 and RV10) did not fully comply with the inclusion/exclusion criteria 
and are disregarded. 
The process that reduces muscle strength in CFS/ME is a matter of debate. The primary 
philosophy behind the effectiveness of the treatment used in this study is that the prescribed 
manual treatment increases blood and lymph flow. Articulatory techniques of the thorax 
and soft tissue plus cranial techniques are all designed to improve respiratory mechanisms 
and fluid movement within the body. This leads to consequential improvement in 
oxygenation of the diseased tissues (Lay, 1997; Upledger and Vredevoogd, 1983; Magoun 
1966; Still 1899,1902). The success of the treatment implies that the fatigue in CFS/ME is 
possibly due to reduced blood flow, oxygenation and/or lymph drainage. 
Merton et al., (1973) proposed that impaired blood flow leads to a reduced oxygen supply 
to a muscle resulting in fatigue. It has long been accepted that the rate of blood flow 
through contracted skeletal muscle has an important bearing on myochemistry, and is a 
factor leading to fatigue (Barcroft and Millen, 1939). Earlier research has scientifically 
validated the use of massage to improve circulation (Goats, 1994). Point massage produced 
a vasotropic effect in patients suffering from vertebrobasilar insufficiency and trans- 
ischemic attacks and has improved the prognosis in these patients (Gusarova et al., 1998). 
Infant circulation was also improved with a regime of soft tissue massage (Gupta et al., 
2002). Morhenn (2000) postulated that massage stimulates the release of the 
neurotransmitter substance P leading to vasodilation in the local tissues. In more recent 
studies human muscle fatigue has been shown to increase following physiological 
reductions in perfusion pressure. On the other hand Wright et al., (1999) showed that 
although there is a reduction of blood flow in the muscle of the extremities, at the same 
time there is an increase in the body's central blood pressure which may partially offset the 
waning muscle performance. 
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The main purpose of the soft tissue massage used in this study was to increase blood flow 
in the paravertebral muscles and improve upper thoracic mobility. The intention was to 
subsequently stimulate the central lymphatic drainage towards the subclavian veins. The 
replies to the questionnaires and isometric test results indicated that the cognitive and 
physical functions of the treated patients were significantly improved. As this is not a 
double blind study, placebo could not be ruled out, though the psychological elements of 
CSF/ME which should have all responded well to placebo, showed no statistically 
significant improvements at the end of this part of the study. This indicates that there are 
physical or physiological changes being made as a result of the osteopathic approach, 
which may or may not be due to improvement of blood flow and subsequent oxygenation 
of tissues. A prior study by Wong et al., (1992) on patients with CFS/ME has demonstrated 
that the reduced capacity for dynamic exercise is also associated with reaching exhaustion 
much more rapidly than normal subjects, at which point these patients had reduced 
intracellular concentrations of ATP. This latter study concluded that there was a defect in 
oxidative metabolism with a resultant acceleration of glycolysis in the working skeletal 
muscles of a CFS/ME sufferer. Oxidative stress has also been detected in CFS/ME which is 
damaging to DNA and lipids, leading to fatigue (Fulle, 2000). Some recent research has 
also shown that increased oxidative stress and decreased antioxidant defences are related to 
the extent of symptomatology in CFS/ME (Vecchiet et al., 2003). 
The idea of impaired oxygen delivery causing the fatigue associated with CFS/ME has been 
further explored. Oxidative metabolism and oxygen delivery was shown to be reduced in 
patients with CFS/ME (McCully and Natelson, 1999). Conversely, McCully et a[ (2003) 
investigated the association of CFS/ME with reduced blood flow and oxidative delivery to 
skeletal muscle. Muscle blood flow was measured with Doppler ultrasound after cuff 
ischaemia and exercise. Muscle oxygen delivery was measured as the rate of post-exercise 
and post-ischemic oxygen-haem re-saturation using continuous wavelength near-IR 
spectroscopy. Muscle metabolism was measured using (31)P magnetic resonance 
spectroscopy. No significant difference was noted in the patient and control groups. 
McCully and co-workers (2003) concluded that CFS/ME patients showed no deficit in 
blood flow or oxidative metabolism. 
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This does not mean that the observed increase in muscle performance may not occur due to 
an improved cardiovascular system. Aerobic exercise programmes have indeed been shown 
to raise blood supply plus enhance the oxygen intake and supply to tissues (Gan et al., 
2003; Hautala et al., 2003; Valim et at., 2003; Magosso and Ursino, 2002; Irvin, 1996). 
Nevertheless, if motor nerve dysfunction and reduction of blood flow are not the cause for 
the weakness, then one only has to look at the lymphatic drainage capabilities to find a 
highly plausible reason for the functional impairment of the muscle. 
Clinical examination through palpitation in all the 18 CFS/ME patients in this study 
revealed engorged lymphatic vessels in the cervical and thoracic regions. This suggests that 
there is impaired central drainage (Kinmonth, 1960). Oedematous changes in muscles 
undergoing sustained low-level isometric contractions have been implicated as a major 
cause of fatigue (Sjogaard and Bonde-Peterson, 1981). One of the main reasons for this 
oedema could be the lack of adequate lymphatic drainage. The techniques of massage and 
manipulation employed on the patients in this study were specifically used to encourage 
movement of bodily fluids, (including lymph drainage), eliminate dysfunction in the 
motion of the tissues, relax muscular tension and release compressed bones and joints (Still, 
1902; Stoddard, 1982). Kurz and co-workers (1981) have shown that histamine and 
serotonin were released from oedematous tissue following manual lymphatic drainage and 
that circulation was improved through increased output of adrenaline and noradrenalin. The 
improvement of central lymph drainage following the manual treatment advocated by the 
author has been shown to aid the infra muscular lymphatics and subsequently reduce 
fatigue (Bringezu, 1994). 
The main drainage vessel of the lymphatics contains smooth muscle walls controlled by 
sympathetic nerves (Browse, 1968). Dysfunction of sympathetic control of the thoracic 
duct may lead to a reflux of toxins in the resultant retrograde lymph flow causing varicose 
lymphatic vessels predominantly in the abdomen, neck and chest (see Figs. 88-92). It may 
also affect the flow of CSF into the lymphatics (Kinmonth, 1960; 1982). Disturbance of 
normal sympathetic control, as seen in CFS/ME, offers a possible explanation regarding the 
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reduced muscle function seen in this study. Spinal manipulation has been well documented 
as a method to improve afferent and efferent sympathetic activity (Korr, 1978) and, in this 
instance, may aid the symptoms associated with CFS/ME. 
It should be noted that in the present study, the improvement in function in the quadriceps 
was not achieved by any direct treatment on the lower extremity, or by any exercise regime 
to improve muscle strength. In fact subjects were explicitly instructed not to embark on any 
exercise routine during the year of study. The results showed improved peak and impulse 
torque which is a direct measure of the ability of muscles to produce and maintain torque. 
This demonstrates that there was a significant improvement in muscle function following 
treatment. 
207 
Chapter 5 
5 General discussion 
5.1 The aetiological stages of CFS/ME: A new theory 
Three predominant concepts have surfaced from the present clinical trials performed on 
CFS/ME patients as described in the preceding chapters. Firstly, it has been observed that 
muscle fatigue is of a functional nature rather than any recognisable untreatable 
myopathology. As shown in section 4.5 the isometric results showed that only the treated 
patients improved in the peak and impulse torque for the final maximal push at the end of 
the year. However, there was no significant difference in the iEMG and median frequency 
shift between any of the three groups at the beginning and end of the pre-fatigue-exercises 
with no significant change in these values between the beginning and end of the maximal 
push indicating the fatigue is induced extrinsically rather than due to an intrinsic disease 
within the motor unit. 
Secondly, as concluded following detailed MRI scanning, CFS/ME most commonly exists 
in patients with no detectable pathological structural abnormality in the central nervous 
system. As noted in section 3.4.2.1 comparison of the proportionate CSF volume between 
the 3 subject groups at the beginning of the study showed no significant difference between 
either of the CFS/ME patient groups or the control group. Also in section 3.4.2.2, the 
groups showed low levels of \VMH with no evidence of WMH in the basal ganglia or 
infratentorial structures in any patient with CFS/ME. 
However there is much evidence in the preceding chapters to support the hypothesis that 
this disorder is a dysfunctional condition, possibly due to neurotoxic overload affecting the 
sympathetic nervous system brought about by a disturbance of normal lymphatic drainage 
of the neuraxis. 
Thirdly, when examining the scientific rationale behind the treatment programme 
developed by the author, which has been shown to reduce the symptoms of CFS/ME, it 
208 
seems likely that the muscular and cerebral symptoms are linked by the pathophysiological 
process discussed in sections 2.5: 3.5 and 4.5. As stated in this thesis, long lasting 
hyperactivity of innervating sympathetic pathways seems to be a prevailing theme in many 
clinical conditions, involving various organs and tissues (Korr, 1978). Sympathetic nerve 
control of smooth muscle walls causes pulsatile contractions in thoracic duct aided by 
valves along its structure which maintain unidirectional flow (Kinmonth, 1982). 
Dysfunction of sympathetic control of the thoracic duct leads to a reflux of toxins in the 
resultant retrograde lymph flow causing varicose lymphatic vessels predominantly in the 
abdomen, neck and chest (Kinmonth, 1982; 1960). This further reduces flow of CSF into 
the lymphatics (Knopf and Cserr. 1995). The afferent sympathetic outflow, in particular, 
may be modified by the treatment developed by the author. 
Drawing on all the information detailed in the first four chapters with careful consideration 
of the clinical findings, the author has formulated a theoretical model to explain the 
aetiology, symptoms and the rationale behind a novel treatment regime for CFS/ME. This 
treatment programme was developed over the past fifteen years involving manual 
lymphatic drainage and soft tissue massage of primarily the upper thoracic, cervical and 
cranial regions. The osteopathic approach does not set out to directly eliminate toxins from 
the body; rather it facilitates the patient's own inbuilt mechanisms responsible for toxin 
elimination. By modifying afferent sympathetic tone via osteopathic treatment the 
symptoms of CFSIME are diminished. 
A model of the stages of development of this disease is proposed below which may be 
applied to all CFS/ME patients seen by the author over the past one and a half decades. 
Stage 1 Patients with CFS/ME all seem to have a predisposing history of sympathetic 
nervous system overload: 
a. Physically by being an overachiever at work, during study or in sports. Rarely, it can be 
the opposite by being too sedentary (Perrin, 1993). 
b. Chemically by constant exposure to environmental pollution (Rogers, 1990; Dustan et 
al., 1995). 
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c. Immunologically by chronic infections or hypersensitivities to multiple allergens 
(Shepherd, 1998, Crook, 1984). 
d. Psychologically/emotionally by family and or work related mental stress (Black, 1999 
and Sharpe, 1996). 
Stage 2a In patients with CFS/ME the lymphatic drainage of the neuraxis shows signs of 
being compromised in the cranium, mostly in the cribriform plate region of the ethmoid 
bone. 
11,11 Ant. 
Ethmoid Bone 
Crista Gallae 
Perforations 
Cribriform Plate 
Post. 1 
Figure 83 Superior view of the cribriform plate with observed perforations. 
The perforations seen above allow the passage of blood vessels, nerves and cerebrospinal 
fluid from the cerebrum to the nasal sinuses situated directly below the ethmoid bone. 
This drainage problem clinically appears to arise from a prior defect in the skull, usually in 
the frontal/nasal region due to either a congenital, hereditary or traumatic aetiology. This 
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may be exacerbated by chronic sinusitis leading to further congestion affecting the lymph 
channels in the mucous membranes of the nasal sinuses. 
Stage 2b The lymphatic drainage of the neuraxis is subject to further disturbance in the 
spine, usually in the cervical or thoracic region, due to either a congenital, hereditary or 
Figure 84 MRI sagittal image showing spinal defect in 12 year old girl with CFS/ME 
The postural disturbance of the thoracic spine in most cases of CFS/ME is usually not too 
severe with usual evidence of old osteochondrosis with a flattened upper thoracic region. A 
syrinx (cyst within the spinal canal) seen in this MR image is rare but demonstrates the 
extent of possible spinal dysfunction. 
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postural defect and/or prior trauma. 
Defect is evident when 
cerebellar tonsil descends into 
cervical spine 
Figure 85 Upper cervical defect in same 12 year old girl 
A defect at the uppermost region of the cervical spine is found in many cases of CFS/ME. 
The sagittal MR scan shows a partial herniation of the cerebellar tonsil into the spinal canal. 
(If the herniation penetrates further into the cervical region it is known as a Chiari 
Malformation). 
Stage 3 The chronic hyperactivity of the sympathetic nervous system will be compounded 
by toxic affects due to the long term dysfunction of the neuraxis drainage; this further 
overloads the hypothalamus and subsequently the sympathetic nervous system. 
Stage 4A final trigger factor strikes, which usually arises from a viral infection, but may be 
physical or emotional in nature. As already stated in section 2.5.3.1.2 prolonged somatic 
dysfunction often leads to repetitive nociceptive input, a consequential overstimulation of 
the PGi-LC may contribute to the chronic adaptive response that ensues (Aston-Jones et al., 
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1990). The ensuing cascade of sympathetic activity and dysfunction of fluid dynamics in 
the body and most importantly in the lymphatic drainage, leads to observed early symptoms 
of muscular fatigue and disturbance in cognitive ability. 
Stage 5 There will be a disturbance in autonomic, as well as hormonal function, as toxins in 
the cerebral blood flow and ventricular system directly affect control of the hypothalamus. 
Hormonal transport within CSF may also be directly affected by toxic overload. 
Stage 6 Dysfunction of sympathetic control of the thoracic duct leads to a reflux of toxins 
in the resultant retrograde lymph flow causing varicose lymphatic vessels predominantly in 
the abdomen, neck and chest (Kinmonth. 1982; 1960). This further reduces flow of CSF 
into the lymphatics (Knopf and Cserr. 1995). 
Stage 7 Further impairment of toxic drainage of the neuraxis, due to the retrograde 
lymphatics, results in increased hypothalamic dysfunction and an even greater reduction of 
lymphatic drainage. 
Stage 8 The continuing sympatheticonia results in further systemic disturbances. Somatic, 
visceral, emotional, immunological and environmental stressors continue to affect the 
damaged brain stem-hypothalamic mechanisms to increase sympathetic catecholamines and 
adrenal cortical hormones leading to a chronic adaptive state known as CFS/ME. 
5.2 The physical signs of CFS/ME 
The concept of CFS/ME being primarily a physical disorder is foreign to most of the 
medical profession. However. many of them recognise that CFS/ME has physical 
symptoms. There are physical components within the internationally recognised criteria 
that verify the diagnosis of CFSIME. These include sore throat, tender cervical or axillary 
lymph nodes, myalgia, and polyarthralgia (Fukuda et al., 1994). In the fifteen years since 
the author started to examine and treat patients with CFS/ME, repeated patterns of physical 
signs have emerged among sufferers that can not be dismissed as pure coincidence. All the 
physical phenomena seen in CFSI ME can be understood when the pathophysiology of the 
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disease is viewed as being neurolymphatic in origin with impaired drainage resulting in 
sympathetic dysfunction. The main physical signs are shown in the illustration below (Fig. 
86). 
Physical 
Signs 
of 
CFS/ME 
2 
a 
I a. Varicose Lymph b. Perrin's Point 
2. Coeliac Plexus. 
3. Long standing thoracic spinal problem 
(with tenderness at T4/T5/T6 segments). 
4. Reduction in regular sacro-cranial rhythm. 
Figure 86 The observed physical signs of CFS/ME 
These regions of tenderness or dysfunction were identified in all CFS/ME sufferers seen by 
the author over the last ten years in both the university and clinical settings. A full 
description and an explanation of the above findings are detailed below. 
5.2.1 Varicose lymphatics and Perrin's point 
In every CFS/ME patient, whether male or female, there was very tender area in the upper 
lateral region of the breast tissue, roughly 2cm superior and lateral to the left nipple (Fig. 
87). This is the area where the pectoral muscles and lymphatic tissue overlap. This finding 
is significant because this tender area almost always lies on the left side and is level with 
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the position at which the thoracic duct turns to the left. The heart and the main blood 
vessels are supplied with sympathetic nerves via the cardiac plexus which has a greater 
concentration of nerves in the left than the right. The cardiac sympathetics, and those 
innervating the thoracic duct via viscero-somatic reflexes, irritate sensory nociceptors at 
this point in the left breast. The Author refers to this tender spot as "Perrin's Point". 
Figure 87 Examining the patient for `Perrin's point' 
Gentle pressure at a point slightly superior and lateral to the left nipple "Perrin's Point"(X). 
The amount of sensitivity at this point appears to correspond to the severity of lymphatic 
engorgement in the breast tissue and also seems to mirror the gravity of the other 
symptoms. 
This sensitive region, together with congested lymph vessels in the cervical region and 
breast tissue, was palpated in all 18 CFS/ME patients in the second phase of the study. The 
consistency of these lymphatics can best be described as "beady" and similar to varicose 
veins in the leg. Varicosities have been described in the lymphatics (Kinmonth, 1960). 
Large incompetent varicose lymphatics known as megalymphatics have often been seen 
when this backflow occurs. However varicosities in the lymphatics are rarely discussed in 
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medical literature, purely due to the misconception that lymph flow is unidirectional due to 
the valvular system in the lymphatic vessels. Thus the concept of backward pressure is not 
generally known and the possibility of varicose lymph is rarely considered when examining 
lymphatic tissue. It is now established that a chylous reflux does exist (Kinmonth, 1982). 
Downward pressure due to thoracic duct pump dysfunction caused by sympathetic 
disequilibrium may lead to a contra-flow within the lymphatics, damaging the valves and 
creating a pooling of lymphatic fluid with "beading" of the vessels. Stasis in these varicose 
lymphatics creates risk of toxic overload plus further damage to the lymphatics and 
surrounding tissue. Reflux of toxins via lymphatic vessels back into the cerebro-spinal fluid 
will further irritate the central nervous system. Further toxicity within the neuraxis 
continues to overload the sympathetics resulting in a downward spiral of deteriorating 
health. 
From the earliest days of osteopathy, the importance of good lymphatic drainage in the 
thoracic duct has been seen as paramount to sustain health (Still, 1902). It was emphasised 
that alongside good blood supply it was equally important to have perfect drainage. It is the 
above pathway that the author believes to be compromised mechanically as part of the 
common pathogenesis in MFJCFS. Mechanical dysfunction such as this can be detected by 
palpation and can be released by gentle pressure techniques applied to the cranium and the 
spine. 
The healthy lymphatic vessel allows only unidirectional flow due to the valvular system as 
diagrammatically illustrated in Fig. 88. In CFSIME, retrograde flow of the lymphatics is 
produced by the reverse peristaltic wave of the thoracic duct which arises from 
dysfunctional sympathetic control of the duct's smooth muscle wall (Fig. 89). 
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The valves in this healthy vessel are intact preventing any backflow, thus maintaining a 
unidirectional flow of lymphatic fluid. 
Figure 89 Retrograde lymphatic flow 
If the normal peristalstic wave of the thoracic duct is disturbed resulting in a reflux, then 
the ensuing back-pressure will weaken the valves allowing a retrograde flow. 
Eventually the lymphatic reflux causes damage to the valves and allows pooling of fluid in 
between the valves. This leads to distension of the vessel wall with the characteristic 
beaded appearance of a varicose vessel as illustrated in figure 90. 
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Figure 88 Schematic showing normal flow within a healthy lymphatic vessel 
Figure 90 Schematic showing the formation of lymphatic varicosities 
The walls between the collapsed valves become noticeably distended with further reflux of 
lymphatic fluid. 
The above schematics (Figs. 88-90) show the development of varicose lymphatics that were 
palpable in the chests of all cases of CFS/ME seen by the author, including the patients 
involved with this research. This process is similar to the development of deeper abdominal 
lymphatic varicosities as seen in many lymphatic disorders (Kinmonth, 1960; 1982). 
The following photographs (Figs. 91a and b) are of the chest of a 61 year old gentleman 
who suffered severely from CFS/ME for four years before being successfully treated with a 
two year course of osteopathy. For the past four years, since completion of the 2 year 
treatment period, he has been steadily increasing his activity and was found to be virtually 
symptom free when he returned for six-monthly check-ups. However, the pressure on the 
lymphatic system during years of illness has taken its toll on the constitution of the lymph 
vessel valves leaving permanently engorged varicosities. Even though he is now generally 
well, except after extreme exertion, he still has to regularly carry out the lymph drainage 
massage technique. 
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Figure 91 Right and left subclavicular varicose lymphatics in patient with CFS/ME 
In photograph a, taken 4 years after completing a2 year treatment programme, one can 
clearly see five separate varicose lymphatic vessels under the skin at the anterior medial 
aspect of the right shoulder, the central one being the most pronounced. A further example 
of the left subclavicular region in the same patient is seen in photograph b, taken six 
months after the first photograph, with the megalymphatics even more pronounced. 
The beaded appearance in figures 91 a. and b. are due to damaged valves and subsequent 
retrograde flow and pooling of lymphatic fluid. This is similar to the formation of varicose 
veins although it lacks the darker, bluish hue of superficial varicose veins. The creamy 
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appearance of lymph is almost apparent in these engorged vessels which present with a 
much larger diameter than in normal healthy superficial lymphatic vessels. It is extremely 
rare to actually see such obvious superficial varicose megalymphatics as illustrated above. 
In fact this was one of the only times in 15 years that the author had observed such a 
pronounced superficial varicosity. However it was possible to feel the presence of varicose 
lymphatic vessels in the neck and chest of all the CFS/ME patients treated. 
A third case of visible and palpable varicose lymph was observed in patient RV08 from the 
treated patient group of phase 2. He showed visible varicose lymph under the right clavicle 
following effleurage. This 22 yr old male improved slowly with treatment but after a year 
of treatment, he still required further osteopathic treatment plus other therapies to help 
detoxify him. At four years after the beginning of the study he still had visible evidence of 
lymphatic reflux as shown in figure 92. 
Figure 92 Superficial lymphatic varicosities seen in research patient RV08 
The chest of a 22 year old male viewed from above the right sterno-clavicular joint 
showing superficial lymph vessels that are tortuous as they travel towards the right 
subclavian vein. Photograph taken 4 years after commencement of treatment. 
220 
5.2.2 Tenderness in coeliac plexus region 
The largest major autonomic plexus uniting two large coeliac ganglia is known as the 
coeliac plexus. This major plexus is level with the 12'h thoracic/1" lumbar segment and is 
situated posterior to stomach and anterior to crura of diaphragm. Secondary plexuses 
connected to coeliac plexus are: phrenic; splenic; hepatic; left gastric; intermesenteric; 
suprarenal; renal; testicular/ovarian; superior mesenteric and inferior mesenteric. 
Through its connections, it is excellent as an indicator for any visceral disturbances from 
waist down. Clinically it has been observed by the author that tenderness in the 
hypochondrium seems to be directly related to the severity of any lower extremity fatigue 
and or abdominal problem. This tenderness is most likely due to stimulation of connecting 
peripheral somatic nociceptive afferent fibres with sympathetic nerves observed in 
pathological mechanisms (Janig, 1988) see section 2.5.3.1.1. 
5.2.3 PosturaUstructural dysfunction of thoracic spine 
A prevailing observation in the clinical findings of CFSI ME outlined in this thesis is a 
mechanical disorder of the thoracic spine which may be due to bad occupational posture, 
congenital or genetic predisposition. All of the patients in the studies undertaken by the 
author had a particular dysfunction in the thoracic region, whether it was inflammation, 
lordosis, kyphosis or just a restricted area. A good example of the type of spinal problem 
commonly seen in CFS/ME is shown in the case of RV05, a member of the treated group in 
the second phase (Fig. 93). 
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Figure 93 Mechanical dysfunction of thoracic spine 
Lateral a and posterior b views of research patient RV05, a 53 year old married social 
worker. Note the kyphotic dorsal spine with a lateral curvature in dorso-lumbar region (NB 
the patches of vitelego have no known association with CFS/ME). See Appendix A5 for 
patient's previous history. 
Another common structural disturbance seen by the author in CFS/ME patients was a 
flattening of the curvature in the mid thoracic spine, usually accompanied by the presence 
of a kyphotic dorso-lumbar region. An example of the defect seen is shown in the 
accompanying photograph (Fig. 94), which can be compared with the healthy posture as 
shown previously in Figs. 1C and ID. This postural defect is often caused by the prior 
condition osteochondrosis or Scheurmann's disease affecting spinal development in 
adolescence, which may have occurred years before onset of the distinct symptoms of 
CFS/ME. 
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Figure 94 Flattening in upper thoracic spine with signs of previous osteochondrosis 
Female, 43 year old journalist who has been retired for 4 years due to ill health, Married 
with no children. She had a tonsillectomy when 7 y. o. a.; and chronic migraine. Eight years 
prior to consultation she suffered concussion after hitting top of head. 
5.2.4 Change in regular cranio-sacral rhythm 
As described in section 2.2.4.6, there is a palpable rhythmic pulsation along the spinal cord 
and around the brain together with that of normal breathing, which is transmitted to the rest 
of the body and is termed the involuntary mechanism, cranial rhythmic impulse (CRI) or 
the "cranio-sacral rhythm". Most of the osteopathic profession believe the pulse to be a 
movement through the tension and continuity of membranes, dura and fascia. The fascia is 
continuous with the membranes that surround the brain and spinal cord, the meninges, thus 
allowing the different motions, and tensions, of the body to be transmitted everywhere. 
Sutherland proposed that the inherent, involuntary cycle of mobility of the cranial bones 
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and also that of the sacrum between the ilea corresponds with the motility of the neural tube 
and fluctuation in the flow of the cerebrospinal fluid (Sutherland, 1990). 
Sutherland (1990) also proposed that the primary respiratory mechanism produces a 
rhythmic alternation of flexion and extension of structures in the midline. This movement 
occurs simultaneously with rhythmic external and internal rotation of all paired lateral 
structures. It has also been suggested that contractile lymph tissue exists throughout the 
body which creates a powerful pumping mechanism (Kinmonth, 1982). It has been shown 
that the thoracic duct pump influences the drainage of CSF/lymph from the neuraxis. 
Together with the pulse rate and the effects of breathing, a separate underlying rhythm may 
be induced which is very possibly the aforementioned 'involuntary mechanism'. This 
rhythm echoes along the lymphatic system, resonating throughout the entire body and can 
be palpated by trained osteopaths. In CFS/ME patients it is slower and its intensity 
shallower than in normal subjects. This was found to be the case in all the patients in the 
present study. 
5.3 Future developments 
5.3.1 Multidiscipline comparative studies 
Multicenter studies using a much larger cohort of patients are most definitely required in 
the future to further validate the hypothesis explored in this thesis. Also the chosen 
osteopathic method used in this study should be tested alongside other accepted treatments 
in order to gain wider acceptance. 
The treatment plan developed by the author has already been independently validated by a 
recently published survey conducted by a local patient support group (Vernon, 2004). One 
hundred and fifty members of the Stockport M. E. support group answered questionnaires 
related to the services provided by NHS professionals and complementary practitioners. 
One of the outcomes of this independent survey was a list of therapies that the group's 
members found useful in managing their illness. 
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THERAPY / TREATMENT Number of Patients 
Expressing a Preference 
Osteopathy - the cranial/lymphatic approach (as 
practicsed by Raymond Perrin (p. 214 et seq this 
thesis)) 
28 
Nutrition/ Allergy testing 21 
M. E. specialist Dr Andy Wright (who 
recommends many forms of new treatments that 
have shown to help including the author's 
manual approach). 
16 
Healing/ Reiki 15 
Homeopathy 11 
Remedial Yoga 11 
Acupuncture 9 
Meditation 9 
Thyroid specialist 8 
Counselling 7 
Tai Chi 6 
Herbalist 6 
Aromatherapy 5 
Massage 3 
Alexander Technique 2 
Bowens Technique 2 
Table 26 Results of Stockport ME patients support group survey on treatment 
therapies effective In their case: listed in order of preference (Vernon, 2004) 
Some of the 150 patients listed more than one treatment that they had found helpful. This 
explains why the total of all patient numbers in this table add up to 161. 
The data suggests that although aromatherapy, massage, the Alexander and the Bowens 
techniques are also forms of therapy with the emphasis on the physical, they score the 
lowest ratings in the table compared to the manual treatment advocated in this thesis which 
scored the highest. So the observed benefits are not achieved by the mere laying of hands 
by a sympathetic practitioner. The complete treatment approach developed by the author is 
required including spinal, cranial and specialised lymphatic drainage techniques. 
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5.3.2 Lymphatic drainage of the neuraxis and the CRI 
Another area of exploration arising from this thesis that requires further investigation is the 
possibility that the aforementioned CRI (cranial rhythmic impulse) and the drainage of CSF 
into the lymphatics, echoing the thoracic duct pump, are one and the same. 
Attempts have been made to explain the rhythm felt by cranial practitioners. Farasyn 
(1999) suggested that the intrinsic movements of cranial bones, fascia and organs may be 
due to local venomotion pulsation, the reflection of which we may palpate at the skin 
surface. However this theory is difficult to accept due to the absence of contractile tissue in 
the veins and sinuses of the brain. The cerebral veins are unique in that they possess no 
muscular tissue in their very thin walls and have no valves. Consequently any palpable 
venous pulsations in the head are mere remnants of larger vasometric pulsations of the 
inferior vena cava and iliac vein. The cerebral veins descend from the brain into the 
subarachnoid space by penetrating the arachnoid mater and the meningeal layer of the dura 
thereby draining into the cranial venous sinuses. Most significant is the cavernous nodule 
lying at the confluence between the great vein of Galen and the straight sinus and the 
Cavernous sinuses which are situated in the middle of the cranial fossa on each side of the 
sphenoid bone. The internal carotid artery, surrounded by its sympathetic nerve plexus runs 
forward through the sinus (see Fig. 42). 
The main lymphatic vessels are known to be under sympathetic control (Browse 1968). 
When the smooth muscle wall of the thoracic duct is stimulated it produces a wave of 
contraction that aids lymph drainage into the subclavian vein. This produces a negative 
pressure along the lymphatics and further assists lymph drainage. The resulting peristaltic 
wave within the normal human thoracic duct was found to occur at 4 beats per minute with 
a maximum pressure of around 10-mmHg, building up to 50 mmHg if obstructed 
(Kinmonth and Sharpey-Schafer, 1959). The thoracic duct pump acts as suction for the 
lymphatics around the body and influences the drainage of toxins from the central nervous 
system. Together with the pulse rate (72 bpm) and the overall influence of ventilation 
(respiratory frequency is 10-18 breaths per minute in adults) (Bell, Emslie-Smith and 
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Paterson, 1980), a separate underlying rhythm is induced which could indeed be the 
aforementioned `involuntary mechanism'. 
Cerebrospinal fluid (CSF) moves intracranially at the same rate as the heart (i. e. 
approximately 72 beats per minute at rest) and normally moves within the ventricular 
system of the brain at around 600m1/min. The blood flow in the carotid bodies in the neck, 
just after leaving the heart is 2000 ml/g/min, whereas normal blood flow in the brain is 
approximately 65 ml/g/min. The flow of lymph in the thoracic duct is known to be about 1 
to 2 ml/min between meals, but may increase 5 to 10 times during ingestion and absorption 
of a meal (Bell, Emslie-Smith and Paterson, 1980). This was why all the subjects in phase 2 
of this study were instructed to eat a light meal 90 minutes before each session of scans. 
The above data is summarised in the diagram below. 
Ventricular system 
(containing CSF) 
Flow = 600m1/min 
at 72 beats/min 
Cribriform Plate. 
Drainage point of CSF 
into lymphatics. 
Flow rate unknown at 
present. 
At ? beats per min. 
Cerebral 
Blood flow= 65m1/g/min 
At 72 beats/min 
Lymph drainage down neck 
Thoracic 
Duct. 
1-2ml/min 
4beats/min 
Ventilation 
(respiratory movement of 
thorax) 
Frequency= 10- 18breaths/min 
Figure 95 Schematic diagram demonstrating the influences of fluid mechanics 
involved in the drainage of CSF from the neuraxis. 
Immediately arising from this present research, agreement has been reached for a future 
study to be undertaken at the University of Manchester's department of Fluid Mechanics 
and Aeronautical engineering. Researchers, using the above known parameters and 
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computerised models of the bio-mechanical influences affecting the lymphatic drainage of 
the brain are to calculate a possible range of normal values of this drainage and to 
investigate how this hypothesised rhythm compares with the 7-12 beats per minute of 
Sutherlands earliest findings (Sutherland, 1990). 
5.4 Future challenges 
5.4.1 Functional and pharmacological MRI studies 
Functional MRI or pharmacological MR which utilises drug stimulation or suppression of 
certain areas of the brain and observation of resultant MR image changes can be used to 
determine pathophysiological dysfunction in the CNS. Future research into brain 
abnormalities in CFS/ME should utilise these techniques and be directed towards 
identifying functional disturbances in this disorder. In fact, at the present time a paper on a 
Dutch research project, which utilised the latter imaging techniques, has just gone to press 
(De Lange et al., 2004). This was specifically concerned with analysing disturbances in the 
motor nervous system arising from CFS/ME. These researchers measured behavioural 
performance and cerebral activity using rapid event-related functional MRI and showed 
that CFS/ME patients were considerably slower on performance of both motor and visual 
imagery tasks compared with matched healthy controls. 
The results of the functional MRI (fl\RRI) showed that both groups used largely overlapping 
neural resources. However, during the motor imagery task, CFS/ME patients evoked 
stronger responses in visually related structures. Also the ventral anterior cingulate cortex 
was active when healthy controls made an error, but remained inactive when CFS/ME 
patients made an error. The study has also demonstrated that CFS/ME may be associated 
with dysfunctional motivation and motor planning (De Lange et al., 2004). This supports 
one of the central hypotheses of this present study that CFS/1MME is a functional disorder of 
the brain. 
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5.4.2 Genetic research 
As in all areas of medicine, genetic research has a major role to play in improving our 
future understanding of aetiological mechanisms that may pre-dispose patients with 
CFS/ME. Vladutiu and Natelson (2004) have recently discovered variant genotypes 
associated with muscle metabolism and physical endurance in Gulf War veterans that made 
them much more likely to develop US/ME. Clinically one can see a genetic pattern in the 
family history data where there is more than one family member with CFS/NlE. There have 
been cases of occurrences of the disorder in three generations. Structural anomalies of 
cranial bones (Noguchi et al., 2002) have been linked to genetic mutation as have spinal 
deformities (Chatel et al.. 1979). It is logical that there may be genetic predisposition in 
some cases that may cause anomalies in the cribriform plate and /or the spine possibly 
affecting drainage. It is recommended that research into this possibility is undertaken in the 
future. 
5.5 Conclusion 
5.5.1 Supporting the research hypotheses 
The null hypotheses originally listed on page 45, in section 1.6.2 were: 
1. There is no relationship between the mechanical dysfunction of the spine, and the 
incidence of the symptoms arising from CFSIME. 
2. There is no difference in the symptoms associated with CFS/ME following a chosen 
method of osteopathic treatment compared with those of a matched control group, who 
received no such treatment. 
3. Any improvement of symptoms associated with CFS/ME following a chosen method of 
osteopathic treatment compared with those of a matched control group, who received no 
such treatment will not be sustainable or repeatable. 
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4. There is no relationship between pathological findings in the structure of the brain and 
the symptoms in CFS/ME. 
5. There is no relationship between the symptom of muscular fatigue in CFS/ME and 
pathological changes in the muscle. 
The clinical findings, observed by the author over the past fifteen years as presented in 
chapters 1 and 2, show that there is a correlation between mechanical dysfunction of the 
spine and the symptoms arising from CFS/ME. Even though no change in spinal movement 
was seen in phase 1 of the study, the observable findings in both phase 1 and 2 sufficiently 
support the initial research objective thus null hypothesis 1 is rejected. 
The results in both phases of the study indicate that the symptoms diminished significantly 
following the chosen osteopathic treatment and that the improvement was sustained, 
thereby rejecting null hypotheses 2 and 3. 
Although the changes seen in the thoracic duct scans necessitate further investigation with a 
larger study in future research, no abnormality has been detected in brain volume, rate of 
atrophy, white matter lesions, cerebral blood flow or aqueductal CSF flow in a group of 
patients who had satisfied rigorous diagnostic and selection criteria as a CFS/ME subject. 
This does not exclude the possibility that CFS/ME may result from some subtle patterns of 
organic brain lesions. These could produce distinctive imaging findings which might 
represent more severe subgroups in the CFS/ME population that have not yet been studied 
in this research. However, the findings clearly show that the symptom complex described 
as CFS/ME occurs in patients with no identifiable cerebral abnormality. Consequently null 
hypothesis 4 is accepted. These findings point to another cause, undetected by existing MRI 
techniques used in this study, of symptoms associated with CFS/ME which may be 
impaired lymphatic drainage. 
The results of the EMG study have demonstrated that the reduction in motor units recruited 
in CFS/ME is significantly no different to the healthy group following exercise and does 
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not change with treatment (see ch. 4). This suggests that there are no changes in the ion 
transfer within the motor units of the muscle in CFS/ME and implies that the lactic acid 
distribution remains constant. This finding is supported by the aforementioned recent 
research which concluded that the problem is not due to reduced blood flow (McCully et 
al., 2003). 
The results implied that there is no intrinsic muscle disorder. Consequently null hypothesis 
5 is accepted (see page 45). These findings point to another cause of the reduction of 
muscle performance associated with CFS/ME. A plausible alternative explanation of the 
fatigue may be a reduction of the lymphatic drainage of the muscle. 
However the findings of both phases in this study have shown that the chosen osteopathic 
treatment does improve the muscle performance, without the use of an exercise regime. It 
may be that the treatment's success is due to aiding lymph drainage, but perhaps the 
massage techniques generate heat which may benefit the muscle performance. Or it may be 
that the author's treatment stimulates the motor nerve conduction. The reason for the 
muscular dysfunction in CFS/ME continues to remain an enigma that warrants further 
research in these areas. 
The findings of this thesis shed further light into each of the original objectives and warrant 
the necessity for further investigation to the neurolymphatic pathways detailed in this work. 
As technological advances continue, especially in radiological procedures and 
neuroscience, it is only a matter of time before the unanswered questions raised by this 
thesis will be explained. 
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APPENDIX Al: Ethical Approval 
Both clinical trials in phases one and two carried out by the author and his co-workers were 
approved by local health authorities research ethics committees, the details of which are 
listed below: 
Phase 1: 
Approved by Bury and Rochdale Health Authority Research Ethics Committee; 
Chairman: Mrs CA Hopkins, January 1995. Project No. BREC 16. 
Approved by Salford and Trafford Health Authority Research Ethics Committee; 
Chairman: Mrs J. Blunt, February 1995. Project No. 95020. 
Phase 2: 
Approved by Bury and Rochdale Health Authority Research Ethics Committee; 
Chairman: Mr I Buchanan, February 2000. Project No. BRLEC 62. 
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APPENDIX A2: Diagnostic criteria for CFS/ME 
1. The London criteria (Tyrrell et al.. 1994) used by Action for ME in phase 1. 
THE `LONDON' CRITERIA 
DIAGNOSTIC CRITERIA FOR THE SELECTION OF 
SUBJECTS FOR RESEARCH INTO ME/PVFS 
These three criteria must all be present for the diagnosis of ME/PVFS to be made. If any of these are not 
present the volunteer research subject should not be used for the purpose of research into ME/PVFS and an 
alternative diagnosis should be keenly sought. 
A) Exercise-induced fatigue precipitated by trivially small exertion-physical or mental-relative to 
the patient's previous exercise tolerance. 
B) Impairment of short-term memory and loss of powers of concentration, usually coupled with 
other neurological and psychological disturbances such as emotional lability, nominal dysphasia, 
disturbed sleep patterns, disequilibrium or tinnitus. 
C) Fluctuation of symptoms, usually precipitated by either physical or mental exercise (see b) 
above. 
These symptoms should have been present for at least six months and should be ongoing. 
A VIRAL TRIGGER? 
Although ME/PVFS typically follows an infection, usually a viral illness (which may be subclinical) in a 
previously fit and active person, it has also been observed to be triggered by other factors such as 
immunisations, life traumas and exposure to chemicals. Furthermore, in a minority of patients, ME/PVFS 
has a gradual onset with no apparent triggering factor. For these reasons proof of a preceding viral illness 
is not a prerequisite for diagnosis or inclusion in a study group. 
ASSESSMENT, INVESTIGATION AND DIAGNOSIS 
When diagnosing ME for research purposes, particular attention must be paid to two factors: 
" Many of the symptoms and signs evident in people suffering from ME/PVFS could be due 
to a large number of important diseases/conditions. 
" ME may run parallel with other diseases having similar symptoms and signs. 
Because it is vital that the ME study groups we use in research are as 'pure' as possible, the existence of a 
parallel disease would be grounds for disqualification. The most common alternative diagnosis/parallel 
diseases to be borne in mind before referring a research subject volunteer to an ME study group can be 
considered under the following headings: 
Chronic infections: toxoplasmosis, Lyme disease, HIV infection, chronic active hepatitis, 
schistosmosiasis, brucellosis, occult sepsis, tuberculosis, giardia. 
Endocrine disorders: hypothyroidism, thyrotoxicosis, Addison's disease. Cushing's syndrome, diabetes 
mellitus, hyperparathyroidism. 
Neuromuscular disorders: Myasthenia gravis, multiple sclerosis, mitochondrial myopathy, Parkinson's 
disease. 
Cardio-vascular disorders: Cardiac ischaenia. 
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Metabolic disorders: Sleep apnoea syndrome, chronic renal failure. 
Malignant disease: Occult tumours such as undiagnosed lymphomas, retroperitoneal sarcomas: renal 
and liver tumours; frontal lobe tumours. 
Auto-immune disease: Rheumatoid arthritis, systemic lupus Erythematosus, thyroiditis, Sjogrens 
syndrome. 
Haematological disorders: Leukaemias and anemias of varying origin. 
Miscellaneous: Heavy metal poisoning, chronic intoxications due to prolonged exposure to chemicals 
such as petrol, benzene, organo-phosphorous compounds and methylene chloride; 
drug side effects such as those due to beta-blockers and long-term benzodiazepine 
usage; chronic alcoholism; celiac disease. 
Psychiatric: Primary depressive illness, anxiety neurosis. 
OTHER REASONS FOR EXCLUSION FROM RESEARCH INTO ME 
Of particular importance is to eliminate chronic fatigue primarily associated with psychological factors. If 
there are signs of persistent anhedonia, apathy, low self-esteem, feelings of worthlessness and guilt, the 
possibility of primary depressive illness should be actively considered and, if there is any doubt whatsoever, 
the subject eliminated from the research study. 
If the subject has had any other diseases or conditions in the last three months they should be excluded from 
research into ME. 
If the subject has taken any treatments - orthodox, complementary or nutritional- in the last three months they 
may have to be excluded from certain research projects. 
OTHER SYMPTOMS SOMETIMES EXPERIENCED BY PEOPLE WITH ME/PVFS 
Many symptoms are experienced by people suffering from ME/PVFS and in the right symptomatic context 
they contribute to the validity of the diagnosis. Nevertheless, not all people suffering from ME/PVFS 
experience all these symptoms and their absence does not exclude the condition. 
These can be subdivided into the following two categories: 
Autonomic Bouts of inappropriate night or day-time sweating: reynauds phenomenon; postural hypotension; 
disturbance of bowel motility manifesting as a recurrent diarrhoea or occasionally constipation (these 
symptoms are frequently indistinguishable from those of IBS); photophobia; blurred vision due to disturbed 
accommodation; hyperacusis; increased frequency of micturition; nocturia. 
Immunological Symptoms suggesting persistent viral infection, e. g. episodes of low grade fever (i. e. not 
exceeding an oral temperature of 38.6C) combined with feeling feverish (i. e. a down-regulated 'thermostat'); 
sore throat which may be persistent or recurrent (i. e. present for at least one week per month); arthralgia of a 
fixed or migratory nature. 
This list is by no means exhaustive; headaches, nausea and bloating, for instance are common symptoms but 
are not sufficiently discriminative because of their widespread occurrence in many other disorders. The 
curious intolerance to alcohol and hypersensitivity to drugs are highly specific in this context. It should also 
be emphasised that the symptoms of ME tend to vary capriciously from hour to hour and day by day. 
Nevertheless it is absolutely characteristic that they tend to be exacerbated by physical or mental exertion and 
this association should always be sought whilst taking the history. 
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2. The CDC criteria (Fukuda et al., 1994) are the more accepted criteria and were thus 
used by the author in both clinical trials. 
The Centre for Disease Control revised criteria for Chronic Fatigue Syndrome 
(Adapted from Fig. 2, Fukuda, et al., 1994). 
Clinically evaluate cases of chronic fatigue by: 
A. History and physical examination. 
B. Mental status examination (abnormalities require psychiatric, 
Psychological, or neurological examination) 
C. Tests (abnormal results that strongly suggest an exclusionary condition 
must be resolved) 
1. Screening Lab Tests: full blood count, erythrocyte sedimentation rate, 
alanine aminotransferase, total protein, albumin, globulin, alkaline 
phosphatase, calcium, phosphate, glucose, urea and electrolytes, 
creatinine, thyroid stimulating hormone and urinalysis. 
2. Additional tests as clinically indicated to exclude other diagnoses. 
EXCLUDE IF ANOTHER CA USE FOR CHRONIC FATIGUE IS FOUND 
II Classify as either chronic fatigue syndrome or idiopathic chronic fatigue if 
fatigue persists or relapses for 6 months or more. 
CLASSIFYAS IDIOPATHIC CHRONIC FATIGUE IF FATIGUE SEVERITY OR 
SYMPTOM CRITERIA FOR CHRONIC FATIGUE ARE NOT MET. 
Classify as chronic fatigue if both of the following criteria are met: 
A) Unexplained persistent or relapsing fatigue of new or definite onset that is not due to 
ongoing exertion, is not relieved by rest and results in substantial reduction in previous 
levels of activity. 
B) Four or more of the following symptoms are concurrently present for 6 months or 
longer. 
1. Impaired memory or concentration (severe enough to reduce levels of 
occupational, social and personal activity. ) 
2. Sore throat. 
3. Tender cervical or axillary lymph nodes. 
4. Muscle pain 
5. Multijoint pain (without joint swelling or redness). 
6. New headaches 
7. Unrefreshing sleep 
8. Post-exertion malaise (lasting, more than 24 hours) 
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APPENDIX A3: Psychiatric/psychological tests 
Both the HADS and the SCAN systems below were used by the consultant psychiatrist to 
exclude unsuitable volunteers from the second clinical trial. 
1. The Hospital Anxiety and Depression Scale (Zigmond and Snaith, 1983) 
Name .......................................... Date................. . 
Clinicians are aware that emotions play an important part in most illnesses. If your 
clinician knows about these feelings she or he will be able to help you more. 
This questionnaire is designed to help your clinician to know how you feel. Ignore the 
numbers printed on the left of the questionnaire. Read each item and underline the 
response which comes closest to how you have felt in the past week. Don't take too 
long over your replies. Your immediate reaction will probably be more accurate than 
a long thought-out response. 
AI feel tense or `wound up': 
3 Most of the time 
2A lot of the time 
1 From time to time, occasionally 
0 Not at all 
D I still enjoy the things I used to enjoy: 
0 Definitely as much 
1 Not quite so much 
2 Only a little 
3 Hardly at all 
AI get a sort of frightened feeling as if something 
awful is about to happen: 
3 Very definitely and quite badly 
2 Yes, but not too badly 
1A little, but it doesn't worry me 
0 Not at all 
DI can laugh and see the funny side of things: 
0 As much as I always could 
1 Not quite so much now 
2 Definitely not quite so much now 
3 Not at all 
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A Worrying thoughts go through my mind: 
3 A great deal of the time 
2 A lot of the time 
1 From time to time but not too often 
0 Not at all 
D I feel cheerful: 
3 Not at all 
2 Not often 
1 Sometimes 
0 Most of the time 
A I can sit at ease and feel relaxed: 
0 Definitely 
1 Usually 
2 Not often 
3 Not at all 
D I feel as if I am slowed down: 
3 Nearly all the time 
2 Very often 
1 Sometimes 
0 Not at all 
AI get a sort of frightened feeling like `butterflies' in 
the stomach: 
0 Not at all 
1 Occasionally 
2 Quite often 
3 Very often 
D I have lost interest in my appearance: 
3 Definitely 
2 I don't take as much care as I should 
1 I may not take quite as much care 
0 I take just as much care as ever 
A I feel restless as if I have to be on the move: 
3 Very much indeed 
2 Quite a lot 
1 Not very much 
0 Not at all 
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D I look forward with enjoyment to things: 
0 As much as I ever did 
1 Rather less than I used to 
2 Definitely less than I used to 
3 Hardly at all 
A I get sudden feelings of panic: 
3 Very often indeed 
2 Quite often 
1 Not very often 
0 Not at all 
D I can enjoy a good book or radio or TV programme 
0 Often 
1 Sometimes 
2 Not often 
3 Very seldom 
Now check that you have answered all the questions. 
For office use only: 
D: Borderline 8-10 
A: Borderline 8-10 
Zigmond and Snaith (1983). From 'The Hospital Anxiety and Depression Scale', Acta 
Psychiatrica 67: 361-370. Reproduced by kind permission of Munksgaard International 
Publishers Ltd., Copenhagen. This measure is part of Assessment: A Mental Health 
Portfolio, edited by Derek Milne. Once the invoice has been paid, it may be photocopied 
for use within the puchasing institution only. Published by The NFER-NELSON Publishing 
Company Ltd., Darville House, 2 Oxford Road East, Windsor, Berkshire SL41DF, UK. 
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2. The SCAN system (Schedules for Clinical Assessment in Neuropsychiatry) 
(Mavreas, 1990; Tomov and Nikolov, 1990; Ustan, 1990; Wing, 1990) 
DEVELOPMENT AND BASIC PRINCIPLES 
The SCAN system is a set of instruments and manuals aimed at assessing, measuring and 
classifying the psychopathology and behavior associated with the major psychiatric 
disorders of adult life. The SCAN text has 3 components: the tenth edition of the Present 
State Examination (PSE10), the Item Group Checklist (IGC) and the Clinical History 
Schedule (CHS). 
PSE10 itself has two parts. Part I covers somatoform, dissociative, anxiety, depressive and 
bipolar disorders, and problems associated with eating, alcohol and other substance abuse. 
There is also a screen for Part H conditions. Part II covers psychotic and cognitive disorders 
and observed abnormalities of speech, affect and behavior. 
The SCAN system contains two other essential elements: the Glossary of differential 
definitions and CATEGO, a set of computer programs for processing SCAN data and 
providing output. 
Data from the schedules can be entered into CATEGO in a variety of ways: on the SCAN 
Schedules themselves, on SCAN Coding Sheets, and into a computer program. Output from 
CATEGO is presented as a series of options, including a range of profiles of symptom and 
IGC scores, an Index of Definition, ICD-10 and DSM categories, a prediagnostic profile of 
categories, and a list of items rated present. 
In its complete form, used in this study the SCAN text is intended for use only by clinicians 
with an adequate knowledge of psychopathology who have taken a course at a WHO- 
designated SCAN training center. 
SCAN represents the latest stage in a 30-year line of development that began in the late 
1950s. PSE9 was the first of the series to be published, following 15 years of work on 
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earlier versions, including two large multicenter international projects - the US-UK 
Diagnostic Project (1972) and the International Pilot Study of Schizophrenia (IPSS; WHO, 
1973). PSE9 consists of only 140 items, compared to the 500-600 of PSE7 and PSE8. It has 
been widely used, as evidenced by its translation into 35 or more languages, but many users 
have regretted that the longer preceding editions were withdrawn; they would have 
preferred a choice, which is now provided by PSE10. 
The principles underlying the PSE have changed very little during these developments but 
they have gradually been applied to a broader range of disorders, have come to incorporate 
more and more aspects of the clinical history and, through the use of an increasingly 
complex technology, have been preserved without loss of the basic clinical bottom-up 
approach and user friendliness. An understanding of the history is therefore a useful basis 
for an appreciation of SCAN. 
The central principle of the PSE is that the interview, although substantially structured, 
retains the features of a clinical examination. The aim of the interviewer is to discover 
which of a comprehensive list of phenomena have been present during a designated period 
of time and with what degree of severity. The items listed are differentially defined in this 
Glossary, with which the interviewer is expected to be closely familiar. The examination is 
therefore based on a process of matching the respondent's behavior and description of 
subjective experiences against the clinical definitions provided. Applying the central 
principle means that a rich data base of differentially-defined clinical phenomena forms the 
core of SCAN. Numerous classifying algorithms can be applied to generate 'diagnoses' 
according to the criteria of schools that provide sufficiently operational rules. Two of these 
(ICD, and DSM since its third revision) have won wide international acceptance. But any 
other set of rules can be applied. "The flexibility of this approach, the incorporation of 
detailed cross-examination, which allows changes in the order and wording of questions 
according to the way the interview is going, the freedom of the clinician to pursue some 
lines of enquiry while cutting off others, the fact that the examiner and not the patient 
makes the judgement as to whether a symptom is present, do not seriously impair the 
reliability of the procedure" (Wing et al., 1967). 
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This statement was based on experience with the third to the fifth editions of the PSE and it 
still holds good with PSE10. Preparations for a tenth edition of the PSE were started in 
1980, in anticipation of the tenth edition of the ICD. The major emphasis of correspondents 
was on broadening the content, both by returning to the larger item-pool of PSE7 and 
PSE8, and by adding new sections to cover somatoform, dissociative and eating disorders, 
alcohol and drug misuse, and cognitive impairments. A second suggestion was that an extra 
rating point was needed to extend the 0-1-2 scales of severity used for most PSE9 items, 
allowing a mild or 'sub-clinical' level to be used, particularly in population surveys. A 
third, very obvious, requirement was for a better system for rating episodes of disorder, 
adding other information relevant to the history and to the causes of disorder, and 
processing all the information by means of one set of computer programs. 
THE PURPOSE OF THE SCAN SYSTEM 
The purpose of the SCAN system is to provide comprehensive, accurate and technically 
specifiable means of describing and classifying psychiatric phenomena, in order to make 
comparisons. 
Training in SCAN techniques provides a common clinical language in which to compare 
and contrast the experiences and behavior of patients, to consider the usage of different 
clinical schools in relation to a common reference system, to compare epidemiological and 
public health data more precisely, and to make the results of scientific research readily 
available for replication between centres. 
CLINICAL CROSS-EXAMINATION 
The function of the Glossary is to support the process of clinical cross-examination, which 
is the central method of obtaining information about the respondent's subjective 
experiences. Training in the differential definitions provides the examiner with a set of 
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'item concepts', which are matched against the respondent's descriptions. Only when the 
description matches the concept does the examiner make the rating. This process helps to 
eliminate syndromal, diagnostic and other biased misunderstandings. 
Considerable training and experience is needed before the probe system in the SCAN text 
can be used flexibly enough in close conjunction with the Glossary to ensure that the 
ratings most accurately fit the phenomena. 
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APPENDIX A4: Information and consent forms 
During the course of the clinical trials outlined in this thesis all experimentation on human 
volunteers was subject to intense scrutiny by the relevant health authority research ethics 
committee as noted in Appendix Al. A standard requirement of all ethically approved 
research is to inform patients, and their general practitioners, of all procedures to be 
undertaken and any relevant consequences of their involvement in the study. Examples of 
the many information and consent sheets used are included in this section. 
The involvement of cerebrospinal fluid and 
lymphatic drainage in 
chronic fatigue syndrome: a pilot study. 
CONTROL GROUP URGENTLY NEEDED FOR THE ABOVE RESEARCH 
PROJECT 
IF YOU ARE FIT AND HEALTHY AND WISH TO HELP AN IMPORTANT NEW 
RESEARCH PROJECT PLEASE READ THE FOLLOWING 
A new research project is about to begin at the University of Salford, Greater Manchester. 
This projects hopes to spread light on the processes involved in the body that lead to 
Chronic Fatigue Syndrome (commonly known as M. E. ) and how they are affected by a 
treatment program developed by osteopath Raymond Perrin. WE URGENTLY NEED TEN 
HEALTHY VOLUNTEERS WHO WISH TO HELP US DEMONSTRATE A POSSIBLE 
PHYSICAL NATURE OF THE DISEASE. 
The overall aims of this project are: 
1. To examine any changes in the brain and the involvement of alterations in fluid that 
flows around the brain and the spine. (This is known as the cerebrospinal fluid). 
2. To analyse changes in the flow and volume of the lymphatic fluid in the neck and chest. 
One of the possible roles of cerebrospinal fluid is to drain poisons/toxins from the brain and 
spine to the lymph vessels in the head and back. The lymphatic fluid flows into the neck 
and chest area and eventually into the blood stream just below the collar bones. By 
recording a visible increase in volume of fluid in the lymph vessels and an increase of 
cerebrospinal fluid volume in M. E. /Chronic Fatigue Syndrome patients with a noticeable 
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reduction in fluid movement we will demonstrate a possible congestion of drainage in this 
region. 
3. To study the effects of osteopathic treatment on the cerebrospinal fluid and the lymphatic 
drainage by non-invasive techniques before and following a year long course of treatment. 
YOU WILL BE REQUIRED TO HAVE THE FOLLOWING TESTS: 
Scanning of the head neck and chest at two separate occasions. The brain and lymph 
vessels of the neck and chest will be studied by Magnetic Resonance Imaging. This form of 
scanning involves no radiation and thus can be repeated without any harm. These studies 
will be undertaken at the Department of Diagnostic Radiology, University of Manchester. 
2) Muscle fatigue and physical function will be measured by a Kincom isokinetic machine 
and surface electromyography. The former is a specially constructed chair in which you 
will be asked to press your leg against a pad that is connected to a computer. This will 
then measure the amount of fatigue in your thigh muscle. The surface electromyography 
uses rubber pads that are placed on the skin. Electromyography measures the activity of 
the muscle and causes no pain. 
You are not eligible if you suffer from a primary depressive illness, or have suffered from 
any other psychological or neurological disorder, including claustrophobia. (N. B. A 
consultation with a consultant psychiatrist has been arranged before you are accepted 
on the project. ) Any bodily-metallic object will disqualify yourself from being scanned. 
Simple questionnaires will have to be completed at the beginning of the project and at the 
end of the twelve months. 
There are no known potential hazards in this study. The Magnetic Resonance Imaging scan 
may appear daunting, although it presents no hazard. The procedure requires you to lie 
quite still in a tunnel which may seem claustrophobic and surprisingly noisy. However 
expert personnel will be present to explain the points to you. There is a possibility that the 
imaging may reveal another disease state. Any abnormality discovered whilst scanning 
research subjects will be immediately brought to the attention of your GP. In fact your 
doctor will be informed of any results of the research (even ones showing no 
abnormalities). It is important to realise that this information on your medical records may 
have a bearing on future health insurance/mortgage provision. 
Lastly, some filming will take place to record the research (your face will not be filmed 
preserving anonymity). 
ALL EXPENSES WILL BE REIMBURSED IN FULL. 
If you wish to volunteer or if you have any further queries please contact me at the address 
below as soon as possible. 
Yours Faithfully, 
Raymond N. Perrin D. O. 
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INFORMATION FOR SUBJECTS INVOLVED IN THE ABOVE RESEARCH 
PROJECT 
Thank you for volunteering to be a research subject. You are one of 10 patients who have 
been selected to help our research. Before you sign the consent form and we begin the 
actual project there are obviously some important points to clarify. This information sheet 
is to allow you to understand the reasons for the research, what we are going to do over the 
next year, and what we hope to achieve. 
The osteopathic treatment of Chronic fatigue syndrome (commonly known as M. E. ) 
developed by myself consists of gentle manipulation of the spine and massage to stimulate 
drainage in lymphatic vessels of the head, neck, back and chest. In a previous research 
project this approach produced an improvement of the condition (Perrin et al., 1998, J. 
Medical Engineering and Technology, 22,1-13) compared with a group of patients treated 
in other programmes by different conventional therapies (i. e. Psychotherapy, exercise and 
diet programmes and antidepressants). The question is how and why the treatment works? 
This projects hopes to spread light on the processes involved in the body that lead to 
M. E. /Chronic fatigue syndrome and how they are affected by my treatment program. 
The overall aims of this project are: 
1. To examine any changes in the brain and the involvement of alterations in fluid that 
flows around the brain and the spine. (This is known as the cerebrospinal fluid). 
2. To analyse changes in the flow and volume of the lymphatic fluid in the neck and chest. 
One of the possible roles of cerebrospinal fluid is to drain poisons/toxins from the brain and 
spine to the lymph vessels in the head and back. The lymphatic fluid flows into the neck 
and chest area and eventually into the blood stream just below the collar bones. By 
recording a visible increase in volume of fluid in the vessels and an increase of 
Cerebrospinal fluid volume in M. E. /Chronic fatigue syndrome patients with a noticeable 
reduction in fluid movement we will demonstrate a possible congestion of drainage in this 
region. 
3. To study the effects of osteopathic treatment on the cerebrospinal fluid and the lymphatic 
drainage by non-invasive techniques before and following a year long course of treatment. 
You must have been previously tested for any other possible cause of the symptoms. Also, 
if you suffer from a primary depressive illness, or have suffered from any other 
psychological or neurological disorder, including claustrophobia, then you must inform us 
immediately before commencement of the study. (N. B. A consultation with a consultant 
psychiatrist has been arranged before you are accepted on the project. ) Any bodily- 
metallic object will disqualify yourself from being scanned. You must not begin any other 
new treatment for M. E. /CFS for the duration of the project and you must not have received 
any physical therapy for your present symptoms during the previous six months. 
The method of investigation will involve the following: 
1. The brain and lymph vessels of the neck and chest will be studied by Magnetic 
Resonance Imaging. This form of scanning involves no radiation and thus can be repeated 
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without any harm. These studies will be undertaken at the Department of Diagnostic 
Radiology, University of Manchester. 
2. Level of fatigue and of physical function will be measured by a Kincom isokinetic 
machine and surface electromyography. The former is a specially constructed chair in 
which you will be asked to press your leg against a pad that is connected to a computer. 
This will then measure the amount of fatigue in your thigh muscle. The surface 
electromyography uses rubber pads that are placed on the skin. Electromyography measures 
the activity of the muscle and causes no pain. 
You will receive weekly sessions of osteopathic treatment from myself based on the 
protocol devised over the past ten years working in a practice specializing in the 
management of ME/Chronic fatigue syndrome patients. The sessions will include 
i) Articulation and gentle manipulation of the spine and the ribcage. 
ii) Manual stretching and massage of the muscles in the neck and trunk. 
iii) Manual lymphatic drainage using effleurage (stroking techniques) on the head, neck, 
back and chest. 
iv) Cranio-sacral therapy (applying gentle pressure to the head and low back) to stimulate 
the movement of the cerebrospinal fluid. 
Questionnaires will have to be completed at the beginning and end of the project. You will 
also have to follow a self-massage program to further encourage lymphatic drainage from 
the brain and spine. You will also be instructed in gentle mobility exercises and advised to 
use regular contrast bathing techniques (hot & cold compresses) to reduce inflammation of 
the spine. 
You are expected to keep the same weight throughout the year long project. Any major 
change in weight will disqualify you from the research project. 
There are no known potential hazards in this study. The scan may appear daunting, 
although it presents no hazard. The procedure requires you to lie quite still in a tunnel 
which may seem claustrophobic and surprisingly noisy. However expert personnel will be 
present to explain the points to you. There is one problem that may arise when we scan 
your body. Magnetic resonance imaging may reveal another disease state. Any abnormality 
discovered whilst scanning research subjects will be immediately brought to the attention of 
your GP. In fact your doctor will be informed of any results of the research (even ones 
showing no abnormalities). It is important to realise that this information on your medical 
records may have a bearing on future health insurance/ mortgage provision. 
The treatment itself may aggravate symptoms in the initial stages but it is very rare to have 
lasting harmful or painful consequence. Lastly, some filming will take place to record the 
research (your face will not be filmed preserving anonymity). 
Thank you again for your participation. If you have any further queries please contact me at 
my practice. 
Yours Faithfully, 
Raymond N. Perrin D. O. 
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ME/CFS- CONTROL GROUP A. CONSENT FORM 
(me/cfs sufferers) 
Dear .................................. 
Thank you for volunteering to be a control group member in the research into the treatment 
of M. E. /Chronic Fatigue Syndrome by osteopathic methods. 
By volunteering for this project you agree to the following: 
1. To undergo Magnetic Resonance Scanning of the head neck and chest four times in total 
over a period of one year. (Twice at the beginning of the trial and twice at the end of the 
year long treatment). 
2. To allow the testing of post-exercise muscle fatigue before and after a year long period 
using the 'Kincom' isokinetic machine and to have your muscles tested by surface 
electromyogram (sEMG). 
3. To attend a preliminary interview with a consultant psychiatrist to evaluate your mental 
and emotional state. 
4. To avoid any osteopathic or other manual treatment for the treatment of ME/CFS for the 
duration of the trial. 
5. To supply reliable information to the researchers concerning any other therapy for that 
you may undergo for ME/CFS during the year's trial. 
6. To complete two sets of questionnaires relating to your health at the beginning and end 
of the project. 
7. To allow the filming of consultations, examinations and tests by Mr Perrin, as long as 
anonymity is preserved at all times. 
N. B. You have the right to leave the project at any time. 
Please print your name clearly below, sign, witness and date the form below: 
I ............................... Agree to the seven terms mentioned above and wish to join the 
research project as one of the ME/CFS sufferers control group for a period of one year. 
Signed: ............................................. Date: :: 2000 
Witnessed by ....................................... Date: :: 2000 
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LETTER SEEKING GENERAL PRACTITIONER'S CONSENT RE: MEMBER OF 
PATIENT GROUP 
To Dr ......................... 
RE: ........................ 
D. O. B ......................... 
ADDRESS ....................................................... 
Dear Dr ........................ This patient has volunteered to take part in a research program involving specialist 
osteopathic treatment for the fatigue condition diagnosed as myalgic encephalomyelitis/ 
chronic fatigue syndrome. 
I have been involved since 1989 in the treatment of patients with symptoms associated with 
M. E. /CFS and have spent the past eleven years researching into this debilitating disorder. I 
have published two scientific papers (1,2) and written information booklets and treatment 
guides for this disease. I completed a controlled trial into the efficiency of osteopathic 
treatment for symptoms associated with M. E. This was carried out over a two year period at 
Salford university and Hope hospital. The research carried out together with bio-engineer 
Prof. Jack Edwards and health psychologist Dr. Pat Hartley demonstrated that my treatment 
techniques developed since 1989 did help reduce the symptoms and restored patients to a 
much better quality of life(2). 
I am now involved in further research at Salford University's dept. of biological sciences 
for a doctorate in the treatment of M. E. /CFS, together with neuro-biologist Dr. Vic 
Pentreath. The research findings at present point to alterations in the flow of cerebrospinal 
fluid and lymphatic drainage of the neuraxis. My treatment aims at improving the drainage 
from the head, and spine using standard osteopathic techniques. 
During the year-long clinical trials we intend to use M. R. scanning of the brain, cervical 
and thoracic lymphatics, and to test muscle fatigue utilising the Kin-Com isokinetics 
machine with surface EMG. These investigative techniques will all be performed by highly 
qualified specialists at the Universities of Salford and Manchester. Your patient has been 
explained the procedures involved and has agreed to take part, subject to your approval. 
Please find attached a copy of the CDC criteria for CFS. 
If you feel that the patient does not fulfil the strict criteria please inform us. Also if you feel 
that the patient will not be suitable for the research for any other reason please let us know 
as soon as possible. If you do feel that the patient would be a suitable candidate for the 
project, please fill out the enclosed consent form and return it to us in the stamped 
addressed envelope. 
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This research project is extremely important and is a very costly undertaking. Due to the 
controversy surrounding the acceptance of this disorder it is imperative that we are as 
thorough as possible in using only patients that fulfil the criteria. To this end we have 
enlisted the services of a consultant psychiatrist to conduct a preliminary interview for a 
detailed psychological profile of the patient. You as the patient's general 
practitioner/consultant are needed to give an independent clarification of the diagnosis 
before the patient is accepted onto our subject group. 
We are aware of the limited time you have in your day, but we ask you to give the matter of 
consent serious thought before replying. As with the first stage of this project, ethical 
approval has been given from Bury & Rochdale Health Authority research ethics 
committee. If you have any further questions please do not hesitate in contacting myself on 
0161 773 0123. 
Thank you for your co-operation, 
Yours Sincerely, 
Raymond N. Perrin D. O. 
Dept. of Biological Sciences 
University of Salford. 
REFERENCES: 
1. PERRIN R, N. 1993 CHRONIC FATIGUE SYNDROME, A REVIEW FROM THE 
BIOMECHANICAL PERSPECTIVE. BRITISH OSTEOPATHIC JOURNAL; VOL XI. 
2. PERRIN RN, EDWARDS J AND HARTLEY P (JANUARY/FEBRUARY 1998) AN EVALUATION 
OF THE EFFECTIVENESS OF OSTEOPATHIC TREATMENT ON SYMPTOMS ASSOCIATED WITH 
MYALGIC ENCEPHALOMYELITIS. A PRELIMINARY REPORT. JOURNAL OF MEDICAL 
ENGINEERING AND TECHNOLOGY, 22(1), 1-13. 
Tel: 0161 773 0123 Fax: 0161 773 7288 Email forme@eng. net 
249 
GPCFSI 
GENERAL PRACTITIONERS AUTHORISATION FORM 
MEICFS RESEARCH PROJECT - UNIVERSITY OF SALFORD 
RE: Patient's name ............................................ 
Address .................................................... 
D. O. B ...................................................... 
I, Dr ..................................... agree that the above named patient may be 
chosen as a subject in the patient group for the research project into the 
involvement of cerebrospinal fluid and lymphatic drainage in chronic fatigue 
syndrome (CFS). 
I verify that he/she fulfils the CDC criteria for chronic fatigue syndrome as 
defined by Fekuda et al (1994). 
Signed: ................................................ 
Date: " ............................................... 
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LETTER SEEKING GENERAL PRACTITIONER'S CONSENT RE: MEMBER OF 
HEALTHY CONTROL GROUP 
To Dr ......................... 
RE: ........................ 
D. O. B ......................... 
ADDRESS ....................................................... 
Dear Dr ....................... +, 
This patient has volunteered to be a member of a healthy-norm control group in a research 
program involving specialist osteopathic treatment for the fatigue condition diagnosed as 
myalgic encephalomyelitis/ chronic fatigue syndrome. 
I have been involved since 1989 in the treatment of patients with symptoms associated with 
CFS/ME and have spent the past eleven years researching into this debilitating disorder. I 
have published two scientific papers (1,2) and written information booklets and treatment 
guides for this disease. I completed a controlled trial into the efficiency of osteopathic 
treatment for symptoms associated with CFS/ME This was carried out over a two year 
period at Salford university and Hope hospital. The research carried out together with bio- 
engineer Prof. Jack Edwards and health psychologist Dr. Pat Hartley demonstrated that my 
treatment techniques developed since 1989 did help reduce the symptoms and restored 
patients to a much better quality of life(2). 
I am now involved in further research at Salford University's dept. of biological sciences 
for a doctorate in the treatment of CFS/ME, together with neuro-biologist Dr. Vic 
Pentreath. The research findings at present point to alterations in the flow of cerebrospinal 
fluid and lymphatic drainage of the neuraxis. My treatment aims at improving the drainage 
from the head, and spine using standard osteopathic techniques. 
During the year-long clinical trials we intend to use M. R. scanning of the brain, cervical 
and thoracic lymphatics, and to test muscle fatigue utilising the Kin-Corn isokinetics 
machine with surface EMG. These investigative techniques will all be performed by highly 
qualified specialists at the Universities of Salford and Manchester. Your patient has been 
explained the procedures involved and has agreed to take part, subject to your approval. 
NO TREATMENT WILL BE GIVEN BY THE RESEARCH TEAM: THE PATIENT 
HAS BEEN GIVEN PERMISSION TO RECEIVE ANY TREATMENT OF THEIR 
CHOOSING WITH THE EXCEPTION OF OSTEOPATHY, PHYSIOTHERAPY 
AND MASSAGE (Without prior permission from the research team) FOR THE 
DURATION OF THE YEAR-LONG PROJECT. 
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If you feel that the patient will not be suitable for the research for any reason please let us 
know as soon as possible. If you do feel that the patient would be a suitable candidate for 
the project, please fill out the enclosed consent form and return it to us in the stamped 
addressed envelope. 
We are aware of the limited time you have in your day, but we ask you to give the matter of 
consent serious thought before replying. As with the first stage of this project, ethical 
approval has been given from Bury & Rochdale Health Authority research ethics 
committee. If you have any further questions please do not hesitate in contacting myself on 
0161 773 0123. 
Thank you for your co-operation, 
Yours Sincerely, 
Raymond N. Perrin D. O. 
Dept. of Biological Sciences 
University of Salford. 
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GPCFS3 
GENERAL PRACTITIONERS AUTHORISATION FORM 
CFSIME RESEARCH PROJECT - UNIVERSITY OF SALFORD 
RE: Patient's name ............................................ 
Address .................................................... 
D. O. B ...................................................... 
I, Dr ..................................... agree that the above named patient may be 
chosen as a member of the control group for the research project into the 
involvement of cerebrospinal fluid and lymphatic drainage in chronic fatigue 
syndrome (CFS). 
I verify that he/she is in good health and that there are no medical reasons why 
he/she cannot be part of this study. 
Signed: ................................................ 
Date" " ................................................ 
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APPENDIX A5: Examples of research subjects' records 
Code: RVO5 
Sex: Male 
Age: 52 
Occupation: Part time social worker (18hrs per week) 
Pastimes/hobbies (before ill) Amateur dramatics 
Status: Married; 2 sons aged 25 and 29 
Date of Initial Consultation: 11: 02: 99 
Height: 6' 2" 
Weight: l5st. 71b 
PAST MEDICAL HISTORY: 
Birth: Cord wrapped around head but no abnormalities detected after birth. 
Pre-teen: Emotional Trauma: Mother left home when pt. 2 y. o. a. Stayed in children's home 
for two years then went to live with father. 
Chronic tonsilitis, prescribed plenty of antibiotics in early years. 
Suffered from boils for no apparent reason. 
Chicken pox 
Teenage Yrs: 16+ fell off motorbike several times injuring head. 
Adulthood 18yrs+: Tonsilectomy 19yoa. 
Emotional Trauma: Father died when pt was only 24 y. o. a. 
1 Brother and 2 sisters all seriously ill 
Knocked off bike 1987; Injured head and neck. 
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Oesophagitis: 1988 treated with zantac and losec 
Glandular Fever: 1989 
Emotional Stress: Marital and work related mental stress. 
Onset of symptoms related to CFS/ME: 1989/1990 insidious onset. 
Blood Tests: FBC Normal; Melatonin level low, DHEA level low. 
Other investigations: EEG Normal 
EMG Normal 
Prior Treatment: Prozac for 3 months no relief; Melatonin and DHEA for 6 months; 
Evening primrose oil and multivitamins taken for 2 years. 
PRESENTING SYMPTOMS: Fatigue 
Head Pain 
'Muzziness' in head 
Sleep disturbance 
Vivid/weird dreams 
Back pain 
Neck pain 
Peripheral joint pain 
Myalgia 
Numbness 
Paraesthesia 
Redness in chest 
Cognitive ability reduced 
Emotional state disturbed 
Photophobia 
Hyperacusis 
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Temperature regulation. 
GI disturbance: IBS 
GU: Irritation to bladder 
Breathless 
Oral Temperature (Norm 36.9): 36.3 
Physical Signs of CFS/ME (see Ch. 5) 
Thoracic Spine: slight tender T4/5; Flattened upper thoracic; Kyphotic lower thoracic and 
upper lumbar spine; Harrison sulcus in sternum. 
Breast tissue: Varicose Lymph palpated in both breasts; Perrin's point +ve 
Coeliac plexus region: Tender 
Cranial Flow (Involuntary mechanism): Lower than normal. 
Treatment Commenced: 16: 06: 00 
36 treatment sessions in first year: Symptoms improved. 
Epilogue: 13: 07: 04 Pt. continues to come for monthly treatment. Working longer hours 
with much less symptoms with occasional periods of exacerbated symptoms following too 
much activity or physical and mental stress. 
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Code: RVO6 
Sex: Female 
Age: 19 (20 at start of research programme) 
Occupation: Unemployed (ex-student) 
Pastimes/hobbies (before ill): Roller skating (dance), tapestry 
Status: Single, lives with parents. 
Date of Initial Consultation: 07: 02: 00 
Height: 5' 10" 
Weight: l3st 
PAST MEDICAL HISTORY: 
Birth: Intra-uterine scans revealed slow cranial growth. High cavity forceps. 
Pre-teen: Eczema; Chronic tonsilitis, prescribed plenty of antibiotics in early years. 
Genu Valgum with "irritable hip" 
Teenage Yrs: Osgood Schlatters Disease. 
Emotional Trauma: 14yoa father made redundant 
16yoa: severe bout of gastroenteritis and tonsilitis plus mental stress of 
GCSE examinations at time of onset. 
Emotional Trauma: 3grandparents die within a few years of each other. 
Adulthood 18yrs+: Back Pain 
Onset of symptoms related to CFS/ME: March 1997 sudden onset following viral 
infection. 
Blood Tests: FBC Normal; EBV -ve 
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Other investigations: None 
Prior Treatment: Prozac for 6 weeks taken 2 years ago, no relief. 
Homeopathic medicine also taken without improvement. 
PRESENTING SYMPTOMS: Fatigue 
Head Pain 
`Muzziness' in head 
Vivid/weird dreams 
Sleeps too much 
Back and neck pain 
Peripheral joint pain 
Myalgia 
Numbness and paraesthesia in extremities 
Cognitive ability reduced 
Anxiety 
Photophobia 
Temperature regulation dampened. 
Pain in chest. 
Taking contraceptive pill to regulate periods. 
Oral Temperature (Norm 36.9): 36.6C 
Physical Signs of CFS/ME (see Ch. 5) 
Thoracic Spine: Flattened, slightly scoliotic mid-thoracic spine with pelvic torsion. 
Breast tissue: Varicose Lymph palpated in both breasts; Perrin's point +ve 
Coeliac plexus region: painful 
Cranial Flow (Involuntary mechanism): Lower than normal. 
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Code: CP09 
Sex: Female 
Age: 21 
Occupation: Student, degree in sports rehabilitation. 
Pastimes/hobbies (before ill) modem/ballet dancing. 
Status: Single 
Date of Initial Consultation: 09: 01: 01 
Height: 5' 6" 
Weight: l0st. 61b 
PAST MEDICAL HISTORY: 
Birth: Cord wrapped around neck but no abnormalities detected after birth. 
Pre-teen: Talipes equino varus, required physiotherapy from 3 to 4yoa. 
Teenage Yrs: 13yoa injured low back (L5) in a trampolening accident. Suffered low 
back 
pain and sciatica. Treated by physio. 
15yoa Slipped badly on ice, fractured right radius and bruised coccyx 
16yoa Coin thrown injuring bridge of nose, began to pass out the 
following day. 
Adulthood 18yrs+: Tonsilitis 18yoa. 
Emotional Trauma. Failed first year exams which increased the stress 
exacerbating the symptoms. 
Twisted knee causing a right Medial meniscus tear. 
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Onset of symptoms related to CFS/ME: September 1998 a year following major viral (flu) 
infection which never really recovered. 
Blood Tests: FBC Normal; EBV -ve 
Other investigations: none 
Prior Treatment: Effexor (antidepressant) 75mg/day for last two years, not helped overall 
symptoms; Acupuncture; Reiki. 
PRESENTING SYMPTOMS: Fatigue 
Head Pain 
`Muzziness' in head 
Difficulty getting to sleep 
Vivid/weird dreams 
Back pain 
Neck pain 
Peripheral joint pain 
Myalgia 
Numbness in extremities 
Paraesthesia in extremities 
Redness in face, neck and chest. 
Cognitive ability reduced 
Emotional state disturbed: depressed secondary to illness. 
Photophobia 
Hyperacusis 
Temperature regulation disturbed. 
GI disturbance: IBS 
GU: Irritation to bladder increased frequency 
Slightly asthmatic. 
Dry skin with occasional acne. 
Non-exudative pharyngitis. 
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Oral Temperature (Norm 36.9): 36.9 
Physical Signs of CFS/ME (see Ch. 5) 
Thoracic Spine: slight tender mid-segments; Flattened upper segments; Kyphotic lower 
segments. 
Breast tissue: Varicose Lymph and tenderness bilaterally; Perrin's point +ve 
Coeliac plexus region: Tender 
Cranial Flow (Involuntary mechanism): Lower than normal. 
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APPENDIX A6: Self report questionnaires 
Questionnaire No. 1. GENERAL HEALTH QUESTIONNAIRE (Perrin et al., 1998) 
SUBJECT NO. 
6. PLEASE INDICATE THE SEVERITY OF THE DIFFERENT COMPLAINTS THAT YOU 
HAVE BEEN SUFFERING FROM DURING THIS PAST WEEK; 
WHERE: - 
1. - NO PROBLEM WITH T IS COMPLAINT. 
2. - SLIGHT PROBLEM WITH THIS COMPLAINT. 
3. -FAIRLY SEVERE 
4. - VERY SEVERE. 
a) MID RECURRENT FEVERS 
b) SORE THROAT 
c) PHYSICAL WEAKNESS 
d) NAUSEA 
e) PROLONGED FATIGUE AFTER EXERCISE 
E 
f)HEADACHE 
F] 
S) EAR ACHE 
El 
h) IRRITABLE BOWEL 
i) MUSCLE PAIN IN ARMS AND LEGS F-I 
j) PAIN IN CHEST 
El 
k) PAINFUL JOINTS 
fl 
I) FEELING HOT/COLD 
fl 
m) SWEATING 
n) SHIVERING 
F] 
o) DISTURBED SLEEP 
p) RACING HEART 
LI 
FORM Q/OST/M. E. 1.. 
DATE 
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SUBJECT NO. 
QUESTION 6. CONT. 
q) PAIN IN NECK 
E 
r) PAIN IN SHOULDERS 
D 
s) PAIN IN BACK 
El 
t) SENSITIVE TO LIGHT F] 
u) SENSITIVE TO SOUND 
v)DEPRESSED 
El 
w FEELINGS OF ANXIETY/PANIC 
x) LOSS OF CONCENTRATION 
E 
y) LOSS OF MEMORY 
rI 
z) ALLERGIES U 
N. B. WHERE- 
I. - NO PROBLEM WITH THIS COMPLAINT. 
2. - SLIGHT PROBLEM WITH THIS COMPLAINT. 
3. - FAIRLY SEVERE 
4. - VERY SEVERE. 
IF YOU ARE SUFFERING FROM ANY OTHER COMPLAINT. PLEASE SPECIFY IN THE 
SPACE PROVIDED BELOW. 
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Questionnaire No. 2. BACK PAIN (Perrin et al., 1998) 
SUBJECT NO. 
A. left neck 
oý 
B. left upper 
back ýi\ý 
(shoulder-level) 
C. left 
mid-back 
(cheat-level) 
D. left 
low-back 
(waist-level) 
FORM Q/OST/M. E. 2.1 
BACK SYMPTOMS 
E. right 
neck 0 
F. right 
upper 
back 
0 
G. right 
mid-back 
H. right 
low-back 
Please indicate the region/s of pain 
on the above diagram by placing a score 
in the relevant circle. 
.= 
no discomfort (pain-free) Where. 
_ slight discomfort 
OO = moderate pain 
severe pain 
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BACK SYMPTOMS cont. 
SUBJECT NO. FORM Q/OST/M. E. 2.2 
Please indicate the region/s of pain, in 
the spine, on the below diagram by 
placing a score in the relevant circle. 
Where: 
(j)= no discomfort (pain-free) 
Q= slight discomfort 
Q= moderate pain 
severe pain 
N. B.. This 
section only 
applies to any 
central pain 
felt on the 
actual spinal 
column. Any pain 
at the side of 
the spine should 
be recorded in 
the previous chart. 
I. neck0 
J. upper 
back 
(shoulder-level) 
K. mid-back 
(chest-level) 
L. lower back O 
(waist-level) 
Date: 
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Questionnaire No. 3. THE REVISED BECK DEPRESSION INVENTORY (Beck et 
al., 1979) 
instructions: On this questionnaire are groups of statements. Please read each 
group of statements carefully. Then circle the statement in each group which best 
describes the way you have been feeling in the last week, including today! 'Circle 
the number beside the statement you have picked. It several statements in the group 
seem to apply equally well, circle each one. Be sure to read all the statements in 
each group before making your choice. 
1. On I do not feet sad. 
In I feel sad. 
2=1 am sad all of the time and I can't snap out of it. 
3= 1 am so sad or unhappy that 1 can't stand it. 
2. On I am not particularly discouraged about the future. 
In I feel discouraged about the future. 
2= I feel that I have nothing to look forward to. 
3= I feet that the future 13 hopeless and that things cannot Improve. 
3. Q=1 do not feel like a failure. 
In I feel I have failed more than the average person. 
2= As I look back on my life, all I cV% see is a lot of failures. 
3= 1 feel I am a complete failure as a person. 
4. Oz I get as much satisfaction out of things as I used to. 
t: I don't enjoy things the way I used to. 
2= I don't get real satisfaction out of anything anymore. 
3= 1 an. dissatisfied or bored with everything. 
5. O= I don't feel particularly guilty. 
1. I feel guilty a good part of the time. 
2=1 feel quite guilty most of the time. 
3=1 feet guilty all of the time. 
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" 6. On I don't feel I am being punished. 
in I feel I may be punished. 
2= I expect to be punished. 
3=1 feel I am being punished. 
7. OI don"t feel disappointed in myself. 
1=I am disappointed in myself. 
2= I am disgusted with myself. 
3=1 hate myself. 
8.0=I don't feel I am any worse than anybody else. 
1= I am critical of myself for my weaknesses and mistakes. 
2= I blame myself for all my faults. 
3= 1 blame myself for everything bad that happens. 
9. On I don't have any thoughts of killing myself. 
t= I have thoughts of killing myself. but I would never carry them out. 
2=1 would like to kill myself. 
3= 1 would kill myself 01 had the chance. 
10.0=1 don't cry any more than usual. 
1= I cry more than I used to. 
2=1 cry all the time now. 
3=1 used to be able to cry. but now I can't cry even though I want to. 
11. on I am no more irritated now than i ever am. 
I= I get annoyed or irritated more easily than I used to. 
2= t feel irritated all the time now. 
3= 1 don't get irritated at all by the things that used to irritate me. 
12. On I have not lost interest in other people. 
I= I am less interested in other people than I used to be. 
2=1 have lost most of my interest in other people. 
3=1 have lost all of my interest In other people. 
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13. On I make decisions about as well as I ever could. 
In I put off making decisions more than I used to. 
2= 1 have greater difficulty in making decisions than before. 
3= 1 can't make decisions at all anymore. 
14.0* I don't feel I look any worse than I used to. 
1= I am worried that I am looking old or unattractive. 
2a 1 feel that there are permanent changes In my appearance that make me 
look unattractive. 
3= 1 believe that I look ugly. 
15. Ow I can work about as well as before. 
In It takes an extra effort to get started at doing something. 
2a I have to push myself very hard to do anything. 
3a $ can't do any work at all. 
16. NI can sleep as well as usual. 
1. I don't sleep as well as I used to. 
2= I wake up 1-2 hours earlier than usual and find it hard to get back to sleep. 
3" 1 wake up several hours earlier than I used to and cannot get back to sleep. 
17.0. I don't get more tired than usual. 
1. I get tired more easily than I used to. 
2= I get tired from doing almost anything. 
3- 1 am too tired to do anything. '' 
18. On My appetite is no worse than usual. 
1= My appetite is not as good as ft used to be. 
2= My appetite is much worse now. 
3= 1 have no appetite at all anymore. 
19.0= I haven't lost much weight. It any, lately. 
In I have lost more than 5 pounds. """ 
2= I have lost more than 10 pounds. """ 
3= I have lost more than 15 pounds. """ 
""" I am purposely trying to lose weight by eating less . Yes_ No_ 
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20. OI am no more worried about my heahh than usual. 
In I am worried about physical problems such as aches and pains; or upset 
stomach; or constipation. 
2= I am very worried about physical problems and Its hard to think of much 
else. 
3=1 am so worried about my physical problems that I cannot think of 
anything else. 
21.0*1 have not noticed any recent change in my interest in sex. 
In I am less interested in sex than I used to be. 
2=1 am much less interested in sex now. 
3: 1 have lost interest in sex completely. 
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Questionnaire No. 4. THE BECK ANXIETY INVENTORY (Beck eta!., 1988). 
CODE ALW Rtl 
--- 
QUESTIONNAI 
- 
RE 0/OST/INi. E. 4. 
PLEASE CAJUU. LY READ EACH flu4 N TM LIST BELOW. LQ1CAT5 HOW 
MUCH YOU 1ä1i'8 RUN BOTHERED BY EACH SY>, QT'OM DC NO THE PAST 
V61 X. L CLMM TODAY BY MCD OA SCORE N THE CORAESPQ%MNG BOX 
viaii- 0"NOTATALL 
I" lCLDI. Y(4 64 w both w much) 
2" MOLL ATILY(h w vay unplewm bit 1 oaM sued it) 
3" M13L .Y (I caW4 by stud it) 
2. Fly hot Q 
3 Wabbliaar in kg Q 
4 Viable w rasa 
Q 
S. Far tw wui I. ppeninj 
Q 
6 Dun w Soh6c j a 
T. Heart poued ig or nogg a 
"- Q 
f. Tvtºfied. Q 
10 Navo. a Q 
11. Fdmp dclotiit1 a 
12 Hmds nmbliag. Q 
I3 Sbakp Q 
FORM QOST/%* E 4. 
DATE 
270 
CODE %'WCSEA 
-- -- -- 
1.3 0. NOT AT ALL 
I" I-m. DLY(rt dd m Sotser me euch) 
2.1 ATILY(tt w vay uepkuw* b%d I could wd k) 
3- $L u aY p @a" ! may gd 1) 
14 fwdIO&V --oA 0 
It few dcýi% El 
17, fand 0 
19 1aä fa d" of &oomf 1ü "mea 
a 
It fist 
20. Fam ßukha 
21. Si aoaf(ea &4 16 ºený 0 
71mt rcu to c=pkda dri tam. Place dbeck that you lave lükd is iU yar reales. 
clog. y 
FORV Q'OST .LE4. 
OATS 
I 
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Questionnaire No. S. TIHE MORGAN-GLEDHILL SLEEP QUESTIONNAIRE (Tomeny 
and Morgan, 1990) 
Scoring system is outlined in red. 
$-t" I. 
M. E. RESEARCH PROJECT 
SLEEP QUESTIONNAIRE 
CODE 
NUMBER: DATE: 
---------- 
Below are some questions concerning 
your sleep at night. please answer 
all the questions. If your times for 
going to bed and so vary greatly, give 
ranges (e. g.. 10-11pm, 30-60 mins). 
For how long do you usually sleep 
at night? Compare with sleep/age norms 
2 After settling down, how long does it 
usually take you to fall asleep? 
Divide minutes by 10 
How often do you wake up too early in 
the morning? (tick one): 
Never Q Score 
Seldom Q 
Sometimes Q 
Of ten Q 
All the time Q 
Never=0 to All the time=4 
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ft 
NN 2. 
FSFARCH PRÖ TFCT 
! RT_FFP O7 
_4TTONNA 
R1? ' 
CODE 
NUMDER 
4 Do you usually wake up Yes J 
during the night? (tick one) : No 
If Yes: What usually awakes you? 
(answer in your own words) 
6 How many times (on average) do 
you awake each night? ýj I 
Score I for each time 
: 71 For how long are you awake on each 
of these occasions? rscorelforeachhourl 
8 At what time do you usually go 
to bed? I 
rh-k--di 
9 At what time do you usually wake up i (in the morning) ? 
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Mf. 3" 
[ý_t_ PfARCH PROTFGT 
ý LFPP Ö! TI NNATRF 
CODE 
IVJKBER s DATE sss 
ý01 At what time do you usually 
get up? 
How refreshed do 
score: very refreshed = 0 Very refreshed O 
you usually feel Quite refreshed O 
when you wake up 
Unretreshed 
Tired 
0 
O 
in the morning (tick one) ? Shattered o 
In general, how much sleep do you 2 think a person your age needs? 
3 How long have you had your present 
sleep problem 
4 What do you think is the cause of 
your present sleep problem? 
s Have you ever had serious Yes o 
trouble with your sleep in No 0 
the past? 
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0 
tat$ 4. 
M_R_ EsrARCH PRO ECT 
ST. FrP OU! STICNNAI F 
CODE 
NUMBER: DATE: __. __. 
16 Have you gained or Yes, I have gained weight 
lost weight in the Yes, I have lost weight o 
last few months? No, I'm about the same 
(tick one) 
17 Sub"scorc tro 0=%, ery good sleeper to 4= very poor sleeper 
Before the present Ann good sleeper o 
problem how would A °°°d sleeper ° An average sleeper 0 
; you have described pmr sleeps o 13 
yourself? (tick one) p°°= sleeper "s 
18 º Sub-score from 0=very good sleeper to 4 =very poor sleeper 
s How would you % very good sleeper O describe yourself A good sleeper Q An average sleeper O now? 
A poor sleeper O 
A very poor sleeper 13 
Score difference of Q. 18-Q-17 
19 Do you usually take a Yes Q 
nap during the day? No Q 
Score yes =1 no=0 
20 When do usually nap? 
(give length of each nap) 
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Use sleep/age norms with answer in Q. 1. 
Score 1 for each hour difference- 
SLEEP/ AGE NORMS 
AGE HOURS 
of SLEEP 
19-30 = 7.75 
33-45 =7 
50 =6 
90 = 5.75 
Source: Revised by Roffwarg et al since 
publication in Science, Vol 152 
(1966) pp. 604-19. 
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Questionnaire No. 6. BROADBENT'S COGNITIVE 
FUNCTION QUESTIONNAIRE (Broadbent et al., 1982) 
U 
" 
CFO 
The b$owwp criso4 ti wo about terror v stak" which everyone makes from Ums 
u on4a. Dut wrr* ot wfuch h* . 's more often than oMers. We want to know how 
ottwn tt. s4 etw+s have M p+, wd to yoct in Me psi stz months. Pluaaa circle tM 
* opr ata n r, bsr. 
very quits cots.. very never 
often often bnany rarely 
1. Do you read scwtotl ng and 
fir+d you Mwnt DNn 43210 
zmk about k and ttxtst 
raid it R; an7 
2. 00 you h+d you knot why 
you want tromp one dart of 4 3 2 1 0 
V* hoUss b"Ctt»A 
3. Do you tal to Baca s i+- 4 3 2 1 0 
posts on 1M road? 
4. Do you tend that you ccrºtusa 
"aha Iii tin gWig a 3 2 1 0 
ait. ct ohs? 
S. Do you bump into paop4t 4 3 2 1 0 
I. Do you Mid Cut you forgot 
wttits w ypulti txr d an 4 3 2 1 0 
a"or a two or locked 
to door? 
7. Do you tai 1o istsn to 
Mole's times wren you a 3 2 1 0 
are mtawq ttwnl 
S. Do you uy some wq and 
rrah" alwwards ttsat k 4 3 2 1 0 
matt be taken as irssAng? 
S. Do you taxi t0 .ap. op+. 
s0aajcng to you wtwn you a 3 2 1 0 
are dorq som. **+ arse? 
10. Do you lote your t 4 3 2 1 0 
and tttn regret N7 
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vV y quits occas- very never 
often often lonalty rarefy 
11. Oo you isarw arporartt 4 3 2 1 0 
Irras unanswered be days? 
12. Do wtuch 
waybt monan you 4 3 2 1 0 
know w*A but rarely usN 
13. 00 you t&A lo a" what you 
wem In a sst 4 3 2 1 0 
(Lou k's V W4)7 
14. Do you Md yourself sud? eº 
wW4er nQ whom er you've 4 3 2 1 0 
used a word corn y? 
1S. Do you have trains maksrV 4 3 2 1 0 
your mVQ? 
IL Do you brp t appon vi ants? 4 3 2 1 0 
17. 00 you knot whers you PA 
50m4 ng kka a nsws, -4LW 4 3 2 1 0 
or a book? 
1$. Do you find you acmdadaly 
Cuow away V* V*V you wan 
and keep wtut you muard b 
rnwaway"asInt s 4 3 2 1 0 
wmpta of ttuowir away 
the ma hbox and p. nQ V* 
used ma in your pocket? 
IL Do you daydream when you 4 3 2 1 0 
ougd b be Istaning b 
somabing? 
20. Do you W you bet 4 3 2 1 0' 
People's names? 
21. Do you start doing one ring 
at h=e a, 'Id pst dimctb 4 3 2 1 0 
ir»a doing something else 
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S 
very Quite octal- very never 
often often WADY rarely 
2Z Oo you Md somea ng you 
tanl CuY'. e famember 4321 '0 
23. Do you Lid IhX you forgot 
tt you =no to rw shops 4 
b bur? 
24. Do you fto tº_'º 4 
2$. Do you Orb your call zxrtx 4 
of &, TIwV %o say7 
3 2 1 0 
3 2 1 0 
3 s 1 0 
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Questionnaire No. 7. TIHE NOTTINGHAM HEALTH QUESTIONNAIRE 
Score: YES= I NO=2 (Hunt et al., 1981) 
Please 
" not wr: in this 
margin 
LIST RILC1f 2 $C3 11CItD(3 PiOPLs WI=T E17! 
IN mu cAnT L29ts. 
Rx= TZI LIST CUSM. LY 1XO PUT A TICK Ix Tit 
14Z 
Q 
mczx ui tca An PZOILDI TZmT AJP1LXIS 
TO TM IT ? ri MCMD(T. T%cx Ttt sax Wcza r9 
10* MY IL: 1LZX Slit DOZ! WT APPLY TO TOD. 
Pf-M15äaXTWTZ rrxly =1=1. IF YOM An NOT XU 
Nmw TO AXSVR1 Tt: C1 N0. TZCL W=CEZw issm 
TM Tin iS W. TiTi AT TU KOeaNT. 
TU NO 
2's tired all the time 
a a 
I have pain at night 
11 Q 
Things are getting me doss 
El a 
us No I have unbearable pain El a 
I take tablets to help so sleep 
Q Q 
love forgotten what We like to enjoy myself 
Tsf MO 
I'm feeling on edge 
a 
I find it painful to change position 
a a 
I feel lonely 
a 11 
Please turn over 
1 
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not r 
LM ts: 
sar; it 
ns ýro 
2 can way walk about indoors 
0a 
I find it hard to head na MzytMzg is as effort 11 n 
YU )O 
I'  vakiz up in tha early 
Lcurs of the aorýiaq 
a a 
I'm unable to walk at all 
a a 
I's ficdiaq it hard to make 
ecpl" Contact with 
a 
p 
t. D[DaIx 2, TOII Ui = =x wxrrmm TO 1XSW A 'US' Cl 'NO' 
SO PýC1bD(. S2CT. Iß2BZ4ý 31ts1R2 TOQ TZ Holz TR4! 1T 
US go 
2bs days sass to drag 
aQ 
I have trouble Setting up and down QQ 
stairs or steps 
I find it hard to reach for things 
11 D 
7! S 310 
I'  in pain when I walk 
aQ 
I lose ey tenses easily these days 
Qa 
I feel tyeze is nobody I an close to 
Q0 
Please turn over 
2 
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us xo 
I lie awake for most of the night 
a El 
I feel as if I'm losing control 
Q a 
i"" in pain when I'm standing 
a Q 
Ts! Ito 
I find it hard to dress myself 
a a 
I soon rum out-of snaggy 
Q 0 
I find it hard to stand for long 
(eq at the kitchen sink. waiting for a bus) 
0 
ns xo 
Zen in constant pain 
EI D 
It takes me a long time to get to sleep 
Q a 
I feel 1 an a burden to people 
Q a 
n! No 
Worry is keeping me awake at night 
a a 
I feel that life is not worth living 
cj 
I sleep badly at night 
El 0 
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" Pleas 
not W 
in tb 
uargi 
TU NO 
too finding it hard to get an with people 
Q Q 
I aced help to walk about outside (sq a 
walking aid or someone to support me) 
13 a 
TU WO 
Ia in pain when going up and down 
s stairs or ste 
Q Q 
p 
I wake up feeling depressed 
a 0 
1a in pain wban I's sitting 
[J a 
NOW PL211Z 00 SICZ TO 1AGt 1 1M 30M SVU TW YOU 
liVI AXSWU Glue Cl "$Q" TO SUUT QCZSTZOft. Cet 
ALL MCI PLR! Of TU Q4u? IOYw1T .. 
TIAU TOII 701 7041 I= 
4 
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Questionnaire No. 8. 
THE PROFILE OF FATIGUE RELATED STATES (Ray et al.. 1992) 
PEAS 
B. +ow is a ist of probwns .. noch may or may not appy a you. For each problem 
Pease say to what extant you have axparioncad this during V %o PAST WEEK 
(Including today). Do rot think for too long before answering but give your 
rnmeftto roacaon. Pt"" be carats not to mess out any of the Items. Remember. 
we era talking about the past w. s and not your lunass in general, G1w your answer 
by cursing any rx, mbsr from I to 7 to the Nrd of I* hern. when: 
Ia not at alt 
4a modeMsay 
7. "xtranMy 
1. Fssing phywA y tired avian rufen taking 1 2 3 4 5 6 7 
things e&V. 
2. Yov knbs teeing heavy. 1 2 S 4 S 6 7 
3. Gsmnq easily upset by things. 1 2 3 4 5 6 7 
4. Dmk uty oot sntsw+p- 1 2 3 4 5 6 7 
S. sbmsch pain. 1 2 3 4 5 6 7 
6. Not having ttw p4ywal energy to do anything .1 2 3 4 5 6 7 
7. Ddßaity standing for long. 1 2 3 4 5 6 7 
"6. Losing yow wv Dsv sas+ay. 1 2 3 4 5 6 7 
f. Ddfia+tty ºsmor-boing flings. 1 2 3 4 5 6 7 
10. tos feel weak even attar mfinq. 1 2 3 4 5 6 7 
11. FssJ. depressed 1 2 3 4 5 6 7 
12. Muscles tender to tns buck 1 2 3 4 5 6 7 
13. Siowr+su of tnaptu 1 2 3 4 5 6 7 
14. Tremor or twain . 1 2 3 4 5 6 7 
1$. The tightest oxerass MaJJrV you 1 2 3 4 5 6 7 
phys+caJy trod 
1S. 6.0'6wrts 1 2 3 4 5 6 7 
17. OdficIty reasoning rings out 1 2 3 4 5 6 7 
284 
Ia not at an 
4a modwatily 
7a utr. mily 
1$. 8uming. t ngl" or uawt, ng saruaaor+s. 1 2 3 4 5 6 7 
1s. NumOy+as3 in son* part of your body 1 2 3 4 5 6 7 
20. Back prin. 1 2 3 4 5 6 7 
21. F dV anzci s. 1 2 3 4 5 6 7 
22. A f.. g of cor&sion ('martial fog). 1 2 3 4 5 6 7 
23. Bouts of twsatug (day of Nftt). 1 2 3 4 5 6 7 
24. FWng My catty dran MQ. 1 2 3 4 5 6 7 
25. Otuiniu or g ddmus. 1 2 3 4 5 6 7 
21. Absan*. mrw+d. Onass. 1 2 3 4 5 6 7 
27. Wortywq about rwVs tMt do rot maaK. 1 2 3 4 6 6 7 
21. Fs&An9 phymaly trod even attar a good 1 2 3 4 5 5 7 
rupnt's s: ap. 
29. Odfcutly urdsntar gag. what i meona 1 2 3 4 5 6 7 
was uy" b yew 
30. Fsabnq p. ssimisac about tae tu re. 1 2 3 4 5 6 7 
31. Cold har+ds or t. sL 1 2 3 4 5 6 7 
32. MavhQ to stop dwv sornesting. tAai was 1 2 3 4 5 6 7 
easy in bad. because R made you trod. 
33. Musddu 160nq weak after stght aaräse. 1 2 3 4 5 6 7 
34. D cIIy* owigturpseq_as 1 2 3 4 5 6 7 
plot on TV. 
35. Hot or C: 4 "1s 1 2 3 4 5 6 7 
30. Fsaknq tens.. 1 2 3 4 5 6 7 
37. Faaiug tart 1 2 3 4 5 6 7 
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I" not at an 
4" moderat 
7" extremely 
3$. DAU ty ? ding " MM word 1 2 3 4 5 6 7 
3$. Faabng ctWW or attiwry. 1 2 3 4 5 6 7 
4& Toartuh+oss. 1 2 3 4 5 6 7 
41. Iffog" or rz d Muttau. 1 2 3 4 5 $ 7 
4t F. akng wonhi. ss. 1 2 3 4 5 6 7 
43. For . tw p what you *Ka trying b say. 1 2 3 4 5 6 7 
44. Being easiy angered when t gs want wrong. 1 2 3 4 5 6 7 
45. Feeling msnt ly bred even after a good 1 2 3 4 5 6 7 
Khfs stat0- 
44. Oiumaa or consapaaat. 1 2 3 4 5 6 7 
47. FLnq nuvout 1 2 3 4 5 6 7 
4$. Foohng tad. 1 2 3 4 5 a 7 
49. The &%ghw t . dort making you rw afy End. 1 2 3 4 5 6 7 
$0. Feeling tka you had a tampers ss. 1 2 3 4 5 a 7 
$1. Otter people wMyirq you. 1 2 3 4 5 6 7 
$2. A son rwoat. 1 2 3 4 5 6 7 
$3. Fis of r. w mwvL 1 2 3 4 5 6 7 
54. Being slow b react 1 2 3 4 5 6 7 
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APPENDIX A7: The Borg Scale of Perceived Exertion 
(Borg and Linderholm, 1970) 
BORG SCALE OF PERCEIVED EXERTION 
Test no: 
Code no: 
Please rate how much strain you are under doing this 
exercise. 
6 
7 Very, very light 
8 
9 Very light 
10 
11 Fairly light 
12 
13 Somewhat hard 
14 
15 Hard 
16 
17 Very hard 
18 
19 Very, very hard 
20 
THANK YOU! 
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APPENDIX A8: Probe Position Calibration Chart 
Calibration chart for the portioning of probes used in spinal movement analysis 
(phase 1 of study). 
PROBE POSITIONS 
o. 
C. 
T. 
L. 
CODE NO. 
CM. 
cm. 
cm. 
"S" 
"SS 
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APPENDIX A9: Statistical analysis of questionnaires (phase 1) 
The full statistical analysis of individual subject's score of each group and at each stage of 
the year's trial above using two-sample t tests on the reductions in scores from start to 
months 3,6,9 and 12. Statistical software package used: SPSS for Windows. 
The most important statistic from each test is the p-value. which is 0.180 for the first test, 
and so on. Those tests with pc0.05 indicate significant differences between the mean 
reductions of the control group and the patient group at the 5% level of significance. 
health 
Two-Sample T"Test and CI: health Q1 s"3, group 
Two-sample T for Health Q1 s-3 
group N Mean St. Dev SE Mean 
1 24 2.38 6.44 1.3 
2 34 5.7 10.7 1.8 
Difference =p (1) -p (2) 
Estimate for difference: -3.33 
95% CI for difference: (-8.25.1 49) 
T-Test of difference =0 (vs not =): T-Value = -1.36 p-value = 0.180 DF = 56 
Both use Pooled St. Dev = 9.21 
Two-Sample T-Test and CI: Health QI s-6, group 
Two-sample T for Health Q1 s-6 
group N Mean St. Dev SE Mean 
1 24 2.00 6.98 1.4 
2 33 10.3 10.8 1.9 
Difference =µ (1) - p(2) 
Estimate for difference: "8.30 
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95% CI for difference: (-13.36, -3.25) 
T-Test of difference =0 (vs not =): T-Value = -3.29 p-value = 0.002 DF = 55 
Both use Pooled St. Dev = 9.40 
Two-Sample T"Test and CI: Health Q1 s. 9. group 
Two-sample T for Health Q1 s"9 
group N Mean St. Dev SE Mean 
1 24 0.88 7.38 1.5 
2 33 11.12 9.77 1.7 
Difference =p(I)-µ(2) 
Estimate for difference: -10.25 
95% CI for difference: (-15.00. -5.49) 
T-Test of difference =0 (vs not =): T-Value = -4.32 p-value = 0.000 DF = 55 
Both use Pooled St. Dev = 8.85 
Two-Sample T"Test and Cl: Health Q1 s-12, group 
Two-sample T for Health Q1 s-12 
group N Mean St. Dev SE Mean 
1 24 -1.79 8.07 1.6 
2 33 13.5 10.5 1.8 
Difference =p (1) -p (2) 
Estimate for difference: -15.25 
95% CI for difference: (-20.37. -10.12) 
T-Test of difference =0 (vs not =): T-Value = -5.96 p-value = 0.000 DF = 55 
Both use Pooled St. Dev = 9.53 
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Back Pain 
Two-Sample T"Test and Cl: Back Q2 s-3. group 
Two-sample T for Back Q2 s-3 
group N Mean St. Dev SE Mean 
1 24 "0.50 5.18 1.1 
2 34 2.21 7.98 1.4 
Difference= p (1) -p (2) 
Estimate for difference: -2.71 
95% CI for difference: (-6.42,1.01) 
T-Test of difference =0 (vs not =): T-Value = -1.46 p-value = 0.151 DF = 56 
Both use Pooled St. Dev = 6.96 
Two-Sample T-Test and Cl: Back Q2 s-6, group 
Two-sample T for Back Q2 s-6 
group N Mean St. Dev SE Mean 
1 24 "0.29 4.96 1.0 
2 33 4.67 7.19 1.3 
Difference =p (1) -p (2) 
Estimate for difference: -4.96 
95% CI for difference: (-8.38, -1.54) 
T-Test of difference =0 (vs not =): T-Value = -2.91 p-value = 0.005 DF = 55 
Both use Pooled St. Dev = 636 
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Two-Sample T"Test and Cl: Hack Q2 s-9, group 
Two-sample T for Back Q2 s"9 
group N Mean St. Dev SE Mean 
1 24 . 0.92 4.57 0.93 
2 33 5.39 6.86 1.2 
Difference =p (1) -p (2) 
Estimate for difference: -6.31 
95% CI for difference: (-9.54. -3.08) 
T-Test of difference =0 (vs not =): T-Value = -3.91 p-value = 0.000 DF = 55 
Both use Pooled St. Dev = 6.01 
Two-Sample T-Tost and Cl: Back Q2 s-l2, group 
Two-sample T for Back Q2 s"12 
group N Mean St. Dev SE Mean 
1 24 -0.83 6.27 1.3 
2 33 5.55 8.00 1.4 
Difference =p (1) -p (2) 
Estimate for difference: -6.38 
95% CI for difference: (-10.32, -2.44) 
T-Test of difference =0 (vs not =): T-Value = -3.24 p-value = 0.002 DF = 55 
Both use Pooled St. Dcv = 7.33 
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Depression 
Two-Sample T"Test and Cl: DDI Q3 s-3, group 
Two-sample T for BD1 Q3-s-3 
group N Mean St. Dcv SE Mean 
1 24 1.00 4.77 0.97 
2 34 4.06 5.03 0.86 
Difference =p (1) -p (2) 
Estimate for difference: -3.06 
95% CI for difference: (-5.69. -0.43) 
T-Test of difference =0 (vs not =): T-Value = -2.33 p-value = 0.023 DF = 56 
Both use Pooled St. Dev = 4.92 
Two-Sample T-Test and Cl: BDI Q3 s-6, group 
Two-sample T for BDI Q3 s-6 
group N Mean St. Dev SE Mean 
1 24 3.58 4.69 0.96 
2 33 6.73 5.79 1.0 
Difference = p(1) - µ(2) 
Estimate for difference: -3.14 
95% Cl for difference: (-6.03. -0.26) 
T-Test of difference =0 (vs not =): T-Value = -2.19 p-value = 0.033 DF = 55 
Both use Pooled St. Dev = 5.36 
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Two-Sample T"Test and Cl: DDI Q3 s-9, group 
Two-sample T for DDi Q3 s"9 
group N Mean St. Dcv SE Mean 
1 24 2.79 6.02 1.2 
2 33 8.00 6.44 1.1 
Difference = µ(1) - p(2) 
Estimate for difference: -5.21 
95% Cl for difference: (-8.58. -1.84) 
T-Test of difference =0 (vs not =): T-Value = -3.10 p-value = 0.003 DF = 55 
Both use Pooled St. Dev = 6.27 
Two-Sample T-Tost and Cl: UDI Q3 s. 12, group 
Two-sample T for BDI Q3 s-12 
group N Mean St Dev SE Mean 
1 24 1.75 6.14 1.3 
2 33 8.03 6.05 1.1 
Difference = p(l) - p(2) 
Estimate for difference: -6.28 
95% CI for difference: (-9.55, -3.01) 
T-Test of difference =0 (vs not =): T-Value = -3.85 p-value = 0.000 DF = 55 
Both use Pooled St. Dev = 6.09 
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Anxiety 
Two"Sample T"Test and Cl: BAI Q4 s-3, group 
Two-sample T for BAI Qt s"3 
group N Mean St Dev SE Mean 
1 24 0.50 7.31 1.5 
2 34 5.00 7.15 1.2 
Difference = µ(1) - µ(2) 
Estimate for difference: -3.50 
95% CI for difference: (-835, -0.65) 
T-Test of difference =0 (vs not =): T-Value = -2.34 p-value = 0.023 DF = 56 
Both use Pooled Sc. Dev = 7.21 
Two-Sample T"Test and Cl: BAI Q4 s-6, group 
Two-sample T for BAI Q4_s-6 
group N Mean St. Dev SE Mean 
1 24 "0.83 6.38 1.3 
2 33 5.73 6.80 1.2 
Difference = µ(1) - µ(2) 
Estimate for difference: -6.56 
95% CI for difference: (-10.12, -3.00) 
T-Test of difference =0 (vs not =): T-Value = -3.69 p-value = 0.001 DF = 55 
Both use Pooled St. Dev = 6.63 
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Two-Sample T-Tcst and Cl: BAI Q4 s-9, group 
Two-sample T for BAI Q4_s-9 
group N Mean St. Dev SE Mean 
1 24 -0.42 6.52 1.3 
2 33 7.97 6.73 1.2 
Difference = µ(1) - p(2) 
Estimate for difference: -8.39 
95% CI for difference: (-11.96.4.81) 
T-Test of difference =0 (vs not =): T-Value = -4.70 p-value = 0.000 DF = 55 
Both use Pooled St. Dev = 6.65 
MTB > TwoT'BAI Q4_s-I2''group'; 
SUBC > Pooled. 
Two-Sample T"Test and Cl: BAI Q4 s"12, group 
Two-sample T for BAI Q4 s-12 
group N Mean Si. Dev SE Mean 
1 24 -1.71 8.23 1.7 
2 33 6.48 6.78 1.2 
Difference = p(l) - p(2) 
Estimate for difference: -8.19 
95% Cl for difference: (-12.18,4.20) 
T-Test of difference =0 (vs not =): T-Value = -4.11 p-value = 0.000 DF = 55 
Both use Pooled St. Dev = 7.42 
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Sleep 
Two-Sample T-Test and Cl: Sleep QS s-3, group 
Two-sample T for Sleep Q5_s-3 
group N Mean St. Dcv SE Mean 
1 24 0.71 4.88 1.0 
2 34 1.16 4.19 0.72 
Difference = p(l) - p(2) 
Estimate for difference:. 0.45 
95% CI for difference: (. 2-85.1.94) 
T-Test of difference =0 (vs not =): T-Value = -0.38 p-value = 0.706 DF = 56 
Both use Pooled St. Dev = 4.49 
Two-Sample T"Test and CI: Sleep QS s-6. group 
Two-sample T for Sleep Q5 s"6 
group N Mean St. Dev SE Mean 
1 24 1.10 4.54 0.93 
2 33 1.98 5.64 0.98 
Difference = µ(1) - p(2) 
Estimate for difference: -0.87 
95% CI ford if ference: (-3.67.1.93) 
T -Test of difference =0 (vs not =): T-Value = -0.62 p-value = 0.535 DF = 55 
Both use Pooled St. Dev = 5.21 
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Two-Sample T"Tat and Cl: Sleep QS s"9. group 
Two-sample T for Sleep QS s-9 
group N Mean St. 1kv SE Mean 
1 24 -1.48 5.97 1.2 
2 33 2.73 4.88 0.85 
Difference = µ(1) - p(2) 
Estimate for difference: -4.21 
95% CI for difference: (-7.09. -1.32) 
T-Test of difference =0 (vs not =): T-Value = -2.92 p-value = 0.005 DF = 55 
Both use Pooled St. Dev = 537 
Two-Sample T"Test and Cl: Sleep QS s-l2. group 
Two-sample T for Sleep QS s"12 
group N Mean St. Dev SE Mean 
1 24 0.54 5.73 1.2 
2 33 4.45 4.66 0.81 
Difference = p(l) - µ(2) 
Estimate for difference: -3.91 
95% Cl for difference: (-6.67. -1.15) 
T-Test of difference =0 (vs not =): T-Value = -2.84 p-value = 0.006 DF = 55 
Both use Pooled St. Dev = 5.13 
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Cognitive Function 
Two-Sample T-Test and Cl: CFQ Q6 s-3, group 
Two-sample T for CFQ Q6_s-3 
group N Mean St. Dev SE Mean 
1 24 3.08 7.29 1.5 
2 34 3.50 9.11 1.6 
Difference = p(1) - µ(2) 
Estimate for difference: -0.32 
95% CI for dif ference: (-4.91,4.07) 
T-Test of difference =0 (vs not =): T-Value = -0.19 p-value = 0.853 DF = 56 
Both use Pooled St. Dev = 8.41 
Two-Sample T"Test and Cl: CFQ Q6 s"6, group 
Two-sample T for CFQ Q6 s"6 
group N Mean St. Dev SE Mean 
1 24 0.33 8.13 1.7 
2 33 7.73 9.91 1.7 
Difference = µ(1) - p(2) 
Estimate for difference: -7.39 
95% CI ford if ference: (-12.34. -144) 
T-Test of difference =0 (vs not =): T-Value = -2.99 p-value = 0.004 DF = 55 
Both use Pooled St. Dev = 9.21 
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Two-Sample T"Test and Cl: CFQ Q6 s-9, group 
Two-sample T for CFQ Q6 s-9 
group N Mean St. 13ev SE Mean 
1 24 1.21 7.56 1.5 
2 33 10.3 12.3 2.2 
Difference = N(l) - p(2) 
Estimate for difference: -9.13 
95% Cl for difference: (-14.85, -3.40) 
T-Test of difference =0 (vs not =): T-Value = -3.19 p-value = 0.002 DF = 55 
Both use Pooled St. Dev =10.7 
T%o-Sample T-Test and Cl: CFQ Q6 s-12, group 
Two-sample T for CFQ Q6_s-12 
group N Mean St. Dev SE Mean 
1 24 "0.33 7.48 1.5 
2 33 13.1 10.7 1.9 
Difference = µ(1) - µ(2) 
Estimate for difference: "13.42 
95% CI for difference: (-18.51, -8.33) 
T-Test of difference =0 (vs not =): T-Value = -5.29 p-value = 0.000 DF = 55 
Both use Pooled St. Dev = 9.47 
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Nottingham Health Questionnaire 
Two-Sample T -Test and Cl: Nom Q7_s-3. group 
Two-sample T for Nott. Q7 s-3 
group N Mean St. Dcv SE Mean 
1 24 0.71 2.99 0.61 
2 34 2.82 6.09 1.0 
Difference = N(1) - p(2) 
Estimate for difference: -2.12 
95% CI for difference: (. 4.81.0.58) 
T-Test of difference =0 (vs not =): T-Value = -157 p-value = 0.122 DF = 56 
Both use Pooled St. Dev = 5.05 
Two-Sample T"Test and Cl: Nom Q7-S-6. group 
Tao-sample T for Nom Q7 s-6 
group N Mean St. Dev SE Mean 
1 24 0.50 3.62 0.74 
2 33 5.52 6.45 1.1 
Difference = p(I) - p(2) 
Estimate for difference: -5.02 
95% CI for difference: (. 7.95. -2.08) 
T -Test of difference =0 (%s not =): T-Value = -3.43 p-value = 0.001 DF = 55 
Both use Pooled St. Dev = 5.45 
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Two-Simple T -Test and Cl: Nou. Q7 s"9, group 
Two-sample T for Nott. Q7 s-9 
group N Mean St. Dev SE Mean 
1 24 0.46 3.96 0.81 
2 33 6.12 6.20 1.1 
Difference = p(1) - p(2) 
Estimate for difference:. 5.66 
95% Cl for difference: (-8.55, -2.77) 
T -Test of difference =0 (vs not =): T-Value = -3.92 p-value = 0.000 DF = 55 
Both use Pooled St. Dev = 5.38 
Tao-Sample T-Test and Cl: Non. Q7-s- IZ group 
Two-sample T for Nom Q7 s"12 
group N Mean St. Dev SE Mean 
1 24 "0.92 4.87 0.99 
2 33 6.85 6.50 1.1 
Difference = p(1) - p(2) 
Estimate for difference: -7.77 
95% Cl for difference: (. 10.92. -d. 61) 
T-Tat of difference =0 (vs not =): T-Value = . 4.93 p-value = 0.000 DF = 55 
Both use Pooled St. Dev = 5.87 
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Profile of Fatigue Related States 
Ts"o-Sample T -Test and Cl: PFRS Q8 s"3, group 
Two-sample T for PFRS Q8 s"3 
group N Mean St. Dcv SE Mean 
1 24 6.2 30.6 6.3 
2 34 34.1 56.3 9.7 
Difference = p(1) - µ(2) 
Estimate for difference: . 27.9 
95% Cl for diffcrence: (-53.3, -2.6) 
T-Test of difference =0 (vs not =): T"Value = -2.21 p-value = 0.032 DF = 56 
Both use Pooled St. Dev = 37.5 
Two-Sample T-Test and CI: PFRS Q8 s-6, group 
Two-sample T for PFRS Q8 s-6 
group N Mean St. Dev SE Mean 
1 24 9.3 28.8 5.9 
2 33 58.6 56.4 9.8 
Difference = µ(1) - p(2) 
Estimate for difference: -49.4 
95% CI for difference: (-73.5, -24.2) 
T-Test of difference =0 (vs not =): T-Value = -3.93 p-value = 0.000 DF = 55 
Both use Pooled St. Dev = 46.9 
303 
Two-Simple T-Test and Cl: PFRS Q4-0. group 
Two-sample T for PFRS Q8 s-9 
group N Mean St. Dcv SE Mean 
1 24 7.6 41.4 8.4 
2 33 66.7 59.5 10 
Difference = p(1) - p(2) 
Estimate for difference: -59.1 
95% CI for difference: (-87.4. -30.8) 
T-Test of difference =0 (vs not =): T-Value = -4.18 p-value = 0.000 DF = 55 
Both use Pooled St. Dev = 52.7 
Two-Sample T-Test and Cl: PFRS Q8_s-12, group 
Two-sample T for PFRS Q8_s"12 
group N Mean St. Dtv SE Mean 
1 24 -8.0 42.1 8.6 
2 33 70.2 56.2 9.8 
Difference = p(1) - p(2) 
Estimate for difference: -78.2 
95% CI for difference: (-105.5, -50.9) 
T -Test of difference =0 (vs not =): T-Value = -5.74 p-value = 0.000 DF = 55 
Both use Pooled St. Dev = 50.8 
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Follow Up Study 
For each questionnaire a one-sample t test of the hypothesis that there is no change from month 12 
until follow up was carried out for patients only. There are no significant changes for these data. as 
the p-values all exceed 0.05. 
One-Sample T: I tealth Q 1_12"f. Buk Q2_12d. BDI Q3_1 2-f. BAI Q4_12-f, Sleep Q5_12-f 
CFQ Q6_12-f, Hott. Q7 12"f, PFRS Q8 12-f. 
Test of p=0 vs p not =0 
Variable N Mean St. Dev SE Mean 
Health Q1_ 12-f 16 . 0.84 7.96 1.99 
Back Q2_ 12-f 16 0.94 5.82 1.46 
BDI Q3_ 124 16 1.75 6.50 1.62 
BAI Q4_ 12"1 16 3.88 7.92 1.98 
Sleep Q5_ 12"1 16 -0.156 3.249 0.812 
CFQ Q6 12-f 16 0.63 11.96 2.99 
Nott. Q7 124 16 0.563 3.633 0.908 
PFRS Q8_ 124 16 -10.69 31.42 7.85 
Variable 95. (% Cl T p 
Health Q1 12-f ("5.09.3.40) -0.42 0.678 
Back Q2_1 2-f (-2.7,4.04) 0.64 0.529 
BDI Q3_1 2-f (-1.71.5.21) 1.08 0.298 
BAI Q4_12-f (-0.34,8.09) 1.96 0.069 
Sleep Q5 12-f (-1.89,1.58) -0.19 0.850 
CFQ Q6 12-f (. 5.75,7.00) 0.21 0.837 
Nott. Q7_12-f ("1.373.2.498) 0.62 0.545 
PFRS Q8 12-f (-27.43,6.05) -1.36 0.194 
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APPE\'DIX At 0: Statistical analysis of questionnaires (phase 2) 
Statistical software package used: SPSS for Windows. 
1 treated group; 2" eon-treated cfs/me group; 3- healthy group 
Kruskai-Wallis Test: HEALTH versus Group 
Croup N X.. ilan Avw Rank 2 
1 9 0.96I. 00 20.6 3.03 
2 9 O. OCt"00 11.0 -1.39 
3 9 O. CCr. 03 10.4 -1.65 
Overall 27 14.0 
H 9.36 Cr -2p-O. C09 (adjusted for ties) 
Kruskal-WalUs Test: Back Pain versus Group 
Croup N Median Ave Rank z 
1 9 1.95! "01 21.5 3.47 
2 9 O. 0^. F"00 10.4 -1.65 
3 9 0. C^.!. 00 10.1 -1.83 
Overall 27 14.0 
x- 12.18 DF -2p-0.032 (adjusted for ties) 
Kruskal-Waills Test: Depression versus Group 
Group N kadlan Avo Rank z 
1 9 7.95E+00 18.9 2.29 
2 9 -3.21.00 10.3 -1.72 
3 9 0.0CE. C3 12.8 -0.57 
Overall 27 14.0 
H 5.74 cr "2p"0.057 (adjusted for ties) 
Kruskal-Wallis Test: Anxiety versus Group 
Group N Median Ave Rank z 
1 9 7.95E+00 16.3 1. C8 
2 9 4.77E+00 13.6 -0.18 
3 9 0. CC1.0O 12.1 -0.90 
Overall 27 14.0 
H 1.36 C? "2p-0.507 (adjusted for ties) 
Kruskal-WalUs Test: Sleep versus Group 
Groiup N Median Ave Rank z 
1 9 9. C90 18.9 2.26 
2 9 -4.540 10.7 -1.52 3 9 -2.270 12.4 -0.75 Overall 27 14.0 
H"5.33 tf "2p"O. c69 (adjusted for ties) 
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Kruskal-Wallis Test: Cognition versus Group 
Group N Median Ave Rank z 
1 9 9.000 20.1 2.80 
2 9 -3.000 10.4 -1.65 
3 9 -9.000 11.5 -1.16 
Overall 27 14.0 
H=7.97 DF -2p-0.019 (adjusted for ties) 
Kruskal-Wallis Test: Nott. Health versus Group 
Group N Median Ave Rank z 
1 9 2.63E+00 16.0 0.93 
2 9 0.00E+00 15.4 0.67 
3 9 0.00E+00 10.6 -1.59 
overall 27 14.0 
H-2.67 DF -2p-0.263 (adjusted for ties) 
Kruskal-Wallis Test: PFRS. versus Group 
Group N Median Ave Rank z 
1 9 1.98E+01 20.4 2.98 
2 9 -1.6E+00 8.8 -2.42 
3 9 0.00E+00 12.8 -0.57 
Overall 27 14.0 
H= 10.06 DF =2p=0.007 (adjusted for ties) 
NB A -ve score indicates mean worsening of symptoms. 
A p-value less than 0.05 indicates significance at the 5% level. Hence significant difference 
were found for questionnaires 1,2,6 and 8, but not for questionnaires 3,4,5, and 7. For all 
eight questionnaires the estimated median increase is greatest in the treated patients 
(group1). 
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APPENDIX All: Detailed data from MRI scans 
The following charts contains the values for CSF proportional volume, change in 
proportional volume, ventricle proportional volume and change in ventricle proportional 
volume Data was arranged in patient groups matched for age and sex. 
Ia= first scan at start 
lb = second scan at start 
2a = first scan 1 year later 
Since there was no change between the la and lb data of 2b (second scan at end on year) 
was not calculated. 
Data is in mm3 
The proportion of CSF volume expressed as a percentage of the total volume of the bounding box 
is shown in the following table 
treated cfs untreated cfs normals 
2.342 3.009 4.218 
2.460 4.986 3.002 
3.516 4.220 3.923 
3.122 4.138 2.201 
5.153 3.245 2.959 
4.054 3.473 4.145 
6.575 6.867 4.121 
5.802 3.516 5.697 
5.322 6.262 3.989 
CSF proportion of bounding box at start/% 
Source SS Df MS Chi-sq Prob>Chi- 
Columns 16.2222 2 8.1111 2.163 0.33909 
Interaction 33.7778 4 8.4444 
Error 130 18 7.2222 
Total 180 26 
Friedman's ANOVA Table for statistical analysis of above data 
(statistical software package used: MATLAB) 
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The proportion of CSF volume change expressed as a percentage of the total volume of the 
bounding box is shown below. 
treated cfs Untreated cfs Normals 
1.142 1.046 1.025 
1.116 1.054 1.199 
1.011 1.256 1.083 
1.075 0.755 1.181 
0.970 0.980 1.015 
0.995 1.010 1.059 
1.031 0.979 0.993 
0.971 1.127 0.975 
1.052 1.015 1.075 
Proportional change in CFS proportion of bounding box after 1 year/ % 
Source SS Of MS Chi-sq Prob>Chi-sq 
Columns 6 2 3 0.8 0.67032 
Interaction 25.3333 4 6.3333 
Error 148.6667 18 8.2593 
Total 180 26 
Friedman's ANOVA Table for statistical analysis of above data 
The proportion of CSF volume in just the ventricles expressed as a percentage of the total 
volume of the bounding box is shown below. 
Treated cfs untreated cfs Normals 
0.168 0.092 0.144 
0.113 0.258 0.212 
0.214 0.203 0.080 
0.096 0.132 0.075 
0.091 0.177 0.194 
0.219 0.081 0.181 
0.194 0.280 0.191 
0.206 0.218 0.176 
0.138 0.215 0.155 
Ventricular proportion of CSF bounding box at start/% 
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Source SS Df MS Chi-sq Prob>Chi-sq 
Columns 16.2222 2 8.1111 2.163 0.33909 
Interaction 32.4444 4 8.1111 
Error 131.3333 18 7.2963 
Total 180 26 
Friedman's ANOVA Table for statistical analysis of above data 
treated cfs Untreated cfs Normals 
0.985 1.043 0.952 
1.058 0.959 1.026 
0.992 1.100 0.970 
1.036 0.777 1.134 
1.001 1.007 0.943 
0.961 1.050 1.030 
0.998 0.948 0.977 
1.004 1.067 1.022 
1.050 1.039 1.030 
Proprtional change in Ventricular volume over 1 year/% 
Source SS Df MS Chi-sq Prob>Chi-sq 
Columns 4.667 2.000 2.3333 0.62222 0.73263 
Interaction 12.667 4.000 3.1667 
Error 162.667 18.000 9.037 
Total 180.000 26.000 
Raw measurements of ventricular volume 
(statistical software package used: MATLAB) 
310 
lb space 
% of la 
la csf% 
of box 
lb csf% 
of box 
2a csf% 
of box 
Mean 
lalb 
2a as a% 
of µ (lalb) 
RV06 99.149 2.412 2.273 2.674 2.342 114.160 
RV08 100.704 2.505 2.416 2.745 2.460 111.577 
RV03 99.908 3.451 3581 3.555 3.516 101.093 
RV10 101.613 3.072 3.172 3.355 3.122 107.472 
RVOI 100.000 5.158 5.148 4.999 5.153 97.017 
RV07 104.288 4.097 4.011 4.034 4.054 99.490 
RV04 98588 6.499 6.652 6.780 6.575 103.106 
RV09 100.137 5.804 5.800 5.636 5.802 97.133 
RV05 104.469 5.404 5.240 5.597 5.322 105.160 
CP09 99.080 2.939 3.078 3.146 3.009 104.562 
CP05 103.865 5.126 4.846 5.257 4.986 105.430 
CP08 99.947 4.326 4.113 5.300 4.220 125.602 
CP06 95.421 4.227 4.048 3.125 4.138 75518 
CP03 103.925 3.316 3.174 3.181 3.245 98.024 
CP02 94.637 3.366 3580 3.508 3.473 101.001 
CPO1 103.042 6.971 6.763 6.723 6.867 - 97.899 
CP04 107.169 3503 3.529 3.963 3.516 112.702 
CP07 99548 6.141 6.382 6.355 6.262 101.492 
NC07 101.527 4.264 4.171 4.324 4.218 102520 
NC08 97.761 3.125 2.878 3.600 3.002 119.918 
NC05 100.000 3.779 4.067 4.250 3.923 108.344 
NC09 96.048 2.075 2.327 2.600 2.201 118.128 
NC03 98.216 3.045 2.874 3.003 2.959 101.488 
NC04 98.469 4.208 4.081 4.391 4.145 105.938 
NC06 99.048 4.172 4.070 4.093 4.121 99.319 
NCO1 98.507 5.464 5.930 5.555 5.697 97.511 
NC02 102.381 4.031 3.946 4.289 3.989 107.523 
Change in CSF Proportions expressed as a percentage 
No significant difference was seen between the first scan 1a and 90 minutes later (1 b). Thus only 
csf proportions of 2a, at the end of the year, were analysed. (Final column = 100 x (2a)/µ (1 a+1 b)) 
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1a total 1b total 2a total lb as % of la 
2aas°%of 
1a 
RV05 132014.4 133719.2252 133535.2 101.291362 101.152 
RV04 168218.6 169768.3682 157047 100.921305 93.35893 
RV09 153108 153201.5835 134687.9 100.061153 87.96921 
RVO1 145533.3 145262.056 135743.7 99.8136394 93.27328 
RV03 98974.51 102597.1788 98041.39 103.660206 99.05722 
RV07 84722.75 86508.25214 82672.48 102.107471 97.58003 
RV06 54711.39 51114.5504 57297.63 93.4257905 104.7271 
RV10 68582.16 71962.67499 73732.04 104.929148 107.5091 
RVO8 68210.85 66257.44852 71940.07 97.1362285 105.4672 
CP06 118666.7 108438.0102 82543.33 91.380294 69.55895 
CP09 79385.6 82398.03809 79960.32 103.79469 100.724 
C P05 149643.5 146941.0146 151238.5 98.1940593 101.0659 
C P08 118718.4 112809.7574 145439.6 95.0229814 122.5081 
CP03 79886.06 79479.23599 71843.21 99.4907459 89.9321 
CPO1 188340.2 188291.7847 182974 99.9742864 97.15079 
CP02 98955.13 99578.28473 102358.3 100.629731 103.4391 
C P04 100701.9 10 8722.144 111699.1 107.964348 110.9205 
C P07 165645.2 171353.694 16 8254.1 10 3.446194 101.575 
NC01 150909.2 161338.0684 139689.2 106.910718 92.5651 
NC02 114010.9 114256.2428 125579.5 100.215231 110.147 
NC04 123261.3 117707.7917 121091.5 95.4945518 98.23973 
NC06 94338 91147.9859 97234.2 96.6185235 103.07 
NC05 101841.6 109610.0523 120875.2 107.627926 118.6894 
NC09 42445.32 45728.97284 52912.97 107.736193 124.6615 
NC07 114772.8 113994.7105 109342.1 99.3220227 95.26824 
NC03 74468.19 69027.7284 68840.46 92.6942432 92.44277 
NC08 88054.83 79272.59326 99746.18 90.0264002 113.2774 
Raw measurements of CSF and bounding box volumes in mm3 
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lb space % 
of la 
la csf% of 
box 
lb csf% of 
box 
2a csf% of 
box mean 1 a1 b dif 1 year 
RV05 104.4691648 5.40415148 5.239764918 5.596557359 5.321958199 105.1597391 
RV04 98.5880357 6.498528023 6.6523278 6.779661154 6.575427911 103.1060069 
RV09 100.136842 5.804161396 5.799774318 5.635623642 5.801967857 97.13296903 
RVO1 100 5.157585959 5.147974251 4.999084254 5.152780105 97.01722472 
RV03 99.90801183 3.451385738 3.581007681 3.554629873 3.516196709 101.0930322 
RV07 104.2878758 4.097068004 4.011408304 4.033553762 4.054238154 99.48980817 
RV06 99.14941582 2.411838758 2.272609886 2.673879008 2.342224322 114.1598174 
RV10 101.6129023 3.071515031 3.171757199 3.35488068 3.121636115 107.4718691 
RV08 100.7042191 2.504623745 2.415883927 2.745088052 2.460253836 111.577432 
CP06 95.42143531 4.227397961 4.048365729 3.124854761 4.137881845 75.51822112 
CP09 99.07994959 2.93858916 3.07842254 3.145768607 3.00850585 104.5624893 
CP05 103.8647335 5.125882367 4.846025982 5.256702132 4.985954174 105.4302135 
CPO8 99.94704448 4.326426424 4.113277583 5.300222311 4.219852004 125.60209 
CP03 103.9253684 3.315857414 3.174365724 3.180981731 3.245111569 98.02380175 
CP01 103.0416943 6.97054186 6.763038527 6.722540064 6.866790194 97.89930774 
CP02 94.63727948 3.366447179 3.579611278 3.5077897 3.473029229 101.000869 
CP04 107.1688043 3.503303361 3.52930935 3.962953538 3.516306355 112.7021692 
CP07 99.54810563 6.141313705 6.381794271 6.355000001 6.261553988 101.4923773 
NC01 98.50746344 5.463635705 5.929715345 5.554870537 5.696675525 97.51074136 
NC02 102.3809524 4.031156961 3.945883658 4.288581044 3.98852031 107.5231091 
NC04 98.46856059 4.208483905 4.081376654 4.391054742 4.14493028 105.9379639 
NC06 99.04777904 4.171842265 4.069523253 4.092601366 4.120682759 99.31852572 
NC05 100 3.778534655 4.066758474 4.249954621 3.922646565 108.3440619 
NC09 96.04796644 2.074646793 2.327113793 2.599850443 2.200880293 118.1277533 
NC07 101.5267168 4.2638456 4.171254456 4.323838988 4.217550028 102.5201588 
NC03 98.21574652 3.04468796 2.873521366 3.003143866 2.959104663 101.4882611 
NC08 97.76119558 3.125343736 2.878068791 3.599575745 3.001706264 119.9176544 
Raw measurements of CSF and bounding box volumes in mm3 cont. 
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1a csf spa ce 1b csf space 2a csf space 
RV05 2442833.832 2552008.102 2386023.743 
RV04 2588564.073 2552014.472 2316443.853 
RV09 2637899.641 2641509.395 2389937.02 
RVO1 2821732.374 2821732.374 2715370.545 
RV03 2867674.467 2865036.546 2758132.263 
RV07 2067887.208 2156555.643 2049618.901 
RV06 2268451.476 2249156.387 2142865.544 
RV10 2232844.65 2268858.253 2197754.349 
RV08 2723397.141 2742575.824 2620683.627 
CP06 2807086.885 2678562.597 2641509.373 
CP09 2701486.888 2676631.846 2541837.35 
CP05 2919370.298 3032196.179 2877060.418 
CP08 2744028.958 2742575.844 2744028.958 
CP03 2409212.733 2503783.209 2258523.184 
c pol 2701945.091 2784130.002 2721798.776 
CP02 2939453.039 2781818.387 2918027.012 
CP04 2874484.005 3080550.138 2818581.168 
CP07 2697228.075 2685039.454 2647585.823 
NC01 2762064.851 2720840.023 2514715.885 
NC02 2828241.543 2895580.628 2928229.981 
NC04 2928875.741 2884021.783 2757686.754 
NC06 2261303.216 2239770.613 2375853.243 
NC05 2695268.308 2695268.308 2844152.95 
NC09 2045905.886 1965050.999 2035231.355 
NC07 2691768.302 2732863.979 2528819.117 
NC03 2445839.92 2402199.936 2292279.845 
NCO8 2817444.639 2754367.564 2771053.835 
Raw measurements of CSF space 
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Numbers of DWMH in regions of brain reported by radiologist from FLAIR scan 
Scan 
code No T2 T2 T2 T2 T2 T2 T2 T2 
no. frontal Parietal Occipital Temporal frontal Parietal Occipital Temporal PVH 
rv01 1 0 0 0 0 0 0 0 0 0 
rv01 2 0 0 0 0 0 0 0 0 0 
rv01 3 0 0 0 0 0 0 0 0 0 
rv01 4 0 0 0 0 0 0 0 0 0 
rv01 5 0 0 0 0 0 0 0 0 0 
rv01 6 0 0 0 0 0 0 0 0 0 
rv03 1 3 0 0 0 0 0 0 0 0 
rv03 2 3 0 0 0 0 0 0 0 0 
rv03 3 3 0 0 0 0 0 0 0 0 
rv03 4 3 0 0 0 0 0 0 0 0 
rv03 5 3 0 0 0 0 0 0 0 0 
rv03 6 3 0 0 0 0 0 0 0 0 
rv04 1 0 0 0 0 0 0 0 0 0 
rv04 2 0 0 0 0 0 0 0 0 0 
rv04 3 0 0 0 0 0 0 0 0 0 
rv04 4 0 0 0 0 0 0 0 0 0 
rv04 5 0 0 0 0 0 0 0 0 0 
rv04 6 0 0 0 0 0 0 0 0 0 
rv05 1 0 3 0 3 0 0 0 0 0 
rv05 2 0 3 0 3 0 0 0 0 0 
rv05 3 0 3 0 3 0 0 0 0 0 
rv05 4 0 3 0 3 0 0 0 0 0 
rv05 5 0 3 0 3 0 0 0 0 0 
rv05 6 0 0 0 1 0 0 0 0 0 
rv06 1 0 0 0 0 0 0 0 0 0 
rv06 2 0 0 0 1 0 0 0 0 0 
rv06 3 0 0 0 1 0 0 0 0 0 
rv06 4 0 0 0 1 0 0 0 0 0 
rv06 5 0 0 0 1 0 0 0 0 0 
rv06 6 0 0 0 1 0 0 0 0 0 
rv07 1 3 0 0 0 0 0 0 0 0 
rv07 2 3 0 0 0 0 0 0 0 0 
rv07 3 3 0 0 0 0 0 0 0 0 
rv07 4 3 0 0 0 0 0 0 0 0 
rv07 5 3 0 0 0 0 0 0 0 0 
rv07 6 3 0 0 0 0 0 0 0 0 
rv08 1 0 0 0 0 0 0 0 0 0 
rv08 2 0 0 0 0 0 0 0 0 0 
rvO8 3 0 0 0 0 0 0 0 0 0 
rv08 4 0 0 0 0 0 0 0 0 0 rv08 5 0 0 0 0 0 0 0 0 0 rv08 6 0 0 0 0 0 0 0 0 0 
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Numbers of DWMH in regions of brain reported by radiologist from FLAIR scan cont. 
code Scan T2 T2 T2 T2 T2 T2 T2 T2 
no. No frontal Parietal Occipital Temporal frontal Parietal Occipital Temporal PVH 
rvO9 1 0 1 0 3 0 0 0 0 0 
rvO9 2 0 1 0 3 0 0 0 0 0 
rvO9 3 0 1 0 3 0 0 0 0 0 
rvO9 4 0 1 0 3 0 0 0 0 0 
rvO9 5 0 1 0 3 0 0 0 0 0 
rv09 6 0 1 0 3 0 0 0 0 0 
rv10 1 0 0 0 0 0 0 0 0 0 
rv10 2 0 0 0 0 0 0 0 0 0 
rv10 3 0 0 0 0 0 0 0 0 0 
rv10 4 0 0 0 0 0 0 0 0 0 
rv10 5 0 0 0 0 0 0 0 0 0 
rv10 6 0 0 0 0 0 0 0 0 0 
DWMH: complete findings of scans of treated group 
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code Scan T2 T2 T2 T2 T2 T2 T2 T2 
number No frontal Parietal Occipital Temporal frontal Parietal Occipital Temporal PVH 
cp01 1 0 0 0 0 0 0 1 0 0 
cp01 2 0 0 0 0 0 0 1 0 0 
cp01 3 0 0 0 0 0 0 1 0 0 
cp01 4 0 0 0 0 0 0 0 0 0 
cp02 1 0 0 0 0 0 0 0 0 0 
cp02 2 0 0 0 0 0 0 0 0 0 
cp02 3 0 0 0 0 0 0 0 0 0 
cp02 4 0 0 0 0 0 0 0 0 0 
cp02 5 0 0 0 0 0 0 0 0 0 
cp02 6 0 0 0 0 0 0 0 0 0 
cp03 1 0 0 0 0 0 0 0 0 0 
cp03 2 0 0 0 0 0 0 0 0 0 
cp03 3 0 0 0 0 0 0 0 0 0 
cp03 4 0 0 0 0 0 0 0 0 0 
cp04 1 3 2 3 1 2 3 3 1 2 
cp04 2 3 2 3 1 2 3 3 1 2 
cp04 3 3 2 3 1 2 3 3 1 2 
cp04 4 3 2 3 1 2 3 3 1 2 
cp05 1 0 0 0 0 0 0 0 0 0 
cp05 2 0 0 0 0 0 0 0 0 0 
cp05 3 0 0 0 0 0 0 0 0 0 
cp05 4 0 0 0 0 0 0 0 0 0 
cp06 1 0 0 0 0 0 0 0 0 0 
cp06 2 0 0 0 0 0 0 0 0 0 
cp06 3 0 0 0 0 0 0 0 0 0 
cp06 4 0 0 0 0 0 0 0 0 0 
cp07 1 3 1 3 1 2 1 0 0 1 
cp07 2 3 1 3 1 2 1 0 0 1 
cp07 3 3 1 3 1 2 1 0 0 1 
cp07 4 3 1 3 1 2 1 0 0 1 
cp08 1 1 0 0 0 0 0 0 0 0 
cp08 2 1 0 0 0 0 0 0 0 0 
cp08 3 1 0 0 0 0 0 0 0 0 
cpO8 4 1 0 0 0 0 0 0 0 0 
cp09 1 0 0 0 0 0 0 0 0 0 
cp09 2 0 0 0 0 0 0 0 0 0 
cp09 3 0 0 0 0 0 0 0 0 0 
cp09 4 0 0 0 0 0 0 0 0 0 
D WMH: complete findings of scans of untreat ed cfs/me group 
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code Scan T2 T2 T2 T2 T2 T2 T2 T2 
number No frontal Parietal Occipital Temporal frontal Parietal Occipital Temporal PVH 
nc01 1 0 2 0 2 3 3 1 2 0 
nc01 2 0 2 0 2 3 3 1 2 0 
nc01 3 0 2 0 2 3 3 1 2 0 
nc01 4 0 2 0 2 3 3 1 2 0 
nc02 1 1 0 0 0 1 0 0 0 0 
nc02 2 1 0 0 0 1 0 0 0 0 
nc02 3 1 0 0 0 1 0 0 0 0 
nc02 4 1 0 0 0 1 0 0 0 0 
nc05 1 0 0 0 0 0 0 0 0 0 
nc05 2 0 0 0 0 0 0 0 0 0 
nc05 3 0 0 0 0 0 0 0 0 0 
nc05 4 0 0 0 0 0 0 0 0 0 
nc06 1 0 0 0 0 0 0 0 0 0 
ncO6 2 0 0 0 0 0 0 0 0 0 
nc06 3 0 0 0 0 0 0 0 0 0 
nc06 4 0 0 0 0 0 0 0 0 0 
nc07 1 0 0 0 0 0 0 0 0 0 
nc07 2 0 0 0 0 0 0 0 0 0 
nc07 3 0 0 0 0 0 0 0 0 0 
nc07 4 0 0 0 0 0 0 0 0 0 
ncO9 1 1 3 1 0 3 1 0 0 0 
ncO9 2 1 3 1 0 3 1 0 0 0 
ncO9 3 1 3 1 0 3 1 0 0 0 
ncO9 4 1 3 1 0 3 1 0 0 0 
nco3 1 0 0 0 0 0 0 0 0 0 
nco3 2 0 0 0 0 0 0 0 0 0 
nco3 3 0 0 0 0 0 0 0 0 0 
nco3 4 0 0 0 0 0 0 0 0 0 
nco4 1 0 0 0 0 0 0 0 0 0 
nco4 2 0 0 0 0 0 0 0 0 0 
nco4 3 0 0 0 0 0 0 0 0 0 
nco4 4 0 0 0 0 0 0 0 0 0 
nco8 1 0 0 0 0 0 1 0 0 1 
nco8 2 0 0 0 0 0 1 0 0 1 
nco8 3 0 0 0 0 0 1 0 0 1 
nco8 3 0 0 0 0 0 1 0 0 1 
DWMH: complete findings of scans of healthy group 
318 
age_ 
y 
Sex 
No 
we 
div 
no - 
ve 
div 
Sum 
+ve 
ml/min 
um 
-ve 
mimin 
net flow 
ml/min 
max 
+ve 
ml/sec 
max - 
ve 
mVsec 
Ist 0 
cross 
2nd 0 
cross 
Max 
drf 
ml/sec 
RV06 20 F 64 86 2.19 -3.60 -1.41 0.14 -0.19 7.40 13.80 0.34 
RV08 22 M 63 87 0.95 -1.33 -0.38 0.06 -0.05 7.60 13.90 0.12 
RV03 28 M 66 84 1.60 -2.38 -0.78 0.11 -0.10 8.10 14.70 0.22 
RV 10 28 F 73 77 3.82 -3.67 0.16 0.20 -0.17 7.50 14.80 0.37 
RVO1 29 F 85 65 4.82 -2.27 2.55 0.23 -0.19 5.00 13.50 0.42 
RV07 42 F 71 79 3.30 -4.86 -1.57 0.18 -0.24 7.10 14.20 0.42 
RV04 44 M 66 84 0.43 -0.66 -0.24 0.04 -0.05 6.60 13.20 0.09 
RV09 52 M 66 84 2.24 -4.16 -1.92 0.12 -0.21 7.30 13.90 0.33 
RV05 53 M 69 81 1.41 -2.24 -0.83 0.09 -0.12 6.90 13.80 0.20 
CP09 22 F 61 89 2.64 -3.41 -0.78 0.15 -0.15 7.40 13.50 0.30 
CPO5 26 M 72 78 10.10 -6.44 3.66 0.56 -0.37 6.90 14.10 0.93 
CP08 30 M 88 62 2.36 -1.42 0.94 0.13 -0.11 4.00 12.80 0.23 
CP06 25 F 64 86 1.05 -1.36 -0.31 0.07 -0.07 8.50 14.90 0.14 
CP03 29 F 79 71 4.22 -3.11 1.10 0.21 -0.19 6.70 14.60 0.40 
CP02 42 F 68 82 1.09 -1.88 -0.79 0.08 -0.09 6.80 13.60 0.17 
CP01 44 M 64 86 1.95 -4.00 -2.05 0.11 -0.17 8.00 14.40 0.28 
CP04 52 M 66 84 3.08 -4.44 -1.36 0.17 -0.18 8.20 14.80 0.35 
CP07 55 M 74 76 4.02 -5.91 -1.88 0.20 -0.30 6.30 13.70 0.50 
NC07 20 F 73 77 5.10 -6.19 -1.09 0.29 -0.29 7.50 14.80 0.58 
NC08 25 M 67 83 4.57 -4.52 0.05 0.29 -0.25 8.00 14.70 0.54 
NC05 27 M 67 83 0.95 -0.92 0.03 0.07 -0.05 7.10 13.80 0.12 
NC09 30 F 98 52 1.54 -1.19 0.34 0.09 -0.08 5.60 15.40 0.17 
NC03 30 F 75 75 0.59 -1.18 -0.59 0.08 -0.09 8.20 15.70 0.17 
NC04 41 F 77 73 0.97 -0.69 0.28 0.04 -0.05 7.40 15.10 0.09 
NC06 46 M 65 85 4.66 -7.65 -2.98 0.26 -0.33 7.70 14.20 0.59 
NC01 53 M 73 77 4.80 -6.31 -1.51 0.24 -0.30 7.40 14.70 0.54 
NC02 53 M 81 69 0.21 -0.23 -0.02 0.01 -0.02 3.30 11.40 0.04 
Cerebral Aqueduct Analysis of 150 slices (15 time points each divided into 10 slices) 
At start of year 
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Cerebral Aqueduct Statistical Analysis at start of year 
Net flow 
Friedman's ANOVA Table 
Source SS Df MS Chi-sq Prob>Chi-sq 
Columns 1.5556 2 0.77778 1.5556 0.45943 
Error 16.4444 16 1.0278 
Total 18 26 
negative flow width proportio n 
Friedman's ANOVA Table 
Source SS Of MS Chi-sq Prob>Chi-sq 
Columns 2.7222 2 1.3611 2.8 0.2466 
Error 14.7778 16 0.92361 
Total 17.5 26 
dif between max +ve and -ve flow 
Fried man's ANOVA Table 
Source SS Of MS Chi-sq Prob>Chi-sq 
Columns 0.22222 2 0.11111 0.22222 0.89484 
Error 17.7778 16 1.1111 
Total 18 26 
negative flow total 
Friedman's ANOVA Table 
Source SS Of MS Chi-sq Prob>Chi-sq 
Columns 0.88889 2 0.44444 0.88889 0.64118 
Error 17.1111 16 1.0694 
Total 18 26 
positive flow total 
Friedman's ANOVA Table 
Source SS Of MS Chi-sq Prob>Chi-s 
Columns 0.66667 2 0.33333 0.66667 0.71653 
Error 17.3333 16 1.0833 
Total 18 26 
max systolic flow 
Fried man's ANOVA Table 
Source SS Df MS Chi-sq Prob>Chi-sq 
Columns 0.22222 2 0.11111 0.22222 0.89484 
Error 17.7778 16 1.1111 
Total 18 26 
SS = sum of squares df = degrees of freedom MS = mean square 
(statistical software package used: MATLAB) 
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age 
y 
Sex 
No 
+ve 
div 
No 
-ve 
div 
um 
+ve 
mi/min 
Sum 
-ve 
mi/min 
net flow 
mUmin 
max 
+ve 
miser 
max 
-ve 
ml/sec 
1st 0 
cross 
2nd 0 
cross 
Max 
di 
ml/sec 
RV06 20 F 56 94 1.94 -4.94 -3.00 0.13 -0.19 8.00 13.60 0.33 
RV08 22 M 56 94 0.57 -1.21 -0.64 0.05 -0.05 8.40 14.00 0.11 
RV03 28 M 68 82 2.62 -2.80 -0.18 0.15 -0.12 8.20 15.00 0.27 
RV10 28 F 71 79 2.94 -3.41 -0.47 0.15 -0.17 8.20 15.30 0.32 
RV01 29 F 70 80 3.24 -3.08 0.16 0.18 -0.17 7.30 14.30 0.35 
RV07 42 F 70 80 2.55 -4.57 -2.01 0.15 -0.21 6.80 13.80 0.36 
RV04 44 M 47 103 1.08 -2.45 -1.37 0.10 -0.15 6.90 11.60 0.25 
RV09 52 M 74 76 3.10 -3.18 -0.09 0.15 -0.15 7.30 14.70 0.30 
RVOS 53 M 71 79 3.36 -2.48 0.88 0.18 -0.12 7.40 14.50 0.30 
CP09 22 F 61 89 2.63 -3.38 -0.75 0.15 -0.15 7.40 13.50 0.30 
CP05 26 M 72 78 10.57 -7.22 3.35 0.60 -0.50 7.20 14.40 1.10 
CP08 30 M 88 62 2.29 -1.39 0.90 0.12 -0.10 4.00 12.80 0.23 
CP06 25 F 7 143 0.00 -1.53 -1.53 0.00 -0.06 15.90 16.60 0.07 
CP03 29 F 79 71 4.24 -3.13 1.10 0.21 -0.20 6.70 14.60 0.40 
CP02 42 F 73 77 1.46 -1.49 -0.03 0.10 -0.09 7.50 14.80 0.19 
CPOI 44 M 63 87 2.23 -4.51 -2.28 0.14 -0.21 8.00 14.30 0.34 
CP04 52 M 67 83 2.85 -4.14 -1.29 0.16 -0.20 8.10 14.80 0.36 
CP07 55 M 83 67 5.84 -7.39 -1.56 0.25 -0.47 5.80 14.10 0.73 
NC07 20 F 73 77 5.27 -6.28 -1.00 0.28 -0.30 7.50 14.80 0.58 
NC08 25 M 67 83 3.57 -5.27 -1.70 0.19 -0.23 8.00 14.70 0.42 
NC05 27 M 68 82 1.15 -1.47 -0.32 0.07 -0.08 7.10 13.90 0.15 
NC09 30 F 38 112 0.11 -0.65 -0.54 0.01 -0.02 9.40 13.20 0.04 
NC03 30 F 75 75 4.35 -3.27 1.08 0.22 -0.17 8.10 15.60 0.39 
NC04 41 F 70 80 1.97 -2.14 -0.17 0.11 -0.14 7.50 14.50 0.25 
NC06 46 M 69 81 5.57 -7.24 -1.66 0.30 -0.35 7.50 14.40 0.65 
NC01 53 M 73 77 5.11 -6.23 -1.12 0.25 -0.28 7.30 14.60 0.53 
NC02 53 M 61 89 0.34 -0.91 -0.56 0.02 -0.04 8.20 14.30 0.06 
Cerebral Aqueduct Analysis of 150 slices (15 time points each divided into 10 slices) 
At end of year 
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Cerebral Aqueduct Statistical Analysis at end of year 
net flow 
Friedman's ANOVA Table 
Source SS Df MS Chi-sq Prob>Chi-sq 
Columns 0.66667 2 0.33333 0.66667 0.71653 
Error 17.3333 16 1.0833 
Total 18 26 
negative flow width proportion 
Friedman's ANOVA Table 
Source SS Of MS Chi-sq Prob>Chi-sq 
Columns 2 2 1 2.1176 0.34686 
Error 15 16 0.9375 
Total 17 26 
dif between max +ve and -ve flow 
Friedman's ANOVA Table 
Source SS Of MS Chi-sq Prob>Chi-sq 
Columns 0.22222 2 0.11111 0.22222 0.89484 
Error 17.7778 16 1.1111 
Total 18 26 
negative flow tot al 
Friedman's ANOVA Table 
Source SS Of MS Chi-sq Prob>Chi-sq 
Columns 0.66667 2 0.33333 0.66667 0.71653 
Error 17.3333 16 1.0833 
Total 18 26 
positive flow tot al 
Friedman's ANOVA Table 
Source SS Df MS Chi-sq Prob>Chi-sq 
Columns 0.66667 2 0.33333 0.66667 0.71653 
Error 17.3333 16 1.0833 
Total 18 26 
max systolic flow 
Friedman's ANOVA Table 
Source SS Df MS Chi-sq Prob>Chi-sq 
Columns 0.22222 2 0.11111 0.22222 0.89484 
Error 17.7778 16 1.1111 
Total 18 26 
SS = sum of squares df = degrees of freedom MS = mean square 
(statistical software package used: MATLAB) 
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Carotid Basilar Blood Flow mls/min 
la lb 2a 2b difslatb dif2a2b mean 1atb mean2a2b 
Diff 
means 
RVO5 1076.53 1042.12 1075.51 835.07 34.41 240.44 1059.32 955.29 104.03 
RV04 919.44 816.58 745.30 766.03 102.86 -20.73 868.01 755.66 112.35 
RV09 701.70 654.45 644.33 643.84 47.25 0.48 678.08 644.08 33.99 
RVO1 1015.18 911.69 756.79 726.88 103.49 29.92 963.44 741.84 221.60 
RV03 998.75 1096.34 1290.01 1175.96 -97.59 114.05 1047.54 1232.98 -185.44 
RV07 1512.63 1486.12 1287.51 1316.20 26.51 -28.70 1499.37 1301.85 197.52 
RV06 927.07 855.20 945.85 838.36 71.86 107.50 891.13 892.11 -0.97 
RV10 741.55 739.27 855.50 936.77 2.28 -81.26 740.41 896.13 -155.72 
RV08 672.13 708.29 513.21 481.65 -36.16 31.56 690.21 497.43 192.78 
CP06 1203.19 1181.51 1222.73 1192.69 21.68 30.04 1192.35 1207.71 -15.36 
CP09 1483.39 1103.06 1232.00 1135.42 380.34 96.58 1293.22 1183.71 109.52 
CP05 841.09 822.54 1063.06 966.15 18.55 96.91 831.81 1014.60 -182.79 
CP08 1071.07 1165.46 1492.52 1531.66 -94.39 -39.14 1118.26 1512.09 -393.82 
CP03 1185.69 1153.60 1277.21 1394.83 32.09 -117.62 1169.64 1336.02 -166.37 
C1p01 1582.16 1630.21 1694.07 #DN/01 -48.05 #DN/01 1606.18 1694.07 -87.89 
CP02 1156.22 854.28 1190.71 1199.01 301.93 -8.30 1005.25 1194.86 -189.61 
CP04 903.15 1016.39 989.71 967.82 -113.24 21.89 959.77 978.76 -18.99 
CP07 1229.58 1217.83 1188.41 1127.43 11.75 60.98 1223.70 1157.92 65.78 
NC01 1126.24 1085.58 1478.74 1362.36 40.66 116.37 1105.91 1420.55 -314.64 
NC02 1078.51 913.68 878.26 727.58 164.83 150.68 996.10 802.92 193.18 
N004 1102.70 954.51 1229.17 1099.28 148.19 129.89 1028.60 1164.23 -135.63 
NC06 1265.65 1007.45 1111.82 1166.75 258.20 -54.93 1136.55 1139.28 -2.74 
NC05 1185.85 1034.08 1388.48 1163.54 151.76 224.94 1109.97 1276.01 -166.04 
NC09 1073.88 1372.72 1161.82 1172.69 -298.84 -10.86 1223.30 1167.26 56.04 
NC07 960.99 958.00 1400.87 1075.57 2.99 325.29 959.49 1238.22 -278.73 
NC03 1198.25 1371.70 1123.70 1177.19 -173.45 -53.49 1284.98 1150.45 134.53 
NC08 1026.49 894.80 922.95 926.69 131.69 -3.75 960.64 924.82 35.82 
-15.3623 -314.644 Friedma n's ANOVA Table 
109.5158 193.1756 Source SS MS Chi-sq Prob>Chi-s 
-182.789 -135.625 Columns 22.2222 11.1111 2.963 0.2273 
-393.824 -2.73764 Interaction 7.1111 1.7778 
-166.375 -166.043 Error 150.6667 8.3704 
-87.8859 56.04426 Total 180 
-189.611 -278.73 Test for co lumn effects after row effects are removed 
-18.9906 134.5274 
65.78453 35.82181 
Statistical Analysis of Carotid Basilar blood flow 
(Statistical software package used: MATLAB) 
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APPENDIX A12: EMG data 
Treated 
group Frequency/Hz 
Code rv la lb 
Frequency 
shift at start 
la-lb 2a 2b 
Frequency 
shift at 
end 
2a-2b 
1 51 43 8 40 39 1 
2 41 45 -4 
3 78 72 6 57 51 6 
4 70 67 3 39 35 4 
5 51 49 2 43 41 2 
6 51 49 37 12 
7 49 49 0 47 49 -2 
8 53 
9 76 71 5 57 55 2 
10 53 53 0 47 45 2 
mean 57 56 3 47 44 3 
sd 13 12 4 7 7 4 
P= 0.305854 
Iemg/ micro- 
Volt 
seconds 
rv la lb la-lb 2a 2b 2a-2b 
1 5.59E+02 4.94E+02 -65 0 
2 5.33E+02 5.57E+02 24 
3 5.77E+02 6.15E+02 5.60E+02 -55 
4 4.03E+02 2.36E+02 3.77E+02 140 
5 7.20E+02 6.98E+02 -23 9.48E+02 9.57E+02 9 
6 5.46E+02 5.57E+02 11 3.55E+02 4.78E+02 124 
7 4.95E+02 5.48E+02 53 6.12E+02 6.92E+02 80 
8 5.43E+02 4.80E+02 4.40E+02 -40 
9 3.96E+02 5.08E+02 111 6.98E+02 7.31 E+02 33 
10 4.48E+02 6.20E+02 172 4.68E+02 4.92E+02 24 
mean 530 551 40 551 591 35 
sd 95 82 80 219 191 68 
P= 0.962408 
Frequency shift and integrated electromyography data on treated group 
(Statistical software package used: SPSS for Windows) 
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Cfs/me 
Control 
group Frequency/Hz 
Codecp la Ib 
Frequency 
shift at start 
la-lb 2a 2b 
Frequency 
shift at 
end 
2a-2b 
1 47 39 8 51 49 2 
2 43 39 4 38 39 -1 
3 37 36 1 45 26 19 
4 38 38 0 41 36 5 
5 43 45 -2 
6 
7 
8 57 57 0 57 49 8 
9 
10 
mean 44 42 2 46 40 7 
sd 7 8 4 8 10 8 
P= 0.418433 
lemg/ micro- 
Volt 
seconds 
cp la lb 2a 2b 
1 7.28E+02 7.68E+02 40 4.89E+01 6.31E+01 14 
2 3.11E+02 2.90E+02 -20 3.28E+02 3.97E+02 70 
3 1.71E+02 1.55E+02 -16 2.27E+02 2.34E+02 7 
4 4.97E+02 4.44E+02 -53 3.45E+02 3.61E+02 16 
5 9.12E+02 8.56E+02 -56 
6 
7 
8 6.15E+02 6.60E+02 45 5.70E+02 5.15E+02 -55 
9 0 0 
10 0 0 
mean 539 529 -7 304 314 7 
sd 272 278 37 190 172 36 
p= 0.748303 
Frequency shift and integrated electromyography data on 
untreated cfs/me group 
(Statistical software package used: SPSS for Windows) 
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Healthy 
control 
group Frequency/Hz 
Code nc 1a 1b 
Frequency 
shift at start 
la-lb 2a 2b 
requency 
shift at end 
2a-2b 
1 47 49 -2 36 30 6 
2 54 54 0 43 37 6 
3 41 45 -4 43 39 4 
4 51 43 8 43 45 -2 
5 45 45 0 37 45 -8 
6 45 57 -12 
7 53 51 2 45 45 0 
8 39 49 -10 47 43 4 
9 49 45 4 47 45 2 
10 
mean 47 49 -2 43 41 2 
sd 5 5 6 4 5 5 
P= 0.579255 
lern 
nc 1a 1b 2a 2b 
1 3.86E+02 3.74E+02 -12 2.22E+02 2.50E+02 29 
2 8.33E+02 7.99E+02 -33 7.40E+02 6.30E+02 -110 
3 5.75E+02 6.48E+02 73 4.08E+02 5.01 E+02 93 
4 5.33E+02 3.30E+02 -203 3.50E+02 2.47E+02 -103 
5 5.30E+02 5.57E+02 27 6.74E+02 7.08E+02 35 
6 5.78E+02 6.86E+02 108 
7 6.26E+02 7.29E+02 103 8.44E+02 7.21 E+02 -123 
8 4.74E+02 4.47E+02 -27 4.49E+02 4.00E+02 -50 
9 7.45E+02 7.97E+02 52 5.60E+01 6.66E+01 11 
10 
mean 587 597 10 468 440 -27 
sd 135 178 96 269 240 80 
p- 0.495906 
Frequency shift and integrated electromyography data on 
Healthy control group 
(Statistical software package used: SPSS for Windows) 
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